

AUSTRALIAN NSP SURVEY
NATIONAL DATA REPORT

2003 - 2007

**PREVALENCE OF HIV, HCV AND
INJECTING AND SEXUAL BEHAVIOUR
AMONG IDUs AT NEEDLE AND SYRINGE PROGRAMS**



National Centre in HIV
Epidemiology and Clinical Research
The University of New South Wales

May 2008

The National Centre in HIV Epidemiology and
Clinical Research is funded by the Australian
Government Department of Health and Ageing,
and is affiliated with the Faculty of Medicine,
The University of New South Wales

©National Centre in HIV Epidemiology and Clinical Research 2008

ISSN 1448-5915

This publication is available at: <http://www.nchechr.unsw.edu.au>

Suggested citation:

National Centre in HIV Epidemiology and Clinical Research.
Australian NSP Survey National Data Report 2003-2007.
National Centre in HIV Epidemiology and Clinical Research,
The University of New South Wales, Sydney, NSW. 2008.

National Centre in HIV Epidemiology and Clinical Research
Level 2, 376 Victoria Street, Darlinghurst NSW 2010 Australia

Telephone: **02 9385 0900** Facsimile: **02 9385 0920** International prefix: **612** E-mail: recept@nchechr.unsw.edu.au

AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and sexual behaviour
among IDUs at Needle and Syringe Programs

NATIONAL DATA REPORT
2003 - 2007

Report prepared by Jenny Iversen, Rachel Deacon and Lisa Maher

National Centre in HIV Epidemiology and Clinical Research
The University of New South Wales

May 2008

The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales.

Acknowledgements

We would like to acknowledge everyone who assisted in the development and conduct of the 2007 Australian NSP Survey, including the clients who participated, the staff at the survey sites, the laboratory staff at the Centre for Immunology, in particular Philip Cunningham and Taurie Phillips, the project investigators and the original steering committee responsible for developing the survey methodology. Special thanks are also due to Libby Topp, Anna Bates and Jarliene Enriquez from NCHECR, The Wrigley Company for supplying sugar free gum to survey participants and Greg Smith, Data Processing Manager at Educational Assessment Australia, for scanning and validating completed surveys.

We acknowledge the support and input of the following members of the Australian NSP Survey advisory group during 2007: Ms Tracey Dobie (ACT); Mr Owen Westcott (NSW); Mr Shayne Kilford (NT); Mr Robert Kemp/Mr Gregory Perry (QLD); Mr Stephen Lymb/Ms Danielle Bament (SA); Ms Tania Hunt/Ms Francine Smith (TAS); Mr Roland Jauering (VIC); Ms Jude Bevan (WA); Ms Fiona Poeder (Australian Injecting and Illicit Drug Users League); Mr John Ryan (ANEX), Dr Libby Topp (Centre for Health Research in Criminal Justice) and Dr Tony Butler (National Drug Research Institute). We are particularly grateful to Dr. Alex Wodak (Drug & Alcohol Services, St Vincent's Hospital) for chairing the group.

We would also like to recognise the contribution of the late Craig Scott (Scottie), who was involved in coordinating survey participation in both Western Australia and the Northern Territory from 1999 to 2006 and who served on the advisory group from 2005 to 2007.

Ethical approvals for the survey were obtained from Institutional Ethics Committees associated with the investigators and with each NSP site. The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales.

While the survey is the result of collaboration between many organisations and individuals, its success is due to the dedication and vision of the late Dr. Margaret MacDonald, who was responsible for its development and conduct from 1994 to 2003.

Table of contents

Summary

Introduction.....	2
Injecting behaviour.....	3
Sexual behaviour.....	5
HIV antibody prevalence.....	6
HCV antibody prevalence.....	7

Tables

National	9
Australian Capital Territory	33
New South Wales.....	47
Northern Territory.....	71
Queensland.....	91
South Australia	115
Tasmania.....	139
Victoria.....	153
Western Australia	177

Methodological Notes	195
NSP Survey Questionnaire	197
Participating NSP sites	201
List of Tables	203

Summary

Key Points

HIV and HCV antibody prevalence:

- HIV antibody prevalence remained low, nationally, at less than two percent, except among participants reporting male homosexual identity (26% in 2007).
- HCV antibody prevalence has remained high nationally (62% in 2007).
- During the period 2003 to 2007, HCV antibody prevalence was lowest among those participants aged less than 20 years and injecting for less than 3 years.
- HCV antibody prevalence among participants reporting Indigenous background exceeded prevalence in non-Indigenous participants in all years (2003 – 2007).
- HCV antibody prevalence was higher among those reporting recent incarceration compared to those not reporting recent incarceration.
- HCV antibody prevalence was lower among participants reporting meth/amphetamine as last drug injected compared to those last injecting heroin, methadone or morphine/other opioids.

Demographic characteristics:

- The median age of survey participants increased from 31 years in 2003 to 35 years in 2007.
- The proportion of participants aged less than 25 years decreased annually from 21% in 2003 to 10% in 2007. Participants reporting less than three years duration of drug injection also decreased from 8% in 2003 to 5% in 2007.

Injecting behaviour:

- Participants reporting daily or more frequent injection in the month prior to the survey remained stable, ranging from 46% (2003) to 49% (2005).
- Participants reporting use of sterile needles and syringes for all injections in the previous month was high in all age groups and remained stable between 2003 and 2007 (71-75%).
- Re-use of someone else's used needle and syringe in the last month ranged between 13-18% from 2003 to 2007.
- In 2007, the proportion of participants reporting heroin and meth/amphetamine as the drug last injected were comparable at 31% (heroin) and 30% (meth/amphetamine).
- The proportion of participants reporting morphine or other opioids (such as MS Contin, OxyContin, Endone or Homebake) as the last drug injected increased from 9% in 2003 to 14% in 2007.

Introduction

The annual Australian Needle and Syringe Program (NSP) survey forms the basis of human immunodeficiency virus (HIV) and hepatitis C surveillance among injecting drug users (IDUs). Monitoring behavioural indices of risk, in addition to prevalence of infection, provides important information for planning prevention, treatment and support policies and services. Each year, all clients attending selected NSPs during the designated survey week are asked to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and hepatitis C virus (HCV) antibody testing. This report presents national, state and territory data for the period 2003 to 2007.

In 2007, 53 NSP sites participated in the survey. Of these, 32 (60%) had participated in each of the preceding five years. The number of survey participants decreased from 2495 in 2003 to between 1800 and 2035 in the years since 2004. In 2007 there were 1912 participants. The annual response rate varied from 36% to 50% (Table 1). The male to female ratio of survey participants was approximately 2:1 in all survey years.

The proportion of Indigenous participants remained relatively stable over the five year period at between 8 to 11%. During the same period, the proportion of participants from a non-English speaking background and those born in Asia decreased from 11% to 5% and 6% to 1% respectively. This decline is attributable to the withdrawal of a NSP targeting this group. The proportion of participants reporting incarceration during the preceding year ranged from 18% (2004) to 13% (2006 and 2007). Of those that were incarcerated, the proportion of participants reporting injection in prison varied from 53% (2004) to 35% (2005) (Table 1).

In all survey years, around two-thirds of participants reported that they had been tested for HIV or HCV antibody in the year preceding the survey (Table 6). During the period 2003 to 2007 the proportion of participants currently in methadone maintenance treatment remained relatively stable (29% to 33%) as did the proportion reporting other current pharmacotherapy treatment (12% to 15%) (Table 3).

The median age of first drug injection remained stable at 18 years for all survey years. Median age at the time of the survey increased annually from 31 years in 2003 to 35 years in 2007. Duration of injecting also increased from 11 years in 2003 to 15 years in 2007, while the proportion of new injectors (injecting for less than 3 years) declined from 8% in 2003 to 5% in 2007.


In 2006, additional information was collected from NSP clients who declined to participate in the NSP survey. This was done in order to ascertain whether participants in the NSP survey were representative of the broader NSP client population and, whether the NSP survey was inadvertently accessing an ageing cohort of participants. It was found that inferences derived from the NSP survey can reasonably be applied to the broader population of NSP, although

some groups, such as female pharmaceutical injectors, may be over-represented. It was also found that the majority of survey participants (80%) were new to the survey each year, and that repeat participants were unlikely to be unduly influencing results (Topp et al, 2008b).

Injecting behaviour

Between 2003 and 2007, approximately one third of participants reported heroin as the last drug injected (26% to 36%) and a further third reported meth/amphetamine as the last drug injected (30% to 38%) (Figure 1). Of the remaining one third, relatively small proportions reported having last injected anabolic steroids, cocaine, subutex/buprenorphine or more than one drug in all years, while the proportion of participants who reported methadone or morphine/other opioids as the last drug injected increased between 2003 and 2007 (6% to 10% and 9% to 14% respectively) (Table 2).

Figure 1 Participants reporting meth/amphetamine, heroin and morphine/other opioids as the type of drug last injected by state and territory, 2003 – 2007



The proportion of participants reporting use of sterile needles and syringes for all injections in the month preceding the survey was high among all age groups (Figure 2). Meth/amphetamine injectors were more likely than heroin injectors to report use of sterile needles and syringes for all injections in the month prior to the survey, regardless of duration of drug injection (Figure 3).

Figure 2 Participants reporting use of new or sterile needles and syringes for all injections in the month preceding the survey by age group, 2003 – 2007






Figure 3 Participants reporting use of new or sterile needles and syringes for all injections in the month preceding the survey by type and duration of drug injection, 2003 – 2007




The proportion of participants reporting re-use of someone else’s used needle and syringe in the previous month (receptive sharing) remained relatively stable at between 13% and 18% during the preceding five years (Table 2). Participants aged less than 25 years were more likely to report receptive sharing of needles and syringes in the previous month compared to older age groups in all years (Figure 4). Among those who reported re-use of someone else’s used needle and syringe, re-use after only one person was most commonly reported, typically a regular sex partner or close friend (Table 2).

Figure 4 Participants reporting re-use of someone else’s used needle and syringe in the month preceding the survey by age group, 2003 - 2007



During the period 2003 to 2007, the proportion of participants reporting at least one public injection in the last month ranged between 39% and 48%, with heroin injectors more likely to report recent public injecting than meth/amphetamine injectors in all years (Figure 5).

Figure 5 Participants reporting at least one public injection* in the month preceding the survey, 2003 – 2007



* Public injection: any street, car, public toilet, and/or squat.

Sexual behaviour

In 2007, 23% of participants reported condom use with their regular sex partner in the last month, while 63% reported condom use with non-regular sex partner/s. The proportion of participants reporting commercial sex work in the month preceding survey completion was low at between 6 and 8%, while use of condoms at last commercial sex work was high at between 86% and 95% in all years from 2003 to 2007 (Table 5).

HIV antibody prevalence

Nationally, HIV antibody prevalence remained low at 1.5% or less over the period 2003 to 2007. In 2007, HIV antibody prevalence was approximately 2% in New South Wales and Queensland and these two states accounted for 89% of participants testing HIV antibody positive. HIV antibody prevalence was approximately 1% in Western Australia and South Australia, with no HIV antibody positive participants in the remaining states and territories in 2007 (Figure 6).

HIV prevalence was consistently higher among homosexual male participants than among bisexual or heterosexual male participants or female participants in all survey years (Figure 7).

Figure 6 HIV antibody prevalence by state and territory, 2003 – 2007




Figure 7 HIV antibody prevalence by gender and sexual identity, 2003 – 2007



HCV antibody prevalence

Nationally, HCV antibody prevalence increased from 58% in 2003 to 62% in 2006 and 2007 (Table 21). HCV antibody prevalence continued to be highest among participants aged over 30 years (Figure 8) and among those who had been injecting for more than 10 years (Figure 9).

Figure 8 HCV antibody prevalence by age group, 2003 – 2007





Figure 9 HCV antibody prevalence by duration of injecting, 2003 – 2007



HCV antibody prevalence was also higher among participants reporting imprisonment in the preceding year compared to those not reporting recent imprisonment (Figure 10) and among Indigenous background participants, compared to those from a non-Indigenous background (Figure 11).

HCV antibody prevalence was also higher among participants reporting heroin, methadone or morphine/other opioids as last drug injected compared to those reporting meth/amphetamine as last drug injected in all years (Figure 12).

Figure 10 HCV antibody prevalence among participants by imprisonment in the previous year, 2003 – 2007




Figure 11 HCV antibody prevalence among participants by indigenous status, 2003 – 2007





Figure 12 HCV antibody prevalence among participants by last drug injected, 2003 – 2007



National 2003 – 2007

Table 1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	48	43	52	45	53
N° surveyed	N = 2495	N=2035	N=1800	N=1961	N=1912
Response (%)	45	50	42	36	36
Gender (%)					
Male	1650 (66)	1360 (67)	1149 (64)	1265 (65)	1241 (65)
Female	819 (33)	659 (32)	642 (36)	683 (35)	660 (35)
Transgender	16 (<1)	7 (<1)	8 (<1)	10 (<1)	9 (<1)
Not reported	10 (<1)	9 (<1)	1 (<1)	3 (<1)	2 (<1)
Sexual identity (%)					
Heterosexual	1908 (77)	1669 (82)	1464 (81)	1611 (82)	1570 (82)
Bisexual	243 (10)	173 (9)	150 (8)	176 (9)	177 (9)
Homosexual	134 (5)	84 (4)	99 (6)	109 (6)	116 (6)
Not reported	210 (8)	109 (5)	87 (5)	65 (3)	49 (3)
Age and duration of injection (years)					
<i>Median age</i>	31	32	34	34	35
<i>Age range</i>	15-64	16-65	15-66	13-68	14-69
<i>Age group (%)</i>					
<25 years	512 (21)	389 (19)	258 (14)	237 (12)	183 (10)
25+ years	1978 (79)	1637 (80)	1542 (86)	1717 (88)	1726 (90)
Not reported	5 (<1)	9 (<1)	--	7 (<1)	3 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	3-50	5-56	9-55	10-52	10-56
N° not reported	82	53	67	71	51
<i>Median years IDU</i>	11	11	13	14	15
<i>Range</i>	<1-45	<1-71	<1-46	<1-45	<1-49
<i>Duration of drug injection (%)</i>					
<3 years	206 (8)	154 (7)	161 (9)	108 (6)	102 (5)
3+ years	2204 (88)	1827 (90)	1559 (87)	1779 (91)	1759 (92)
Not reported	85 (4)	54 (3)	80 (4)	74 (4)	51 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	2221 (89)	1813 (89)	1563 (87)	1695 (86)	1663 (87)
Yes	203 (8)	165 (8)	185 (10)	203 (10)	203 (11)
Not reported	71 (3)	57 (3)	51 (3)	63 (3)	46 (2)
Region/Country of birth					
Australia	2026 (81)	1613 (79)	1551 (86)	1668 (85)	1649 (86)
Other Oceania	93 (4)	63 (3)	54 (3)	62 (3)	46 (2)
Asia	145 (6)	145 (7)	14 (1)	17 (<1)	22 (1)
UK & Ireland	114 (4)	91 (5)	95 (5)	105 (5)	85 (4)
Other	91 (4)	83 (4)	72 (4)	73 (4)	72 (4)
Not reported	26 (1)	40 (2)	14 (1)	36 (2)	38 (2)
Main language spoke at home by parents					
English speaking	2111 (84)	1354 (67)	1534 (85)	1735 (88)	1778 (93)
Non-English speaking	267 (11)	228 (11)	266 (15)	121 (6)	102 (5)
Not reported	117 (5)	453 (22)	--	105 (5)	32 (2)
Imprisonment last year (%)					
No	2047 (82)	1631 (80)	1477 (82)	1622 (83)	1569 (82)
Yes	406 (16)	373 (18)	252 (14)	247 (13)	254 (13)
Not reported	42 (2)	31 (2)	71 (4)	92 (5)	89 (5)
Injected in prison last year (%)					
Yes	134 (33)	198 (53)	87 (35)	90 (36)	95 (37)
Frequency of injection last month (%)					
Not last month	226 (9)	145 (7)	160 (9)	182 (9)	155 (8)
Less than weekly	470 (19)	348 (17)	297 (17)	368 (19)	337 (18)
Weekly not daily	610 (24)	530 (26)	458 (25)	476 (24)	484 (25)
Daily or more	1149 (46)	982 (48)	879 (49)	919 (47)	900 (47)
Not reported	40 (2)	30 (2)	6 (<1)	16 (<1)	36 (2)

National

Table 2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 2495	N=2035	N=1800	N=1961	N=1912
Anabolic steroids	52 (2)	25 (1)	29 (1)	36 (2)	20 (1)
Cocaine	26 (1)	52 (2)	53 (3)	44 (2)	33 (2)
Heroin	902 (36)	738 (36)	618 (34)	510 (26)	593 (31)
Methadone	154 (6)	135 (7)	166 (9)	180 (9)	187 (10)
Meth/Amphetamine	831 (33)	665 (33)	573 (32)	737 (38)	574 (30)
Morphine/Other Opioids	213 (9)	164 (8)	158 (9)	236 (12)	268 (14)
Subutex/Buprenorphine	14 (<1)	42 (2)	56 (3)	101 (5)	99 (5)
More than one	178 (7)	136 (7)	40 (2)	36 (2)	53 (3)
Other	78 (3)	27 (2)	39 (2)	32 (21)	51 (3)
Not reported	47 (2)	51 (2)	68 (4)	49 (3)	34 (2)
N° Injected last month	N = 2229	N = 1860	N=1634	N=1763	N=1721
Places injected last month (%)*					
Own home	1838 (82)	1508 (81)	1319 (81)	1498 (90)	1488 (89)
Friend's home	916 (41)	756 (41)	618 (38)	703 (42)	714 (43)
Dealer's home	375 (17)	319 (17)	233 (14)	279 (17)	278 (17)
Street, park, beach	548 (25)	431 (23)	351 (21)	352 (21)	385 (23)
Car	701 (31)	586 (32)	487 (30)	548 (33)	561 (33)
Public toilet	525 (24)	413 (22)	344 (21)	363 (22)	389 (23)
Commercial injecting room	75 (3)	36 (2)	47 (3)	43 (3)	47 (3)
Squat	162 (7)	117 (6)	74 (5)	104 (6)	102 (6)
Use of sterile needles & syringes last month (%)					
All injections	1671 (75)	1328 (71)	1184 (72)	1262 (72)	1234 (72)
Most of the time	447 (20)	411 (22)	371 (23)	371 (21)	374 (22)
Half of the time	43 (2)	39 (2)	36 (2)	47 (3)	41 (2)
Some of the time	32 (1)	36 (2)	18 (1)	24 (1)	25 (1)
Not last month	7 (<1)	11 (1)	4 (0)	17 (<1)	3 (<1)
Not reported	29 (1)	35 (2)	21 (1)	42 (2)	44 (3)
Re-used someone else's used needle & syringe last month (%)					
None	1848 (83)	1473 (79)	1345 (83)	1432 (81)	1381 (80)
Once	121 (5)	113 (6)	60 (4)	88 (5)	104 (6)
Twice	73 (3)	92 (5)	57 (4)	64 (4)	53 (3)
3-5 times	77 (3)	83 (5)	55 (3)	62 (4)	70 (4)
>5 times	49 (2)	45 (2)	37 (2)	47 (3)	36 (2)
Not reported	61 (3)	54 (3)	73 (4)	70 (4)	77 (4)
Number of people needle & syringe was re-used after last month (%)					
None	1793 (80)	1473 (79)	1277 (78)	1432 (81)	1381 (80)
One	216 (10)	168 (9)	147 (9)	129 (7)	125 (7)
Two	28 (1)	31 (2)	13 (1)	19 (1)	22 (1)
Three to five	17 (<1)	14 (1)	13 (1)	8 (<1)	14 (<1)
More than five	12 (<1)	9 (1)	10 (1)	11 (<1)	8 (<1)
Don't know	47 (2)	44 (2)	67 (4)	46 (3)	43 (3)
Not reported	116 (5)	121 (6)	107 (7)	118 (7)	128 (7)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	165 (7)	122 (7)	137 (8)	104 (6)	119 (7)
Casual sex partner	26 (1)	17 (1)	6 (<1)	14 (<1)	12 (<1)
Close friend	93 (4)	81 (4)	66 (4)	57 (3)	64 (4)
Acquaintance	44 (2)	36 (2)	31 (2)	26 (1)	23 (1)
Other	9 (<1)	16 (1)	13 (1)	10 (<1)	16 (1)
Equipment used after someone else last month (%)*					
Spoon	628 (28)	507 (27)	365 (22)	351 (20)	379 (24)
Water	460 (21)	400 (22)	293 (18)	255 (15)	274 (17)
Filter	368 (17)	299 (16)	201 (12)	173 (10)	208 (13)
Drug mix	292 (13)	224 (12)	193 (12)	140 (8)	136 (9)
Tourniquet	255 (11)	216 (12)	192 (12)	166 (10)	168 (11)
None**	---	---	---	1064 (62)	1024 (65)
Injected by someone after that person injected themselves or others last month (%)					
No	1842 (83)	1538 (83)	1321 (81)	1451 (82)	1402 (81)
Yes	320 (14)	258 (14)	217 (13)	240 (14)	235 (14)
Not reported	67 (3)	64 (3)	96 (6)	72 (4)	84 (5)

* More than one option could be selected

** New variable in 2006

Table 3 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 2495	N=2035	N=1800	N=1961	N=1912
Any treatment/therapy for drug use (%)					
No	838 (34)	421 (21)	406 (23)	414 (21)	370 (19)
Yes	1647 (66)	1552 (76)	1374 (76)	1495 (76)	1504 (79)
Not reported	10 (<1)	62 (3)	20 (1)	51 (3)	38 (2)
History of methadone maintenance treatment (%)					
Currently	725 (29)	621 (31)	600 (33)	575 (29)	605 (32)
Previously	617 (25)	467 (23)	426 (24)	519 (26)	539 (28)
Never	1139 (46)	842 (41)	753 (42)	821 (42)	740 (39)
Not reported	14 (<1)	105 (5)	21 (1)	46 (2)	28 (1)
History of other pharmacotherapy treatment (%)					
Currently	288 (12)	297 (15)	278 (15)	252 (13)	261 (14)
Previously	432 (17)	377 (18)	360 (20)	429 (22)	437 (23)
Never	1731 (69)	1294 (64)	1135 (63)	1230 (63)	1168 (61)
Not reported	44 (2)	67 (3)	27 (2)	50 (3)	46 (2)

Table 4 Number (percentage) of respondents by source of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007*
N° surveyed	N = 2495	N=2035	N=1800	N=1961	--
From an NSP last month (%)					
Daily or almost daily	294 (12)	226 (11)	227 (13)	220 (11)	--
A couple of times each week	679 (27)	571 (28)	473 (26)	596 (30)	--
Less than weekly	648 (26)	580 (29)	472 (26)	468 (24)	--
Once last month	459 (18)	353 (17)	387 (22)	373 (19)	--
Not in the last month	360 (14)	257 (13)	220 (12)	267 (14)	--
Not reported	55 (2)	48 (2)	20 (1)	37 (2)	--
From a chemist last month (%)					
Daily or almost daily	102 (4)	83 (4)	57 (3)	66 (3)	--
A couple of times each week	239 (10)	194 (10)	133 (7)	168 (9)	--
Less than weekly	332 (13)	293 (14)	191 (11)	256 (13)	--
Once last month	431 (17)	365 (18)	310 (17)	360 (18)	--
Not in the last month	1312 (53)	1306 (51)	1060 (59)	1033 (53)	--
Not reported	79 (3)	64 (3)	49 (3)	78 (4)	--

* Not asked in this form in 2007, see Table 7.

Table 5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N = 2495	N=2035	N=1800	N=1961	
Sex last month (%) †					
No	531 (21)	618 (30)	--	--	--
Yes	1916 (77)	1368 (67)	--	--	--
Not reported	48 (2)	49 (3)	--	--	--
Condom use at last sex (%)†					
No	1677 (67)	1382 (68)	--	--	--
Yes	756 (30)	601 (29)	--	--	--
Not reported	62 (3)	52 (3)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	758 (66)	626 (68)	--	--	--
Sometimes	136 (12)	114 (12)	--	--	--
Always	259 (22)	183 (20)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	338 (45)	300 (46)	--	--	--
Sometimes	117 (15)	107 (17)	--	--	--
Always	304 (40)	239 (37)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	317 (45)	260 (45)	--	--	--
Sometimes	107 (15)	106 (19)	--	--	--
Always	274 (39)	208 (36)	--	--	--
Duration of regular sexual relationship (%)**†					
One month	81 (7)	73 (8)	--	--	--
2 - 6 months	146 (12)	109 (11)	--	--	--
6 - 12 months	174 (15)	120 (13)	--	--	--
>12 months	794 (66)	639 (68)	--	--	--
Sex with a regular partner last month (%) ****					
No	--	--	800 (44)	831 (42)	813 (43)
Yes	--	--	966 (54)	1074 (55)	1026 (54)
Not reported	--	--	34 (2)	56 (3)	73 (4)
Condom used with regular partner last month (%)****					
N=****			N=966	N=1074	N=1026
Never	--	--	686 (71)	750 (70)	756 (74)
Sometimes	--	--	133 (14)	150 (14)	131 (13)
Every time	--	--	103 (11)	96 (9)	103 (10)
Not reported	--	--	44 (5)	78 (7)	36 (4)
Sex with other partner/s last month (%)****					
No	--	--	1461 (81)	1569 (80)	1562 (82)
Yes	--	--	296 (16)	296 (15)	279 (15)
Not reported	--	--	43 (2)	96 (5)	71 (4)
Condom used with other partner/s last month (%)****					
N=****			N=296	N=296	N=279
Never	--	--	74 (25)	77 (26)	91 (33)
Sometimes	--	--	76 (26)	74 (25)	69 (25)
Every time	--	--	135 (46)	127 (43)	105 (38)
Not reported	--	--	11 (4)	18 (6)	14 (5)
Sex work last month (%)					
No	2230 (89)	1808 (89)	1653 (92)	1736 (89)	1721 (90)
Yes	183 (7)	172 (8)	108 (6)	125 (6)	115 (6)
Not reported	82 (3)	55 (3)	39 (2)	100 (5)	76 (4)
Condom used at last sex work last month (%)**					
Yes	148 (89)	149 (90)	204 (95)	101 (86)	92 (87)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 6 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey

	2003	2004	2005	2006	2007
N° surveyed	N = 2495	N=2035	N=1800	N=1961	N=1912
Previous HIV test (%)					
Yes, last year	1562 (63)	1223 (60)	1035 (58)	1117 (57)	1077 (56)
> 1 year ago	651 (26)	560 (28)	564 (31)	618 (32)	617 (32)
Never tested	256 (10)	214 (10)	191 (11)	187 (10)	187 (10)
Not reported	26 (1)	38 (2)	10 (1)	39 (2)	31 (2)
HBV infection (%)					
No	1778 (71)	1407 (69)	1255 (70)	1368 (70)	1314 (69)
Yes	451 (18)	370 (18)	316 (18)	336 (17)	362 (19)
Don't know	238 (10)	206 (10)	207 (12)	207 (11)	197 (10)
Not reported	28 (1)	52 (3)	22 (1)	50 (3)	39 (2)
HBV vaccination (%)*					
No	661 (32)	550 (33)	452 (30)	460 (28)	442 (29)
Yes	1143 (56)	886 (53)	806 (54)	925 (57)	897 (58)
Don't know	195 (10)	174 (11)	204 (14)	194 (12)	173 (11)
Not reported	45 (2)	55 (3)	22 (1)	46 (3)	38 (2)
Previous HCV test (%)					
Yes, last year	1590 (64)	1287 (63)	1089 (61)	1176 (60)	1147 (60)
> 1 year ago	598 (24)	527 (26)	521 (29)	579 (30)	596 (31)
Never tested	285 (11)	191 (9)	179 (10)	166 (8)	141 (7)
Not reported	22 (1)	30 (2)	11 (1)	40 (2)	28 (1)
Any treatment for HCV (%)	N = 1110	N = 931	N=826	N=894	N=848
Interferon	39 (4)	32 (3)	26 (3)	25 (3)	20 (2)
Interferon+Ribarvarin	7 (<1)	19 (2)	13 (2)	25 (3)	23 (3)
Other	32 (3)	27 (3)	20 (2)	18 (2)	17 (2)
No treatment	1006 (91)	824 (89)	759 (92)	791 (88)	747 (88)
Not reported	26 (2)	29 (3)	8 (1)	35 (4)	41 (5)
Current treatment for HCV	N = 19	N = 21	N=20	N=21	N=15
Interferon	2	7	5	3	2
Interferon+Ribarvarin	5	5	6	8	4
Other	12	9	9	10	9

* Number (percentage) among participants not reporting HBV infection

Table 7 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N° surveyed	N=1912		
Needle/syringe acquisition at time of survey completion (%)			
No	266 (14)		
Yes	1521 (80)		
Not reported	125 (7)		
Source of needles/syringes (%)** N=1490***	In last week	In last month	
Chemist/Pharmacy	226 (15)	387 (26)	
Needle Syringe Program	647 (43)	1285 (86)	
Dispensing/Vending Machine	115 (8)	180 (12)	
Friend/Dealer	210 (14)	313 (21)	
Other	43 (3)	64 (4)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=387	60 (16)	327 (85)
Needle Syringe Program	N=1285	819 (64)	466 (36)
Dispensing/Vending Machine	N=180	29 (16)	151 (84)
Friend/Dealer	N=313	45 (14)	268 (86)
Other	N=64	15 (23)	49 (77)

* New table in 2007

** More than one could be selected

*** Excludes pick up at time of survey completion. Also excludes missing data.

National

HIV antibody prevalence

Table 8 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	1600	22 (1.4)	794	2 (0.3)	2418	25 (1.0)
2004	1216	17 (1.4)	595	3 (0.5)	1825	20 (1.1)
2005	1072	15 (1.4)	611	0 (0.0)	1692	15 (0.9)
2006	1223	26 (2.1)	661	2 (0.3)	1897	29 (1.5)
2007	1195	25 (2.1)	639	2 (0.3)	1845	28 (1.5)
χ^2 trend p value		0.057		0.939		0.075

* Total includes people whose gender was not reported or reported as transgender

Table 9 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heterosexual	1336	7 (0.5)	513	1 (0.2)	1856	8 (0.4)
Bisexual	60	2 (3.3)	168	1 (0.6)	232	4 (1.7)
Homosexual	73	12 (16.4)	48	0 (0.0)	124	12 (9.7)
p value		<0.001		0.6		<0.001
2004						
Heterosexual	1058	1 (0.1)	435	2 (0.5)	1496	3 (0.2)
Bisexual	45	1 (2.2)	108	1 (0.9)	155	2 (1.3)
Homosexual	45	13 (28.9)	30	0 (0.0)	75	13 (17.3)
p value		<0.001		0.6		<0.001
2005						
Heterosexual	939	4 (0.4)	439	0 (0.0)	1379	4 (0.3)
Bisexual	37	0 (0.0)	106	0 (0.0)	144	0 (0.0)
Homosexual	53	11 (20.8)	32	0 (0.0)	90	11 (12.2)
p value		<0.001		<0.001		<0.001
2006						
Heterosexual	1070	3 (0.3)	484	1 (0.2)	1557	4 (0.3)
Bisexual	55	4 (7.3)	110	1 (0.9)	171	6 (3.5)
Homosexual	59	19 (32.2)	46	0 (0.0)	107	19 (17.8)
p value		<0.001		0.428		<0.001
2007						
Heterosexual	1055	5 (0.5)	458	2 (0.4)	1514	7 (0.5)
Bisexual	47	2 (4.3)	119	0 (0.0)	170	3 (1.8)
Homosexual	69	18 (26.1)	42	0 (0.0)	114	18 (15.8)
p value		<0.001		1.000		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 10 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
< 20 years	46	0 (0.0)	47	0 (0.0)	93	0 (0.0)
20 – 24	264	5 (1.9)	145	0 (0.0)	412	5 (1.2)
25 – 29	324	3 (0.9)	187	0 (0.0)	515	3 (0.6)
30 + years	963	14 (1.5)	413	2 (0.5)	1393	17 (1.2)
p value		0.6		0.6		0.5
2004						
< 20 years	30	0 (0.0)	33	0 (0.0)	64	0 (0.0)
20 – 24	176	2 (1.1)	103	1 (1.0)	279	3 (1.1)
25 – 29	239	1 (0.4)	125	0 (0.0)	366	1 (0.3)
30 + years	768	13 (1.7)	334	2 (0.6)	1108	15 (1.4)
p value		0.6		0.6		0.4
2005						
< 20 years	17	0 (0.0)	22	0 (0.0)	39	0 (0.0)
20 – 24	109	1 (0.9)	90	0 (0.0)	199	1 (0.5)
25 – 29	177	0 (0.0)	137	0 (0.0)	315	0 (0.0)
30 + years	769	14 (1.8)	362	0 (0.0)	1,139	14 (1.2)
p value		0.3		---		0.2
2006						
< 20 years	19	0 (0.0)	24	0 (0.0)	43	0 (0.0)
20 – 24	101	2 (2.0)	81	0 (0.0)	182	2 (1.1)
25 – 29	230	0 (0.0)	124	0 (0.0)	357	1 (0.3)
30 + years	868	24 (2.8)	430	2 (0.5)	1308	26 (2.0)
p value		0.032		1.000		0.095
2007						
< 20 years	18	0 (0.0)	15	0 (0.0)	33	0 (0.0)
20 – 24	72	0 (0.0)	69	0 (0.0)	142	0 (0.0)
25 – 29	202	3 (1.5)	131	0 (0.0)	334	3 (0.9)
30 + years	901	22 (2.4)	423	2 (0.5)	1333	25 (1.9)
p value		0.649		1.000		0.281

* Total includes people whose gender was not reported or reported as transgender

Table 11 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
<3 years	132	2 (1.5)	68	0 (0.0)	201	2 (1.0)
3 to 5 years	192	3 (1.6)	119	0 (0.0)	313	3 (1.0)
6 to 10 years	379	7 (1.9)	226	0 (0.0)	610	8 (1.3)
10 + years	842	9 (1.1)	357	2 (0.6)	1211	11 (0.9)
p value		0.7		0.5		0.9
2004						
<3 years	84	2 (2.4)	51	0 (0.0)	135	2 (1.5)
3 to 5 years	138	2 (1.5)	84	0 (0.0)	224	2 (0.9)
6 to 10 years	312	3 (1.0)	161	0 (0.0)	474	3 (0.6)
10 + years	656	9 (1.4)	290	3 (1.0)	949	12 (1.3)
p value		0.7		0.8		0.6
2005						
<3 years	54	2 (3.7)	29	0 (0.0)	84	2 (2.4)
3 to 5 years	100	2 (2.0)	74	0 (0.0)	175	2 (1.1)
6 to 10 years	97	0 (0.0)	106	0 (0.0)	204	0 (0.0)
10 + years	775	9 (1.2)	372	0 (0.0)	1,153	9 (0.8)
p value		0.2		---		0.2
2006						
<3 years	59	1 (1.7)	42	0 (0.0)	102	1 (1.0)
3 to 5 years	81	2 (2.5)	67	0 (0.0)	148	2 (1.4)
6 to 10 years	227	4 (1.8)	159	1 (.6)	390	6 (1.5)
10 + years	799	18 (2.3)	378	1 (.3)	1185	19 (1.6)
p value		0.936		0.658		1.000
2007						
<3 years	61	1 (1.6)	37	0 (0.0)	98	1 (1.0)
3 to 5 years	67	2 (3.0)	58	0 (0.0)	126	2 (1.6)
6 to 10 years	210	2 (1.0)	132	0 (0.0)	345	2 (0.6)
10 + years	826	19 (2.4)	394	2 (0.5)	1227	22 (1.8)
p value		0.537		1.000		0.411

* Total includes people whose gender was not reported or reported as transgender

Table 12 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heroin	564	7 (1.2)	311	2 (0.6)	884	10 (1.1)
Meth/Amphetamine	538	11 (2.0)	253	0 (0.0)	797	11 (1.4)
More than one	134	2 (1.5)	64	0 (0.0)	199	2 (1.0)
Other/Not reported	364	2 (0.6)	166	0 (0.0)	538	2 (0.4)
p value		0.3		0.4		0.4
2004						
Heroin	464	4 (0.9)	207	1 (0.5)	676	5 (0.7)
Meth/Amphetamine	360	9 (2.5)	221	1 (0.5)	581	10 (1.7)
More than one	75	2 (2.7)	45	1 (2.2)	120	3 (2.5)
Other/Not reported	317	2 (0.6)	122	0 (0.0)	448	2 (0.5)
p value		0.08		0.4		0.06
2005						
Heroin	353	3 (0.8)	235	0 (0.0)	590	3 (0.5)
Meth/Amphetamine	333	5 (1.5)	196	0 (0.0)	534	5 (0.9)
More than one	24	1 (4)	15	0 (0.0)	39	1 (2.5)
Other/Not reported	355	6 (1.7)	168	0 (0.0)	525	6 (1.1)
p value		0.362		---		0.3
2006						
Heroin	303	4 (1.3)	187	0 (0.0)	495	4 (0.8)
Meth/Amphetamine	448	17 (3.8)	261	1 (0.4)	713	19 (2.7)
More than one	26	1 (3.9)	9	0 (0.0)	35	1 (2.9)
Other/Not reported	446	4 (0.9)	204	1 (0.5)	654	5 (0.8)
p value		0.012		1.000		0.012
2007						
Heroin	348	4 (1.2)	222	0 (0.0)	574	4 (0.7)
Meth/Amphetamine	348	10 (2.9)	204	1 (0.5)	552	11 (2.0)
More than one	31	0 (0.0)	18	0 (0.0)	49	0 (0.0)
Other/Not reported	468	11 (2.4)	195	1 (0.5)	670	13 (1.9)
p value		0.384		0.565		0.183

* Total includes people whose gender was not reported or reported as transgender

National

Table 13 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Not last month	138	0 (0.0)	79	2 (2.5)	217	2 (0.9)
Less than weekly	317	3 (1.0)	131	0 (0.0)	451	3 (0.7)
Weekly not daily	400	5 (1.3)	189	0 (0.0)	597	6 (1.0)
Daily or more	724	13 (1.8)	380	0 (0.0)	1115	13 (1.2)
p value		0.3		<0.001		0.8
2004						
Not last month	80	0 (0.0)	47	0 (0.0)	129	0 (0.0)
Less than weekly	198	1 (0.5)	113	1 (0.9)	311	2 (0.6)
Weekly not daily	313	12 (3.8)	158	1 (0.6)	471	13 (2.8)
Daily or more	611	3 (0.5)	274	1 (0.4)	891	4 (0.5)
p value		0.001		0.8		0.001
2005						
Not last month	93	1 (1.1)	56	0 (0.0)	150	1 (0.7)
Less than weekly	166	5 (3.0)	101	0 (0.0)	270	5 (1.9)
Weekly not daily	294	7 (2.4)	142	0 (0.0)	439	7 (1.6)
Daily or more	517	2 (0.4)	308	0 (0.0)	827	2 (0.2)
p value		0.3		---		0.3
2006						
Not last month	109	1 (0.9)	66	1 (1.5)	178	2 (1.1)
Less than weekly	222	8 (3.6)	134	0 (0.0)	357	8 (2.2)
Weekly not daily	309	10 (3.2)	149	1 (0.7)	461	11 (2.4)
Daily or more	572	7 (1.2)	308	0 (0.0)	886	8 (0.9)
p value		0.062		0.138		0.103
2007						
Not last month	89	5 (5.6)	59	0 (0.0)	149	5 (3.4)
Less than weekly	220	5 (2.3)	111	1 (0.9)	332	6 (1.8)
Weekly not daily	293	6 (2.1)	165	0 (0.0)	462	7 (1.5)
Daily or more	572	8 (1.4)	292	1 (0.3)	869	9 (1.0)
p value		0.086		0.538		0.156

* Total includes people whose gender was not reported or reported as transgender

Table 14 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	1181	18 (1.5)	585	0 (0.0)	1785	19 (1.1)
Yes	216	3 (1.4)	98	0 (0.0)	317	3 (1.0)
p value		0.9		---		0.8
2004						
No	872	13 (1.5)	446	3 (0.7)	1322	16 (1.2)
Yes	217	2 (0.9)	85	0 (0.0)	304	2 (0.7)
p value		0.7		1.0		0.6
2005						
No	800	13 (1.6)	456	0 (0.0)	1,262	13 (1.0)
Yes	130	1 (0.8)	68	0 (0.0)	200	1 (0.5)
p value		0.5		---		0.5
2006						
No	896	20 (2.2)	485	0 (0.0)	1387	20 (1.4)
Yes	161	4 (2.5)	86	0 (0.0)	249	5 (2.0)
p value		0.776		---		0.571
2007						
No	869	15 (1.7)	467	2 (0.4)	1343	18 (1.3)
Yes	162	4 (2.5)	79	0 (0.0)	244	4 (1.6)
p value		0.522		1.000		0.764

* Total includes people whose gender was not reported or reported as transgender

Table 15 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	1260	16 (1.3)	704	2 (0.3)	1982	19 (1.0)
Yes	314	6 (1.9)	75	0 (0.0)	395	6 (1.5)
p value		0.4		0.6		0.3
2004						
No	927	15 (1.6)	522	2 (0.4)	1456	17 (1.2)
Yes	270	2 (0.7)	68	1 (1.5)	340	3 (0.9)
p value		0.4		0.3		1.0
2005						
No	845	15 (1.8)	533	0 (0.0)	1386	15 (1.1)
Yes	179	0 (0.0)	59	0 (0.0)	239	0 (0.0)
p value		0.07		---		0.1
2006						
No	971	25 (2.6)	583	2 (0.3)	1566	28 (1.8)
Yes	181	1 (0.6)	61	0 (0.0)	243	1 (0.4)
p value		0.106		1.000		0.165
2007						
No	946	23 (2.4)	560	2 (0.4)	1514	25 (1.7)
Yes	190	2 (1.0)	59	0 (0.0)	249	2 (0.8)
p value		0.412		1.000		0.413

* Total includes people whose gender was not reported or reported as transgender

National

Table 16 HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	1048	12 (1.2)	564	2 (0.4)	1628	14 (0.9)
Yes	513	9 (1.8)	210	0 (0.0)	730	10 (1.4)
p value		0.3		0.4		0.3
2004						
No	805	11 (1.4)	422	2 (0.5)	1235	13 (1.1)
Yes	385	6 (1.6)	157	1 (0.6)	543	7 (1.3)
p value		0.8		1.0		0.6
2005						
No	389	1 (0.3)	300	0 (0.0)	690	1 (0.1)
Yes	177	4 (2.3)	88	0 (0.0)	267	4 (1.5)
p value		0.02		---		0.009
2006**						
No	533	6 (1.1)	339	1 (0.3)	880	8 (0.9)
Yes	57	3 (5.3)	35	0 (0.0)	92	3 (3.3)
p value		0.047		1.000		0.077
2007**						
No	506	4 (0.8)	344	2 (0.6)	856	7 (0.8)
Yes	66	1 (1.5)	31	0 (0.0)	98	1 (1.0)
p value		0.460		1.000		0.581

* Total includes people whose gender was not reported or reported as transgender

**Question changed to "condom use with regular partner in last month" in 2005.

Table 17 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	1481	17 (1.2)	666	2 (0.3)	2162	19 (0.9)
Yes	68	5 (7.4)	103	0 (0.0)	178	6 (3.4)
p value		<0.001		0.6		0.002
2004						
No	1123	14 (1.3)	487	2 (0.4)	1615	16 (1.0)
Yes	64	2 (3.1)	93	1 (1.1)	161	3 (1.9)
p value		0.2		0.4		0.2
2005						
No	1021	14 (1.4)	525	(0.0)	1553	14 (0.9)
Yes	27	1 (3.7)	73	(0.0)	102	1 (1.0)
p value		0.3		---		0.9
2006						
No	1123	24 (2.1)	548	2 (0.4)	1678	26 (1.6)
Yes	34	2 (5.9)	81	0 (0.0)	121	3 (2.5)
p value		0.176		1.000		0.440
2007						
No	1108	23 (2.1)	541	2 (0.4)	1656	25 (1.5)
Yes	34	1 (2.9)	76	0 (0.0)	114	2 (1.8)
p value		0.519		1.000		0.691

* Total includes people whose gender was not reported or reported as transgender

Table 18 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	1448	17 (1.2)	687	1 (0.2)	2154	18 (0.8)
Yes	106	3 (2.8)	84	1 (1.2)	194	5 (2.6)
p value		0.1		0.08		0.02
2004						
No	1097	15 (1.4)	522	2 (0.4)	1631	17 (1.0)
Yes	87	1 (1.2)	56	1 (1.8)	145	2 (1.4)
p value		1.0		0.3		0.7
2005						
No	946	15 (1.6)	521	0 (0.0)	1,475	15 (1.0)
Yes	95	0 (0.0)	74	0 (0.0)	170	0 (0.0)
p value		0.2		---		0.2
2006						
No	1074	24 (2.2)	556	2 (0.4)	1639	27 (1.7)
Yes	109	2 (1.8)	89	0 (0.0)	199	2 (1.0)
p value		1.000		1.000		0.763
2007						
No	1045	21 (2.0)	548	2 (0.4)	1602	23 (1.4)
Yes	118	3 (2.5)	80	0 (0.0)	200	4 (2.0)
p value		0.728		1.000		0.532

* Total includes people whose gender was not reported or reported as transgender

Table 19 HIV antibody prevalence by region/country of birth, gender and year of survey

	Male		Female		Total *	
2003						
Australia	1267	16 (1.3)	670	2 (0.3)	1959	19 (1.0)
Other Oceania	51	2 (3.9)	39	0 (0.0)	91	2 (2.2)
Asia	123	1 (0.8)	21	0 (0.0)	144	1 (0.7)
UK & Ireland	76	3 (4.0)	33	0 (0.0)	110	3 (2.7)
Other	64	0 (0.0)	24	0 (0.0)	88	0 (0.0)
p value		0.1		>0.9		0.3
2004						
Australia	941	14 (1.5)	498	3 (0.6)	1450	17 (1.2)
Other Oceania	29	0 (0.0)	27	0 (0.0)	56	0 (0.0)
Asia	119	0 (0.0)	19	0 (0.0)	138	0 (0.0)
UK & Ireland	58	2 (3.5)	23	0 (0.0)	81	2 (2.5)
Other	46	0 (0.0)	21	0 (0.0)	69	0 (0.0)
p value		0.4		1.0		0.4
2005						
Australia	911	13 (1.4)	541	0 (0.0)	1,459	13 (0.9)
Other Oceania	31	1 (3.2)	14	0 (0.0)	47	1 (2.1)
Asia	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
UK & Ireland	61	1 (1.6)	32	0 (0.0)	93	1 (1.1)
Other	52	0 (0.0)	15	0 (0.0)	67	0 (0.0)
p value		0.8		---		0.8
2006						
Australia	1026	22 (2.1)	577	2 (0.4)	1611	24 (1.5)
Other Oceania	38	1 (2.6)	23	0 (0.0)	62	2 (3.2)
Asia	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
UK & Ireland	73	2 (2.7)	30	0 (0.0)	104	2 (1.9)
Other	49	1 (2.0)	21	0 (0.0)	71	1 (1.4)
p value		0.824		1.000		0.535
2007						
Australia	1023	22 (2.2)	557	2 (0.4)	1590	25 (1.6)
Other Oceania	25	1 (4.0)	19	0 (0.0)	45	1 (2.2)
Asia	13	0 (0.0)	9	0 (0.0)	22	0 (0.0)
UK & Ireland	56	2 (3.6)	28	0 (0.0)	84	2 (2.4)
Other	51	0 (0.0)	19	0 (0.0)	70	0 (0.0)
p value		0.506		1.000		0.640

* Total includes people whose gender was not reported or reported as transgender

Table 20 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	1304	19 (1.5)	721	2 (0.3)	2048	22 (1.1)
English speaking	214	2 (0.9)	47	0 (0.0)	262	2 (0.8)
Non-English speaking		0.5		0.7		0.6
p value						
2004	755	11 (1.5)	454	2 (0.4)	1219	13 (1.1)
English speaking	162	0 (0.0)	43	0 (0.0)	205	0 (0.0)
Non-English speaking		0.2		1.0		0.2
p value						
2005	888	15 (1.7)	546	0 (0.0)	1,441	15 (1.0)
English speaking	184	0 (0.0)	65	0 (0.0)	251	0 (0.0)
Non-English speaking		0.1		---		0.1
p value						
2006						
English speaking	1063	24 (2.3)	610	2 (0.3)	1683	27 (1.6)
Non-English speaking	84	2 (2.4)	28	0 (0.0)	114	2 (1.8)
p value		0.715		1.000		0.706
2007						
English speaking	1100	24 (2.2)	609	2 (0.3)	1719	27 (1.6)
Non-English speaking	70	1 (1.4)	27	0 (0.0)	98	1 (1.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 21 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	1604	914 (57)	794	483 (61)	2422	1412 (58)
2004	1223	715 (58)	599	371 (62)	1836	1093 (60)
2005	1076	657 (61)	609	377 (62)	1694	1040 (61)
2006	1217	736 (60)	656	419 (64)	1886	1162 (62)
2007	1140	695 (61)	605	388 (64)	1756	1091 (62)
χ^2 trend p value		0.015		0.144		0.004

* Total includes people whose gender was not reported or reported as transgender

Table 22 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	1337	772 (58)	513	297 (58)	1857	1074 (58)
Bisexual	60	32 (53)	168	112 (67)	232	146 (63)
Homosexual	76	34 (45)	48	29 (60)	127	64 (50)
p value		0.07		0.1		0.07
2004						
Heterosexual	1065	619 (58)	439	272 (62)	1507	892 (59)
Bisexual	45	28 (62)	108	66 (61)	155	95 (61)
Homosexual	45	25 (56)	30	19 (63)	75	44 (59)
p value		0.8		0.9		0.9
2005						
Heterosexual	943	578 (61)	437	267 (61)	1381	845 (61)
Bisexual	37	20 (54)	106	64 (60)	144	85 (59)
Homosexual	54	31 (57)	32	24 (75)	91	59 (65)
p value		0.6		0.3		0.7
2006						
Heterosexual	1065	669 (63)	481	308 (64)	1549	979 (63)
Bisexual	55	25 (45)	109	76 (70)	170	102 (60)
Homosexual	59	26 (44)	45	23 (51)	106	51 (48)
p value		0.001		0.094		0.008
2007						
Heterosexual	1009	627 (62)	431	278 (65)	1441	906 (63)
Bisexual	45	25 (56)	116	77 (66)	165	105 (64)
Homosexual	63	30 (48)	41	21 (51)	107	53 (50)
p value		0.053		0.200		0.023

* Total includes people whose gender was not reported or reported as transgender

Table 23 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	46	9 (20)	47	21 (45)	93	30 (32)
20 – 24	264	100 (38)	145	67 (46)	412	169 (41)
25 – 29	324	148 (46)	187	113 (60)	515	261 (51)
30 + years	967	656 (68)	413	281 (68)	1397	950 (68)
p value		<0.001		<0.001		<0.001
2004						
< 20 years	30	6 (20)	33	12 (36)	64	18 (28)
20 – 24	178	65 (37)	104	56 (54)	282	121 (43)
25 – 29	240	120 (50)	125	57 (46)	367	179 (49)
30 + years	772	522 (68)	337	246 (73)	1115	772 (69)
p value		<0.001		<0.001		<0.001
2005						
< 20 years	22	10 (45)	17	3 (18)	39	13 (33)
20 – 24	90	46 (51)	110	34 (31)	200	80 (40)
25 – 29	137	74 (54)	177	92 (52)	315	167 (53)
30 + years	772	528 (68)	360	247 (69)	1140	780 (68)
p value		<0.001		<0.001		<0.001
2006						
< 20 years	18	1 (6)	23	6 (26)	41	7 (17)
20 – 24	100	42 (42)	81	44 (54)	181	86 (48)
25 – 29	230	118 (51)	124	77 (62)	357	196 (55)
30 + years	864	571 (66)	426	290 (68)	1300	867 (67)
p value		<0.001		<0.001		<0.001
2007						
< 20 years	18	4 (22)	14	5 (36)	32	9 (28)
20 – 24	67	23 (34)	63	32 (51)	131	56 (43)
25 – 29	190	97 (51)	126	75 (60)	317	173 (55)
30 + years	863	569 (66)	401	276 (69)	1273	851 (67)
p value		<0.001		0.002		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 24 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	132	29 (22)	68	14 (21)	201	43 (21)
3 to 5 years	193	66 (34)	119	52 (44)	314	119 (38)
6 to 10 years	381	191 (50)	226	136 (60)	612	329 (54)
10 + years	843	609 (72)	357	271 (76)	1212	889 (73)
p value		<0.001		<0.001		<0.001
2004						
<3 years	84	23 (27)	51	11 (22)	135	34 (25)
3 to 5 years	140	43 (31)	84	32 (38)	226	75 (33)
6 to 10 years	313	167 (53)	163	97 (60)	477	265 (56)
10 + years	660	468 (71)	292	225 (77)	955	696 (73)
p value		<0.001		<0.001		<0.001
2005						
<3 years	96	22 (23)	46	22 (48)	144	45 (31)
3 to 5 years	100	32 (32)	74	25 (34)	175	58 (33)
6 to 10 years	97	46 (47)	106	58 (55)	204	105 (51)
10 + years	736	529 (72)	353	253 (72)	1094	785 (72)
p value		<0.001		<0.001		<0.001
2006						
<3 years	58	9 (16)	41	9 (22)	100	18 (18)
3 to 5 years	79	25 (32)	67	19 (28)	146	44 (30)
6 to 10 years	227	111 (49)	158	102 (65)	389	214 (55)
10 + years	797	558 (70)	375	280 (75)	1180	844 (72)
p value		<0.001		<0.001		<0.001
2007						
<3 years	59	8 (14)	37	11 (30)	96	19 (20)
3 to 5 years	67	22 (33)	55	29 (53)	123	52 (42)
6 to 10 years	197	85 (43)	124	68 (55)	324	154 (48)
10 + years	786	558 (71)	372	267 (72)	1165	831 (71)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 25 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	59	16 (27)	813	586 (72)	885	612 (69)
Meth/Amphetamine	93	18 (19)	690	331 (48)	799	354 (44)
More than one	6	2 (33)	184	118 (64)	199	127 (64)
Other/Not reported	43	7 (16)	451	302 (67)	539	319 (59)
p value		0.5		<0.001		<0.001
2004						
Heroin	35	12 (34)	639	449 (70)	681	468 (69)
Meth/Amphetamine	62	14 (23)	515	229 (44)	584	248 (42)
More than one	6	2 (33)	109	70 (64)	121	75 (62)
Other/Not reported	32	6 (19)	395	288 (73)	450	302 (67)
p value		0.4		<0.001		<0.001
2005						
Heroin	30	14 (47)	563	389 (69)	593	403 (68)
Meth/Amphetamine	58	9 (16)	482	241 (50)	540	250 (46)
More than one	1	1 (100)	39	32 (82)	40	33 (83)
Other/Not reported	55	19 (35)	477	343 (72)	532	362 (68)
p value		0.003		<0.001		<0.001
2006						
Heroin	12	3 (25)	464	349 (75)	493	364 (74)
Meth/Amphetamine	53	4 (8)	635	305 (48)	710	319 (45)
More than one	0	(0)	33	23 (70)	34	24 (71)
Other/Not reported	35	11 (31)	583	425 (73)	649	455 (70)
p value		0.010		<0.001		<0.001
2007						
Heroin	21	6 (29)	517	359 (69)	545	371 (68)
Meth/Amphetamine	52	10 (19)	460	244 (53)	524	265 (51)
More than one	2	0 (0.0)	37	19 (51)	48	22 (46)
Other/Not reported	21	3 (14)	598	415 (69)	639	433 (68)
p value		0.706		<0.001		<0.001

* Total includes people who did not report duration of drug injection

National

Table 26 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	99	17 (17)	930	539 (58)	1052	566 (54)
Daily or more	76	22 (29)	1018	696 (68)	1115	734 (66)
p value		0.06		<0.001		<0.001
2004						
Less than daily	55	15 (27)	718	425 (59)	785	447 (57)
Daily or more	67	18 (27)	819	550 (67)	897	578 (64)
p value		0.9		0.001		0.002
2005						
Less than daily	77	20 (26)	626	384 (61)	732	421 (58)
Daily or more	48	23 (48)	734	491 (67)	824	542 (66)
p value		0.01		0.03		0.001
2006						
Less than daily	51	4 (8)	740	463 (63)	812	476 (59)
Daily or more	39	11 (28)	801	526 (66)	881	566 (64)
p value		0.611		<0.001		<0.001
2007						
Less than daily	54	8 (15)	687	443 (64)	753	463 (61)
Daily or more	36	8 (22)	768	499 (65)	826	525 (64)
p value		0.408		0.869		0.405

* Total includes people who did not report duration of drug injection

Table 27 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	148	33 (22)	1604	988 (62)	1789	1042 (58)
Yes	20	5 (25)	291	214 (74)	317	224 (71)
p value		0.8		<0.001		<0.001
2004						
No	92	21 (23)	1218	755 (62)	1331	791 (59)
Yes	26	11 (42)	276	189 (68)	304	202 (66)
p value		0.05		0.04		0.02
2005						
No	94	32 (34)	1111	700 (63)	1265	769 (61)
Yes	16	7 (44)	173	124 (72)	198	137 (69)
p value		0.5		0.03		0.02
2006						
No	77	13 (17)	1262	791 (63)	1378	824 (60)
Yes	10	1 (10)	220	156 (71)	248	171 (69)
p value		1.000		0.019		0.007
2007						
No	73	12 (16)	1176	754 (64)	1271	785 (62)
Yes	13	4 (31)	215	145 (67)	235	156 (66)
p value		0.405		0.394		0.187

* Total includes people who did not report duration of drug injection

Table 28 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	174	37 (21)	1743	1050 (60)	1985	1108 (56)
Yes	25	6 (24)	360	261 (73)	396	277 (70)
p value		0.8		<0.001		<0.001
2004						
No	116	29 (25)	1323	774 (59)	1465	815 (56)
Yes	16	5 (31)	317	250 (79)	342	264 (77)
p value		0.6		<0.001		<0.001
2005						
No	124	33 (27)	1205	743 (62)	1386	805 (58)
Yes	13	9 (69)	210	162 (77)	241	187 (78)
p value		<0.001		0.002		<0.001
2006						
No	90	16 (18)	1412	860 (61)	1558	906 (58)
Yes	7	2 (29)	224	176 (79)	240	184 (77)
2007						
No	88	16 (18)	1315	816 (62)	1439	855 (59)
Yes	3	2 (67)	226	170 (75)	238	181 (76)
p value		0.099		0 (0.0)		0 (0.0)

* Total includes people who did not report duration of drug injection

Table 29 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	183	40 (22)	1911	1171 (61)	2165	1236 (57)
Yes	15	3 (20)	158	120 (76)	179	129 (72)
p value		0.9		<0.001		<0.001
2004						
No	124	30 (24)	1466	900 (61)	1625	949 (58)
Yes	7	4 (57)	153	111 (73)	161	116 (72)
p value		0.07		0.007		0.001
2005						
No	140	43 (31)	1345	856 (64)	1555	941 (61)
Yes	2	2 (100)	93	69 (74)	102	76 (75)
p value		0.04		0.04		0.005
2006						
No	90	17 (19)	1515	964 (64)	1699	1017 (61)
Yes	5	1 (20)	114	75 (66)	121	77 (64)
p value		1.000		0.687		0.629
2007						
No	82	16 (20)	1452	938 (65)	1573	983 (62)
Yes	7	2 (29)	98	63 (64)	110	68 (62)
p value		0.626		1.000		0.919

* Total includes people who did not report duration of drug injection

Table 30 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	1452	820 (56)	687	417 (61)	2158	1248 (58)
Yes	106	67 (63)	84	52 (62)	194	122 (63)
p value		0.2		0.8		0.2
2004						
No	1103	640 (58)	524	320 (61)	1639	966 (59)
Yes	88	58 (66)	58	41 (71)	148	100 (68)
p value		0.1		0.2		0.04
2005						
No	950	576 (61)	521	313 (60)	1479	894 (60)
Yes	95	63 (66)	72	56 (78)	168	120 (71)
p value		0.3		0.003		0.006
2006						
No	1069	639 (60)	553	339 (61)	1631	981 (60)
Yes	108	69 (64)	87	68 (78)	196	138 (70)
p value		0.471		0.003		0.003
2007						
No	998	599 (60)	523	333 (64)	1530	939 (61)
Yes	112	80 (71)	73	48 (66)	187	129 (69)
p value		0.019		0.795		0.046

* Total includes people whose gender was not reported or reported as transgender

Table 31 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	1270	707 (56)	670	402 (60)	1962	1123 (57)
Other Oceania	51	29 (57)	39	27 (69)	91	56 (62)
Asia	124	86 (69)	21	15 (71)	145	101 (70)
UK & Ireland	76	41 (54)	33	21 (64)	110	63 (57)
Other	64	40 (63)	24	14 (58)	88	54 (61)
p value		0.05		0.6		0.05
2004						
Australia	946	532 (56)	501	309 (62)	1458	846 (58)
Other Oceania	29	16 (55)	27	18 (67)	56	34 (61)
Asia	120	88 (73)	19	10 (53)	139	98 (71)
UK & Ireland	59	37 (63)	23	15 (65)	82	52 (63)
Other	46	26 (57)	22	15 (68)	70	42 (60)
p value		0.009		0.8		0.07
2005						
Australia	914	551 (60)	539	331 (61)	1460	887 (61)
Other Oceania	31	14 (45)	14	9 (64)	47	24 (51)
Asia	10	4 (40)	4	1 (25)	14	5 (36)
UK & Ireland	61	46 (75)	32	22 (69)	93	68 (73)
Other	53	37 (70)	15	10 (67)	68	47 (69)
p value		0.01		0.5		0.01
2006						
Australia	1021	613 (60)	573	366 (64)	1602	984 (61)
Other Oceania	38	20 (53)	23	17 (74)	62	37 (60)
Asia	11	6 (55)	4	2 (50)	15	8 (53)
UK & Ireland	73	49 (67)	30	19 (63)	104	68 (65)
Other	48	28 (58)	20	9 (45)	69	37 (54)
p value		0.651		0.336		0.559
2007						
Australia	975	592 (61)	526	334 (64)	1511	934 (62)
Other Oceania	24	16 (67)	17	9 (53)	42	25 (60)
Asia	12	9 (75)	8	6 (75)	20	15 (75)
UK & Ireland	53	33 (62)	28	20 (71)	81	53 (65)
Other	50	31 (62)	19	14 (74)	69	45 (65)
p value		0.880		0.631		0.715

* Total includes people whose gender was not reported or reported as transgender

National

Table 32 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	1307	737 (56)	721	435 (60)	2051	1186 (58)
Non-English speaking	215	133 (62)	47	29 (62)	263	163 (62)
p value		0.1		0.9		0.2
2004						
English speaking	758	431 (57)	456	281 (62)	1224	715 (58)
Non-English speaking	163	109 (67)	44	25 (57)	207	134 (65)
p value		0.02		0.5		0.09
2005						
English speaking	892	546 (61)	544	333 (61)	1443	884 (61)
Non-English speaking	184	111 (60)	65	44 (68)	251	156 (62)
p value		0.8		0.3		0.8
2006						
English speaking	1058	643 (61)	607	391 (64)	1675	1039 (62)
Non-English speaking	83	45 (54)	27	14 (52)	112	60 (54)
p value		0.246		0.219		0.088
2007						
English speaking	1048	642 (61)	576	369 (64)	1634	1018 (62)
Non-English speaking	68	41 (60)	26	17 (65)	95	59 (62)
p value		0.898		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Australian Capital Territory 2003 – 2007

Table 33 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	1	1	1	1	1
N° surveyed	N = 60	N=28	N=39	N=52	N=22
Response (%)	58	---	70	---	---
Gender (%)					
Male	41 (68)	23 (82)	30 (77)	31 (60)	12 (55)
Female	19 (32)	5 (18)	9 (23)	20 (39)	10 (45)
Transgender	---	---	---	1 (2)	---
Not reported	---	---	---	---	---
Sexual identity (%)					
Heterosexual	43 (72)	23 (82)	33 (85)	44 (85)	19 (86)
Bisexual	7 (12)	1 (4)	2 (5)	7 (13)	1 (5)
Homosexual	5 (8)	2 (7)	1 (3)	1 (2)	2 (9)
Not reported	5 (8)	2 (7)	3 (8)	---	---
Age and duration of injection (years)					
<i>Median age</i>	33.5	34	36	33	29.5
<i>Age range</i>	18-58	17-50	15-57	15-60	17-61
<i>Age group (%)</i>					
<25 years	10 (17)	5 (18)	6 (15)	7 (13)	5 (23)
25+ years	50 (83)	23 (82)	33 (85)	44 (85)	17 (77)
Not reported	---	---	--	1 (2)	---
<i>Median age 1st IDU</i>	18	18	17	17	16
<i>Age range</i>	8-40	14-45	11-28	12-39	12-33
Not reported	1	1	9	2	1
<i>Median years IDU</i>	12	14	18	13	11
<i>Range</i>	<1-44	<1-35	<1-32	<1-45	2-47
<i>Duration of drug injection (%)</i>					
<3 years	3 (5)	3 (11)	1 (3)	2 (4)	1 (5)
3+ years	56 (93)	24 (86)	38 (97)	48 (92)	20 (91)
Not reported	1 (2)	1 (3)	--	2 (4)	1 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	56 (93)	23 (82)	31 (79)	49 (94)	21 (95)
Yes	4 (7)	3 (11)	7 (18)	3 (6)	---
Not reported	---	2 (7)	1 (3)	---	1 (5)
Region/Country of birth (%)					
Australia	52 (87)	26 (92)	32 (82)	43 (83)	18 (82)
Other Oceania	---	---	1 (3)	2 (4)	---
Asia	3 (5)	1 (4)	1 (3)	1 (2)	1 (5)
UK & Ireland	4 (7)	1 (4)	2 (5)	1 (2)	2 (9)
Other	1 (1)	---	3 (8)	4 (8)	1 (5)
Not reported	---	---	---	1 (2)	---
Main language spoken at home by parents (%)					
English speaking	59 (98)	23 (82)	30 (77)	42 (81)	20 (91)
Non-English speaking	1 (2)	---	9 (23)	7 (13)	2 (9)
Not reported	---	5 (18)	---	3 (6)	---
Imprisonment last year (%)					
No	49 (82)	22 (79)	33 (85)	44 (85)	19 (86)
Yes	11 (18)	6 (21)	4 (10)	7 (13)	2 (9)
Not reported	---	---	2 (5)	1 (2)	1 (5)
Injected in prison (%)	N = 11	N = 6	N=4	N=7	N=2
Yes	1 (9)	2 (33)	2 (50)	4 (57)	1 (50)
Frequency of injection last month (%)					
Not last month	1 (2)	1 (3)	8 (21)	7 (13)	3 (14)
Less than weekly	11 (18)	8 (29)	4 (10)	13 (25)	1 (5)
Weekly not daily	14 (23)	5 (18)	15 (38)	19 (37)	9 (41)
Daily or more	34 (57)	12 (43)	12 (31)	13 (25)	8 (36)
Not reported	---	2 (7)	---	---	1 (5)

ACT

Table 34 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 60	N=28	N=39	N=52	N=22
Anabolic steroids	---	---	---	---	---
Cocaine	3 (5)	---	---	---	---
Heroin	30 (50)	14 (50)	14 (36)	20 (38)	9 (41)
Methadone	5 (8)	4 (14)	3 (8)	6 (12)	---
Meth/Amphetamine	17 (28)	9 (32)	10 (26)	21 (40)	9 (41)
Morphine/Other Opioids	---	---	2 (5)	1 (2)	1 (5)
Subutex/Buprenorphine	1 (2)	---	---	3 (6)	2 (9)
More than one	2 (3)	---	2 (5)	---	1 (5)
Other drug	2 (3)	1 (4)	---	1 (2)	---
Not reported	---	---	8 (20)	---	---
N° Injected last month	N = 59	N = 25	N=31	N=45	N=18
Places injected last month (%)*					
Own home	50 (85)	17 (68)	20 (65)	35 (81)	16 (94)
Friend's home	37 (63)	13 (52)	11 (35)	20 (47)	11 (65)
Dealer's home	14 (24)	7 (28)	6 (19)	14 (33)	8 (47)
Street, park, beach	27 (46)	6 (24)	9 (29)	11 (26)	8 (47)
Car	30 (51)	8 (32)	11 (35)	20 (47)	8 (47)
Public toilet	31 (53)	12 (48)	11 (35)	16 (37)	9 (53)
Commercial injecting room	1 (2)	---	2 (6)	1 (2)	1 (6)
Squat	7 (12)	4 (16)	6 (19)	8 (19)	2 (12)
Use of new sterile needles & syringes last month (%)					
All injections	40 (68)	17 (68)	19 (61)	32 (71)	9 (50)
Most of the time	16 (27)	8 (32)	11 (35)	12 (27)	6 (33)
Half of the time	1 (2)	---	---	1 (2)	1 (6)
Some of the time	1 (2)	---	1 (3)	---	1 (6)
Not last month	1 (2)	---	---	---	---
Not reported	---	---	---	---	1 (6)
Re-used another's used needle & syringe last month (%)					
None	41 (70)	20 (80)	25 (81)	35 (78)	9 (50)
Once	7 (12)	2 (8)	1 (3)	3 (7)	3 (17)
Twice	4 (7)	1 (4)	---	---	1 (6)
3-5 times	2 (3)	1 (4)	---	3 (7)	2 (11)
>5 times	3 (5)	---	---	3 (7)	2 (11)
Not reported	2 (3)	1 (4)	5 (16)	1 (2)	1 (6)
Number of people needle & syringe was re-used after last month (%)					
None	39 (66)	20 (80)	21 (68)	35 (78)	9 (50)
One	6 (10)	1 (4)	4 (13)	3 (7)	2 (11)
Two	1 (2)	---	---	2 (4)	3 (17)
Three to five	2 (3)	---	---	1 (2)	---
More than five	2 (3)	---	---	1 (2)	---
Don't know	4 (7)	1 (4)	2 (6)	1 (2)	2 (11)
Not reported	5 (9)	3 (12)	4 (13)	2 (4)	2 (11)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	3 (15)	1 (4)	3 (10)	4 (9)	2 (11)
Casual sex partner	1 (5)	---	---	1 (2)	---
Close friend	4 (20)	1 (4)	2 (6)	3 (7)	3 (17)
Acquaintance	3 (15)	---	1 (3)	3 (7)	2 (11)
Other	1 (5)	---	---	---	1 (6)
Equipment used after someone else last month (%)*					
Spoon	26 (44)	11 (44)	10 (32)	17 (40)	6 (35)
Water	14 (24)	7 (28)	9 (29)	12 (28)	9 (53)
Filter	15 (25)	7 (28)	5 (16)	7 (16)	4 (24)
Drug mix	21 (36)	5 (20)	7 (23)	7 (16)	4 (24)
Tourniquet	5 (8)	1 (4)	2 (6)	9 (21)	4 (24)
None**	---	---	---	21 (49)	5 (30)
Injected by someone after that person injected themselves or others last month (%)					
No	53 (90)	18 (72)	21 (68)	37 (82)	10 (56)
Yes	6 (10)	7 (28)	4 (13)	7 (16)	6 (33)
Not reported	---	---	6 (19)	1 (2)	2 (11)

* More than one option could be selected

** New variable in 2006

Table 35 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 60	N=28	N=39	N=52	N=22
Any treatment/therapy for drug use (%)					
No	10 (17)	5 (18)	13 (33)	7 (13)	5 (23)
Yes	50 (83)	23 (82)	25 (64)	45 (87)	17 (77)
Not reported	---	---	1 (3)	---	---
History of methadone maintenance treatment (%)					
Currently	22 (37)	9 (32)	14 (36)	20 (38)	5 (23)
Previously	17 (28)	6 (21)	9 (23)	11 (21)	9 (41)
Never	21 (35)	12 (43)	15 (38)	21 (40)	8 (36)
Not reported	---	1 (4)	1 (3)	---	---
History of other pharmacotherapy treatment (%)					
Currently	5 (8)	3 (11)	4 (10)	6 (12)	4 (18)
Previously	10 (17)	4 (14)	6 (15)	17 (33)	6 (27)
Never	45 (75)	21 (75)	27 (69)	29 (56)	12 (55)
Not reported	---	---	2 (5)	---	---

Table 36 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Syringe acquisition	2003	2004	2005	2006	2007*
N° surveyed	N = 60	N=28	N=39	N=52	---
From an NSP last month (%)					
Daily or almost daily	17 (29)	6 (21)	8 (21)	8 (15)	---
A couple of times each week	18 (30)	11 (39)	7 (18)	23 (44)	---
Less than weekly	14 (23)	3 (11)	8 (21)	10 (19)	---
Once last month	8 (13)	4 (14)	1 (3)	3 (6)	---
Not in the last month	3 (5)	3 (11)	13 (33)	7 (13)	---
Not reported	---	1 (4)	2 (5)	1 (2)	---
From a chemist last month (%)					
Daily or almost daily	4 (6)	---	2 (5)	2 (4)	---
A couple of times each week	6 (10)	5 (18)	2 (5)	1 (2)	---
Less than weekly	10 (17)	4 (14)	5 (13)	11 (21)	---
Once last month	10 (17)	7 (25)	5 (13)	11 (21)	---
Not in the last month	30 (50)	11 (39)	23 (59)	23 (44)	---
Not reported	---	1 (4)	2 (5)	4 (2)	---

* Not asked in this form in 2007, see Table 39.

Table 37 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N ^o surveyed	N = 60	N=28	N=39	N=52	N=22
Sex last month (%) †					
No	22 (37)	13 (46)	--	--	--
Yes	37 (62)	14 (50)	--	--	--
Not reported	1 (1)	1 (4)	--	--	--
Condom use at last sex (%)†					
No	39 (65)	23 (82)	--	--	--
Yes	20 (33)	5 (18)	--	--	--
Not reported	1 (2)	---	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	14 (67)	5 (72)	--	--	--
Sometimes	2 (9)	1 (14)	--	--	--
Always	5 (24)	1 (14)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	7 (39)	2 (50)	--	--	--
Sometimes	4 (22)	1 (25)	--	--	--
Always	7 (39)	1 (25)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	7 (44)	5 (71)	--	--	--
Sometimes	3 (19)	2 (29)	--	--	--
Always	6 (37)	---	--	--	--
Duration of regular sexual relationship (%)** †					
One month	1 (4)	1 (11)	--	--	--
2 - 6 months	1 (4)	1 (11)	--	--	--
6 - 12 months	1 (4)	1 (11)	--	--	--
>12 months	21 (88)	6 (67)	--	---	---
Sex with a regular partner last month (%) ****					
No	--	--	19 (49)	30 (58)	11 (50)
Yes	--	--	19 (49)	22 (42)	9 (41)
Not reported	--	--	1 (3)	---	2 (9)
Condom used with regular partner last month (%)****			N=19*****	N=22	N=9
Never	--	--	14 (74)	15 (68)	7 (78)
Sometimes	--	--	2 (11)	1 (5)	2 (22)
Every time	--	--	1 (5)	5 (23)	---
Not reported	--	--	2 (11)	1 (5)	---
Sex with other partner/s last month (%)****					
No	--	--	2 (40)	40 (77)	14 (64)
Yes	--	--	3 (60)	10 (19)	7 (32)
Not reported	--	--	---	2 (4)	1 (5)
Condom used with other partner/s last month (%)****			N=5	N=10	N=7
Never	--	--	6 (15)	4 (40)	3 (43)
Sometimes	--	--	3 (8)	1 (10)	2 (29)
Every time	--	--	1 (3)	4 (40)	2 (29)
Not reported	--	--	29 (74)	1 (10)	---
Sex work last month (%)					
No	54 (90)	26 (93)	38 (97)	47 (90)	20 (91)
Yes	4 (7)	2 (7)	1 (3)	3 (6)	1 (5)
Not reported	2 (3)	---	---	2 (4)	1 (5)
Condom used at last sex work last month (%)**					
Yes	4 (100)	2 (100)	1 (100)	2 (67)	1 (100)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 38 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey

	2003	2004	2005	2006	2007
N° surveyed	N = 60	N=28	N=39	N=52	N=22
Previous HIV test (%)					
Last year	34 (57)	19 (68)	20 (51)	39 (75)	13 (59)
> 1 year ago	22 (37)	3 (11)	14 (36)	12 (23)	9 (41)
Never tested	3 (5)	5 (18)	4 (10)	1 (2)	---
Not reported	1 (1)	1 (3)	1 (3)	---	---
HBV infection (%)					
No	32 (53)	18 (64)	25 (64)	36 (70)	16 (73)
Yes	14 (23)	6 (22)	8 (21)	13 (25)	4 (18)
Don't know	13 (22)	4 (14)	6 (15)	3 (6)	2 (9)
Not reported	1 (2)	---	---	---	---
HBV vaccination (%)*					
No	7 (15)	7 (32)	11 (35)	8 (21)	2 (11)
Yes	30 (65)	12 (54)	14 (45)	29 (74)	14 (78)
Don't know	8 (18)	3 (14)	6 (19)	2 (5)	2 (11)
Not reported	1 (2)	---	---	---	---
Previous HCV test (%)					
Last year	39 (65)	17 (61)	24 (62)	38 (73)	12 (55)
> 1 year ago	17 (28)	6 (21)	11 (28)	12	10 (45)
Never tested	4 (7)	5 (18)	2 (5)	1	---
Not reported	---	---	2 (5)	1	---
Any treatment for HCV (%)	N= 37	N = 17	N=21	N=34	N=12
Interferon	1 (3)	---	---	1 (3)	1 (8)
Interferon + Ribavirin	1 (3)	---	1 (5)	1 (3)	---
Other	1 (3)	---	17 (81)	---	---
No treatment	34 (91)	17 (100)	2 (10)	31 (91)	11 (92)
Not reported	---	---	1 (5)	1 (3)	---
Current treatment for HCV	N = 0	N = 0	N=1	N=1	N=0
Interferon	---	---	1	---	---
Interferon+Ribavirin	---	---	---	---	---
Other	---	---	---	1	---

* Number (percentage) among participants not reporting HBV infection

Table 39 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N° surveyed	N=22		
Needle/syringe acquisition at time of survey completion (%)			
No	5 (23)		
Yes	15 (68)		
Not reported	2 (9)		
Source of needles/syringes (%)** N=1490***	In last week	In last month	
Chemist/Pharmacy	10 (48)	12 (57)	
Needle Syringe Program	10 (48)	19 (90)	
Dispensing/Vending Machine	6 (29)	8 (38)	
Friend/Dealer	5 (24)	6 (29)	
Other	1 (5)	1 (5)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=12	1 (8)	11 (92)
Needle Syringe Program	N=19	7 (37)	12 (63)
Dispensing/Vending Machine	N=8	0 (0)	8 (100)
Friend/Dealer	N=6	0 (0)	6 (100)
Other	N=1	0 (0)	1 (100)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 40 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	41	0 (0.0)	19	0 (0.0)	60	0 (0.0)
2004	18	0 (0.0)	5	0 (0.0)	23	0 (0.0)
2005	23	0 (0.0)	7	0 (0.0)	30	0 (0.0)
2006	30	0 (0.0)	18	0 (0.0)	49	0 (0.0)
2007	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
χ^2 trend p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 41 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	41	30 (73)	19	18 (95)	60	48 (80)
2004	18	12 (67)	5	4 (80)	23	16 (70)
2005	24	16 (67)	7	7 (100)	31	23 (74)
2006	29	23 (79)	16	10 (63)	46	33 (72)
2007	10	10 (100)	8	6 (75)	18	16 (89)
χ^2 trend p value		0.171		0.038		0.961

* Total includes people whose gender was not reported or reported as transgender

Table 42 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	33	26 (79)	10	9 (90)	43	35 (81)
Bisexual	2	2 (100)	5	5 (100)	7	7 (100)
Homosexual	4	1 (25)	1	1 (100)	5	2 (40)
p value		0.5		0.7		0.03
2004						
Heterosexual	16	11 (69)	3	2 (67)	19	13 (68)
Bisexual	1	0 (0)	1	0 (100)	1	0 (0)
Homosexual	0	0	1	0 (100)	1	1 (100)
p value		-		-		-
2005						
Heterosexual	20	14 (70)	6	6 (100)	26	20 (77)
Bisexual	1	0 (0)	1	1 (100)	2	1 (50)
Homosexual	1	1 (100)	0	0	1	1 (100)
p value		0.3		-		0.6
2006						
Heterosexual	28	22 (79)	10	7 (70)	38	29 (76)
Bisexual	---	---	6	3 (50)	7	3 (43)
Homosexual	1	1 (100)	---	---	1	1 (100)
p value		1.000		0.607		0.223
2007						
Heterosexual	9	9 (100)	7	5 (71)	16	14 (88)
Bisexual	---	---	1	0 (0)	2	0 (0)
Homosexual	1	1 (100)		1 (100)		1 (100)
p value		---		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 43 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	-	-	2	2 (100)	2	2 (100)
20 – 24	4	2 (50)	4	3 (75)	8	5 (63)
25 – 29	11	8 (73)	2	2 (100)	13	10 (77)
30 + years	26	20 (77)	11	11 (100)	37	31 (84)
p value		0.5		0.3		0.5
2004						
< 20 years	--	--	1	1 (100)	1	1 (100)
20 – 24	2	1 (50)	2	2 (100)	4	3 (75)
25 – 29	2	1 (50)	--	--	2	1 (50)
30 + years	14	10 (71)	2	1 (50)	16	11 (69)
p value		0.7		0.4		0.8
2005						
< 20 years	1	0 (0)	--	---	1	0 (0)
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	2	2 (100)	3	3 (100)	5	5 (100)
30 + years	19	14 (74)	3	3 (100)	22	17 (77)
p value		0.5		0.06		0.6
2006						
< 20 years	---	---	1	0 (0)	1	0 (0)
20 – 24	3	1 (33)	2	1 (50)	5	2 (40)
25 – 29	6	5 (83)	5	3 (60)	11	8 (73)
30 + years	19	16 (85)	8	6 (75)	28	22 (79)
p value		0.144		0.685		0.107
2007						
< 20 years	1	1 (100)	1	1 (100)	2	2 (100)
20 – 24	---	---	3	3 (100)	3	3 (100)
25 – 29	4	4 (100)	2	1 (50)	6	5 (83)
30 + years	5	5 (100)	2	1 (50)	7	6 (86)
p value		---		0.571		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 44 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	2	2 (100)	2	2 (100)	4	4 (100)
3 to 5 years	3	1 (33)	4	4 (100)	7	5 (71)
6 to 10 years	8	5 (63)	5	4 (80)	13	9 (69)
10 + years	28	22 (79)	8	8 (100)	36	30 (83)
p value		<0.001		<0.001		<0.001
2004						
<3 years	2	1 (50)	1	1 (100)	3	2 (67)
3 to 5 years	-	-	1	0 (0)	1	0 (0)
6 to 10 years	2	1 (50)	2	2 (100)	4	3 (75)
10 + years	14	10 (71)	1	1 (100)	15	11 (73)
p value		<0.001		<0.001		<0.001
2005						
<3 years	8	1 (13)	-	-	8	1 (13)
3 to 5 years	-	-	-	-	-	-
6 to 10 years	-	-	1	1 (100)	1	1 (100)
10 + years	16	15 (94)	6	6 (100)	22	21 (95)
p value						
2006						
<3 years	---	---	1	0 (0)	1	0 (0)
3 to 5 years	1	0 (0)	1	1 (100)	2	1 (50)
6 to 10 years	9	7 (78)	6	3 (50)	15	10 (67)
10 + years	17	14 (82)	8	6 (75)	26	20 (70)
p value		0.329		0.519		0.263
2007						
<3 years	1	1 (100)	---	---	1	1 (100)
3 to 5 years	---	---	2	2 (100)	2	2 (100)
6 to 10 years	3	3 (100)	2	2 (100)	5	5 (100)
10 + years	6	6 (100)	3	1 (33)	9	7 (78)
p value		---		0.238		0.669

* Total includes people whose gender was not reported or reported as transgender

Table 45 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	3	3 (100)	27	22 (81)	30	25 (83)
Meth/Amphetamine	-	-	17	14 (82)	17	14 (82)
More than one	-	-	2	1 (50)	2	1 (50)
Other/Not reported	1	1 (100)	10	7 (70)	11	8 (73)
p value		0.5		<0.001		<0.001
2004						
Heroin	-	-	12	9 (75)	12	9 (75)
Meth/Amphetamine	2	1 (50)	4	2 (50)	6	3 (50)
More than one	-	-	-	-	-	-
Other/Not reported	1	1 (100)	4	3 (75)	5	4 (80)
p value		0.4		<0.001		<0.001
2005						
Meth/Amphetamine	2	0 (0)	8	7 (88)	10	7 (70)
Heroin	---	---	14	14 (100)	14	14 (100)
More than one	---	---	2	2 (100)	2	2 (100)
Other/Not reported	8	1 (13)	5	5 (100)	13	6 (46)
p value		1.000		0.517		0.005
2006						
Heroin	---	---	16	13 (81)	17	14 (82)
Meth/Amphetamine	1	0 (0)	18	10 (56)	20	11 (55)
More than one	---	---	---	---	---	---
Other/Not reported	---	---	9	8 (89)	9	8 (9)
p value		---		0.164		0.116
2007						
Heroin	---	---	7	5 (71)	7	5 (71)
Meth/Amphetamine	1	1 (100)	6	6 (100)	8	8 (100)
More than one	---	---	---	---	---	---
Other/Not reported	---	---	3	3 (100)	3	3 (100)
p value		---		0.650		0.294

* Total includes people who did not report duration of drug injection

Table 46 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	---	---	26	18 (69)	26	18 (69)
Daily or more	4	4 (100)	30	26 (87)	34	30 (88)
p value		---		0.1		0.07
2004						
Less than daily	---	---	10	7 (70)	10	7 (70)
Daily or more	2	1 (50)	9	6 (67)	11	7 (64)
p value		---		0.9		0.8
2005						
Less than daily	8	1 (13)	14	13 (93)	22	14 (64)
Daily or more	---	---	9	9 (100)	9	9 (100)
p value		---		0.4		0.04
2006						
Less than daily	---	---	28	22 (79)	30	24 (80)
Daily or more	1	0 (0)	9	4 (44)	10	4 (40)
p value		---		0.091		0.041
2007						
Less than daily	1	1 (100)	7	6 (86)	8	7 (88)
Daily or more	--	---	6	5 (83)	7	6 (86)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 47 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	2	2 (100)	39	29 (74)	41	31 (76)
Yes	2	2 (100)	14	12 (86)	16	14 (88)
p value				0.4		0.3
2004						
No	2	1 (50)	14	10 (71)	16	11 (69)
Yes	-	-	3	2 (67)	3	2 (67)
p value		-		0.9		0.9
2005						
No	-	-	18	17 (94)	18	17 (94)
Yes	-	-	1	1 (100)	1	1 (100)
p value		-		0.8		0.8
2006						
No	---	---	31	23 (74)	32	24 (75)
Yes	1	0 (0)	6	3 (50)	7	3 (43)
p value		---		0.335		0.172
2007						
No	1	1 (100)	7	5 (71)	8	6 (75)
Yes	---	---	5	5 (100)	6	6 (100)
p value		---		0.470		0.473

* Total includes people who did not report duration of drug injection

Table 48 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	3	3 (100)	46	36 (78)	49	39 (80)
Yes	1	1 (100)	10	8 (80)	11	9 (82)
p value				0.9		0.9
2004						
No	3	2 (67)	14	9 (64)	17	11 (65)
Yes	-	-	6	5 (83)	6	5 (83)
p value				0.4		0.4
2005						
No	6	1 (17)	21	20 (95)	27	21 (78)
Yes	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.7		0.8		0.4
2006						
No	1	0 (0)	37	26 (70)	39	27 (69)
Yes	---	---	6	5 (83)	6	5 (83)
p value		---		0.659		0.656
2007						
No	1	1 (100)	14	12 (86)	16	14 (88)
Yes	---	---	2	2 (100)	2	2 (100)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 49 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	3	1 (100)	51	39 (76)	54	42 (78)
Yes	1	1 (100)	3	3 (100)	4	4 (100)
p value		-		0.3		0.3
2004						
No	2	1 (50)	19	13 (68)	21	14 (67)
Yes	1	1 (100)	1	1 (100)	2	2 (100)
p value		0.4		0.5		0.3
2005						
No	8	1 (13)	23	22 (96)	31	23 (74)
Yes	-	-	-	-	-	-
p value						
2006						
No	1	0 (0)	39	31 (79)	41	32 (78)
Yes	---	---	3	0 (0)	3	3 (100)
p value		---		0.014		0.017
2007						
No	1	1 (100)	15	13 (87)	17	15 (88)
Yes	---	---	---	---	---	---
p value		---		---		---

* Total includes people who did not report duration of drug injection

Table 50 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	38	29 (76)	18	17 (94)	56	46 (82)
Yes	3	1 (33)	1	1 (100)	4	2 (50)
p value		0.1		0.8		0.1
2004						
No	16	10 (63)	3	2 (67)	19	12 (63)
Yes	1	1 (100)	2	2 (100)	3	3 (100)
p value		0.2		0.3		0.4
2005						
No	18	13 (72)	6	6 (100)	24	19 (79)
Yes	5	3 (60)	1	1 (100)	6	4 (67)
p value		0.3		0.003		0.006
2006						
No	27	21 (78)	15	9 (60)	43	30 (70)
Yes	2	2 (100)	1	1 (100)	3	3 (100)
p value		1.000		1.000		0.548
2007						
No	10	10 (100)	7	6 (86)	17	16 (94)
Yes	---	---	---	---	---	---
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 51 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	37	27 (73)	15	15 (100)	52	42 (81)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	1	1 (100)
UK & Ireland	3	3 (100)	1	1 (100)	4	4 (100)
Other	1	0 (0)	1	1 (100)	3	1 (33)
p value		0.1		0.03		0.1
2004						
Australia	16	11 (69)	5	4 (80)	21	15(71)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	2	1 (50)	---	---	2	1 (50)
p value		0.009		---		---
2005						
Australia	20	14 (70)	6	6 (100)	26	20 (77)
Other Oceania	---	---	---	---	---	---
Asia	1	0 (0)	---	---	1	0 (0)
UK & Ireland	---	---	1	1 (100)	1	1 (100)
Other	3	2 (67)	---	---	3	2 (67)
p value		0.3		---		0.3
2006						
Australia	27	21 (78)	13	10 (77)	40	31 (78)
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)
Asia	---	---	---	---	---	---
UK & Ireland	---	---	1	0 (0)	1	1 (100)
Other	---	---	1	0 (0)	2	0 (0)
p value		1.000		0.036		0.020
2007						
Australia	10	10 (100)	6	5 (83)	16	15 (94)
Other Oceania	---	---	---	---	---	---
Asia	---	---	1	1 (100)	1	1 (100)
UK & Ireland	---	---	1	0 (0)	1	0 (0)
Other	---	---	---	---	---	---
p value		---		0.464		0.216

* Total includes people whose gender was not reported or reported as transgender

Table 52 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	41	30 (73)	18	17 (94)	59	47 (80)
Non-English speaking	---	---	1	1 (100)	1	1 (100)
p value		---		0.8		0.6
2004						
English speaking	15	10 (67)	4	3 (75)	19	13 (68)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---
2005						
English speaking	17	13 (76)	7	7 (100)	24	20 (83)
Non-English speaking	7	3 (43)	---	---	7	3 (43)
p value		0.1		---		0.03
2006						
English speaking	23	20 (87)	15	10 (67)	38	30 (79)
Non-English speaking	3	1 (33)	1	0 (0)	5	1 (20)
p value		0.085		0.375		0.017
2007						
English speaking	10	10 (100)	8	6 (75)	18	16 (89)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

**New South Wales
2003 – 2007**

Table 53 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	19	17	23	21	21
N° surveyed	N = 785	N = 646	N = 729	N=683	N=701
Response (%)	39	40	41	37	35
Gender (%)					
Male	543 (69)	436 (67)	464 (64)	434 (64)	450 (64)
Female	233 (30)	205 (32)	259 (36)	242 (35)	247 (35)
Transgender	4 (<1)	2 (<1)	6 (1)	6 (<1)	3 (<1)
Not reported	5 (<1)	3 (<1)	0	1 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	610 (78)	523 (81)	590 (81)	553 (81)	575 (82)
Bisexual	66 (8)	49 (8)	58 (8)	65 (10)	64 (9)
Homosexual	38 (5)	27 (4)	48 (7)	45 (7)	45 (6)
Not reported	71 (9)	47 (7)	33 (5)	20 (3)	17 (2)
Age and duration of injection (years)					
<i>Median age</i>	32	33	34	36	37
<i>Age range</i>	15 - 64	16 - 65	17-66	15-65	16-69
<i>Age group (%)</i>					
<25 years	163 (21)	106 (16)	89 (12)	61 (9)	59 (8)
25+ years	622 (79)	539 (83)	640 (88)	619 (91)	642 (92)
Not reported	0	1 (<1)	0	3 (<1)	---
<i>Median age 1stIDU</i>	18	18	18	18	18
<i>Age range</i>	8 - 50	5 - 50	9-55	10-52	10-56
N° not reported	21	14	26	3	21
<i>Median years IDU</i>	11	12	13	15	16
<i>Range</i>	<1 - 45	<1 - 45	<1-46	<1-43	<1-49
<i>Duration of drug injection (%)</i>					
<3 years	74 (9)	47 (7)	60 (8)	31 (5)	23 (3)
<3+ years	690 (88)	585 (91)	642 (88)	625 (92)	657 (94)
Not reported	21 (3)	14 (2)	27 (4)	27 (4)	21 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	677 (86)	546 (84)	590 (81)	571 (84)	575 (82)
Yes	91 (12)	81 (13)	115 (16)	87 (13)	105 (15)
Not reported	17 (2)	19 (3)	24 (3)	25 (4)	21 (3)
Region/Country of birth (%)					
Australia	547 (70)	454 (70)	628 (86)	575 (84)	592 (84)
Other Oceania	33 (4)	16 (2)	25 (3)	29 (4)	18 (3)
Asia	131 (17)	114 (18)	4 (1)	5 (<1)	10 (1)
UK & Ireland	27 (3)	17 (3)	31 (4)	35 (5)	26 (4)
Other	42 (5)	31 (5)	33 (5)	28 (4)	38 (5)
Not reported	5 (1)	14 (2)	8 (1)	11 (2)	17 (2)
Main language spoken at home by parents (%)					
English speaking	553 (70)	344 (53)	629 (86)	593 (87)	648 (92)
Non-English speaking	197 (25)	143 (22)	100 (14)	60 (9)	37 (5)
Not reported	35 (4)	159 (25)	0	30 (4)	16 (2)
Imprisonment last year (%)*					
No	599 (76)	493 (76)	568 (78)	556 (81)	566 (81)
Yes	169 (22)	148 (23)	130 (18)	94 (14)	103 (15)
Not reported	17 (2)	5 (1)	31 (4)	33 (5)	32 (5)
Injected in prison (%)					
Yes	N = 169	N = 148	N=130	N=94	N=103
	60 (36)	67 (45)	38 (29)	40 (43)	37 (36)
Frequency of injection last month (%)					
Not last month	84 (11)	40 (6)	71 (10)	88 (13)	81 (12)
Less than weekly	160 (20)	118 (18)	121 (17)	131 (19)	136 (19)
Weekly not daily	168 (21)	167 (26)	176 (24)	169 (25)	167 (24)
Daily or more	359 (46)	312 (48)	357 (49)	285 (42)	298 (43)
Not reported	14 (2)	9 (2)	4 (1)	10 (1)	19 (3)

Table 54 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 785	N = 646	N=729	N=683	N=701
Anabolic steroids	37 (5)	11 (2)	20 (3)	16 (2)	12 (2)
Cocaine	17 (2)	41 (6)	45 (6)	36 (5)	30 (4)
Heroin	416 (53)	320 (50)	296 (41)	231 (34)	254 (36)
Methadone	66 (8)	50 (8)	105 (14)	96 (14)	88 (13)
Meth/Amphetamine	140 (18)	148 (23)	183 (25)	197 (29)	185 (26)
Morphine/Other Opioids	16 (2)	21 (3)	24 (3)	49 (7)	57 (8)
Subutex/Buprenorphine	1 (<1)	3 (<1)	2 (<1)	16 (2)	20 (3)
More than one	47 (6)	33 (5)	11 (2)	9 (<1)	26 (4)
Other	11 (1)	6 (1)	5 (<1)	4 (<1)	18 (3)
Not reported	14 (2)	7 (1)	25 (3)	20 (3)	11 (2)
N° Injected last month	N = 687	N = 597	N=654	N=585	N=601
Places injected last month (%)*					
Own home	522 (76)	474 (79)	520 (80)	506 (90)	517 (88)
Friend's home	239 (35)	201 (34)	228 (35)	219 (39)	226 (39)
Dealer's home	85 (12)	68 (11)	100 (15)	84 (15)	101 (17)
Street, park, beach	177 (26)	129 (22)	160 (24)	126 (22)	143 (24)
Car	170 (25)	136 (23)	157 (24)	144 (26)	159 (27)
Public toilet	137 (20)	110 (18)	134 (20)	110 (20)	137 (23)
Commercial injecting room	63 (9)	29 (5)	42 (6)	38 (7)	39 (7)
Squat	55 (8)	35 (6)	24 (4)	41 (7)	39 (7)
MSIC	30 (4)	43 (7)	42 (6)	59 (11)	62 (11)
Use of new sterile needles & syringes last month (%)					
All injections	509 (74)	416 (70)	472 (72)	407 (70)	431 (72)
Most of the time	138 (20)	137 (23)	146 (22)	129 (22)	130 (22)
Half of the time	13 (2)	10 (2)	15 (2)	12 (2)	17 (3)
Some of the time	12 (2)	18 (3)	6 (1)	10 (2)	9 (2)
Not last month	4 (<1)	4 (<1)	1 (<1)	11 (2)	---
Not reported	11 (1)	12 (2)	14 (2)	16 (3)	14 (2)
Re-used another's used needle & syringe last month (%)					
None	561 (82)	473 (79)	532 (82)	477 (82)	485 (81)
Once	39 (6)	41 (7)	26 (4)	31 (5)	42 (7)
Twice	23 (3)	28 (5)	24 (4)	20 (3)	19 (3)
3-5 times	29 (4)	27 (4)	26 (4)	17 (3)	17 (3)
>5 times	14 (2)	10 (2)	16 (2)	14 (2)	6 (1)
Not reported	21 (3)	18 (3)	28 (4)	26 (4)	32 (5)
Number of people needle & syringe was re-used after last month (%)					
None	551 (80)	473 (79)	504 (77)	477 (82)	485 (81)
One	66 (10)	58 (10)	65 (10)	43 (7)	42 (7)
Two	7 (1)	10 (2)	5 (1)	7 (1)	7 (1)
Three to five	8 (1)	3 (<1)	5 (1)	2 (<1)	5 (<1)
More than five	5 (<1)	3 (<1)	3 (<1)	2 (<1)	2 (<1)
Don't know	9 (1)	13 (2)	28 (4)	16 (3)	12 (2)
Not reported	41 (6)	37 (6)	44 (7)	38 (7)	48 (8)
Relationship to people needle & syringe was re-used after last month* (%)					
Regular sex partner	50 (7)	43 (7)	60 (9)	30 (5)	36 (6)
Casual sex partner	7 (1)	4 (1)	3 (<1)	5 (<1)	2 (<1)
Close friend	31 (5)	24 (4)	29 (4)	15 (3)	27 (4)
Acquaintance	13 (2)	16 (3)	10 (2)	12 (2)	12 (2)
Other	6 (1)	6 (1)	4 (1)	4 (<1)	4 (<1)
Equipment used after someone else last month (%)*					
Spoon	211 (31)	181 (30)	152 (23)	114 (20)	134 (25)
Water	147 (21)	125 (21)	107 (16)	68 (12)	101 (19)
Filter	121 (18)	89 (15)	66 (10)	36 (6)	62 (11)
Drug mix	87 (13)	59 (10)	67 (10)	45 (8)	45 (8)
Tourniquet	70 (10)	67 (11)	71 (11)	47 (8)	58 (11)
None**	---	---	---	358 (62)	353 (65)
Injected by someone after that person injected themselves or others last month (%)					
No	574 (84)	502 (84)	528 (81)	497 (85)	494 (82)
Yes	92 (13)	72 (12)	87 (13)	60 (10)	77 (13)
Not reported	21 (3)	23 (4)	41 (6)	28 (5)	30 (5)

* More than one option could be selected

** New variable in 2006

Table 55 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 785	N = 646	N=729	N=683	N=701
Any treatment/therapy for drug use (%)					
No	208 (27)	80 (12)	123 (17)	97 (14)	106 (15)
Yes	575 (73)	555 (86)	599 (82)	565 (82)	578 (82)
Not reported	2 (<1)	11 (2)	7 (1)	21 (3)	17 (2)
History of methadone maintenance treatment (%)					
Currently	331 (42)	285 (44)	320 (44)	298 (44)	286 (41)
Previously	173 (22)	153 (24)	153 (21)	169 (25)	182 (26)
Never	279 (35)	198 (31)	250 (34)	201 (29)	218 (31)
Not reported	2 (<1)	10 (1)	6 (1)	15 (2)	15 (2)
History of other pharmacotherapy treatment (%)					
Currently	83 (11)	70 (11)	76 (10)	62 (9)	63 (9)
Previously	145 (18)	141 (22)	160 (22)	147 (22)	159 (23)
Never	544 (69)	413 (64)	481 (66)	455 (67)	458 (65)
Not reported	13 (2)	22 (3)	12 (2)	19 (3)	21 (3)

Table 56 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007
N° surveyed	N = 785	N = 646	N=729	N=683	---
From an NSP last month (%)					
Daily or almost daily	115 (15)	85 (13)	117 (16)	77 (11)	---
A couple of times each week	174 (22)	160 (25)	193 (26)	194 (28)	---
Less than weekly	189 (24)	174 (27)	159 (22)	164 (24)	---
Once last month	135 (17)	122 (19)	160 (22)	134 (20)	---
Not in the last month	152 (19)	87 (13)	95 (13)	98 (14)	---
Not reported	20 (3)	18 (3)	5 (1)	16 (2)	---
From a chemist last month (%)					
Daily or almost daily	40 (5)	41 (6)	28 (4)	21 (3)	---
A couple of times each week	77 (10)	59 (9)	61 (8)	57 (8)	---
Less than weekly	110 (14)	95 (15)	63 (9)	83 (12)	---
Once last month	92 (12)	87 (13)	127 (17)	122 (18)	---
Not in the last month	440 (56)	341 (53)	430 (59)	364 (53)	---
Not reported	26 (3)	23 (4)	20 (3)	36 (5)	---

* Not asked in this form in 2007, see Table 59.

Table 57 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N = 785	N = 646	N=729	N=683	N=701
Sex last month (%) †					
No	216 (28)	204 (31)	--	--	--
Yes	558 (71)	431 (67)	--	--	--
Not reported	11 (1)	11 (2)	--	--	--
Condom use at last sex (%)†					
No	504 (64)	413 (64)	--	--	--
Yes	261 (33)	220 (34)	--	--	--
Not reported	20 (3)	13 (2)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	225 (62)	177 (68)	--	--	--
Sometimes	46 (13)	32 (12)	--	--	--
Always	91 (25)	52 (20)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	85 (39)	80 (46)	--	--	--
Sometimes	34 (16)	29 (17)	--	--	--
Always	98 (45)	64 (37)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	108 (47)	63 (39)	--	--	---
Sometimes	33 (14)	31 (19)	--	--	---
Always	91 (39)	68 (42)	--	--	---
Duration of regular sexual relationship (%)** †					
One month	19 (5)	18 (7)	--	--	--
2 - 6 months	41 (11)	27 (10)	--	--	--
6 - 12 months	62 (17)	31 (12)	--	--	--
>12 months	240 (66)	190 (71)	--	--	--
Sex with a regular partner last month (%) ****					
No	--	--	314 (43)	288 (42)	300 (43)
Yes	--	--	397 (54)	376 (55)	375 (54)
Not reported	--	--	18 (2)	19 (3)	26 (4)
Condom used with regular partner last month (%)****			N=397*****	N=376	N=375
Never	--	--	277 (70)	259 (69)	275 (73)
Sometimes	--	--	59 (15)	51 (14)	38 (10)
Every time	--	--	46 (12)	28 (7)	49 (13)
Not reported	--	--	15 (4)	38 (10)	13 (3)
Sex with other partner/s last month (%)****					
No	--	--	583 (80)	525 (77)	570 (81)
Yes	--	--	125 (17)	124 (18)	100 (14)
Not reported	--	--	21 (3)	34 (5)	31 (4)
Condom used with other partner/s last month (%)****			N=125	N=124	N=100
Never	--	--	31 (25)	26 (21)	28 (28)
Sometimes	--	--	34 (27)	38 (31)	17 (17)
Every time	--	--	56 (45)	53 (43)	47 (47)
Not reported	--	--	4 (3)	7 (6)	8 (8)
Sex work last month (%)					
No	693 (88)	568 (88)	660 (91)	586 (86)	618 (88)
Yes	62 (8)	65 (10)	52 (7)	59 (9)	50 (7)
Not reported	30 (4)	13 (2)	17 (2)	38 (6)	33 (5)
Condom used at last sex work last month (%)**					
Yes	50 (89)	59 (94)	72 (94)	49 (88)	47 (98)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 58 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey

	2003	2004	2005	2006	2007
N° surveyed	N = 785	N = 646	N=729	N=683	N=701
Previous HIV test (%)					
Yes, last year	501 (64)	411 (64)	436 (60)	409 (60)	392 (56)
> 1 year ago	199 (25)	176 (27)	226 (31)	199 (29)	228 (33)
Never tested	81 (10)	54 (8)	64 (9)	60 (9)	65 (9)
Not reported	4 (<1)	5 (1)	3 (0)	15 (2)	16 (2)
HBV infection (%)					
No	523 (67)	425 (66)	477 (65)	430 (63)	445 (63)
Yes	187 (24)	148 (23)	151 (21)	150 (22)	162 (23)
Don't know	74 (9)	61 (9)	89 (12)	88 (13)	76 (11)
Not reported	1 (<1)	12 (2)	12 (2)	15 (2)	18 (3)
HBV vaccination (%)*					
No	229 (38)	174 (35)	163 (28)	169 (32)	171 (32)
Yes	305 (51)	267 (54)	315 (55)	277 (52)	290 (54)
Don't know	55 (9)	45 (9)	89 (15)	72 (14)	60 (11)
Not reported	9 (2)	12 (2)	11 (2)	15 (3)	18 (3)
Previous HCV test (%)					
Yes, last year	492 (63)	429 (66)	452 (62)	420 (61)	420 (60)
> 1 year ago	199 (25)	165 (26)	211 (29)	203 (30)	215 (31)
Never tested	90 (11)	45 (7)	64 (9)	47 (7)	52 (7)
Not reported	4 (<1)	7 (1)	2 (0)	13 (2)	14 (2)
Any treatment for HCV (%)	N = 389	N = 341	N=372	N=363	N=344
Interferon	13 (3)	9 (3)	16 (4)	8 (2)	2 (<1)
Interferon+Ribarvarin	3 (1)	7 (2)	3 (1)	9 (2)	10 (3)
Other	5 (1)	13 (4)	4 (1)	8 (2)	4 (1)
No treatment	357 (92)	302 (88)	346 (93)	327 (90)	312 (91)
Not reported	12 (3)	10 (3)	3 (1)	11 (3)	16 (5)
Current treatment for HCV	N = 6	N = 6	N=3	N=7	N=3
Interferon	---	---	2	1	1
Interferon+Ribarvarin	2	3	1	2	1
Other	4	3	---	4	1

* Number (percentage) among participants not reporting HBV infection

Table 59 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N° surveyed	N=701		
Needle/syringe acquisition at time of survey completion (%)			
No	153 (22)		
Yes	496 (71)		
Not reported	52 (7)		
Source of needles/syringes (%)** N=1490***	In last week	In last month	
Chemist/Pharmacy	78 (15)	136 (25)	
Needle Syringe Program	246 (46)	456 (85)	
Dispensing/Vending Machine	95 (18)	129 (24)	
Friend/Dealer	61 (11)	86 (16)	
Other	23 (4)	30 (6)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=136	21 (15)	115 (85)
Needle Syringe Program	N=456	284 (62)	172 (38)
Dispensing/Vending Machine	N=129	23 (18)	106 (82)
Friend/Dealer	N=86	11 (13)	75 (87)
Other	N=30	7 (23)	23 (77)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 60 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	533	12 (2.3)	230	0 (0.0)	772	13 (1.7)
2004	407	6 (1.5)	194	1 (0.5)	606	7 (1.2)
2005	436	6 (1.4)	243	0 (0.0)	685	6 (0.9)
2006	424	12 (2.8)	232	1 (0.4)	663	14 (2.1)
2007	439	12 (2.7)	240	2 (0.8)	683	15 (2.2)
χ^2 trend p value		0.331		0.181		0.222

* Total includes people whose gender was not reported or reported as transgender

Table 61 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heterosexual	460	6 (1.3)	138	0 (0.0)	600	6 (1.0)
Bisexual	16	0 (0)	47	0 (0.0)	65	1 (1.5)
Homosexual	17	6 (35.3)	19	0 (0.0)	37	6 (16.2)
p value		<0.001		---		<0.001
2004						
Heterosexual	345	0 (0.0)	141	1 (0.7)	487	1 (0.2)
Bisexual	15	0 (0.0)	33	0 (0.0)	48	0 (0.0)
Homosexual	14	6 (42.9)	11	0 (0.0)	25	6 (24.0)
p value		<0.001		1.0		<0.001
2005						
Heterosexual	386	1 (0.3)	171	0 (0.0)	557	1 (0.2)
Bisexual	10	0 (0.0)	44	0 (0.0)	55	0 (0.0)
Homosexual	24	5 (20.8)	16	0 (0.0)	44	5 (11.4)
p value		<0.001		---		<0.001
2006						
Heterosexual	366	2 (0.6)	170	1 (0.6)	537	3 (0.6)
Bisexual	23	3 (13.0)	38	0 (0)	64	4 (6.3)
Homosexual	27	7 (25.9)	16	0 (0)	44	7 (15.9)
p value		<0.001		1.000		<0.001
2007						
Heterosexual	383	4 (1.0)	174	2 (1.2)	558	6 (1.1)
Bisexual	21	0 (0.0)	42	0 (0.0)	64	1 (1.6)
Homosexual	25	8 (32.0)	19	0 (0.0)	44	8 (18.2)
p value		<0.001		1.000		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 62 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
< 20 years	19	0 (0.0)	12	0 (0.0)	31	0 (0)
20 – 24	92	3 (3.3)	40	0 (0.0)	132	3 (2.3)
25 – 29	94	1 (1.1)	57	0 (0.0)	152	1 (0.7)
30 + years	328	8 (2.4)	121	0 (0.0)	457	9 (2.0)
p value		0.7		---		0.6
2004						
< 20 years	10	0 (0.0)	6	0 (0.0)	16	0 (0.0)
20 – 24	53	0 (0.0)	30	1 (3.3)	83	1 (1.2)
25 – 29	75	1 (1.3)	38	0 (0.0)	115	1 (0.9)
30 + years	268	5 (1.9)	120	0 (0.0)	391	5 (1.3)
p value		0.9		0.2		1.0
2005						
< 20 years	6	0 (0.0)	5	0 (0.0)	11	0 (0.0)
20 – 24	36	1 (2.8)	34	0 (0.0)	70	1 (1.4)
25 – 29	63	0 (0.0)	57	0 (0.0)	121	0 (0.0)
30 + years	331	5 (1.5)	147	0 (0.0)	483	5 (1.0)
p value		0.7		---		0.7
2006						
< 20 years	3	0 (0)	6	0 (0)	9	0 (0.0)
20 – 24	31	1 (3.2)	19	0 (0)	50	1 (2.0)
25 – 29	67	0 (0)	42	0 (0)	111	1 (0.9)
30 + years	322	11 (3.4)	163	1 (0.6)	490	12 (2.7)
p value		0.353		1.000		0.576
2007						
< 20 years	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
20 – 24	25	0 (0.0)	23	0 (0.0)	48	0 (0.0)
25 – 29	59	3 (5.1)	40	0 (0.0)	100	3 (3.0)
30 + years	352	9 (2.6)	172	2 (1.2)	527	12 (2.3)
p value		0.518		1.000		0.684

* Total includes people whose gender was not reported or reported as transgender

Table 63 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
<3 years	59	2 (3.4)	15	0 (0.0)	74	2 (2.7)
3 to 5 years	77	3 (3.9)	37	0 (0.0)	114	3 (2.6)
6 to 10 years	113	3 (2.7)	62	0 (0.0)	177	4 (2.3)
10 + years	270	4 (1.5)	110	0 (0.0)	386	4 (1.0)
p value		0.6		---		0.5
2004						
<3 years	26	2 (7.7)	17	0 (0.0)	43	2 (4.7)
3 to 5 years	44	0 (0.0)	18	0 (0.0)	62	0 (0.0)
6 to 10 years	106	0 (0.0)	50	0 (0.0)	157	0 (0.0)
10 + years	223	4 (1.8)	107	1 (0.9)	331	5 (1.5)
p value		0.06		1.0		0.07
2005						
<3 years	19	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3 to 5 years	35	2 (5.7)	18	0 (0.0)	53	2 (3.8)
6 to 10 years	42	0 (0.0)	49	0 (0.0)	92	0 (0.0)
10 + years	324	2 (0.6)	157	0 (0.0)	485	2 (0.4)
p value		0.03		---		0.02
2006						
<3 years	19	1 (5.3)	11	0 (0)	30	1 (3.3)
3 to 5 years	27	1 (3.7)	18	0 (0)	45	1 (2.2)
6 to 10 years	67	2 (3.0)	47	1 (2.1)	118	4 (3.4)
10 + years	292	8 (2.7)	149	0 (0)	444	8 (1.8)
p value		0.576		0.338		0.437
2007						
<3 years	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)
3 to 5 years	31	1 (3.2)	19	0 (0.0)	51	1 (1.0)
6 to 10 years	61	0 (0.0)	42	0 (0.0)	104	0 (0.0)
10 + years	326	11 (3.4)	158	2 (1.3)	486	14 (2.9)
p value		0.520		1.000		0.312

* Total includes people whose gender was not reported or reported as transgender

Table 64 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heroin	277	5 (1.8)	126	0 (0.0)	408	6 (1.5)
Meth/Amphetamine	100	4 (4.0)	37	0 (0.0)	138	4 (2.9)
More than one	44	1 (2.3)	21	0 (0.0)	66	1 (1.5)
Other/Not reported	114	2 (1.8)	46	0 (0.0)	162	2 (1.2)
p value		0.8		---		0.8
2004						
Heroin	216	2 (0.9)	86	0 (0.0)	304	2 (0.7)
Meth/Amphetamine	82	3 (3.7)	54	1 (1.9)	136	4 (2.9)
More than one	21	1 (4.8)	10	0 (0.0)	31	1 (3.2)
Other/Not reported	88	0 (0.0)	44	0 (0.0)	135	0 (0.0)
p value		0.09		0.6		0.05
2005						
Heroin	183	2 (1.1)	109	0 (0.0)	286	2 (0.7)
Meth/Amphetamine	101	3 (3.0)	65	0 (0.0)	170	3 (1.8)
More than one	7	0 (0.0)	23	0 (0.0)	11	0 (0.0)
Other/Not reported	146	1 (0.7)	46	0 (0.0)	219	1 (0.5)
p value		0.392		---		0.6
2006						
Heroin	133	2 (1.5)	88	0 (0.0)	223	2 (0.9)
Meth/Amphetamine	124	8 (6.5)	64	0 (0.0)	192	9 (4.7)
More than one	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
Other/Not reported	162	2 (1.2)	76	1 (1.3)	239	3 (1.3)
p value		.057		0.621		0.055
2007						
Heroin	153	4 (2.6)	91	0 (0.0)	246	4 (1.6)
Meth/Amphetamine	109	4 (3.7)	71	1 (1.4)	180	5 (2.8)
More than one	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
Other/Not reported	164	4 (2.4)	73	1 (1.4)	239	6 (2.5)
p value		0.871		0.543		0.762

* Total includes people whose gender was not reported or reported as transgender

****New question in 2005.

Table 65 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Not last month	61	0 (0.0)	22	0 (0.0)	83	0 (0.0)
Less than weekly	119	1 (0.8)	37	0 (0.0)	157	1 (0.6)
Weekly not daily	113	1 (0.9)	49	0 (0.0)	167	2 (1.2)
Daily or more	234	10 (4.3)	115	0 (0.0)	351	10 (2.9)
p value		0.05		---		0.1
2004						
Not last month	22	0 (0.0)	14	0 (0.0)	38	0 (0.0)
Less than weekly	67	0 (0.0)	44	0 (0.0)	111	0 (0.0)
Weekly not daily	100	5 (5.0)	52	0 (0.0)	152	5 (3.3)
Daily or more	212	1 (0.5)	83	1 (1.2)	297	2 (0.7)
p value		0.02		1.0		0.07
2005						
Not last month	208	0 (0.0)	127	0 (0.0)	336	0 (0.0)
Less than weekly	116	3 (2.6)	53	0 (0.0)	171	3 (1.8)
Weekly not daily	68	3 (4.4)	38	0 (0.0)	108	3 (2.8)
Daily or more	43	0 (0.0)	22	0 (0.0)	66	0 (0.0)
p value		0.03		---		0.02
2006						
Not last month	49	1 (2.0)	36	1 (2.8)	86	2 (2.3)
Less than weekly	77	2 (2.6)	50	0 (0.0)	127	2 (1.6)
Weekly not daily	119	6 (5.0)	45	0 (0.0)	166	6 (3.6)
Daily or more	172	3 (1.7)	99	0 (0.0)	275	4 (1.5)
p value		0.433		0.157		0.483
2007						
Not last month	47	2 (4.3)	32	0 (0.0)	80	2 (2.5)
Less than weekly	87	1 (1.2)	47	1 (2.1)	134	2 (1.5)
Weekly not daily	99	3 (3.0)	59	0 (0.0)	161	4 (2.5)
Daily or more	196	6 (3.1)	96	1 (1.0)	292	7 (2.4)
p value		0.713		0.625		0.927

* Total includes people whose gender was not reported or reported as transgender

Table 66 HIV antibody prevalence by re-use of someone else's used needle & syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	380	11 (2.9)	163	0 (0.0)	550	12 (2.2)
Yes	72	1 (1.4)	31	0 (0.0)	104	1 (1.0)
p value		0.5		---		0.4
2004						
No	290	4 (1.4)	152	1 (0.7)	442	5 (1.1)
Yes	77	1 (1.3)	23	0 (0.0)	102	1 (1.0)
p value		1.0		1.0		1.0
2005						
No	321	6 (1.9)	176	0 (0.0)	501	6 (1.2)
Yes	54	0 (0.0)	34	0 (0.0)	89	0 (0.0)
p value		0.3		---		0.3
2006						
No	294	9 (3.1)	166	0 (0)	464	9 (1.9)
Yes	56	2 (3.6)	22	0 (0)	79	3 (3.8)
p value		0.691		---		0.396
2007						
No	306	6 (2.0)	165	2 (1.2)	474	9 (1.9)
Yes	56	4 (7.1)	26	0 (0.0)	82	4 (4.9)
p value		0.053		1.000		0.110

* Total includes people whose gender was not reported or reported as transgender

Table 67 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	387	8 (2.1)	196	0 (0.0)	590	9 (1.5)
Yes	135	4 (3.0)	28	0 (0.0)	165	4 (2.4)
p value		0.6		---		0.4
2004						
No	287	5 (1.7)	167	0 (0.0)	458	5 (1.1)
Yes	117	1 (0.9)	25	1 (4.0)	143	2 (1.4)
p value		0.7		0.1		0.7
2005						
No	327	6 (1.8)	201	0 (0.0)	533	6 (1.1)
Yes	90	0 (0.0)	34	0 (0.0)	125	0 (0.0)
p value		0.2		---		0.2
2006						
No	331	12 (3.6)	200	1 (0.5)	538	14 (2.6)
Yes	66	0 (0.0)	27	0 (0.0)	93	0 (0.0)
p value		0.230		1.000		0.242
2007						
No	342	10 (2.9)	205	2 (1.0)	550	12 (2.2)
Yes	76	2 (2.6)	26	0 (0.0)	102	2 (2.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 68 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	328	7 (2.1)	163	0 (0.0)	496	7 (1.4)
Yes	189	5 (2.7)	63	0 (0.0)	256	6 (2.3)
p value		0.7		---		0.4
2004						
No	251	4 (1.6)	129	1 (0.8)	385	5 (1.3)
Yes	148	2 (1.4)	60	0 (0.0)	208	2 (1.0)
p value		1.0		1.0		1.0
2005**						
No	164	0 (0.0)	113	0 (0.0)	277	0 (0.0)
Yes	84	2 (2.4)	39	0 (0.0)	125	2 (1.6)
p value		0.05		---		0.04
2006						
No	190	2 (1.1)	113	0 (0.0)	306	3 (1.0)
Yes	15	1 (6.7)	12	0 (0.0)	27	1 (3.7)
p value		0.205		---		0.288
2007						
No	181	2 (1.1)	119	2 (1.7)	303	5 (1.7)
Yes	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
p value		0.361		1.000		0.589

* Total includes people whose gender was not reported or reported as transgender

** Question changed to "condom use with regular partner in last month" in 2005.

Table 69 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	489	9 (1.8)	188	0 (0.0)	683	9 (1.3)
Yes	22	3 (13.6)	35	0 (0.0)	59	4 (6.8)
p value		<0.001		---		0.002
2004						
No	376	5 (1.3)	151	1 (0.7)	531	6 (1.1)
Yes	25	1 (4.0)	37	0 (0.0)	63	1 (1.6)
p value		0.3		1.0		0.5
2005						
No	415	5 (1.2)	202	0 (0.0)	621	5 (0.8)
Yes	12	1 (8.3)	35	0 (0.0)	49	1 (2.0)
p value				---		0.4
2006						
No	383	10 (2.6)	182	1 (0.6)	568	11 (1.9)
Yes	18	2 (11.1)	36	0 (0.0)	58	3 (5.0)
p value		0.096		1.000		0.132
2007						
No	407	11 (2.7)	190	2 (1.1)	600	13 (2.2)
Yes	9	1 (11.1)	40	0 (0.0)	50	2 (4.0)
p value		0.234		1.000		0.323

* Total includes people whose gender was not reported or reported as transgender

Table 70 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	481	10 (2.1)	184	0 (0.0)	670	10 (1.5)
Yes	40	2 (5.0)	42	0 (0.0)	85	3 (3.5)
p value		0.2		---		0.2
2004						
No	353	5 (1.4)	160	0 (0.0)	516	5 (1.0)
Yes	42	1 (2.4)	29	1 (3.5)	73	2 (2.7)
p value		0.5		0.2		0.2
2005						
No	369	6 (1.6)	185	0 (0.0)	559	6 (1.1)
Yes	54	0 (0.0)	48	0 (0.0)	103	0 (0.0)
p value		0.4		---		0.3
2006						
No	372	12 (3.2)	176	1 (0.6)	554	14 (2.5)
Yes	39	0 (0.0)	47	0 (0.0)	86	0 (0.0)
p value		0.615		1.000		0.235
2007						
No	366	10 (2.8)	190	2 (1.1)	559	12 (2.2)
Yes	56	1 (1.8)	47	0 (0.0)	104	2 (1.9)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 71 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Australia	343	9 (2.6)	183	0 (0.0)	525	10 (1.9)
Other Oceania	17	1 (5.9)	16	0 (0.0)	33	1 (3.0)
Asia	114	1 (0.9)	16	0 (0.0)	130	1 (0.8)
UK & Ireland	21	1 (4.8)	6	0 (0.0)	27	1 (3.7)
Other	34	0 (0.0)	8	0 (0.0)	42	0 (0.0)
p value		0.5		---		0.6
2004						
Australia	259	6 (2.3)	158	1 (0.6)	420	7 (1.7)
Other Oceania	4	0 (0.0)	12	0 (0.0)	16	0 (0.0)
Asia	100	0 (0.0)	12	0 (0.0)	112	0 (0.0)
UK & Ireland	14	0 (0.0)	3	0 (0.0)	17	0 (0.0)
Other	21	0 (0.0)	6	0 (0.0)	28	0 (0.0)
p value		0.6		1.0		0.7
2005						
Australia	368	5 (1.4)	216	0 (0.0)	588	5 (0.9)
Other Oceania	13	1 (7.7)	8	0 (0.0)	23	1 (4.4)
Asia	4	0 (0.0)	---	---	4	0 (0.0)
UK & Ireland	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
Other	26	0 (0.0)	6	0 (0.0)	32	0 (0.0)
p value		0.3		---		0.4
2006						
Australia	347	11 (3.2)	208	1 (0.5)	559	12 (2.2)
Other Oceania	17	0 (0.0)	11	0 (0.0)	29	1 (3.5)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	28	0 (0.0)	7	0 (0.0)	35	0 (0.0)
Other	23	1 (4.4)	3	0 (0.0)	26	1 (3.9)
p value		0.793		1.000		0.503
2007						
Australia	365	11 (3.0)	208	2 (1.0)	576	14 (2.4)
Other Oceania	9	1 (11.1)	8	0 (0.0)	18	1 (5.6)
Asia	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	9	0 (0.0)	37	0 (0.0)
p value		0.461		1.000		0.643

* Total includes people whose gender was not reported or reported as transgender

Table 72 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
English speaking	337	10 (3.0)	195	0 (0.0)	541	11 (2.0)
Non-English speaking	167	2 (1.2)	29	0 (0.0)	196	2 (1.0)
p value		0.2		---		0.4
2004						
English speaking	183	2 (1.1)	134	1 (0.8)	319	3 (0.9)
Non-English speaking	114	0 (0.0)	24	0 (0.0)	138	0 (0.0)
p value		0.5		1.0		0.6
2005						
English speaking	366	6 (1.6)	218	0 (0.0)	589	6 (1.0)
Non-English speaking	70	0 (0.0)	25	0 (0.0)	96	0 (0.0)
p value		0.3		---		0.3
2006						
English speaking	361	11 (3.1)	214	1 (0.5)	581	13 (2.2)
Non-English speaking	42	1 (2.4)	12	0 (0.0)	54	1 (1.9)
p value		1.000		1.000		1.000
2007						
English speaking	403	12 (3.0)	225	2 (0.9)	632	15 (2.4)
Non-English speaking	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 73 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	535	359 (67)	230	161 (70)	774	526 (68)
2004	409	288 (70)	197	141 (72)	611	433 (71)
2005	439	302 (69)	243	168 (69)	688	474 (69)
2006	424	292 (69)	232	173 (75)	663	468 (71)
2007	428	289 (68)	231	169 (73)	663	460 (69)
χ^2 trend p value		0.994		0.317		0.585

* Total includes people whose gender was not reported or reported as transgender

Table 74 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	461	305 (66)	138	90 (65)	601	397 (66)
Bisexual	16	10 (63)	47	36 (77)	65	47 (72)
Homosexual	18	13 (72)	19	15 (79)	38	28 (74)
p value		0.8		0.2		0.4
2004						
Heterosexual	347	242 (70)	144	104 (72)	492	346 (70)
Bisexual	15	8 (53)	33	25 (76)	48	33 (69)
Homosexual	14	10 (71)	11	7 (64)	25	17 (68)
p value		0.4		0.7		0.9
2005						
Heterosexual	389	270 (69)	171	112 (66)	560	382 (68)
Bisexual	10	7 (70)	44	34 (77)	55	42 (76)
Homosexual	24	15 (63)	16	13 (81)	44	31 (70)
p value		0.8		0.2		0.5
2006						
Heterosexual	366	263 (72)	170	130 (76)	537	393 (73)
Bisexual	23	14 (61)	38	27 (71)	64	41 (64)
Homosexual	27	11 (41)	16	9 (56)	44	21 (48)
p value		0.003		0.191		0.001
2007						
Heterosexual	374	264 (71)	166	121 (73)	541	386 (71)
Bisexual	20	11 (55)	41	34 (83)	62	45 (73)
Homosexual	24	8 (33)	19	9 (47)	43	17 (40)
p value		<0.001		0.020		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 75 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	19	4 (21)	12	7 (58)	31	11 (36)
20 – 24	92	45 (49)	40	21 (53)	132	66 (50)
25 – 29	94	55 (59)	57	39 (68)	152	94 (62)
30 + years	330	255 (77)	121	94 (78)	459	355 (77)
p value		<0.001		0.02		<0.001
2004						
< 20 years	10	4 (40)	6	1 (17)	16	5 (31)
20 – 24	53	26 (49)	31	20 (65)	84	46 (55)
25 – 29	76	48 (63)	38	22 (58)	116	72 (62)
30 + years	269	209 (78)	122	98 (80)	394	309 (78)
p value		<0.001		0.001		<0.001
2005						
< 20 years	6	1 (17)	5	2 (40)	11	3 (27)
20 – 24	36	12 (33)	34	24 (71)	70	36 (51)
25 – 29	63	39 (62)	57	34 (60)	121	74 (61)
30 + years	334	250 (75)	147	108 (73)	486	361 (74)
p value		<0.001		0.1		<0.001
2006						
< 20 years	3	1 (33)	6	4 (67)	9	5 (56)
20 – 24	31	16 (52)	19	14 (74)	50	30 (60)
25 – 29	67	39 (58)	42	30 (71)	111	69 (62)
30 + years	322	236 (73)	163	123 (75)	490	362 (74)
p value		0.004		0.868		0.015
2007						
< 20 years	3	0 (0.0)	5	3 (60)	8	3 (38)
20 – 24	22	6 (27)	22	13 (50)	44	19 (43)
25 – 29	56	27 (48)	39	25 (64)	96	53 (55)
30 + years	347	256 (74)	165	128 (78)	515	385 (75)
p value		<0.001		0.090		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 76 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	59	17 (29)	15	5 (33)	74	22 (30)
3 to 5 years	78	36 (46)	37	23 (62)	115	59 (51)
6 to 10 years	114	83 (73)	62	41 (66)	178	125 (70)
10 + years	270	219 (81)	110	90 (82)	386	313 (81)
p value		<0.001		<0.001		<0.001
2004						
<3 years	26	8 (31)	17	4 (24)	43	12 (28)
3 to 5 years	44	23 (52)	18	6 (33)	62	29 (47)
6 to 10 years	107	74 (69)	51	36 (71)	159	111 (70)
10 + years	224	177 (79)	109	93 (85)	334	271 (81)
p value		<0.001		<0.001		<0.001
2005						
<3 years	33	10 (30)	19	12 (63)	53	22 (42)
3 to 5 years	35	13 (37)	18	7 (39)	53	20 (38)
6 to 10 years	42	22 (52)	49	33 (67)	92	56 (61)
10 + years	313	245 (78)	148	110 (74)	465	358 (77)
p value		<0.001		0.02		<0.001
2006						
<3 years	19	2 (11)	11	3 (27)	30	5 (17)
3 to 5 years	27	11 (41)	18	7 (39)	45	18 (40)
6 to 10 years	67	38 (57)	47	37 (79)	118	76 (64)
10 + years	292	231 (79)	149	121 (81)	444	354 (80)
p value		<<0.001		<<0.001		<<0.001
2007						
<3 years	11	1 (9)	11	4 (36)	22	5 (23)
3 to 5 years	31	11 (35)	18	15 (83)	50	27 (54)
6 to 10 years	57	24 (42)	40	24 (60)	98	48 (49)
10 + years	319	247 (77)	153	119 (78)	474	367 (77)
p value		<0.001		0.004		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 77 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	38	11 (29)	367	277 (76)	408	291 (71)
Meth/Amphetamine	10	6 (60)	127	82 (65)	138	88 (64)
More than one	4	1 (25)	59	49 (83)	66	52 (79)
Other/Not reported	22	4 (18)	126	89 (71)	162	95 (59)
p value		0.1		0.03		0.004
2004						
Heroin	20	7 (35)	284	215 (76)	307	225 (73)
Meth/Amphetamine	12	2 (17)	123	80 (65)	137	84 (61)
More than one	1	1 (100)	29	23 (79)	32	26 (81)
Other/Not reported	10	2 (20)	119	93 (78)	135	98 (73)
p value		0.3		0.07		0.03
2005						
Heroin	14	5 (36)	272	202 (74)	286	207 (72)
Meth/Amphetamine	13	5 (38)	158	93 (59)	171	98 (57)
More than one	0	0 (0)	11	10 (91)	11	10 (91)
Other/Not reported	25	11 (44)	196	148 (76)	221	159 (72)
p value		0.934		0.001		0.001
2006						
Heroin	133	100 (75)	88	71 (81)	223	172 (77)
Meth/Amphetamine	124	72 (58)	64	39 (61)	192	112 (58)
More than one	5	5 (100)	4	4 (100)	9	9 (100)
Other/Not reported	162	115 (71)	76	59 (78)	239	175 (73)
p value		0.009		0.027		<<0.001
2007						
Heroin	10	2 (20)	229	163 (71)	241	167 (69)
Meth/Amphetamine	6	3 (50)	162	110 (68)	172	116 (67)
More than one	---	---	11	7 (64)	18	10 (56)
Other/Not reported	6	0 (0.0)	220	162 (74)	323	167 (72)
p value		0.119		0.594		0.430

* Total includes people who did not report duration of drug injection

Table 78 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	32	10 (31)	285	199 (70)	326	212 (65)
Daily or more	29	10 (35)	319	244 (77)	351	257 (73)
p value		0.8		0.06		0.02
2004						
Less than daily	13	3 (23)	248	177 (71)	265	184 (69)
Daily or more	24	9 (38)	271	205 (76)	299	218 (73)
p value		0.5		0.3		0.4
2005						
Less than daily	30	10 (33)	304	207 (68)	347	225 (65)
Daily or more	20	11 (55)	305	226 (74)	337	247 (73)
p value		0.1		0.1		0.02
2006						
Less than daily	16	0 (0)	269	199 (74)	293	201 (69)
Daily or more	11	3 (27)	251	183 (73)	275	197 (72)
p value		0.056		0.843		0.464
2007						
Less than daily	11	2 (18)	272	202 (74)	287	208 (72)
Daily or more	10	3 (30)	265	180 (68)	282	189 (67)
p value		0.635		0.107		0.171

* Total includes people who did not report duration of drug injection

Table 79 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	53	17 (32)	488	353 (72)	552	376 (68)
Yes	5	2 (40)	98	78 (80)	104	80 (77)
p value		0.7		0.1		0.2
2004						
No	27	7 (26)	412	304 (74)	446	318 (71)
Yes	9	5 (56)	92	66 (72)	102	72 (71)
p value		0.1		0.7		0.9
2005						
No	33	12 (36)	452	316 (70)	503	342 (68)
Yes	9	6 (67)	77	63 (82)	89	71 (80)
p value		0.1		0.03		0.03
2006						
No	24	3 (13)	429	313 (73)	464	320 (69)
Yes	2	0 (0)	69	53 (77)	79	61 (77)
p value		1.000		0.559		0.146
2007						
No	14	4 (29)	439	309 (70)	460	320 (70)
Yes	5	1 (20)	72	53 (74)	79	56 (71)
p value		1.000		0.675		0.895

* Total includes people who did not report duration of drug injection

Table 80 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	57	19 (33)	516	366 (71)	591	389 (66)
Yes	17	3 (18)	146	115 (79)	166	121 (73)
p value		0.2		0.02		0.02
2004						
No	31	7 (23)	424	299 (71)	462	310 (67)
Yes	11	5 (45)	127	110 (87)	144	121 (84)
p value		0.1		<0.001		<0.001
2005						
No	44	15 (34)	473	323 (68)	535	350 (65)
Yes	6	5 (83)	113	93 (82)	126	104 (83)
p value		0.02		0.003		<0.001
2006						
No	26	4 (15)	492	347 (71)	538	361 (67)
Yes	3	1 (33)	86	76 (88)	93	80 (86)
p value		0.446		<<0.001		<<0.001
2007						
No	20	5 (25)	499	350 (70)	533	363 (68)
Yes	---	---	95	72 (76)	99	76 (77)
p value		---		0.323		0.096

* Total includes people who did not report duration of drug injection

Table 81 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	65	20 (31)	599	434 (73)	684	460 (67)
Yes	9	2 (22)	51	41 (80)	60	43 (72)
p value		0.6		0.4		0.5
2004						
No	41	11 (27)	483	354 (73)	536	374 (70)
Yes	1	1 (100)	61	48 (79)	63	50 (79)
p value		0.3		0.4		0.1
2005						
No	52	21 (40)	549	387 (70)	624	424 (68)
Yes	1	1 (100)	46	37 (80)	49	40 (82)
p value		0.2		0.2		0.05
2006						
No	26	4 (15)	520	388 (75)	568	404 (71)
Yes	2	1 (50)	54	37 (69)	58	39 (67)
p value		0.331		0.331		0.546
2007						
No	19	5 (26)	548	393 (72)	581	408 (70)
Yes	1	0 (0.0)	45	32 (71)	49	33 (67)
p value		1.000		1.000		0.746

* Total includes people who did not report duration of drug injection

Table 82 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	483	319 (66)	184	129 (70)	672	451 (67)
Yes	40	32 (80)	42	28 (67)	85	62 (73)
p value		0.07		0.7		0.3
2004						
No	354	246 (69)	162	117 (72)	519	366 (71)
Yes	43	33 (77)	30	21 (70)	75	55 (73)
p value		0.3		0.8		0.7
2005						
No	372	258 (69)	185	124 (67)	562	385 (69)
Yes	54	38 (70)	48	39 (81)	103	78 (76)
p value		0.8		0.06		0.1
2006						
No	372	257 (69)	176	125 (71)	554	384 (69)
Yes	39	27 (69)	47	42 89)(86	69 (80)
p value		1.000		0.008		0.041
2007						
No	358	239 (67)	184	135 (73)	545	376 (69)
Yes	54	42 (78)	44	31 (70)	99	73 (74)
p value		0.118		0.708		0.405

* Total includes people whose gender was not reported or reported as transgender

Table 83 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	344	233 (68)	183	127 (69)	536	366 (68)
Other Oceania	17	11 (65)	16	10 (63)	33	21 (64)
Asia	115	82 (71)	16	11 (69)	131	93 (71)
UK & Ireland	21	13 (62)	6	6 (100)	27	19 (70)
Other	34	18 (53)	8	6 (75)	42	24 (57)
p value		0.4		0.5		0.5
2004						
Australia	260	174 (67)	160	117 (73)	423	293 (69)
Other Oceania	4	3 (75)	12	8 (67)	16	11 (69)
Asia	101	79 (78)	12	6 (50)	113	85 (75)
UK & Ireland	14	9 (64)	3	3 (100)	17	12 (71)
Other	21	14 (67)	7	5 (71)	29	20 (69)
p value		0.3		0.4		0.8
2005						
Australia	371	252 (68)	216	148 (69)	591	403 (68)
Other Oceania	13	8 (62)	8	7 (88)	23	16 (70)
Asia	4	2 (50)	---	---	4	2 (50)
UK & Ireland	21	18 (86)	10	7 (70)	31	25 (81)
Other	26	19 (73)	6	3 (50)	32	22 (69)
p value		0.4		0.5		0.6
2006						
Australia	347	241 (69)	208	155 (75)	559	397 (71)
Other Oceania	17	12 (71)	11	9 (82)	29	21 (72)
Asia	3	3 (100)	1	0 (0)	4	3 (75)
UK & Ireland	28	19 (68)	7	4 (57)	35	23 (66)
Other	23	13 (57)	3	3 (100)	26	16 (62)
p value		0.616		0.292		0.792
2007						
Australia	356	237 (67)	200	145 (73)	559	384 (69)
Other Oceania	9	7 (78)	7	5 (71)	17	12 (71)
Asia	5	3 (60)	5	3 (60)	10	6 (60)
UK & Ireland	17	14 (82)	7	7 (100)	24	21 (88)
Other	28	21 (75)	9	7 (78)	37	28 (76)
p value		0.568		0.516		0.273

* Total includes people whose gender was not reported or reported as transgender

Table 84 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	338	231 (68)	195	136 (70)	542	373 (69)
Non-English speaking	168	107 (64)	29	19 (66)	197	126 (64)
p value		0.3		0.6		0.2
2004						
English speaking	184	121 (66)	135	103 (76)	321	225 (70)
Non-English speaking	115	85 (74)	25	13 (52)	140	98 (70)
p value		0.1		0.01		1.0
2005						
English speaking	369	253 (69)	218	151 (69)	592	407 (69)
Non-English speaking	70	49 (70)	25	17 (68)	96	67 (70)
p value		0.8		0.9		0.8
2006						
English speaking	361	253 (70)	214	159 (74)	581	414 (71)
Non-English speaking	42	25 (60)	12	8 (67)	54	33 (61)
p value		0.163		0.517		0.122
2007						
English speaking	392	266 (68)	216	158 (73)	612	426 (70)
Non-English speaking	23	16 (70)	14	10 (71)	37	26 (70)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Northern Territory 2003 – 2007

Table 85 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	1	1	3	1	3
N ^o surveyed	N = 62	N=23	N=29	N=20	N=31
Response (%)	78	16	36	---	29
Gender (%)					
Male	44 (71)	16 (70)	19 (66)	9 (45)	22 (71)
Female	18 (29)	6 (26)	10 (34)	11 (55)	9 (29)
Transgender	---	1 (4)	---	---	---
Not reported	---	---	---	---	---
Sexual identity (%)					
Heterosexual	48 (77)	19 (83)	26 (90)	13 (65)	28 (90)
Bisexual	6 (10)	4 (17)	2 (7)	4 (20)	1 (3)
Homosexual	2 (3)	---	1 (3)	3 (15)	2 (6)
Not reported	6 (10)	---	---	---	---
Age and duration of injection (years)					
<i>Median age</i>	37	38	35	33	38
<i>Age range</i>	20-53	21-50	19-56	24-52	25-59
<i>Age group (%)</i>					
<25 years	3 (5)	2 (9)	4 (14)	1 (5)	---
25+ years	58 (93)	21 (91)	25 (86)	19 (95)	31 (100)
Not reported	1 (2)	---	---	---	---
<i>Median age 1st IDU</i>	19	18	20	19.5	17
<i>Age range</i>	8-40	13-35	11-41	14-30	12-42
Not reported	2	---	2	---	1
<i>Median years IDU</i>	14	19	15	11.5	18
<i>Range</i>	1-36	3-32	1-36	5-36	3-36
<i>Duration of drug injection (%)</i>					
<3 years	4 (6)	---	2 (7)	---	---
3+ years	56 (90)	23 (100)	26 (90)	20 (100)	30 (97)
Not reported	2 (3)	---	1 (3)	---	1 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	54 (87)	21 (92)	27 (93)	17 (85)	---
Yes	6 (10)	1 (4)	1 (3)	3 (15)	30 (97)
Not reported	2 (3)	1 (4)	1 (3)	---	1 (3)
Region/Country of birth (%)					
Australia	52 (84)	20 (87)	28 (97)	19 (95)	28 (90)
Other Oceania	3 (5)	---	---	1 (5)	1 (3)
Asia	1 (1)	1 (4)	---	---	---
UK & Ireland	6 (10)	---	---	---	1 (3)
Other	---	1 (4)	---	---	---
Not reported	---	1 (4)	1 (3)	---	1 (3)
Main language spoken at home by parents (%)					
English speaking	59 (95)	17 (74)	25 (86)	18 (90)	29 (94)
Non-English speaking	1 (2)	---	4 (14)	---	1 (3)
Not reported	2 (3)	6 (26)	---	2 (10)	1 (3)
Imprisonment last year (%)					
No	56 (90)	17 (74)	26 (90)	19 (95)	29 (94)
Yes	6 (10)	5 (22)	2 (7)	1 (5)	1 (3)
Not reported	---	1 (4)	1 (3)	---	1 (3)
Injected in prison (%)					
Yes	N = 6 2 (33)	N = 5 3 (60)	N=2 1 (50)	N=1 0 (0)	N=1 1 (100)
Frequency of injection last month (%)					
Not last month	1 (2)	---	---	---	2 (6)
Less than weekly	4 (7)	4 (18)	5 (17)	5 (25)	3 (10)
Weekly not daily	9 (14)	1 (4)	2 (7)	4 (20)	6 (19)
Daily or more	48 (77)	18 (78)	22 (76)	11 (55)	20 (65)
Not reported	---	---	---	---	---

Northern Territory

Table 86 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 62	N = 23	N=29	N=20	
Anabolic steroids	---	---	---	---	---
Cocaine	---	---	---	---	---
Heroin	2 (3)	---	---	---	---
Methadone	5 (8)	1 (4)	4 (14)	---	5 (16)
Meth/Amphetamine	15 (24)	7 (30)	8 (28)	7 (35)	5 (16)
Morphine/Other Opioids	33 (53)	13 (57)	14 (48)	12 (60)	16 (52)
Subutex/Buprenorphine	---	---	1 (3)	---	4 (13)
More than one	3 (5)	2 (9)	---	1 (5)	---
Other	2 (3)	---	1 (3)	---	---
Not reported	1 (2)	---	1 (3)	---	1 (3)
N° Injected last month	N = 61	N = 23	N=29	N=17	N=29
Places injected last month (%)*					
Own home	56 (92)	22 (96)	24 (83)	16 (94)	26 (93)
Friend's home	29 (48)	12 (52)	9 (31)	9 (53)	8 (29)
Dealer's home	11 (18)	5 (22)	2 (7)	4 (24)	1 (4)
Street, park, beach	8 (13)	1 (4)	2 (7)	3 (18)	1 (4)
Car	12 (20)	4 (17)	3 (10)	4 (24)	3 (11)
Public toilet	14 (23)	3 (13)	1 (3)	2 (12)	6 (21)
Commercial injecting room	---	---	---	---	---
Squat	3 (5)	1 (4)	2 (7)	---	---
Use of new sterile needles & syringes last month (%)					
All injections	53 (86)	21 (92)	26 (90)	15 (75)	26 (90)
Most of the time	6 (10)	1 (4)	1 (3)	4 (20)	2 (7)
Half of the time	---	1 (4)	2 (7)	---	1 (3)
Some of the time	1 (2)	---	---	---	---
Not last month	---	---	---	---	---
Not reported	1 (2)	---	---	1 (5)	---
Re-used another's used needle & syringe last month (%)					
None	52 (84)	23 (100)	27 (93)	18 (90)	26 (90)
Once	3 (5)	---	---	---	---
Twice	1 (2)	---	---	---	---
3-5 times	1 (2)	---	1 (3)	---	1 (3)
>5 times	3 (5)	---	---	1 (5)	---
Not reported	1 (2)	---	1 (3)	1 (5)	2 (7)
Number of people needle & syringe was re-used after last month (%)					
None	52 (85)	23 (100)	27 (93)	18 (90)	26 (90)
One	3 (5)	---	---	---	---
Two	2 (3)	---	1 (3)	---	---
Three to five	---	---	---	1 (5)	---
More than five	---	---	---	---	---
Don't know	---	---	---	---	---
Not reported	4 (7)	---	1 (3)	1 (5)	3 (10)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	3 (5)	---	---	1 (5)	---
Casual sex partner	---	---	---	---	---
Close friend	4 (7)	---	1 (3)	---	---
Acquaintance	1 (2)	---	1 (3)	1 (5)	---
Other	---	---	---	---	---
Equipment used after someone else last month (%)*					
Spoon	16 (26)	7 (30)	8 (28)	3 (16)	4 (17)
Water	6 (10)	2 (9)	4 (14)	---	1 (4)
Filter	7 (11)	5 (22)	3 (10)	2 (11)	1 (4)
Drug mix	5 (8)	---	5 (17)	1 (5)	1 (4)
Tourniquet	10 (16)	2 (9)	7 (24)	1 (5)	1 (4)
None**	---	---	---	14 (74)	16 (67)
Injected by someone after that person injected themselves or others last month (%)					
No	56 (92)	21 (91)	26 (90)	18 (90)	22 (76)
Yes	4 (6)	2 (9)	2 (7)	---	4 (14)
Not reported	1 (2)	---	1 (3)	2 (10)	3 (10)

* More than one option could be selected

** New variable in 2006

Table 87 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 62	N = 23	N=29	N=20	N=31
Any treatment/therapy for drug use (%)					
No	29 (47)	9 (39)	13 (45)	12 (60)	13 (42)
Yes	33 (53)	14 (61)	16 (55)	8 (40)	17 (55)
Not reported	---	---	---	---	1 (3)
History of methadone maintenance treatment					
Currently	10 (16)	5 (22)	4 (14)	1 (5)	4 (13)
Previously	12 (19)	3 (13)	10 (34)	2 (10)	10 (32)
Never	40 (65)	15 (65)	15 (52)	17 (85)	16 (52)
Not reported	---	---	---	---	1 (3)
History of other pharmacotherapy treatment (%)					
Currently	6 (10)	4 (17)	2 (7)	---	---
Previously	8 (13)	4 (17)	6 (21)	4 (20)	7 (23)
Never	48 (77)	15 (66)	21 (72)	16 (80)	23 (74)
Not reported	---	---	---	---	1 (3)

Table 88 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007
N° surveyed	N = 62	N = 23	N=29	N=20	---
From an NSP last month (%)					
Daily or almost daily	5 (8)	1 (4)	4 (14)	1 (5)	---
A couple of times each week	10 (16)	3 (13)	7 (24)	3 (15)	---
Less than weekly	16 (26)	5 (22)	8 (28)	7 (35)	---
Once last month	26 (42)	13 (57)	9 (31)	8 (40)	---
Not in the last month	5 (8)	1 (4)	1 (3)	1 (5)	---
Not reported	---	---	---	---	---
From a chemist last month (%)					
Daily or almost daily	2 (3)	---	---	1 (5)	---
A couple of times each week	3 (5)	2 (9)	---	---	---
Less than weekly	6 (10)	---	---	3 (15)	---
Once last month	9 (14)	3 (13)	5 (17)	2 (10)	---
Not in the last month	40 (65)	18 (78)	22 (76)	13 (65)	---
Not reported	2 (3)	---	2 (7)	1 (5)	---

* Not asked in this form in 2007, see Table 91.

Table 89 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N = 62	N = 23	N=29	N=20	N=31
Sex last month (%) †					
No	24 (39)	12 (52)	--	--	--
Yes	38 (61)	11 (48)	--	--	--
Not reported	---	---	--	--	--
Condom use at last sex (%)†					
No	39 (63)	16 (70)	--	--	--
Yes	21 (34)	6 (26)	--	--	--
Not reported	2 (3)	1 (4)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	20 (69)	5 (71)	--	--	--
Sometimes	1 (3)	---	--	--	--
Always	8 (28)	2 (29)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	6 (32)	6 (86)	--	--	--
Sometimes	2 (10)	---	--	--	--
Always	11 (58)	1 (14)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	5 (26)	6 (100)	--	--	--
Sometimes	2 (11)	---	--	--	--
Always	12 (63)	---	--	--	--
Duration of regular sexual relationship (%)** †					
One month	2 (6)	2 (28)	--	--	--
2 - 6 months	5 (15)	---	--	--	--
6 - 12 months	5 (15)	2 (28)	--	--	--
>12 months	21 (64)	3 (44)	--	--	--
Sex with a regular partner last month (%) ****					
No	--	--	16 (55)	8 (40)	16 (52)
Yes	--	--	12 (41)	12 (60)	13 (42)
Not reported	--	--	1 (3)	--	2 (6)
Condom used with regular partner last month (%)****			N=12*****	N=12	N=13
Never	--	--	8 (67)	9 (75)	10 (77)
Sometimes	--	--	1 (8)	---	---
Every time	--	--	1 (8)	1 (8)	3 (23)
Not reported	--	--	2 (17)	2 (17)	---
Sex with other partner/s last month (%)****					
No	--	--	25 (86)	16 (80)	24 (77)
Yes	--	--	4 (14)	4 (20)	6 (19)
Not reported	--	--	---	---	1 (3)
Condom used with other partner/s last month (%)****			N=4	N=4	N=6
Never	--	--	3 (75)	1 (25)	2 (33)
Sometimes	--	--	---	1 (25)	---
Every time	--	--	1 (25)	2 (50)	4 (67)
Not reported	--	--	---	---	---
Sex work last month (%)					
No	57 (92)	23 (100)	28 (97)	15 (75)	28 (90)
Yes	3 (5)	---	---	4 (20)	1 (3)
Not reported	2 (3)	---	1 (3)	1 (5)	2 (6)
Condom used at last sex work last month (%)**					
Yes	3 (100)	---	---	4 (100)	1 (100)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 90 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey

	2003	2004	2005	2006	2007
N ^o surveyed	N = 62	N = 23	N=29	N=20	N=31
Previous HIV test (%)					
Yes, last year	33 (53)	13 (57)	15 (52)	15 (75)	16 (52)
> 1 year ago	21 (34)	7 (30)	12 (41)	4 (20)	12 (39)
Never tested	7 (11)	3 (13)	2 (7)	---	2 (6)
Not reported	1 (2)	---	---	1 (5)	1 (3)
HBV infection (%)					
No	39 (63)	18 (78)	24 (83)	16 (80)	16 (52)
Yes	10 (16)	3 (13)	4 (14)	2 (10)	8 (26)
Don't know	11 (18)	2 (9)	1 (3)	2 (10)	6 (19)
Not reported	2 (3)	---	---	---	1 (3)
HBV vaccination (%)*					
No	21 (40)	8 (40)	8 (32)	4 (22)	7 (30)
Yes	18 (35)	8 (40)	15 (60)	11 (61)	10 (43)
Don't know	10 (19)	4 (20)	2 (8)	3 (17)	5 (22)
Not reported	3 (6)	---	---	---	1 (4)
Previous HCV test (%)					
Yes, last year	32 (52)	18 (78)	14 (48)	15 (75)	19 (61)
> 1 year ago	18 (29)	5 (22)	14 (48)	5 (25)	10 (32)
Never tested	11 (18)	---	1 (3)	---	1 (3)
Not reported	1 (1)	---	---	---	1 (3)
Any treatment for HCV (%)	N = 24	N = 12	N=13	N=4	N=17
Interferon	1 (4)	---	---	---	---
Interferon+Ribarvarin	---	---	---	---	---
Other	---	1 (8)	1 (8)	---	2 (12)
No treatment	23 (96)	11 (92)	12 (92)	3(75)	12 (71)
Not reported	---	---	---	1 (25)	3 (18)
Current treatment for HCV	N=1	N = 0	N = 0	N=0	N=1
Interferon	1	---	---	---	---
Interferon+Ribarvarin	---	---	---	---	1
Other	---	---	---	---	---

* Number (percentage) among participants not reporting HBV infection

Table 91 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N ^o surveyed	N=31		
Needle/syringe acquisition at time of survey completion (%)			
No	2 (6)		
Yes	20 (65)		
Not reported	9 (29)		
Source of needles/syringes (%)** N=1490***	In last week	In last month	
Chemist/Pharmacy	0 (0)	0 (0)	
Needle Syringe Program	9 (39)	20 (87)	
Dispensing/Vending Machine	0 (0)	0 (0)	
Friend/Dealer	3 (13)	8 (35)	
Other	0 (0)	0 (0)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=0	0 (0)	0 (0)
Needle Syringe Program	N=20	15 (75)	5 (25)
Dispensing/Vending Machine	N=0	0 (0)	0 (0)
Friend/Dealer	N=8	3 (38)	5 (62)
Other	N=0	0 (0)	0 (0)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 92 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	43	1 (2.3)	18	0 (0.0)	61	1 (1.6)
2004	11	0 (0.0)	4	0 (0.0)	16	0 (0.0)
2005	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
2006	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
2007	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
χ^2 trend p value		0.340		---		0.308

* Total includes people whose gender was not reported or reported as transgender

Table 93 HIV antibody prevalence by sexual identity and year of survey

Sexual identity	N° tested	N° with HIV (%)
2003		
Heterosexual	48	0 (0.0)
Bisexual	6	1 (16.7)
Homosexual	1	0 (0.0)
2004		
Heterosexual	12	0 (0.0)
Bisexual	4	0 (0.0)
Homosexual	---	0 (0.0)
2005		
Heterosexual	22	0 (0.0)
Bisexual	1	0 (0.0)
Homosexual	1	0 (0.0)
2006		
Heterosexual	13	0 (0.0)
Bisexual	4	0 (0.0)
Homosexual	3	0 (0.0)
2007		
Heterosexual	27	0 (0.0)
Bisexual	0	0 (0.0)
Homosexual	1	0 (0.0)

Table 94 HIV antibody prevalence by age group and year of survey

Age group	N° tested	N° with HIV (%)
2003		
< 20 years	---	---
20 – 24	3	0 (0.0)
25 – 29	9	1 (11.1)
30 + years	49	0 (0.0)
2004		
< 20 years	---	---
20 – 24	1	0 (0.0)
25 – 29	1	0 (0.0)
30 + years	14	0 (0.0)
2005		
< 20 years	---	---
20 – 24	2	0 (0.0)
25 – 29	1	0 (0.0)
30 + years	21	0 (0.0)
2006		
< 20 years	---	---
20 – 24	1	0 (0.0)
25 – 29	6	0 (0.0)
30 + years	13	0 (0.0)
2007		
< 20 years	---	---
20 – 24	---	---
25 – 29	6	0 (0.0)
30 + years	23	0 (0.0)

Table 95 HIV antibody prevalence by duration of drug injection and year of survey

Duration of drug injection	N° tested	N° with HIV (%)
2003*		
<3 years	4	0 (0.0)
3 to 5 years	3	0 (0.0)
6 to 10 years	9	0 (0.0)
10 + years	41	0 (0.0)
2004		
<3 years	---	---
3 to 5 years	3	0 (0.0)
6 to 10 years	---	---
10 + years	13	0 (0.0)
2005		
<3 years	2	0 (0.0)
3 to 5 years	2	0 (0.0)
6 to 10 years	2	0 (0.0)
10 + years	17	0 (0.0)
2006		
<3 years	---	0 (0.0)
3 to 5 years	1	0 (0.0)
6 to 10 years	5	0 (0.0)
10 + years	14	0 (0.0)
2007		
<3 years	---	---
3 to 5 years	3	0 (0.0)
6 to 10 years	3	0 (0.0)
10 + years	22	0 (0.0)

Table 96 HIV antibody prevalence by last drug injected and year of survey

Last drug injected	N° tested	N° with HIV (%)
2003		
Heroin	2	0 (0.0)
Meth/Amphetamine	14	1 (7.1)
Morphine/Other Opioids	33	0 (0.0)
Other/Not reported	12	0 (0.0)
2004		
Heroin	---	---
Meth/Amphetamine	6	0 (0.0)
Morphine/Other Opioids	9	0 (0.0)
Other/Not reported	1	0 (0.0)
2005		
Heroin	---	---
Meth/Amphetamine	6	0 (0.0)
Morphine/Other Opioids	11	0 (0.0)
Other/Not reported	7	0 (0.0)
2006		
Heroin	---	---
Meth/Amphetamine	7	0 (0.0)
Morphine/Other Opioids	12	0 (0.0)
Other/Not reported	1	0 (0.0)
2007		
Heroin	---	---
Meth/Amphetamine	5	0 (0.0)
Morphine/Other Opioids	15	0 (0.0)
Other/Not reported	9	0 (0.0)

Table 97 HIV antibody prevalence by frequency of drug injection last month and year of survey

Frequency of drug injection	N° tested	N° with HIV (%)
2003		
Not injected last month	1	0 (0.0)
Less than daily	12	1 (8.3)
Daily or more	48	0 (0.0)
2004		
Not injected last month	---	---
Less than daily	3	0 (0.0)
Daily or more	13	0 (0.0)
2005		
Not injected last month	---	---
Less than daily	5	0 (0.0)
Daily or more	19	0 (0.0)
2006		
Not injected last month	---	---
Less than daily	9	0 (0.0)
Daily or more	11	0 (0.0)
2007		
Not injected last month	2	0 (0.0)
Less than daily	9	0 (0.0)
Daily or more	18	0 (0.0)

Table 98 HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey

Re-used someone else's used needle & syringe	N° tested	N° with HIV (%)
2003		
No	51	1 (2.0)
Yes	8	0 (0.0)
2004		
No	16	0 (0.0)
Yes	---	0 (0.0)
2005		
No	22	0 (0.0)
Yes	1	0 (0.0)
2006		
No	15	0 (0.0)
Yes	1	0 (0.0)
2007		
No	24	0 (0.0)
Yes	1	0 (0.0)

Table 99 HIV antibody prevalence by imprisonment last year and year of survey

Imprisonment last year	N° tested	N° with HIV (%)
2003		
No	55	0 (0.0)
Yes	6	1 (16.7)
2004		
No	12	0 (0.0)
Yes	4	0 (0.0)
2005		
No	6	0 (0.0)
Yes	1	0 (0.0)
2006		
No	16	0 (0.0)
Yes	1	0 (0.0)
2007		
No	28	0 (0.0)
Yes	0	0 (0.0)

Table 100 HIV antibody prevalence by condom use at last sex and year of survey

Condom use at last sex	N° tested	N° with HIV (%)
2003		
No	39	0 (0.0)
Yes	20	1 (5.0)
2004		
No	10	0 (0.0)
Yes	5	0 (0.0)
2005*		
No	6	0 (0.0)
Yes	1	0 (0.0)
2006		
No	9	0 (0.0)
Yes	1	0 (0.0)
2007		
No	10	0 (0.0)
Yes	2	0 (0.0)

*Question changed to "condom use with regular partner in last month" in 2005.

Table 101 HIV antibody prevalence by sex work last month and year of survey

Sex work last month	N° tested	N° with HIV (%)
2003		
No	56	1 (1.8)
Yes	3	0 (0.0)
2004		
No	16	0 (0.0)
Yes	---	---
2005		
No	23	0 (0.0)
Yes	---	---
2006		
No	15	0 (0.0)
Yes	4	0 (0.0)
2007		
No	26	0 (0.0)
Yes	1	0 (0.0)

Table 102 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey

Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)
2003		
No	53	1 (1.9)
Yes	6	0 (0.0)
2004		
No	15	0 (0.0)
Yes	1	0 (0.0)
2005		
No	23	0 (0.0)
Yes	1	0 (0.0)
2006		
No	17	0 (0.0)
Yes	3	0 (0.0)
2007		
No	28	0 (0.0)
Yes	---	---

Table 103 HIV antibody prevalence by region/country of birth and year of survey

Region/Country of birth	N° tested	N° with HIV (%)
2003		
Australia	51	0 (0.0)
Other Oceania	---	---
Asia	---	---
UK & Ireland	6	1 (16.7)
Other	4	0 (0.0)
2004		
Australia	15	0 (0.0)
Other Oceania	---	---
Asia	---	---
UK & Ireland	---	---
Other	1	0 (0.0)
2005		
Australia	24	0 (0.0)
Other Oceania	---	---
Asia	---	---
UK & Ireland	---	---
Other	---	---
2006		
Australia	19	0 (0.0)
Other Oceania	1	0 (0.0)
Asia	---	---
UK & Ireland	---	---
Other	---	---
2007		
Australia	26	0 (0.0)
Other Oceania	1	0 (0.0)
Asia	---	---
UK & Ireland	1	0 (0.0)
Other	---	---

Table 104 HIV antibody prevalence by main language spoken at home by parents and year of survey

Main language spoken at home by parents	N° tested	N° with HIV (%)
2003		
English speaking	58	1 (1.7)
Non-English speaking	1	0 (0.0)
2004		
English speaking	11	0 (0.0)
Non-English speaking	---	---
2005		
English speaking	21	0 (0.0)
Non-English speaking	3	0 (0.0)
2006		
English speaking	18	0 (0.0)
Non-English speaking	---	---
2007		
English speaking	27	0 (0.0)
Non-English speaking	1	0 (0.0)

HCV antibody prevalence

Table 105 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	44	20 (45)	18	9 (50)	62	29 (47)
2004	11	6 (55)	4	3 (75)	16	9 (56)
2005	15	6 (40)	9	6 (67)	24	12 (50)
2006	7	4 (57)	10	1 (10)	17	5 (29)
2007	20	13 (65)	9	5 (56)	29	18 (62)
χ^2 trend p value		0.191		0.437		0.528

* Total includes people whose gender was not reported or reported as transgender

Table 106 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	66	41 (62)	38	19 (50)	104	60 (58)
Bisexual	1	0 (0)	8	6 (75)	9	6 (67)
Homosexual	2	1 (50)	5	1 (20)	7	2 (29)
p value		0.3		0.2		0.4
2004						
Heterosexual	61	38 (62)	35	17 (49)	96	55 (57)
Bisexual	-	-	5	3 (60)	5	3 (60)
Homosexual	4	2 (50)	3	2 (67)	7	4 (57)
P value		0.6		0.8		1.0
2005						
Heterosexual	14	6 (43)	8	5 (63)	22	11 (50)
Bisexual	-	-	1	1 (100)	1	1 (100)
Homosexual	1	0 (0)	-	-	1	0 (0)
p value		0.4		0.5		0.6
2006						
Heterosexual	6	4 (67)	5	0 (0)	11	4 (36)
Bisexual	0	---	4	0 (0)	4	0 (0)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.429		0.100		0.413
2007						
Heterosexual	18	13 (72)	9	5 (56)	27	18 (67)
Bisexual	---	---	---	---	---	---
Homosexual	1	0 (0.0)	---	---	1	0 (0.0)
p value		0.316		---		0.357

* Total includes people whose gender was not reported or reported as transgender

Table 107 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	-	-	-	-	-	-
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	4	2 (50)	5	4 (80)	9	6 (67)
30 + years	38	18 (47)	12	4 (33)	50	22 (44)
p value		0.4		0.1		0.4
2004						
< 20 years	-	-	-	-	-	0 (0)
20 – 24	1	0 (0)	-	-	1	0 (0)
25 – 29	1	1 (100)	-	-	1	1 (100)
30 + years	9	5 (56)	4	3 (75)	14	8 (57)
p value		0.4		-		0.4
2005						
< 20 years	-	-	-	-	-	-
20 – 24	-	-	2	2 (100)	2	2 (100)
25 – 29	1	0 (0)	-	-	1	0 (0)
30 + years	14	6 (43)	7	4 (57)	21	10 (48)
p value		0.4		0.3		0.2
2006						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	---	---	---	---
25 – 29	2	1 (50)	4	0 (0)	6	1 (17)
30 + years	5	3 (60)	6	1 (17)	11	4 (36)
p value		1.000		1.000		0.600
2007						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	---	---	---	---
25 – 29	3	1 (33)	3	2 (67)	6	3 (50)
30 + years	17	12 (71)	6	3 (50)	23	15 (65)
p value		0.270		1.000		0.646

* Total includes people whose gender was not reported or reported as transgender

Table 108 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	5	1 (20)	1	0 (0)	6	1 (17)
3 to 5 years	2	0 (0)	1	1 (100)	3	1 (33)
6 to 10 years	4	1 (25)	6	2 (33)	10	3 (30)
10 + years	29	17 (59)	10	6 (60)	39	23 (59)
p value		<0.001		0.004		<0.001
2004						
<3 years	-	-	-	-	-	-
3 to 5 years	1	0 (0)	2	1 (50)	3	0 (0)
6 to 10 years	-	-	-	-	-	-
10 + years	10	6 (60)	1	0 (0)	13	9 (69)
p value		<0.001		0.02		<0.001
2005						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 5 years	2	1 (50)	-	-	2	1 (50)
6 to 10 years	-	-	2	1 (50)	2	1 (50)
10 + years	10	5 (50)	6	5 (83)	16	10 (63)
p value		0.3		0.2		0.4
2006						
<3 years	---	---	---	---	---	---
3 to 5 years	---	---	---	---	---	---
6 to 10 years	1	1 (100)	4	0 (0)	5	1 (20)
10 + years	6	3 (50)	6	1 (17)	12	4 (33)
p value		1.000		1.000		1.000
2007						
<3 years	---	---	---	---	---	---
3 to 5 years	1	1 (100)	2	1 (50)	3	2 (67)
6 to 10 years	2	0 (0.0)	1	1 (100)	3	1 (33)
10 + years	16	11 (69)	6	3 (50)	22	14 (64)
p value		0.123		1.000		0.792

* Total includes people whose gender was not reported or reported as transgender

Table 109 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Meth/Amphetamine	3	0 (0)	11	3 (27)	15	3 (20)
Heroin	---	---	2	1 (50)	2	1 (50)
More than one	1	1 (100)	1	0 (0)	3	2 (67)
Other/Not reported	2	0 (0)	38	23 (61)	42	23 (55)
p value		0.05		0.2		0.1
2004						
Meth/Amphetamine	---	---	6	4 (67)	6	4 (67)
Heroin	---	---	---	---	---	---
More than one	---	---	1	1 (100)	1	1 (100)
Other/Not reported	---	---	9	4 (44)	9	4 (44)
p value		---		0.5		0.5
2005						
Meth/Amphetamine	1	0 (0)	5	3 (60)	6	3 (50)
Heroin	---	---	---	---	---	---
More than one	---	---	---	---	---	---
Other/Not reported	2	0 (0)	16	9 (56)	18	9 (50)
p value		0.08		0.06		0.03
2006						
Meth/Amphetamine	---	---	6	1 (17)	6	1 (17)
Heroin	---	---	---	---	---	---
More than one	---	---	1	1 (100)	1	1 (100)
Other/Not reported	---	---	10	3 (30)	10	3 (30)
p value		---		0.360		0.360
2007						
Meth/Amphetamine	---	---	4	1 (25)	5	2 (40)
Heroin	---	---	---	---	---	---
More than one	---	---	---	---	---	---
Other/Not reported	---	---	24	16 (67)	24	16 (67)
p value		---		0.269		0.339

* Total includes people who did not report duration of drug injection

Table 110 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	2	0 (0)	10	5 (50)	14	6 (43)
Daily or more	4	1 (25)	42	22 (52)	48	23 (48)
p value		0.4		0.9		0.7
2004						
Less than daily	---	---	3	1 (33)	3	1 (33)
Daily or more	---	---	13	8 (62)	13	8 (62)
p value		---		0.4		0.4
2005						
Less than daily	---	---	5	3 (60)	5	3 (60)
Daily or more	3	0 (0)	15	9 (60)	19	9 (47)
p value		---		>0.9		0.6
2006						
Less than daily	---	---	8	1 (13)	8	1 (13)
Daily or more	---	---	9	4 (44)	9	4 (44)
p value		---		0.294		0.294
2007						
Less than daily	---	---	9	5 (56)	9	5 (56)
Daily or more	---	---	17	11 (65)	18	12 (63)
p value		---		0.692		0.683

* Total includes people who did not report duration of drug injection

Table 111 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	6	1 (17)	43	22 (51)	52	23 (44)
Yes	-	-	8	5 (63)	8	5 (63)
p value		-		0.6		0.3
2004						
No	-	-	16	9 (56)	16	9 (56)
Yes	-	-	-	-	-	-
p value		-		-		-
2005						
No	3	0 (0)	18	10 (56)	22	10 (45)
Yes	-	-	1	1 (100)	1	1 (100)
p value		-		0.4		0.3
2006						
No	---	---	15	5 (33)	15	5 (33)
Yes	---	---	1	0 (0)	1	0 (0)
p value		---		1.000		1.000
2007						
No	---	---	23	14 (61)	24	15 (63)
Yes	---	---	1	1 (100)	1	1 (100)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 112 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	6	1(17)	48	25 (52)	56	26 (46)
Yes	-	-	4	2 (50)	6	3 (50)
p value				0.9		0.9
2004						
No	-	-	12	5 (42)	12	5 (42)
Yes	-	-	4	4 (100)	4	4 (100)
p value				0.04		0.04
2005						
No	3	0(0)	18	10 (56)	22	10 (45)
Yes	-	-	1	1 (100)	1	1 (100)
p value				0.4		0.3
2006						
No	---	---	16	5 (31)	16	5 (31)
Yes	---	---	1	1 (0.0)	1	1 (0.0)
p value				1.000		1.000
2007						
No	---	---	27	17 (63)	27	17 (63)
Yes	---	---	---	---	---	---
p value				---		---

* Total includes people who did not report duration of drug injection

Table 113 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	5	1 (20)	48	26 (54)	57	28 (49)
Yes	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.6		0.1		0.1
2004						
No	-	-	16	9 (56)	16	9 (56)
Yes	-	-	-	-	-	-
p value						
2005						
No	3	0(0)	19	11 (58)	23	11 (48)
Yes	-	-	-	-	-	-
p value						
2006						
No	---	---	13	4 (31)	13	4 (31)
Yes	---	---	4	1 (25)	4	1 (25)
p value				1.000		1.000
2007						
No	---	---	25	17 (68)	26	18 (69)
Yes	---	---	1	0 (0.0)	1	0 (0.0)
p value				0.346		0.333

* Total includes people who did not report duration of drug injection

Table 114 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	37	18 (49)	17	8 (47)	54	26 (48)
Yes	6	1 (17)	-	-	6	1 (17)
p value		0.1				0.1
2004						
No	11	6 (55)	3	2 (67)	15	8 (53)
Yes	-	-	1	1 (100)	1	1 (100)
p value		-		0.4		0.5
2005						
No	14	6 (43)	9	6 (67)	23	12 (52)
Yes	1	0 (0)	-	-	1	0 (0)
p value		0.4				0.4
2006						
No	7	4 (57)	7	1 (14)	14	5 (36)
Yes	---	---	3	0 (0)	3	0 (0)
p value		---		1.000		0.515
2007						
No	19	13 (68)	9	5 (56)	28	18 (64)
Yes	---	---	---	---	---	---
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 115 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	36	17 (47)	16	9 (56)	52	26 (50)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	4	0 (0)	2	0 (0)	6	0 (0)
Other	4	3 (75)	---	---	4	3 (75)
p value		0.09		0.1		0.03
2004						
Australia	10	6 (60)	4	3 (75)	15	9 (60)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	1	0 (0)	---	---	1	0 (0)
p value		0.2		---		0.2
2005						
Australia	15	6 (40)	9	6 (67)	15	6 (67)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p value		---		---		---
2006						
Australia	6	3 (50)	10	1 (10)	16	4 (25)
Other Oceania	1	1 (100)	---	---	1	1 (100)
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p value		1.000		---		0.294
2007						
Australia	17	12 (71)	9	5 (56)	26	17 (65)
Other Oceania	1	1 (100)	---	---	1	1 (100)
Asia	---	---	---	---	---	---
UK & Ireland	1	0 (0.0)	---	---	1	0 (0.0)
Other	---	---	---	---	---	---
p value		0.544		---		0.595

* Total includes people whose gender was not reported or reported as transgender

Table 116 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	41	18 (44)	18	9 (50)	59	27 (46)
Non-English speaking	1	0 (0)	---	---	1	0 (0)
p value		0.4		---		0.4
2004						
English speaking	6	4 (67)	4	3 (75)	11	7 (64)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---
2005						
English speaking	12	6 (50)	9	6 (67)	21	12 (57)
Non-English speaking	3	0 (0)	---	---	3	0 (0)
p value		0.1		---		0.06
2006						
English speaking	6	4 (67)	9	1 (11)	15	5 (33)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---
2007						
English speaking	18	12 (67)	9	5 (56)	27	17 (63)
Non-English speaking	1	1 (100)	---	---	1	1 (100)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Queensland 2003 – 2007

Table 117 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	10	7	7	7	7
N ^o surveyed	N = 745	N=587	N=291	N=501	N=417
Response (%)	50	58	31	33	34
Gender (%)					
Male	512 (69)	407 (69)	198 (68)	353 (70)	282 (68)
Female	226 (30)	179 (30)	91 (31)	145 (29)	131 (31)
Transgender	5 (<1)	1 (<1)	1 (0)	2 (<1)	3 (<1)
Not reported	2 (<1)	---	1 (0)	1 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	577 (77)	492 (84)	236 (81)	411 (82)	350 (84)
Bisexual	70 (9)	46 (8)	23 (8)	37 (7)	32 (8)
Homosexual	42 (6)	27 (4)	19 (7)	39 (8)	25 (6)
Not reported	56 (8)	22 (4)	13 (4)	14 (3)	10 (2)
Age and duration of injection (years)					
<i>Median age</i>	31	31	32	33	35
<i>Age range</i>	15-55	16-61	16-63	13-57	17-60
<i>Age group (%)</i>					
<25 years	170 (23)	117 (20)	43 (15)	75 (15)	49 (12)
25+ years	573 (77)	468 (80)	248 (85)	425 (85)	367 (88)
Not reported	2 (<1)	2 (<1)	--	1 (<1)	1 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	8-49	9-56	11-50	10-52	11-44
Not reported	37	11	9	1	12
<i>Median years IDU</i>	10	11	13	13	14
<i>Range</i>	<1-40	<1-37	<1-37	<1-43	<1-38
Duration of drug injection					
<3 years	65 (9)	45 (8)	18 (6)	39 (8)	32 (8)
3+ years	642 (86)	531 (90)	258 (89)	442 (88)	373 (89)
Not reported	38 (5)	11 (2)	15 (5)	20 (4)	12 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	669 (90)	541 (92)	273 (94)	438 (87)	375 (90)
Yes	51 (7)	33 (6)	14 (5)	49 (10)	38 (10)
Not reported	25 (3)	13 (2)	4 (1)	14 (3)	4 (<1)
Region/Country of birth (%)					
Australia	645 (87)	492 (84)	259 (89)	436 (87)	374 (90)
Other Oceania	37 (5)	31 (5)	11 (4)	21 (4)	15 (4)
Asia	7 (1)	7 (1)	2 (1)	4 (<1)	1 (<1)
UK & Ireland	26 (3)	29 (5)	13 (4)	18 (4)	14 (3)
Other	17 (2)	16 (3)	5 (2)	12 (2)	10 (2)
Not reported	13 (2)	12 (2)	1 (<1)	10 (2)	3 (<1)
Main language spoken at home by parents (%)					
English speaking	692 (93)	453 (77)	259 (89)	465 (93)	395 (95)
Non-English speaking	27 (4)	12 (2)	32 (11)	17 (3)	17 (4)
Not reported	26 (3)	122 (21)	--	19 (4)	5 (1)
Imprisonment last year (%)					
No	636 (85)	499 (85)	250 (86)	412 (82)	363 (87)
Yes	96 (13)	83 (14)	34 (12)	67 (13)	43 (10)
Not reported	13 (2)	5 (1)	7 (2)	22 (4)	11 (3)
Injected in prison (%)					
Yes	N = 96	N = 83	N=34	N=67	N=43
Yes	30 (31)	55 (66)	14 (41)	27 (40)	22 (51)
Frequency of injection last month (%)					
Not last month	88 (12)	59 (10)	35 (12)	61 (12)	32 (8)
Less than weekly	149 (20)	119 (20)	45 (15)	100 (20)	70 (17)
Weekly not daily	196 (26)	141 (24)	89 (31)	96 (19)	119 (29)
Daily or more	297 (40)	265 (45)	120 (41)	243 (49)	188 (45)
Not reported	15 (2)	3 (1)	2 (1)	1 (<1)	8 (2)

Queensland

Table 118 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 745	N=587	N=291	N=501	N=417
Anabolic steroids	11 (2)	8 (1)	6 (2)	13 (3)	5 (1)
Cocaine	2 (<1)	5 (1)	1 (<1)	2 (<1)	1 (<1)
Heroin	194 (26)	165 (28)	85 (29)	115 (23)	106 (25)
Methadone	25 (3)	24 (4)	10 (3)	24 (5)	19 (5)
Meth/Amphetamine	345 (46)	256 (44)	116 (40)	197 (39)	145 (35)
Morphine/Other Opioids	83 (11)	67 (11)	43 (14)	94 (19)	96 (23)
Subutex/Buprenorphine	2 (<1)	14 (2)	10 (3)	30 (6)	28 (7)
More than one	47 (6)	35 (6)	8 (3)	4 (<1)	2 (<1)
Other	13 (2)	5 (1)	2 (<1)	2 (<1)	6 (1)
Not reported	20 (3)	7 (1)	9 (3)	15 (3)	9 (2)
N° Injected last month	N = 642	N = 525	N=254	N=439	N=377
Places injected last month (%)*					
Own home	530 (83)	418 (80)	202 (80)	355 (85)	328 (88)
Friend's home	271 (42)	211 (40)	97 (38)	165 (40)	159 (43)
Dealer's home	119 (19)	99 (19)	38 (15)	65 (16)	53 (14)
Street, park, beach	145 (23)	117 (22)	57 (22)	88 (21)	65 (17)
Car	198 (31)	167 (32)	77 (30)	126 (30)	134 (36)
Public toilet	158 (25)	117 (22)	66 (26)	94 (23)	73 (20)
Commercial injecting room	3 (<1)	4 (1)	2 (1)	1 (<1)	3 (<1)
Squat	45 (7)	31 (6)	25 (10)	35 (8)	17 (5)
Use of new sterile needles & syringes last month (%)					
All injections	484 (75)	392 (75)	187 (74)	332 (76)	282 (75)
Most of the time	129 (20)	104 (20)	55 (22)	85 (19)	71 (19)
Half of the time	13 (2)	6 (1)	5 (2)	9 (2)	9 (2)
Some of the time	7 (1)	7 (1)	4 (2)	2 (<1)	2 (<1)
Not last month	1 (<1)	5 (1)	1 (0)	1 (<1)	3 (<1)
Not reported	8 (1)	11 (2)	2 (1)	10 (2)	10 (3)
Re-used another's used needle & syringe last month (%)					
None	535 (83)	417 (79)	206 (82)	349 (80)	316 (84)
One	34 (5)	33 (6)	10 (4)	29 (7)	16 (4)
Twice	25 (4)	19 (4)	9 (4)	18 (4)	12 (3)
3-5 times	20 (3)	25 (5)	11 (4)	16 (4)	16 (4)
>5 times	9 (2)	12 (2)	8 (3)	9 (2)	9 (2)
Not reported	19 (3)	19 (4)	8 (3)	18 (4)	8 (2)
Number of people needle & syringe was re-used after last month (%)					
None	514 (80)	417 (79)	196 (77)	349 (80)	316 (84)
One	62 (10)	48 (9)	22 (9)	33 (8)	28 (7)
Two	10 (2)	9 (2)	1 (<1)	3 (<1)	5 (1)
Three to five	3 (<1)	4 (1)	5 (2)	2 (<1)	2 (<1)
More than five	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
Don't know	0 (0)	10 (2)	14 (6)	12 (3)	8 (2)
Not reported	32 (5)	36 (7)	15 (6)	38 (9)	17 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	46 (7)	34 (6)	21 (8)	29 (7)	26 (7)
Casual sex partner	11 (2)	4 (1)	---	4 (<1)	2 (<1)
Close friend	29 (5)	20 (4)	8 (3)	12 (3)	13 (3)
Acquaintance	18 (3)	12 (2)	6 (2)	1 (<1)	---
Other	0 (0)	1 (<1)	3 (1)	2 (<1)	5 (1)
Equipment used after someone else last month (%)*					
Spoon	180 (28)	129 (25)	68 (27)	83 (20)	80 (23)
Water	145 (23)	109 (21)	45 (18)	67 (16)	50 (15)
Filter	117 (18)	76 (14)	38 (15)	51 (12)	53 (15)
Drug mix	76 (12)	56 (11)	32 (13)	35 (8)	33 (10)
Tourniquet	72 (11)	55 (10)	26 (10)	41 (10)	27 (8)
None**	---	---	---	268 (63)	239 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	522 (81)	427 (81)	212 (83)	358 (82)	314 (83)
Yes	96 (15)	79 (15)	31 (12)	65 (15)	52 (14)
Not reported	24 (4)	19 (4)	11 (4)	16 (4)	11 (3)

* More than one option could be selected

** New variable in 2006

Table 119 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 745	N=587	N=291	N=501	N=417
Any treatment/therapy for drug use (%)					
No	308 (41)	174 (30)	73 (25)	115 (23)	86 (21)
Yes	432 (58)	407 (69)	215 (74)	374 (75)	323 (77)
Not reported	5 (1)	6 (1)	3 (1)	12 (2)	8 (2)
History of methadone maintenance treatment (%)					
Currently	157 (21)	141 (24)	62 (21)	91 (18)	94 (23)
Previously	165 (22)	120 (21)	87 (30)	140 (28)	132 (32)
Never	417 (56)	318 (54)	137 (47)	253 (51)	189 (45)
Not reported	6 (1)	8 (1)	5 (2)	17 (3)	2 (<1)
History of other pharmacotherapy treatment (%)					
Currently	73 (10)	81 (14)	47 (16)	81 (16)	81 (19)
Previously	108 (14)	93 (16)	61 (21)	110 (22)	87 (21)
Never	550 (74)	396 (67)	180 (62)	300 (60)	241 (58)
Not reported	14 (2)	17 (3)	3 (1)	10 (2)	8 (2)

Table 120 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007
N° surveyed	N = 745	N=587	N=291	N=501	---
From an NSP last month (%)					
Daily or almost daily	65 (9)	53 (9)	25 (9)	52 (10)	---
A couple of times each week	214 (29)	168 (29)	79 (27)	162 (32)	---
Less than weekly	188 (25)	170 (29)	88 (30)	110 (22)	---
Once last month	135 (18)	94 (16)	55 (19)	84 (17)	---
Not in the last month	120 (16)	91 (15)	38 (13)	85 (17)	---
Not reported	23 (3)	11 (2)	6 (2)	8 (2)	---
From a chemist last month (%)					
Daily or almost daily	30 (4)	18 (3)	5 (2)	15 (3)	---
A couple of times each week	69 (9)	60 (10)	22 (8)	39 (8)	---
Less than weekly	105 (14)	98 (17)	41 (14)	71 (14)	---
Once last month	163 (22)	128 (22)	56 (19)	102 (20)	---
Not in the last month	353 (48)	270 (46)	159 (55)	258 (52)	---
Not reported	25 (3)	13 (2)	8 (3)	16 (3)	---

* Not asked in this form in 2007, see Table 123.

Queensland

Table 121 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N = 745	N=587	N=291	N=501	N=417
Sex last month (%) †					
No	195 (26)	161 (27)	--	--	--
Yes	535 (72)	410 (70)	--	--	--
Not reported	15 (2)	16 (3)	--	--	--
Condom use at last sex (%) †					
No	499 (67)	407 (69)	--	--	--
Yes	223 (30)	171 (29)	--	--	--
Not reported	23 (3)	9 (2)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	217 (62)	194 (68)	--	--	--
Sometimes	54 (15)	34 (12)	--	--	--
Always	81 (23)	57 (20)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	119 (48)	101 (48)	--	--	--
Sometimes	40 (16)	33 (16)	--	--	--
Always	88 (36)	74 (36)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	85 (42)	87 (50)	--	--	--
Sometimes	36 (18)	26 (15)	--	--	--
Always	82 (40)	61 (35)	--	--	--
Duration of regular sexual relationship (%)** †					
One month	35 (9)	26 (9)	--	--	--
2 - 6 months	56 (15)	40 (14)	--	--	--
6 - 12 months	52 (14)	29 (10)	--	--	--
>12 months	227 (61)	189 (67)	--	--	--
Sex with a regular partner last month (%) ****					
No	--	--	135 (46)	200 (40)	178 (43)
Yes	--	--	154 (53)	284 (57)	224 (54)
Not reported	--	--	2 (1)	17 (3)	15 (4)
Condom used with regular partner last month (%)****			N=154****	N=284	N=224
Never	--	--	110 (71)	191 (67)	165 (74)
Sometimes	--	--	18 (12)	49 (17)	31 (14)
Every time	--	--	21 (14)	29 (10)	21 (9)
Not reported	--	--	5 (3)	15 (5)	7 (3)
Sex with other partner/s last month (%)****					
No	--	--	246 (85)	410 (82)	347 (83)
Yes	--	--	38 (13)	68 (14)	61 (15)
Not reported	--	--	7 (2)	23 (5)	9 (2)
Condom used with other partner/s last month (%)****			N=38	N=68	N=61
Never	--	--	9 (24)	17 (25)	20 (33)
Sometimes	--	--	9 (24)	15 (22)	22 (36)
Every time	--	--	18 (47)	32 (47)	16 (26)
Not reported	--	--	2 (5)	4 (6)	3 (5)
Sex work last month (%)					
No	681 (91)	535 (91)	275 (95)	458 (91)	387 (93)
Yes	48 (6)	35 (6)	9 (3)	20 (4)	20 (5)
Not reported	16 (2)	17 (3)	7 (2)	23 (5)	10 (2)
Condom used at last sex work last month (%)**					
Yes	36 (86)	31 (94)	32 (94)	17 (85)	11 (65)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 122 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey

	2003	2004	2005	2006	2007
N° surveyed	N = 745	N=587	N=291	N=501	N=417
Previous HIV test (%)					
Yes, last year	466 (62)	364 (62)	179 (62)	297 (59)	239 (57)
> 1 year ago	184 (25)	154 (26)	83 (29)	159 (32)	135 (32)
Never tested	88 (12)	58 (10)	29 (10)	37 (7)	40 (10)
Not reported	7 (1)	11 (2)	--	8 (2)	3 (<1)
HBV infection (%)					
No	546 (73)	432 (74)	217 (75)	365 (73)	294 (71)
Yes	112 (15)	79 (13)	41 (14)	72 (14)	75 (18)
Don't know	72 (10)	60 (10)	29 (10)	48 (10)	41 (10)
Not reported	15 (2)	16 (3)	4 (1)	16 (3)	7 (2)
HBV vaccination (%)*					
No	165 (26)	146 (29)	56 (22)	95 (22)	73 (21)
Yes	390 (62)	289 (57)	162 (65)	276 (64)	227 (66)
Don't know	60 (9)	51 (10)	29 (12)	43 (10)	35 (10)
Not reported	18 (3)	22 (4)	3 (1)	15 (4)	7 (2)
Previous HCV test (%)					
Yes, last year	468 (63)	383 (65)	185 (64)	297 (59)	258 (62)
> 1 year ago	160 (21)	142 (24)	77 (26)	154 (31)	123 (30)
Never tested	105 (14)	54 (9)	28 (10)	38 (8)	32 (8)
Not reported	12 (2)	8 (2)	1 (<1)	12 (2)	4 (1)
Any treatment for HCV (%)	N = 291	N = 248	N=129	N=207	N=188
Interferon	12 (4)	11 (4)	2 (2)	4 (2)	4 (2)
Interferon+Ribarvarin	1 (<1)	4 (2)	5 (4)	8 (4)	8 (4)
Other	16 (6)	7 (3)	7 (5)	3 (1)	5 (3)
No treatment	255 (88)	217 (87)	112 (87)	187 (90)	163 (87)
Not reported	7 (2)	9 (4)	3 (2)	5 (2)	8 (4)
Current treatment for HCV	N = 4	N=8	N=6	N=5	N=4
Interferon	1	3	1	---	---
Interferon+Ribarvarin	3	1	2	3	4
Other	---	4	3	2	---

* Number (percentage) among participants not reporting HBV infection

Table 123 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N° surveyed	N=417		
Needle/syringe acquisition at time of survey completion (%)			
No	43 (10)		
Yes	358 (86)		
Not reported	16 (4)		
Source of needles/syringes (%)** N=1490***	In last week	In last month	
Chemist/Pharmacy	57 (18)	96 (30)	
Needle Syringe Program	117 (36)	276 (85)	
Dispensing/Vending Machine	13 (4)	37 (11)	
Friend/Dealer	43 (13)	62 (19)	
Other	10 (3)	16 (5)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=96	16 (17)	80 (83)
Needle Syringe Program	N=276	172 (62)	104 (38)
Dispensing/Vending Machine	N=37	5 (14)	32 (86)
Friend/Dealer	N=62	7 (11)	55 (89)
Other	N=16	5 (31)	11 (69)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 124 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	505	7 (1.4)	219	0 (0.0)	731	7 (1.0)
2004	379	10 (2.6)	165	1 (0.6)	544	11 (2.0)
2005	188	4 (2.1)	88	0 (0.0)	278	4 (1.4)
2006	350	11 (3.1)	142	1 (0.7)	495	12 (2.4)
2007	279	10 (3.6)	130	0 (0.0)	413	10 (2.4)
χ^2 trend p value		0.046		0.797		0.049

* Total includes people whose gender was not reported or reported as transgender

Table 125 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heterosexual	414	1 (0.2)	152	0 (0.0)	567	1 (0.2)
Bisexual	17	1 (5.9)	50	0 (0.0)	69	1 (1.5)
Homosexual	32	4 (12.5)	6	0 (0.0)	40	4 (10.0)
p value		<0.001		---		<0.001
2004						
Heterosexual	335	1 (0.3)	121	0 (0.0)	456	1 (0.2)
Bisexual	13	1 (7.7)	30	1 (3.3)	43	2 (4.7)
Homosexual	16	7 (43.8)	8	0 (0.0)	24	7 (29.2)
p value		<0.001		0.2		<0.001
2005						
Heterosexual	159	1 (0.6)	67	0 (0.0)	227	1 (0.4)
Bisexual	8	0 (0.0)	14	0 (0.0)	22	0 (0.0)
Homosexual	12	3 (25.0)	5	0 (0.0)	17	3 (17.7)
p value		<0.001		---		<0.001
2006						
Heterosexual	303	0 (0.0)	104	0 (0.0)	408	0 (0.0)
Bisexual	11	0 (0.0)	22	1 (4.5)	34	1 (2.9)
Homosexual	26	11 (42.3)	12	0 (0.0)	39	11 (28.2)
p value		<0.001		0.246		<0.001
2007						
Heterosexual	249	1 (0.4)	98	0 (0.0)	347	1 (0.3)
Bisexual	7	1 (14.3)	22	0 (0.0)	31	1 (3.2)
Homosexual	18	8 (44.4)	6	0 (0.0)	25	8 (32.0)
p value		<0.001		---		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 126 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
< 20 years	19	0 (0.0)	19	0 (0.0)	38	0 (0.0)
20 – 24	92	2 (2.2)	37	0 (0.0)	131	2 (1.5)
25 – 29	114	0 (0.0)	48	0 (0.0)	164	0 (0.0)
30 + years	278	5 (1.8)	115	0 (0.0)	396	5 (1.3)
p value		0.9		---		0.9
2004						
< 20 years	12	0 (0.0)	9	0 (0.0)	21	0 (0.0)
20 – 24	56	1 (1.8)	33	0 (0.0)	89	1 (1.1)
25 – 29	78	0 (0.0)	39	0 (0.0)	117	0 (0.0)
30 + years	232	8 (3.5)	84	1 (1.2)	316	9 (2.9)
p value		0.4		1.0		0.3
2005						
< 20 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
20 – 24	26	0 (0.0)	10	0 (0.0)	36	0 (0.0)
25 – 29	41	0 (0.0)	22	0 (0.0)	63	0 (0.0)
30 + years	118	4 (3.4)	52	0 (0.0)	172	4 (2.3)
p value		0.5		---		0.5
2006						
< 20 years	11	0 (0)	6	0 (0)	17	0 (0)
20 – 24	35	1 (2.9)	22	0 (0)	57	1 (1.8)
25 – 29	68	0 (0)	27	0 (0)	96	0 (0)
30 + years	235	10 (4.3)	87	1 (1)	324	11 (3.4)
p value		0.356		1.000		0.267
2007						
< 20 years	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
20 – 24	2	0 (0.0)	14	0 (0.0)	42	0 (0.0)
25 – 29	48	0 (0.0)	19	0 (0.0)	67	0 (0.0)
30 + years	196	10 (5.1)	96	0 (0.0)	296	10 (3.4)
p value		0.397		---		0.365

* Total includes people whose gender was not reported or reported as transgender

Table 127 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
<3 years	38	0 (0.0)	24	0 (0.0)	63	0 (0.0)
3 to 5 years	66	0 (0.0)	36	0 (0.0)	102	0 (0.0)
6 to 10 years	129	2 (1.6)	54	0 (0.0)	186	2 (1.1)
> 10 years	245	4 (1.6)	96	0 (0.0)	343	4 (1.2)
p value		0.9		---		0.8
2004						
<3 years	29	0 (0.0)	13	0 (0.0)	42	0 (0.0)
3 to 5 years	51	1 (2.0)	28	0 (0.0)	79	1 (1.3)
6 to 10 years	104	3 (2.9)	45	0 (0.0)	149	3 (2.0)
> 10 years	189	5 (2.7)	76	1 (1.3)	265	6 (2.3)
p value		1.0		1.0		1.0
2005						
<3 years	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)
3 to 5 years	25	0 (0.0)	18	0 (0.0)	43	0 (0.0)
6 to 10 years	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
> 10 years	124	3 (2.4)	51	0 (0.0)	177	3 (1.7)
p value		0.4		---		0.3
2006						
<3 years	25	0 (0)	14	0 (0)	39	0 (0)
3 to 5 years	30	1 (3.3)	16	0 (0)	46	1 (2.2)
6 to 10 years	58	2 (3.5)	36	0 (0)	94	2 (2.1)
> 10 years	219	7 (3.2)	74	1 (1)	296	8 (2.7)
p value		1.000		1.000		0.953
2007						
<3 years	23	1 (4.4)	9	0 (0.0)	32	1 (3.1)
3 to 5 years	15	0 (0.0)	10	0 (0.0)	25	0 (0.0)
6 to 10 years	62	1 (1.6)	24	0 (0.0)	86	1 (1.2)
> 10 years	169	7 (4.1)	85	0 (0.0)	258	7 (2.7)
p value		0.791		---		0.799

* Total includes people whose gender was not reported or reported as transgender

Table 128 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with	N° tested	N° with	N° tested	N° with
2003						
Heroin	122	2 (1.6)	70	0 (0.0)	193	2 (1.0)
Meth/Amphetamine	237	4 (1.7)	95	0 (0.0)	336	4 (1.2)
More than one	35	1 (2.9)	13	0 (0.0)	48	1 (2.1)
Other/Not reported	111	0 (0.0)	41	0 (0.0)	154	0 (0.0)
p value		0.7		---		0.7
2004						
Heroin	109	2 (1.8)	45	0 (0.0)	154	2 (1.3)
Meth/Amphetamine	161	6 (3.7)	73	0 (0.0)	234	6 (2.6)
More than one	19	1 (5.3)	16	1 (6.3)	35	2 (5.7)
Other/Not reported	90	1 (1.1)	31	0 (0.0)	121	1 (0.8)
p value		0.4		0.1		0.2
2005						
Heroin	50	0 (0.0)	38	0 (0.0)	79	0 (0.0)
Meth/Amphetamine	74	1 (1.4)	30	0 (0.0)	114	1 (0.8)
More than one	6	1 (16.7)	1	0 (0.0)	8	1 (12.5)
Other/Not reported	58	2 (3.5)	13	0 (0.0)	77	2 (2.6)
p value		0.07		---		0.05
2006						
Heroin	71	1 (1.4)	41	0 (0)	113	1 (0.9)
Meth/Amphetamine	139	7 (5.0)	56	1 (1.8)	195	8 (4.1)
More than one	4	1 (25.0)	---	---	4	1 (25.0)
Other/Not reported	136	2 (1.5)	45	0 (0)	183	2 (1.1)
p value		0.043		1.000		0.022
2007						
Heroin	64	0 (0.0)	41	0 (0.0)	106	0 (0.0)
Meth/Amphetamine	97	4 (4.1)	46	0 (0.0)	143	4 (2.8)
More than one	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
Other/Not reported	114	6 (5.3)	41	0 (0.0)	158	6 (3.8)
p value		0.297		---		0.204

* Total includes people whose gender was not reported or reported as transgender

**New question in 2005.

Queensland

Table 129 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Not last month	58	0 (0.0)	27	0 (0.0)	85	0 (0.0)
Less than weekly	101	2 (2.0)	45	0 (0.0)	147	2 (1.4)
Weekly not daily	135	3 (2.2)	54	0 (0.0)	191	3 (1.6)
Daily or more	200	1 (0.5)	89	0 (0.0)	293	1 (0.3)
p value		0.2		---		0.2
2004						
Not last month	34	0 (0.0)	20	0 (0.0)	54	0 (0.0)
Less than weekly	78	1 (1.3)	35	0 (0.0)	113	1 (0.9)
Weekly not daily	87	6 (6.9)	41	1 (2.4)	128	7 (5.5)
Daily or more	177	2 (1.1)	69	0 (0.0)	246	2 (0.8)
p value		0.04		0.6		0.02
2005						
Not last month	74	0 (0.0)	40	0 (0.0)	114	0 (0.0)
Less than weekly	61	2 (3.3)	21	0 (0.0)	83	2 (2.4)
Weekly not daily	30	2 (6.7)	13	0 (0.0)	44	2 (4.6)
Daily or more	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
p value		0.1		---		0.1
2006						
Not last month	39	0 (0)	20	0 (0)	60	0 (0)
Less than weekly	71	6 (8.5)	27	0 (0)	99	6 (6.1)
Weekly not daily	70	2 (2.9)	24	1 (4.2)	94	3 (3.2)
Daily or more	169	3 (1.8)	71	0 (0)	241	3 (1.3)
p value		0.042		0.310		0.040
2007						
Not last month	24	2 (8.3)	8	0 (0.0)	32	2 (6.3)
Less than weekly	52	4 (7.7)	17	0 (0.0)	70	4 (5.7)
Weekly not daily	73	3 (4.1)	42	0 (0.0)	116	3 (2.6)
Daily or more	123	0 (0.0)	62	0 (0.0)	187	0 (0.0)
p value		0.005		---		0.003

* Total includes people whose gender was not reported or reported as transgender

Table 130 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	357	5 (1.4)	161	0 (0.0)	524	5 (1.0)
Yes	61	1 (1.6)	25	0 (0.0)	87	1 (1.2)
p value		0.9		---		0.9
2004						
No	277	8 (2.9)	112	1 (0.9)	389	9 (2.3)
Yes	54	1 (1.9)	28	0 (0.0)	82	1 (1.2)
p value		1.0		1.0		1.0
2005						
No	136	4 (2.9)	57	0 (0.0)	194	4 (2.1)
Yes	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
p value		0.4		---		0.4
2006						
No	254	9 (3.5)	90	0 (0.0)	345	9 (2.6)
Yes	44	1 (2.3)	27	0 (0.0)	71	1 (1.4)
p value		1.000		---		1.000
2007						
No	207	7 (3.4)	104	0 (0.0)	314	7 (2.2)
Yes	34	0 (0.0)	16	0 (0.0)	51	0 (0.0)
p value		0.598		---		0.600

* Total includes people whose gender was not reported or reported as transgender

Table 131 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	417	7 (1.7)	202	0 (0.0)	624	7 (1.1)
Yes	78	0 (0.0)	14	0 (0.0)	94	0 (0.0)
p value		0.8		---		0.8
2004						
No	311	9 (2.9)	149	1 (0.7)	460	10 (2.2)
Yes	63	1 (1.6)	16	0 (0.0)	79	1 (1.3)
p value		1.0		1.0		1.0
2005						
No	155	4 (2.6)	80	0 (0.0)	237	4 (1.7)
Yes	29	0 (0.0)	5	0 (0.0)	34	0 (0.0)
p value		0.4		---		0.5
2006						
No	273	10 (3.7)	130	1 (0.8)	406	11 (2.7)
Yes	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
p value		0.697		1.000		1.000
2007						
No	238	10 (4.2)	118	0 (0.0)	359	10 (2.8)
Yes	32	0 (0.0)	11	0 (0.0)	43	0 (0.0)
p value		0.613		---		0.609

* Total includes people whose gender was not reported or reported as transgender

Table 132 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	336	5 (1.5)	150	0 (0.0)	490	5 (1.0)
Yes	156	1 (0.6)	61	0 (0.0)	220	1 (0.5)
p value		0.3		---		0.4
2004						
No	253	6 (2.4)	125	0 (0.0)	378	6 (1.6)
Yes	120	4 (3.3)	39	1 (2.6)	159	5 (3.1)
p value		0.7		0.2		0.2
2005**						
No	69	1 (1.5)	40	0 (0.0)	110	1 (0.9)
Yes	32	1 (3.1)	11	0 (0.0)	43	1 (2.3)
p value		0.6		---		0.5
2006**						
No	156	3 (1.9)	77	1 (1.3)	236	4 (1.7)
Yes	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
p value		0.399		1.000		0.442
2007**						
No	117	1 (0.9)	75	0 (0.0)	194	1 (0.5)
Yes	14	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

** Question changed to "condom use with regular partner in last month" in 2005 survey.

Table 133 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	474	6 (1.3)	191	0 (0.0)	669	6 (0.9)
Yes	21	1 (4.8)	24	0 (0.0)	48	1 (2.1)
p value		0.7		---		0.9
2004						
No	351	9 (2.6)	146	1 (0.7)	497	10 (2.0)
Yes	14	0 (0.0)	18	0 (0.0)	32	0 (0.0)
p value		1.0		1.0		1.0
2005						
No	177	4 (2.3)	83	0 (0.0)	262	4 (1.5)
Yes	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
p value		0.7		---		0.7
2006						
No	327	11 (3.7)	123	1 (0.8)	452	12 (2.7)
Yes	6	0 (0.0)	13	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000
2007						
No	263	10 (3.8)	118	0 (0.0)	383	10 (2.6)
Yes	8	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value				---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 134 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	451	5 (1.1)	197	0 (0.0)	654	5 (0.8)
Yes	36	0 (0.0)	14	0 (0.0)	51	0 (0.0)
p value		0.5		---		0.5
2004						
No	347	9 (2.6)	156	1 (0.6)	503	10 (2.0)
Yes	23	0 (0.0)	5	0 (0.0)	28	0 (0.0)
p value		1.0		1.0		1.0
2005						
No	176	4 (2.3)	82	0 (0.0)	260	4 (1.5)
Yes	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
p value		0.6		---		0.6
2006						
No	306	9 (2.9)	128	1 (0.78)	434	10 (2.3)
Yes	34	2 (5.9)	13	0 (0.0)	48	2 (4.2)
p value		0.303		1.000		0.340
2007						
No	250	8 (3.2)	119	0 (0.0)	372	8 (2.2)
Yes	26	2 (7.7)	10	0 (0.0)	37	2 (5.4)
p value		0.240		---		0.226

* Total includes people whose gender was not reported or reported as transgender

Table 135 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Australia	435	5 (1.2)	191	0 (0.0)	632	5 (0.8)
Other Oceania	23	1 (4.4)	13	0 (0.0)	37	1 (2.7)
Asia	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
UK & Ireland	19	1 (5.3)	6	0 (0.0)	25	1 (4.0)
Other	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
p value		0.4		---		0.4
2004						
Australia	322	7 (2.2)	138	1 (0.7)	460	8 (1.7)
Other Oceania	20	0 (0.0)	8	0 (0.0)	28	0 (0.0)
Asia	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
UK & Ireland	21	2 (9.5)	6	0 (0.0)	27	2 (7.4)
Other	6	0 (0.0)	6	0 (0.0)	12	0 (0.0)
p value		0.3		1.0		0.3
2005						
Australia	163	3 (1.8)	83	0 (0.0)	248	3 (1.2)
Other Oceania	9	0 (0.0)	---	0 (0.0)	9	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	9	1 (11.1)	4	0 (0.0)	13	1 (7.7)
Other	5	0 (0.0)	---	0 (0.0)	5	0 (0.0)
p value		0.4		---		0.4
2006						
Australia	302	8 (2.7)	125	1 (0.8)	430	9 (2.1)
Other Oceania	14	1 (7.1)	7	0 (0)	21	1 (4.8)
Asia	4	0 (0)	---	---	4	0 (0)
UK & Ireland	15	2 (13.3)	3	0 (0)	18	2 (11.1)
Other	6	0 (0)	6	0 (0)	12	0 (0)
p value		0.134		1.000		0.144
2007						
Australia	248	9 (3.6)	118	0 (0.0)	370	9 (2.4)
Other Oceania	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
Asia	--	---	1	0 (0.0)	1	0 (0.0)
UK & Ireland	11	1 (9.1)	3	0 (0.0)	14	1 (7.1)
Other	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)
p value		0.663		---		0.499

* Total includes people whose gender was not reported or reported as transgender

Table 136 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
English speaking	468	6 (1.3)	205	0 (0.0)	680	6 (0.9)
Non-English speaking	18	0 (0.0)	7	0 (0.0)	25	0 (0.0)
p value		0.6		---		0.6
2004						
English speaking	291	8 (2.8)	133	0 (0.0)	424	8 (1.9)
Non-English speaking	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.0		---		1.0
2005						
English speaking	166	4 (2.4)	79	0 (0.0)	246	4 (1.6)
Non-English speaking	22	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		0.5		---		0.5
2006						
English speaking	323	10 (3.1)	134	1 (0.8)	459	11 (2.4)
Non-English speaking	12	1 (8.3)	4	0 (0)	17	1 (5.9)
p value		0.335		1.000		0.357
2007						
English speaking	261	9 (3.5)	126	0 (0.0)	391	9 (2.3)
Non-English speaking	13	1 (7.7)	4	0 (0.0)	17	1 (5.9)
p value		0.390		---		0.351

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 137 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	505	241 (48)	219	123 (56)	731	366 (50)
2004	381	188 (49)	166	94 (57)	547	282 (52)
2005	188	105 (56)	86	40 (47)	276	146 (53)
2006	349	185 (53)	142	88 (62)	494	276 (56)
2007	278	158 (57)	129	85 (66)	411	247 (60)
χ^2 trend p value		0.008		0.070		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 138 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	414	202 (49)	152	84 (55)	567	286 (50)
Bisexual	17	4 (24)	50	27 (54)	69	32 (46)
Homosexual	32	15 (47)	6	4 (67)	40	20 (50)
p value		0.1		0.8		0.8
2004						
Heterosexual	337	165 (49)	122	73 (60)	459	238 (52)
Bisexual	13	8 (62)	30	13 (43)	43	21 (49)
Homosexual	16	9 (56)	8	4 (50)	24	13 (54)
p value		0.6		0.3		0.9
2005						
Heterosexual	159	84 (53)	65	32 (49)	225	116 (52)
Bisexual	8	5 (63)	14	4 (29)	22	9 (41)
Homosexual	13	10 (77)	5	3 (60)	18	13 (72)
p value		0.2		0.3		0.1
2006						
Heterosexual	302	165 (55)	104	62 (59.6)	407	228 (56)
Bisexual	11	4 (36)	22	16 (73)	34	21 (62)
Homosexual	26	12 (46)	12	7 (58)	39	20 (51)
p value		0.345		0.521		0.669
2007						
Heterosexual	248	140 (56)	97	62 (64)	345	202 (59)
Bisexual	7	4 (57)	22	16 (73)	31	22 (71)
Homosexual	18	11 (61)	6	3 (50)	25	15 (60)
p value		0.943		0.553		0.414

* Total includes people whose gender was not reported or reported as transgender

Table 139 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	19	3 (16)	19	6 (32)	38	9 (24)
20 – 24	92	26 (28)	37	9 (24)	131	36 (27)
25 – 29	114	35 (31)	48	29 (60)	164	64 (39)
30 + years	278	177 (64)	115	79 (69)	396	257 (65)
p value		<0.001		<0.001		<0.001
2004						
< 20 years	12	2 (17)	9	4 (44)	21	6 (29)
20 – 24	57	15 (26)	33	15 (45)	90	30 (33)
25 – 29	78	22 (28)	39	11 (28)	117	33 (28)
30 + years	233	148 (64)	85	64 (75)	318	212 (67)
p value		<0.001		<0.001		<0.001
2005						
< 20 years	3	0 (0.0)	4	1 (25)	7	1 (14)
20 – 24	26	5 (19)	10	0 (0.0)	36	5 (14)
25 – 29	41	16 (39)	22	10 (45)	63	26 (41)
30 + years	118	84 (71)	50	29 (58)	170	114 (67)
p value		<0.001		0.007		<0.001
2006						
< 20 years	11	0 (0)	6	0 (0)	17	0 (0)
20 – 24	35	11 (31)	22	12 (55)	57	23 (40)
25 – 29	68	27 (40)	27	14 (52)	96	42 (44)
30 + years	234	146 (62)	87	62 (71)	323	210 (65)
p value		<0.001		0.002		<0.001
2007						
< 20 years	6	2 (33)	1	0 (0)	7	2 (29)
20 – 24	28	7 (25)	13	6 (46)	41	13 (32)
25 – 29	48	26 (54)	19	11 (58)	67	37 (55)
30 + years	195	122 (63)	96	68 (71)	295	194 (66)
p value		0.001		0.091		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 140 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	38	4 (11)	24	4 (17)	63	8 (13)
3 to 5 years	66	16 (24)	36	11 (31)	102	27 (26)
6 to 10 years	129	51 (40)	54	26 (48)	186	78 (42)
> 10 years	245	162 (66)	96	77 (80)	343	240 (70)
p value		<0.001		<0.001		<0.001
2004						
<3 years	29	10 (34)	13	2 (15)	42	12 (29)
3 to 5 years	52	10 (19)	28	10 (36)	80	20 (25)
6 to 10 years	104	41 (39)	46	23 (50)	150	64 (43)
> 10 years	190	125 (66)	76	57 (75)	266	182 (68)
p value		<0.001		<0.001		<0.001
2005						
<3 years	17	3 (18)	6	1 (17)	24	5 (21)
3 to 5 years	25	7 (28)	18	3 (17)	43	10 (23)
6 to 10 years	16	6 (38)	11	3 (27)	27	9 (33)
> 10 years	120	85 (71)	46	29 (63)	167	114 (68)
p value		<0.001		0.002		<0.001
2006						
<3 years	25	4 (16)	14	4 (29)	39	8 (21)
3 to 5 years	30	8 (27)	16	4 (25)	46	12 (26)
6 to 10 years	58	24 (41)	36	28 (78)	94	52 (55)
> 10 years	218	140 (64)	74	52 (70)	295	195 (66)
p value		<0.001		<0.001		<0.001
2007						
<3 years	23	4 (17)	9	2 (22)	32	6 (19)
3 to 5 years	15	4 (27)	10	5 (50)	25	9 (36)
6 to 10 years	62	26 (42)	23	11 (48)	85	37 (44)
> 10 years	168	117 (70)	85	66 (78)	257	187 (73)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 141 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	5	1 (20)	185	126 (68)	193	130 (67)
Meth/Amphetamine	44	6 (14)	282	119 (42)	336	128 (38)
More than one	1	0 (0)	45	22 (49)	48	23 (48)
Other/Not reported	13	1 (8)	119	78 (66)	154	85 (55)
p value		0.9		<0.001		<0.001
2004						
Heroin	3	1 (33)	150	85 (57)	156	89 (57)
Meth/Amphetamine	24	9 (38)	210	84 (40)	235	94 (40)
More than one	1	0 (0)	32	18 (56)	35	18 (51)
Other/Not reported	14	2 (14)	104	79 (76)	121	81 (67)
p value		0.4		<0.001		<0.001
2005						
Heroin	4	2 (50)	74	42 (57)	78	44 (56)
Meth/Amphetamine	13	1 (7)	100	39 (39)	113	40 (36)
More than one	---	---	8	6 (75)	8	6 (75)
Other/Not reported	6	1 (17)	71	55 (77)	77	52 (73)
p value		0.3		<0.001		<0.001
2006						
Heroin	3	1 (33)	104	73 (70)	113	78 (69)
Meth/Amphetamine	22	2 (9)	165	70 (42)	195	73 (37)
More than one	---	---	4	3 (75)	4	3 (75)
Other/Not reported	14	5 (36)	162	113 (70)	182	122 (67)
p value		0.093		<0.001		<0.001
2007						
Heroin	4	0 (0.0)	100	66 (66)	106	67 (63)
Meth/Amphetamine	24	5 (21)	119	63 (53)	143	68 (48)
More than one	---	---	5	1 (20)	6	1 (17)
Other/Not reported	4	1 (25)	143	103 (72)	156	111 (71)
p value		1.000		0.002		<0.001

* Total includes people who did not report duration of drug injection

Queensland

Table 142 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	32	3 (9)	298	153 (51)	338	161 (48)
Daily or more	19	3 (16)	266	169 (64)	293	176 (60)
p value		0.5		0.003		0.002
2004						
Less than daily	23	8 (35)	216	108 (50)	241	117 (49)
Daily or more	14	3 (21)	233	142 (61)	249	146 (59)
p value		0.5		0.02		0.03
2005						
Less than daily	20	4 (20)	133	67 (50)	161	75 (47)
Daily or more	2	1 (50)	104	66 (63)	113	71 (63)
p value		0.3		0.04		0.01
2006						
Less than daily	17	1 (6)	169	93 (55)	192	95 (49)
Daily or more	17	6 (35)	212	137 (65)	241	150 (62)
p value		0.085		0.059		0.009
2007						
Less than daily	20	3 (15)	163	92 (56)	168	98 (53)
Daily or more	10	2 (20)	170	124 (73)	185	130 (70)
p value		1.000		0.002		0.001

* Total includes people who did not report duration of drug injection

Table 143 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	45	6 (13)	466	256 (55)	525	270 (51)
Yes	3	0 (0)	83	58 (70)	87	59 (68)
p value		0.5		0.01		0.005
2004						
No	30	8 (27)	359	190 (53)	392	199 (51)
Yes	5	2 (40)	76	50 (66)	82	53 (65)
p value		0.6		0.04		0.02
2005						
No	15	4 (27)	168	90 (54)	194	100 (52)
Yes	1	0 (0)	32	20 (63)	35	21 (60)
p value		0.6		0.4		0.4
2006						
No	30	7 (23)	303	177 (58)	344	189 (55)
Yes	3	0 (0)	61	41 (67)	71	44 (62)
p value		1.000		0.252		0.296
2007						
No	27	4 (15)	280	175 (63)	313	184 (59)
Yes	3	1 (33)	46	37 (80)	50	39 (78)
p value		0.433		0.019		0.012

* Total includes people who did not report duration of drug injection

Table 144 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	58	7 (12)	534	287 (54)	624	304 (49)
Yes	3	1 (33)	87	53 (61)	94	57 (61)
p value		0.5		0.4		0.07
2004						
No	40	12 (30)	414	210 (51)	462	226 (49)
Yes	1	0 (0)	79	55 (70)	80	55 (69)
p value		1.0		0.002		0.001
2005						
No	22	4 (18)	199	108 (54)	235	119 (51)
Yes	2	1 (50)	31	20 (65)	34	22 (65)
p value		0.3		0.3		0.1
2006						
No	34	8 (24)	355	200 (56)	405	214 (53)
Yes	3	0 (0)	62	44 (71)	67	45 (67)
p value		1.000		0.036		0.034
2007						
No	31	5 (16)	317	188 (59)	358	199 (56)
Yes	1	1 (100)	39	34 (87)	42	37 (88)
p value		0.188		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 145 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	60	7 (12)	577	310 (54)	669	328 (49)
Yes	3	1 (33)	43	29 (67)	48	32 (67)
p value		0.3				0.05
2004						
No	40	12 (30)	452	238 (53)	499	252 (51)
Yes	1	0 (0)	31	20 (65)	32	20 (63)
p value		1.0		0.2		0.2
2005						
No	24	5(21)	221	124 (56)	260	137 (53)
Yes	-	-	9	4 (44)	9	4 (44)
p value				0.5		0.6
2006						
No	37	8 (22)	394	229 (58)	451	246 (55)
Yes	---	---	20	14 (70)	20	14 (70)
p value		---		0.357		0.250
2007						
No	29	6 (21)	341	211 (62)	381	224 (59)
Yes	1	0 (0.0)	18	16 (89)	20	17 (85)
p value		1.000		0.023		0.020

* Total includes people who did not report duration of drug injection

Queensland

Table 146 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	452	208 (46)	197	112 (57)	655	321 (49)
Yes	36	21 (58)	14	8 (57)	51	30 (59)
p value		0.2		>0.9		0.2
2004						
No	349	173 (50)	156	86 (55)	505	259 (51)
Yes	23	11 (48)	6	5 (83)	29	16 (55)
p value		1.0		0.2		0.7
2005						
No	176	99 (56)	82	38 (46)	260	138 (53)
Yes	10	4 (40)	2	2 (100)	12	6 (50)
p value		0.3		0.1		0.8
2006						
No	305	161 (53)	128	74 (58)	433	235 (54)
Yes	34	16 (47)	13	13 (100)	48	30 (63)
p value		0.589		0.002		0.289
2007						
No	249	142 (57)	118	76 (64)	370	221 (60)
Yes	26	14 (54)	10	8 (80)	37	23 (62)
p value		0.836		0.492		0.861

* Total includes people whose gender was not reported or reported as transgender

Table 147 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	436	206 (47)	191	105 (55)	633	313 (49)
Other Oceania	23	9 (39)	13	11 (85)	37	20 (54)
Asia	6	3 (50)	1	0 (0)	7	3 (43)
UK & Ireland	19	9 (47)	6	3 (50)	25	12 (48)
Other	11	8 (73)	5	2 (40)	16	10 (63)
p value		0.5		0.2		0.8
2004						
Australia	324	161 (50)	139	80 (58)	463	241 (52)
Other Oceania	20	10 (50)	8	4 (50)	28	14 (50)
Asia	4	2 (50)	3	1 (33)	7	3 (43)
UK & Ireland	21	11 (52)	6	4 (67)	27	15 (56)
Other	6	2 (33)	6	3 (50)	12	5 (42)
p value		0.9		0.9		0.9
2005						
Australia	163	92 (56)	81	38 (47)	246	131 (53)
Other Oceania	9	3 (33)			9	3 (33)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	9	6 (67)	4	2 (50)	13	8 (62)
Other	5	2 (40)	---	---	5	2 (40)
p value		0.4		0.6		0.7
2006						
Australia	301	160 (53)	125	75 (60)	429	238 (55)
Other Oceania	14	4 (29)	7	7 (100)	21	11 (52)
Asia	4	2 (50)	---	---	4	2 (50)
UK & Ireland	15	10 (67)	3	2 (67)	18	12 (67)
Other	6	3 (50)	6	3 (50)	12	6 (50)
p value		0.332		0.135		0.875
2007						
Australia	247	141 (57)	117	77 (66)	368	222 (60)
Other Oceania	9	4 (44)	6	3 (50)	15	7 (47)
Asia	---	---	1	1 (100)	1	1 (100)
UK & Ireland	11	7 (64)	3	2 (67)	14	9 (64)
Other	8	4 (50)	2	2 (100)	10	6 (60)
p value		0.818		0.816		0.821

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 148 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	469	228 (49)	205	117 (57)	681	347 (51)
Non-English speaking	18	6 (33)	7	2 (29)	25	8 (32)
p value		0.2		0.1		0.06
2004						
English speaking	292	147 (50)	134	72 (54)	426	219 (51)
Non-English speaking	6	4 (67)	2	1 (50)	8	5 (63)
p value		0.7		1.0		0.7
2005						
English speaking	166	95 (57)	77	34 (44)	244	130 (53)
Non-English speaking	22	10 (45)	9	6 (67)	32	16 (50)
p value		0.3		0.2		0.7
2006						
English speaking	322	169 (52)	134	83 (62)	458	254 (55)
Non-English speaking	12	7 (58)	4	2 (50)	17	10 (59)
p value		0.774		0.638		1.000
2007						
English speaking	260	150 (58)	125	83 (66)	389	237 (61)
Non-English speaking	13	6 (46)	4	2 (50)	17	8 (47)
p value		0.567		0.605		0.313

* Total includes people whose gender was not reported or reported as transgender

South Australia 2003 – 2007

Table 149 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	6	6	7	6	7
N ^o surveyed	N = 355	N = 255	N=211	N=200	N=220
Response (%)	50	42	47	36	39
Gender (%)					
Male	221 (62)	161 (63)	126 (60)	114 (57)	127 (58)
Female	129 (36)	89 (35)	84 (40)	86 (43)	91 (41)
Transgender	4 (1)	3 (1)	1 (0)	---	2 (1)
Not reported	1 (<1)	2 (1)	---	---	---
Sexual identity (%)					
Heterosexual	265 (75)	203 (80)	166 (79)	160 (80)	175 (80)
Bisexual	45 (13)	34 (13)	27 (13)	17 (9)	23 (10)
Homosexual	25 (7)	8 (3)	9 (4)	10 (5)	15 (7)
Not reported	20 (5)	10 (4)	9 (4)	13 (7)	7 (3)
Age and duration of injection (years)					
<i>Median age</i>	31	30	33	34	34
Age range	16—60	16 – 56	18-59	16-58	19-58
<i>Age group (%)</i>					
<25 years	58 (16)	65 (26)	30 (14)	27 (14)	25 (11)
25+ years	296 (84)	187 (73)	181 (86)	172 (86)	193 (88)
Not reported	1 (<1)	3 (1)	---	1 (<1)	2 (1)
<i>Median age 1stIDU</i>	18	18	18	18	18
Age range	3—48	11 – 52	12-50	10-44	10-47
Not reported	9	13	4	1	5
<i>Median years IDU</i>	12	10	13	14	13
Range	<1—38	<1 – 71	<1-38	<1-41	<1-41
<i>Duration of drug injection (%)</i>					
<3 years	25 (7)	24 (9)	16 (8)	15 (8)	16 (7)
3+ years	320 (90)	217 (85)	187 (89)	180 (90)	199 (90)
Not reported	10 (3)	14 (6)	8 (4)	5 (3)	5 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	317 (89)	228 (90)	186 (88)	176 (88)	202 (92)
Yes	25 (7)	21 (8)	17 (8)	18 (9)	16 (7)
Not reported	13 (4)	6 (2)	8 (4)	6 (3)	2 (1)
Region/Country of birth (%)					
Australia	314 (88)	218 (85)	183 (87)	167 (84)	186 (85)
Other Oceania	2 (1)	3 (1)	2 (1)	1 (<1)	3 (1)
Asia	1 (<1)	8 (3)	2 (1)	5 (3)	2 (<1)
UK & Ireland	20 (6)	13 (5)	16 (8)	18 (9)	18 (8)
Other	14 (4)	9 (4)	7 (3)	8 (4)	8 (4)
Not reported	4 (1)	4 (2)	1 (0)	1 (<1)	3 (1)
Main language spoken at home by parents (%)					
English speaking	290 (82)	179 (70)	174 (82)	166 (83)	195 (89)
Non-English speaking	22 (6)	24 (10)	37 (18)	19 (10)	23 (10)
Not reported	43 (12)	52 (20)	---	15 (8)	2 (1)
Imprisonment last year (%)					
No	304 (86)	197 (77)	179 (85)	174 (87)	173 (79)
Yes	48 (13)	43 (17)	24 (11)	18 (9)	32 (15)
Not reported	3 (1)	15 (6)	8 (4)	8 (4)	15 (7)
Injected in prison (%)					
Yes	N = 48 17 (35)	N = 43 22 (51)	N=24 8 (33)	N=18 4 (22)	N=32 8 (25)
Frequency of injection last month (%)					
Not last month	25 (7)	17 (7)	20 (9)	7 (4)	14 (6)
Less than weekly	60 (17)	34 (13)	42 (20)	37 (19)	40 (18)
Weekly not daily	94 (27)	68 (27)	51 (24)	58 (29)	54 (25)
Daily or more	171 (48)	129 (50)	98 (46)	96 (48)	112 (51)
Not reported	5 (1)	7 (3)	---	2 (1)	---

South Australia

Table 150 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 355	N = 255	N=211	N=200	N=220
Anabolic steroids	3 (1)	1 (<1)	2 (1)	3 (2)	2 (1)
Cocaine	4 (1)	4 (2)	2 (1)	1 (<1)	2 (1)
Heroin	83 (23)	74 (29)	77 (36)	40 (20)	62 (28)
Methadone	14 (4)	12 (5)	5 (2)	7 (4)	11 (5)
Meth/Amphetamine	169 (48)	101(40)	88 (42)	101 (51)	95 (43)
Morphine/Other Opioids	33 (9)	18 (7)	17 (8)	24 (12)	24 (11)
Subutex/Buprenorphine	---	2 (1)	4 (2)	14 (7)	10 (5)
More than one	36 (10)	16 (6)	6 (3)	3 (2)	6 (3)
Other	2 (1)	1 (<1)	1 (<1)	2 (1)	6 (3)
Not reported	8 (2)	24 (9)	7 (3)	5 (2)	2 (1)
N° Injected last month	N = 325	N=231	N=191	N=191	N=206
Places injected last month (%)*					
Own home	287 (88)	191 (83)	164 (86)	168 (92)	176 (88)
Friend's home	145 (45)	112 (48)	88 (46)	85 (47)	90 (45)
Dealer's home	68 (21)	51 (22)	28 (15)	39 (21)	32 (16)
Street, park, beach	72 (22)	43 (19)	34 (18)	28 (15)	45 (23)
Car	123 (38)	89 (39)	87 (46)	63 (35)	84 (42)
Public toilet	64 (20)	43 (19)	30 (16)	33 (18)	44 (22)
Commercial injecting room	1 (<1)	2 (1)	1 (1)	---	1 (<1)
Squat	10 (3)	9 (4)	4 (2)	3 (2)	10 (5)
Use of new sterile needles & syringes last month (%)					
All injections	253 (78)	162 (70)	134 (70)	143 (75)	147 (71)
Most of the time	57 (18)	57 (25)	48 (25)	27 (14)	45 (22)
Half of the time	7 (2)	6 (3)	6 (3)	10 (5)	4 (2)
Some of the time	2 (1)	2 (1)	3 (2)	3 (2)	3 (1)
Not last month	1 (<1)	1 (<1)	---	2 (1)	---
Not reported	5 (1)	3 (1)	---	6 (3)	7 (3)
Re-used another's used needle & syringe last month (%)					
None	278 (86)	181 (78)	163 (85)	157 (82)	166 (81)
Once	12 (4)	8 (3)	8 (4)	5 (3)	11 (5)
Twice	7 (2)	15 (7)	6 (3)	8 (4)	8 (4)
3-5 times	16 (5)	12 (5)	2 (1)	11 (6)	8 (4)
>5 times	5 (1)	11 (5)	4 (2)	5 (3)	4 (2)
Not reported	7 (2)	4 (2)	8 (4)	5 (3)	9 (4)
Number of people needle & syringe was re-used after last month (%)					
None	272 (84)	181 (79)	157 (82)	157 (82)	166 (81)
One	30 (9)	21 (9)	12 (6)	12 (6)	10 (5)
Two	3 (1)	3 (1)	1 (1)	5 (3)	5 (2)
Three to five	---	3 (1)	1 (1)	---	3 (1)
More than five	---	2 (1)	3 (2)	---	1 (<1)
Don't know	5 (1)	7 (3)	8 (4)	7 (4)	5 (2)
Not reported	15 (5)	14 (6)	9 (5)	10 (5)	16 (8)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	25 (47)	13 (6)	15 (8)	10 (5)	15 (7)
Casual sex partner	2 (4)	3 (1)	1 (<1)	2 (1)	4 (2)
Close friend	8 (15)	11 (5)	5 (3)	7 (4)	2 (1)
Acquaintance	4 (8)	6 (3)	3 (2)	4 (2)	1 (<1)
Other	1 (2)	4 (2)	---	3 (2)	2 (1)
Equipment used after someone else last month (%)*					
Spoon	73 (22)	59 (26)	35 (18)	35 (19)	47 (24)
Water	73 (22)	56 (24)	37 (19)	32 (17)	39 (20)
Filter	57 (18)	40 (17)	20 (10)	19 (10)	29 (15)
Drug mix	67 (21)	36 (16)	24 (13)	14 (8)	15 (8)
Tourniquet	50 (15)	38 (16)	30 (16)	16 (9)	30 (15)
None**	---	---	---	112 (60)	118 (60)
Injected by someone after that person injected themselves or others last month (%)					
No	277 (85)	184 (80)	150 (79)	146 (75)	167 (81)
Yes	41 (13)	39 (17)	32 (17)	36 (19)	30 (15)
Not reported	7 (2)	8 (3)	9 (5)	9 (5)	9 (4)

* More than one option could be selected

** New variable in 2006

Table 151 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 355	N = 255	N=211	N=200	N=220
Any treatment/therapy for drug use (%)					
No	147 (41)	51 (20)	72 (34)	69 (35)	60 (27)
Yes	206 (58)	162 (64)	136 (64)	127 (64)	158 (72)
Not reported	2 (1)	42 (16)	3 (1)	4 (2)	2 (1)
History of methadone maintenance treatment (%)					
Currently	72 (20)	47 (18)	45 (21)	25 (13)	51 (23)
Previously	90 (26)	41 (16)	48 (23)	64 (32)	57 (26)
Never	189 (53)	89 (35)	114 (54)	108 (54)	109 (50)
Not reported	4 (1)	78 (31)	4 (2)	3 (2)	3 (1)
History of other pharmacotherapy treatment (%)					
Currently	32 (9)	35 (14)	46 (22)	27 (14)	28 (13)
Previously	55 (15)	39 (15)	32 (15)	38 (19)	46 (21)
Never	259 (73)	156 (61)	128 (61)	130 (65)	143 (65)
Not reported	9 (3)	25 (10)	5 (2)	5 (3)	3 (1)

Table 152 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007
N° surveyed	N = 355	N = 255	N=211	N=200	---
From an NSP last month (%)					
Daily or almost daily	17 (5)	16 (6)	7 (3)	7 (4)	---
A couple of times each week	97 (27)	61 (24)	46 (22)	47 (24)	---
Less than weekly	111 (31)	90 (35)	68 (32)	54 (27)	---
Once last month	85 (24)	49 (19)	60 (28)	59 (30)	---
Not in the last month	41 (12)	30 (12)	27 (13)	28 (14)	---
Not reported	4 (1)	9 (4)	3 (1)	5 (3)	---
From a chemist last month (%)					
Daily or almost daily	14 (4)	6 (2)	5 (2)	5 (2)	---
A couple of times each week	32 (9)	24 (9)	11 (5)	19 (10)	---
Less than weekly	32 (9)	29 (11)	23 (11)	17 (9)	---
Once last month	75 (21)	59 (23)	43 (20)	41 (21)	---
Not in the last month	190 (54)	126 (49)	125 (59)	113 (57)	---
Not reported	12 (3)	11 (4)	4 (2)	5 (2)	---

* Not asked in this form in 2007, see Table 155.

South Australia

Table 153 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N = 355	N = 255	N=211	N=200	N=220
Sex last month (%) †					
No	104 (29)	82 (32)	--	--	--
Yes	241 (68)	167 (66)	--	--	--
Not reported	10 (3)	6 (2)	--	--	--
Condom use at last sex (%)†					
No	249 (70)	166 (65)	--	--	--
Yes	97 (27)	69 (27)	--	--	--
Not reported	9 (3)	20 (8)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	121 (74)	74 (63)	--	--	--
Sometimes	11 (7)	20 (17)	--	--	--
Always	31 (19)	24 (20)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	44 (43)	44 (49)	--	--	--
Sometimes	17 (16)	12 (13)	--	--	--
Always	42 (41)	34 (38)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	38 (42)	34 (42)	--	--	--
Sometimes	19 (21)	23 (28)	--	--	--
Always	33 (37)	25 (30)	--	--	--
Duration of regular sexual relationship (%)** †					
One month	10 (6)	14 (11)	--	--	--
2 - 6 months	18 (10)	11 (9)	--	--	--
6 - 12 months	21 (12)	21 (16)	--	--	--
>12 months	127 (72)	81 (64)	--	--	--
Sex with a regular partner last month (%) ****					
No	--	--	98 (46)	88 (44)	88 (40)
Yes	--	--	107 (51)	111 (56)	122 (55)
Not reported	--	--	6 (3)	1 (<1)	10 (5)
Condom used with regular partner last month (%)****			N=107*****	N=111	N=122
Never	--	--	82 (77)	81 (73)	97 (80)
Sometimes	--	--	15 (14)	14 (13)	17 (14)
Every time	--	--	8 (7)	8 (7)	6 (5)
Not reported	--	--	2 (2)	8 (7)	2 (2)
Sex with other partner/s last month (%)****					
No	--	--	172 (82)	164 (82)	171 (78)
Yes	--	--	34 (16)	30 (15)	42 (19)
Not reported	--	--	5 (2)	6 (3)	7 (3)
Condom used with other partner/s last month (%)****			N=34	N=30	N=42
Never	--	--	7 (21)	9 (30)	21 (50)
Sometimes	--	--	9 (26)	7 (23)	6 (14)
Every time	--	--	17 (50)	12 (40)	14 (33)
Not reported	--	--	1 (3)	2 (7)	1 (2)
Sex work last month (%)					
No	318 (90)	221 (87)	195 (92)	182 (91)	194 (88)
Yes	15 (4)	19 (7)	10 (5)	12 (6)	21 (10)
Not reported	22 (6)	15 (6)	6 (3)	6 (3)	5 (2)
Condom used at last sex work last month (%)**					
Yes	15 (100)	17 (94)	24 (96)	8 (80)	13 (72)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 154 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey

	2003	2004	2005	2006	2007
N ^o surveyed	N = 355	N = 255	N=211	N=200	N=220
Previous HIV test (%)					
Yes, last year	225 (63)	134 (53)	107 (51)	99 (50)	116 (53)
> 1 year ago	96 (27)	76 (30)	77 (36)	67 (34)	76 (35)
Never tested	28 (8)	31 (12)	26 (12)	34 (17)	27 (12)
Not reported	6 (2)	14 (5)	1 (<1)	---	1 (<1)
HBV infection (%)					
No	276 (78)	173 (68)	166 (79)	156 (78)	175 (80)
Yes	43 (12)	38 (15)	24 (11)	22 (11)	25 (11)
Don't know	33 (9)	28 (11)	21 (10)	19 (10)	18 (8)
Not reported	3 (1)	16 (6)	---	3 (2)	2 (1)
HBV vaccination (%)*					
No	106 (34)	67 (31)	66 (35)	55 (31)	58 (30)
Yes	172 (55)	105 (48)	96 (51)	98 (55)	113 (58)
Don't know	27 (9)	31 (14)	24 (13)	23 (13)	22 (11)
Not reported	7 (2)	14 (7)	1 (1)	2 (1)	2 (1)
Previous HCV test (%)					
Yes, last year	223 (63)	138 (54)	113 (54)	117 (59)	123 (56)
> 1 year ago	93 (26)	75 (30)	70 (33)	51 (26)	73 (33)
Never tested	37 (10)	34 (13)	27 (13)	32 (16)	23 (10)
Not reported	2 (1)	8 (3)	1 (<1)	---	1 (<1)
Any treatment for HCV (%)					
	N = 141	N=84	N=70	N=68	N=59
Interferon	2 (1)	2 (2)	2 (3)	3 (4)	---
Interferon+Ribarvarin	1 (1)	1 (1)	1 (1)	2 (3)	2 (3)
Other	5 (4)	2 (2)	1 (1)	2 (3)	1 (2)
No treatment	130 (92)	77 (93)	65 (93)	53 (78)	53 (90)
Not reported	3 (2)	2 (2)	1 (1)	8 (12)	3 (5)
Current treatment for HCV					
	N = 4	N=2	N=2	N=3	N=2
Interferon	---	1	1	---	---
Interferon+Ribarvarin	1	---	---	2	2
Other	3	1	1	1	---

* Number (percentage) among participants not reporting HBV infection

Table 155 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N ^o surveyed	N=220		
Needle/syringe acquisition at time of survey completion (%)			
No	23 (10)		
Yes	183 (83)		
Not reported	14 (6)		
Source of needles/syringes (%)** N=1490***			
	In last week	In last month	
Chemist/Pharmacy	19 (12)	37 (23)	
Needle Syringe Program	63 (38)	141 (86)	
Dispensing/Vending Machine	1 (<1)	2 (1)	
Friend/Dealer	29 (18)	49 (30)	
Other	3 (2)	6 (4)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***			
	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=37	9 (24)	28 (76)
Needle Syringe Program	N=141	89 (63)	52 (37)
Dispensing/Vending Machine	N=2	1 (50)	1 (50)
Friend/Dealer	N=49	8 (16)	41 (84)
Other	N=6	2 (33)	4 (67)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 156 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	190	1 (0.5)	115	1 (0.9)	308	2 (0.7)
2004	145	0 (0.0)	80	1 (1.3)	229	1 (0.4)
2005	122	1 (0.8)	82	0 (0.0)	205	1 (0.5)
2006	112	1 (0.9)	85	0 (0.0)	197	1 (0.5)
2007	120	2 (1.7)	89	0 (0.0)	211	2 (1.0)
χ^2 trend p value		0.189		<0.001		0.721

* Total includes people whose gender was not reported or reported as transgender

Table 157 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heterosexual	159	0 (0.0)	72	1 (1.4)	233	1 (0.4)
Bisexual	11	0 (0.0)	26	0 (0.0)	37	0 (0.0)
Homosexual	11	1 (9.1)	9	0 (0.0)	20	1 (5.0)
p value		<0.001		0.8		0.05
2004						
Heterosexual	131	0 (0.0)	52	1 (1.9)	184	1 (0.5)
Bisexual	7	0 (0.0)	22	0 (0.0)	30	0 (0.0)
Homosexual	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
p value		---		1.0		1.0
2005						
Heterosexual	107	0 (0.0)	55	0 (0.0)	162	0 (0.0)
Bisexual	5	0 (0.0)	21	0 (0.0)	26	0 (0.0)
Homosexual	5	1 (20.0)	2	0 (0.0)	8	1 (12.5)
p value		<0.001		---		<0.001
2006						
Heterosexual	99	1 (1.0)	59	0 (0.0)	158	1 (0.6)
Bisexual	4	0 (0.0)	13	0 (0.0)	17	0 (0.0)
Homosexual	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		1.000		---		1.000
2007						
Heterosexual	103	0 (0.0)	64	0 (0.0)	167	0 (0.0)
Bisexual	5	1 (20.0)	16	0 (0.0)	22	1 (4.6)
Homosexual	8	1 (12.5)	6	0 (0.0)	15	1 (6.7)
p value		0.012		---		0.032

* Total includes people whose gender was not reported or reported as transgender

Table 158 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
< 20 years	---	---	5	0 (0.0)	5	0 (0.0)
20 – 24	28	0 (0.0)	20	0 (0.0)	48	0 (0.0)
25 – 29	41	1 (2.4)	29	0 (0.0)	70	1 (1.4)
30 + years	121	0 (0.0)	60	1 (1.7)	184	1 (0.5)
p value		0.2		0.8		0.8
2004						
< 20 years	4	0 (0.0)	10	0 (0.0)	14	0 (0.0)
20 – 24	28	0 (0.0)	14	0 (0.0)	42	0 (0.0)
25 – 29	33	0 (0.0)	17	0 (0.0)	50	0 (0.0)
30 + years	79	0 (0.0)	39	1 (2.6)	120	1 (0.8)
p value		---		1.0		1.0
2005						
< 20 years	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
20 – 24	12	0 (0.0)	11	0 (0.0)	23	0 (0.0)
25 – 29	17	0 (0.0)	22	0 (0.0)	39	0 (0.0)
30 + years	92	1 (1.1)	45	0 (0.0)	138	1 (0.7)
p value		1.0		---		0.9
2006						
< 20 years	1	0 (0.0)	4	0 (0.0)		0 (0.0)
20 – 24	8	0 (0.0)	13	0 (0.0)		0 (0.0)
25 – 29	17	0 (0.0)	12	0 (0.0)		0 (0.0)
30 + years	85	1 (1.2)	56	0 (0.0)		1 (0.7)
p value		1.000		---		1.000
2007						
< 20 years	---	---	1	0 (0.0)	1	0 (0.0)
20 – 24	7	0 (0.0)	13	0 (0.0)	21	0 (0.0)
25 – 29	23	0 (0.0)	21	0 (0.0)	44	0 (0.0)
30 + years	89	2 (2.3)	53	0 (0.0)	143	2 (1.4)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 159 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
<3 years	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)
3 to 5 years	21	0 (0.0)	18	0 (0.0)	39	0 (0.0)
6 to 10 years	34	1 (2.9)	31	0 (0.0)	65	1 (1.5)
10 + years	120	0 (0.0)	51	1 (2.0)	173	1 (0.6)
p value		0.2		0.8		0.8
2004						
<3 years	13	0 (0.0)	9	0 (0.0)	22	0 (0.0)
3 to 5 years	21	0 (0.0)	17	0 (0.0)	38	0 (0.0)
6 to 10 years	32	0 (0.0)	18	0 (0.0)	50	0 (0.0)
10 + years	71	0 (0.0)	34	1 (2.9)	107	1 (0.9)
p value		---		1.0		1.0
2005						
<3 years	8	1 (12.5)	8	0 (0.0)	16	1 (6.3)
3 to 5 years	11	0 (0.0)	11	0 (0.0)	23	0 (0.0)
6 to 10 years	9	0 (0.0)	16	0 (0.0)	25	0 (0.0)
10 + years	89	0 (0.0)	44	0 (0.0)	133	0 (0.0)
p value		<0.01		---		0.01
2006						
<3 years	5	0 (0.0)	9	0 (0.0)	14	0 (0.0)
3 to 5 years	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
6 to 10 years	22	0 (0.0)	22	0 (0.0)	44	0 (0.0)
10 + years	72	1 (1.4)	44	0 (0.0)	116	1 (0.9)
p value		1.000		---		1.000
2007						
<3 years	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
3 to 5 years	9	1 (11.1)	11	0 (0.0)	20	1 (5.0)
6 to 10 years	18	0 (0.0)	22	0 (0.0)	41	0 (0.0)
10 + years	82	1 (1.2)	47	0 (0.0)	130	1 (0.8)
p value		0.293		---		0.350

* Total includes people whose gender was not reported or reported as transgender

Table 160 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heroin	43	0 (0.0)	30	1 (3.3)	75	1 (1.3)
Meth/Amphetamine	94	1 (1.1)	54	0 (0.0)	148	1 (0.7)
More than one	22	0 (0.0)	14	0 (0.0)	36	0 (0.0)
Other/Not reported	31	0 (0.0)	17	0 (0.0)	49	0 (0.0)
p value		0.8		0.4		0.8
2004						
Heroin	40	0 (0.0)	23	1 (4.4)	65	1 (1.5)
Meth/Amphetamine	48	0 (0.0)	43	0 (0.0)	91	0 (0.0)
More than one	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
Other/Not reported	47	0 (0.0)	10	0 (0.0)	59	0 (0.0)
p value		---		0.5		0.6
2005						
Heroin	39	0 (0.0)	38	0 (0.0)	77	0 (0.0)
Meth/Amphetamine	54	1 (1.9)	30	0 (0.0)	84	1 (1.2)
More than one	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
Other/Not reported	24	0 (0.0)	13	0 (0.0)	38	0 (0.0)
p value		0.8		---		0.7
2006						
Heroin	24	1 (4.2)	16	0 (0.0)	40	1 (2.5)
Meth/Amphetamine	52	0 (0.0)	47	0 (0.0)	99	0 (0.0)
More than one	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
Other/Not reported	34	0 (0.0)	21	0 (0.0)	55	0 (0.0)
p value		0.232		---		0.218
2007						
Heroin	37	0 (0.0)	23	0 (0.0)	60	0 (0.0)
Meth/Amphetamine	45	1 (2.2)	45	0 (0.0)	90	1 (1.1)
More than one	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
Other/Not reported	35	1 (8.9)	18	0 (0.0)	55	1 (1.8)
p value		0.767		---		0.756

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 161 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Not last month	8	0 (0.0)	11	1 (9.1)	19	1 (0.1)
Less than weekly	30	0 (0.0)	17	0 (0.0)	47	0 (0.0)
Weekly not daily	59	0 (0.0)	30	0 (0.0)	89	0 (0.0)
Daily or more	90	1 (1.1)	55	0 (0.0)	148	1 (0.7)
p value						
2004						
Not last month	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)
Less than weekly	19	0 (0.0)	10	0 (0.0)	29	0 (0.0)
Weekly not daily	42	0 (0.0)	17	1 (5.9)	59	1 (1.7)
Daily or more	74	0 (0.0)	43	0 (0.0)	119	0 (0.0)
p value						
2005						
Not last month	9	1 (11.1)	9	0 (0.0)	18	1 (5.6)
Less than weekly	22	0 (0.0)	18	0 (0.0)	40	0 (0.0)
Weekly not daily	34	0 (0.0)	16	0 (0.0)	50	0 (0.0)
Daily or more	56	0 (0.0)	38	0 (0.0)	95	0 (0.0)
p value						
2006						
Not last month	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
Less than weekly	16	0 (0.0)	20	0 (0.0)	36	0 (0.0)
Weekly not daily	31	1 (3.2)	26	0 (0.0)	57	1 (1.8)
Daily or more	60	0 (0.0)	35	0 (0.0)	95	0 (0.0)
p value		0.464		---		0.513
2007						
Not last month	5	1 (20)	7	0 (0.0)	12	1 (8.3)
Less than weekly	21	0 (0.0)	18	0 (0.0)	39	0 (0.0)
Weekly not daily	31	0 (0.0)	18	0 (0.0)	49	0 (0.0)
Daily or more	63	1 (1.6)	46	0 (0.0)	111	1 (0.9)
p value		0.111		---		0.197

Table 162 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	149	0 (0.0)	87	0 (0.0)	239	0 (0.0)
Yes	27	1 (3.7)	12	0 (0.0)	39	1 (2.6)
p value		0.02		---		0.01
2004						
No	99	0 (0.0)	59	1 (1.7)	160	1 (0.6)
Yes	32	0 (0.0)	12	0 (0.0)	44	0 (0.0)
p value		---		1.0		1.0
2005**						
No	93	0 (0.0)	65	0 (0.0)	159	0 (0.0)
Yes	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
p value		---		---		---
2006						
No	83	0 (0.0)	71	0 (0.0)	154	0 (0.0)
Yes	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
p value		0.202		---		---
2007**						
No	93	1 (1.1)	67	0 (0.0)	161	1 (0.6)
Yes	18	0 (0.0)	10	0 (0.0)	29	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

**One HIV antibody positive participant had missing data for re-use of someone else's used needle and syringe last month.

Table 163 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	155	0 (0.0)	105	1 (1.0)	263	1 (0.4)
Yes	35	1 (2.9)	8	0 (0.0)	43	1 (2.3)
p value		0.04		0.8		0.1
2004						
No	107	0 (0.0)	66	1 (1.5)	174	1 (0.6)
Yes	29	0 (0.0)	11	0 (0.0)	41	0 (0.0)
p value		---		1.0		1.0
2005						
No	97	1 (1.0)	76	0 (0.0)	174	1 (0.6)
Yes	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)
p value		0.7		---		0.7
2006						
No	96	1 (1.0)	75	0 (0.0)	171	1 (0.6)
Yes	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
p value		1.000		---		1.000
2007						
No	89	2 (2.3)	75	0 (0.0)	165	2 (1.2)
Yes	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		1.000		---		1.000

Table 164 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	130	0 (0.0)	86	1 (1.2)	219	1 (0.5)
Yes	55	1 (1.8)	25	0 (0.0)	80	1 (1.3)
p value		0.1		0.6		0.5
2004						
No	98	0 (0.0)	52	1 (1.9)	152	1 (0.7)
Yes	40	0 (0.0)	19	0 (0.0)	59	0 (0.0)
p value		---		1.0		1.0
2005**†						
No	44	0 (0.0)	44	0 (0.0)	88	0 (0.0)
Yes	17	0 (0.0)	11	0 (0.0)	28	0 (0.0)
p value		---		---		---
2006**†						
No	52	1 (1.9)	41	0 (0.0)	93	1 (1.1)
Yes	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007**†						
No	58	1 (1.7)	51	0 (0.0)	110	1 (0.9)
Yes	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

**Question changed to "condom use with regular partner in last month" in 2005 survey.

† The one participant who was HIV antibody positive had missing data for condom use with a regular partner in last month.

Table 165 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	171	0 (0.0)	102	1 (1.0)	275	1 (0.4)
Yes	7	1 (14.3)	5	0 (0.0)	13	1 (7.7)
p value		<0.001		0.8		0.002
2004						
No	133	0 (0.0)	64	0 (0.0)	197	0 (0.0)
Yes	8	0 (0.0)	9	1 (11.0)	19	1 (5.3)
p value		---		0.1		0.09
2005						
No	116	0 (0.0)	72	0 (0.0)	189	0 (0.0)
Yes	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		---		---		---
2006						
No	104	1 (1.0)	75	0 (0.0)	179	1 (0.6)
Yes	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
p value		1.000		---		1.000
2007						
No	109	2 (1.8)	75	0 (0.0)	185	2 (1.1)
Yes	9	0 (0.0)	11	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

**The one participant who was HIV antibody positive had missing data for sex work last month.

Table 166 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	170	0 (0.0)	101	1 (1.0)	274	1 (0.4)
Yes	12	1 (8.3)	10	0 (0.0)	22	1 (4.6)
p value		<0.001		0.8		0.02
2004						
No	136	0 (0.0)	65	1 (1.5)	205	1 (0.5)
Yes	7	0 (0.0)	12	0 (0.0)	19	0 (0.0)
p value		---		1.0		1.0
2005**						
No	110	0 (0.0)	71	0 (0.0)	182	0 (0.0)
Yes	6	0 (0.0)	9	0 (0.0)	15	0 (0.0)
p value		---		---		---
2006						
No	99	1 (1.0)	74	0 (0.0)	173	1 (0.6)
Yes	8	0 (0.0)	10	0 (0.0)	18	0 (0.0)
p value		1.000		---		1.000
2007						
No	110	2 (1.8)	82	0 (0.0)	194	2 (1.0)
Yes	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

**One HIV antibody positive participant had missing data for Aboriginal and Torres Strait Islander origin.

Table 167 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Australia	172	1 (0.6)	99	1 (1.0)	274	2 (0.7)
Other Oceania	---	---	---	0 (0.0)	---	---
Asia	---	---	1	0 (0.0)	1	0 (0.0)
UK & Ireland	8	0 (0.0)	9	0 (0.0)	17	0 (0.0)
Other	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
p value		1.0		1.0		1.0
2004						
Australia	123	0 (0.0)	72	1 (1.4)	198	1 (0.5)
Other Oceania	---	0 (0.0)	---	0 (0.0)	---	---
Asia	5	0 (0.0)	---	0 (0.0)	5	0 (0.0)
UK & Ireland	1	0 (0.0)	---	0 (0.0)	1	0 (0.0)
Other	13	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		---		0.7		1.0
2005						
Australia	103	1 (1.0)	73	0 (0.0)	177	1 (0.6)
Other Oceania	2	0 (0.0)	---	0 (0.0)	2	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
Other	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
p value		1.0		---		1.0
2006						
Australia	90	1 (1.1)	74	0 (0.0)	164	1 (0.6)
Other Oceania	1	0 (0.0)	---	0 (0.0)	1	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
Other	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007						
Australia	102	1 (1.0)	73	0 (0.0)	177	1 (0.6)
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
Asia	2	0 (0.0)	---	---	2	0 (0.0)
UK & Ireland	7	1 (14.3)	11	0 (0.0)	18	1 (5.6)
Other	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		0.254		---		0.276

* Total includes people whose gender was not reported or reported as transgender

Table 168 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
English speaking	150	1 (0.7)	101	1 (1.0)	253	2 (0.8)
Non-English speaking	14	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		0.8		0.8		0.7
2004						
English speaking	92	0 (0.0)	66	1 (1.5)	161	1 (0.6)
Non-English speaking	17	0 (0.0)	5	0 (0.0)	22	0 (0.0)
p value		---		0.8		0.7
2005						
English speaking	94	1 (1.1)	74	0 (0.0)	169	1 (0.6)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
p value		0.6		---		0.6
2006						
English speaking	90	1 (1.1)	74	0 (0.0)	164	1 (0.6)
Non-English speaking	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)
p value		1.000		---		1.000
2007						
English speaking	102	2 (2.0)	85	0 (0.0)	188	2 (1.1)
Non-English speaking	17	0 (0.0)	3	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 169 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	190	86 (45)	115	53 (46)	308	142 (46)
2004	147	67 (46)	80	39 (49)	231	108 (47)
2005	122	54 (44)	82	40 (49)	205	95 (46)
2006	112	49 (44)	85	35 (41)	197	84 (43)
2007	120	50 (42)	89	31 (35)	211	82 (39)
χ^2 trend p value		0.509		0.585		0.082

* Total includes people whose gender was not reported or reported as transgender

Table 170 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	159	74 (47)	72	32 (44)	233	108 (46)
Bisexual	11	6 (55)	26	15 (58)	37	21 (57)
Homosexual	11	3 (36)	9	3 (33)	20	7 (35)
p value		0.7		0.4		0.3
2004						
Heterosexual	133	62 (47)	52	27 (52)	186	90 (48)
Bisexual	7	5 (71)	22	9 (41)	30	15 (50)
Homosexual	4	0 (0)	3	1 (33)	7	1 (14)
p value		0.08		0.6		0.2
2005						
Heterosexual	107	47 (44)	55	28 (51)	162	75 (46)
Bisexual	5	2 (40)	21	10 (48)	26	12 (46)
Homosexual	5	1 (20)	2	1 (50)	8	3 (38)
p value		0.6		1.0		0.9
2006						
Heterosexual	99	47 (47)	59	26 (44)	158	73 (46)
Bisexual	4	0 (0)	13	8 (62)	17	8 (47)
Homosexual	2	1 (50)	8	1 (13)	10	2 (20)
p value		0.164		0.089		0.316
2007						
Heterosexual	103	41 (40)	64	26 (41)	167	67 (40)
Bisexual	5	3 (60)	16	3 (19)	22	7 (32)
Homosexual	8	4 (50)	6	2 (33)	15	6 (40)
p value		0.542		0.304		0.759

* Total includes people whose gender was not reported or reported as transgender

Table 171 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	-	-	5	1 (20)	5	1 (20)
20 – 24	28	7 (25)	20	8 (40)	48	15 (31)
25 – 29	41	17 (41)	29	13 (45)	70	30 (43)
30 + years	121	62 (51)	61	31 (51)	185	96 (52)
p value		0.04		0.05		0.04
2004						
< 20 years	4	0 (0)	10	5 (50)	14	5 (36)
20 – 24	29	6 (21)	14	5 (36)	43	11 (26)
25 – 29	33	15 (45)	17	7 (41)	50	22 (44)
30 + years	81	46 (57)	39	22 (56)	124	70 (56)
p value		0.02		0.5		0.04
2005						
< 20 years	1	0 (0)	4	1 (25)	5	1 (20)
20 – 24	12	3 (25)	11	4 (36)	23	7 (30)
25 – 29	17	4 (24)	22	7 (32)	39	11 (28)
30 + years	92	47 (51)	45	28 (62)	138	76 (55)
p value		0.06		0.06		0.004
2006						
< 20 years	1	0 (0)	4	0 (0)	5	0 (0)
20 – 24	8	0 (0)	13	2 (15)	21	2 (10)
25 – 29	17	6 (35)	12	7 (58)	29	13 (45)
30 + years	85	42 (49)	56	26 (46)	141	68 (48)
p value		0.016		0.035		0.001
2007						
< 20 years	---	---	1	0 (0.0)	1	0 (0.0)
20 – 24	7	4 (57)	13	4 (31)	21	9 (43)
25 – 29	23	9 (39)	21	7 (33)	44	16 (36)
30 + years	89	36 (40)	53	20 (38)	143	56 (39)
p value		0.709		0.906		0.939

* Total includes people whose gender was not reported or reported as transgender

Table 172 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	11	1 (9)	11	2 (18)	22	3 (14)
3 to 5 years	21	5 (24)	18	4 (22)	39	9 (23)
6 to 10 years	34	9 (26)	31	14 (45)	65	23 (35)
10 + years	120	70 (58)	51	32 (63)	173	104 (60)
p value		<0.001		0.004		<0.001
2004						
<3 years	13	3 (23)	9	1 (11)	22	4 (18)
3 to 5 years	22	3 (14)	17	7 (41)	39	10 (26)
6 to 10 years	32	12 (38)	18	7 (39)	50	19 (38)
10 + years	72	47 (65)	34	22 (65)	108	71 (66)
p value		<0.001		0.02		<0.001
2005						
<3 years	12	1 (8)	8	1 (13)	20	2 (10)
3 to 5 years	11	0 (0)	11	3 (27)	23	4 (17)
6 to 10 years	9	2 (22)	16	6 (38)	25	8 (32)
10 + years	85	48 (56)	44	29 (66)	129	77 (60)
p value		<0.001		0.007		<0.001
2006						
<3 years	5	1 (20)	9	0 (0.0)	14	1 (7)
3 to 5 years	9	0 (0)	9	1 (11)	18	1 (6)
6 to 10 years	22	4 (18)	22	6 (28)	44	10 (23)
10 + years	72	41 (57)	44	28 (64)	116	69 (59)
p value		<0.001		<0.001		<0.001
2007						
<3 years	8	0 (0.0)	7	4 (57)	15	4 (27)
3 to 5 years	9	3 (33)	11	2 (18)	20	5 (25)
6 to 10 years	18	6 (33)	22	7 (32)	41	13 (32)
10 + years	82	39 (48)	47	17 (36)	130	57 (44)
p value		0.043		0.405		0.209

* Total includes people whose gender was not reported or reported as transgender

Table 173 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	2	0 (0)	68	44 (65)	75	46 (61)
Meth/Amphetamine	16	1 (6)	130	52 (40)	148	53 (36)
More than one	1	1 (100)	34	17 (50)	36	19 (53)
Other/Not reported	3	1 (33)	45	23 (51)	49	24 (49)
p value		0.04		0.01		0.003
2004						
Heroin	5	3 (60)	59	38 (64)	65	42 (65)
Meth/Amphetamine	13	1 (8)	77	24 (31)	92	26 (28)
More than one	2	0 (0)	11	4 (36)	14	5 (36)
Other/Not reported	2	0 (0)	50	34 (68)	60	35 (58)
p value		0.08		<0.001		<0.001
2005						
Heroin	6	2 (33)	71	40 (56)	77	42 (55)
Meth/Amphetamine	12	0 (0)	72	27 (38)	84	27 (32)
More than one	-	-	6	5 (83)	6	5 (83)
Other/Not reported	2	0 (0)	36	21 (58)	38	21 (55)
p value						
2006						
Heroin	1	0 (0)	39	23 (59)	40	23 (58)
Meth/Amphetamine	8	0 (0)	89	22 (25)	99	22 (22)
More than one	---	---	3	0 (0)	3	0 (0)
Other/Not reported	5	1 (7)	47	35 (74)	55	39 (71)
p value		0.429		0.0		0.0
2007						
Heroin	3	2 (67)	57	29 (51)	60	31 (52)
Meth/Amphetamine	9	1 (11)	78	19 (24)	90	23 (26)
More than one	1	0 (0.0)	5	1 (20)	6	1 (17)
Other/Not reported	2	1 (50)	51	26 (51)	55	27 (49)
p value		0.169		0.002		0.002

* Total includes people who did not report duration of drug injection

Table 174 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	13	0 (0)	118	44 (37)	136	45 (33)
Daily or more	8	3 (38)	139	82 (59)	149	87 (58)
p value		0.04		0.001		<0.001
2004						
Less than daily	7	1 (14)	80	35 (44)	90	37 (41)
Daily or more	13	3 (23)	103	60 (58)	119	66 (55)
p value		1.0		0.05		0.04
2005						
Less than daily	15	2 (13)	92	48 (52)	110	51 (46)
Daily or more	5	0 (0)	85	41 (48)	95	44 (46)
p value		0.4		0.6		>0.9
2006						
Less than daily	9	1 (11)	84	36 (43)	93	37 (40)
Daily or more	3	0 (0)	89	43 (48)	95	45 (47)
p value		1.000		0.542		0.307
2007						
Less than daily	10	1 (10)	77	33 (43)	88	35 (40)
Daily or more	4	2 (50)	103	40 (39)	111	44 (40)
p value		0.176		0.646		1.000

* Total includes people who did not report duration of drug injection

Table 175 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	15	1 (7)	218	100 (46)	239	103 (43)
Yes	5	2 (40)	33	21 (64)	39	24 (62)
p value		0.1		0.06		0.03
2004						
No	12	2 (17)	143	70 (49)	161	76 (47)
Yes	7	2 (29)	37	23 (62)	44	25 (57)
p value		0.6		0.2		0.3
2005						
No	13	2 (15)	139	67 (48)	159	72 (45)
Yes	2	0 (0)	17	11 (65)	19	11 (58)
p value		0.6		0.2		0.3
2006						
No	10	0 (0)	141	61 (43)	154	63 (41)
Yes	1	0 (0)	28	14 (50)	29	14 (48)
p value		---		0.538		0.540
2007						
No	13	2 (15)	145	61 (42)	161	64 (40)
Yes	1	1 (100)	27	9 (33)	29	11 (38)
p value		0.214		0.523		1.000

* Total includes people who did not report duration of drug injection

Table 176 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	20	2 (10)	236	110 (47)	263	113 (43)
Yes	2	1 (50)	40	25 (63)	43	27 (63)
p value		0.3		0.06		0.02
2004						
No	19	4 (21)	149	68 (46)	176	75 (43)
Yes	2	0 (0)	39	25 (64)	41	25 (61)
p value		1.0		0.04		0.03
2005						
No	18	2 (11)	151	72 (48)	174	75 (43)
Yes	1	0 (0)	20	11 (55)	23	13 (57)
p value		0.7		0.5		0.2
2006						
No	14	0 (0)	153	67 (44)	171	70 (41)
Yes	---	---	17	8 (47)	18	9 (50)
p value		---		0.803		0.464
2007						
No	12	3 (25)	150	51 (34)	165	55 (33)
Yes	1	0 (0.0)	30	20 (67)	32	21 (66)
p value		1.000		0.002		0.001

* Total includes people who did not report duration of drug injection

Table 177 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	20	3 (15)	246	114 (46)	275	120 (44)
Yes	---	---	13	11 (85)	13	11 (85)
p value		---		0.009		0.004
2004						
No	18	4 (22)	171	84 (49)	199	92 (46)
Yes	2	0 (0)	17	11 (65)	19	11 (58)
p value		1.0		0.2		0.3
2005						
No	19	2 (11)	163	84 (52)	189	89 (47)
Yes	-	-	9	5 (56)	10	6 (60)
p value		-		0.8		0.4
2006						
No	12	1 (8)	163	72 (44)	179	75 (42)
Yes	2	0 (0)	10	6 (60)	12	6 (50)
p value		1.000		0.349		0.764
2007						
No	12	3 (25)	169	70 (41)	185	75 (41)
Yes	2	0 (0.0)	18	4 (22)	21	5 (24)
p value		1.000		0.134		0.161

* Total includes people who did not report duration of drug injection

Table 178 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	170	75 (44)	101	44 (44)	274	122 (45)
Yes	12	10 (83)	10	6 (60)	22	16 (73)
p value		0.008		0.3		0.01
2004						
No	138	61 (44)	65	30 (46)	207	93 (45)
Yes	7	5 (71)	12	8 (67)	19	13 (68)
p value		0.2		0.2		0.05
2005						
No	110	45 (41)	71	34 (48)	182	80 (44)
Yes	6	5 (83)	9	5 (56)	15	10 (67)
p value		0.04		0.7		0.09
2006						
No	99	40 (40)	74	30 (41)	173	70 (41)
Yes	8	6 (75)	10	4 (40)	18	10 (56)
p value		0.072		1.000		0.315
2007						
No	110	43 (39)	82	29 (35)	194	73 (38)
Yes	9	6 (67)	6	2 (33)	15	8 (53)
p value		0.159		1.000		0.275

* Total includes people whose gender was not reported or reported as transgender

Table 179 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	172	77 (45)	99	45 (45)	274	125 (46)
Other Oceania	---	---	---	---	---	---
Asia	---	---	1	1 (100)	1	1 (100)
UK & Ireland	8	4 (50)	9	4 (44)	17	8 (47)
Other	7	4 (57)	5	2 (40)	12	6 (50)
p value		0.8		0.7		0.7
2004						
Australia	124	56 (45)	72	33 (46)	199	91 (46)
Other Oceania	---	---	---	---	---	---
Asia	5	4 (80)	---	---	5	4 (80)
UK & Ireland	1	1 (100)	---	---	1	1 (100)
Other	14	4 (29)	9	4 (44)	23	10 (43)
p value		0.2		0.1		0.3
2005						
Australia	103	48 (47)	73	34 (47)	177	83 (47)
Other Oceania	2	0 (0)	---	---	2	0 (0)
Asia	1	1 (100)	1	1 (100)	2	2 (100)
UK & Ireland	11	4 (36)	5	4 (80)	16	8 (50)
Other	5	1 (20)	2	1 (50)	7	2 (29)
p value		0.3		0.4		0.3
2006						
Australia	90	37 (41)	74	29 (39)	164	66 (41)
Other Oceania	1	0 (0)	---	---	1	0 (0)
Asia	4	1 (25)	1	0 (0)	5	1 (20)
UK & Ireland	11	7 (64)	7	4 (57)	18	11 (61)
Other	5	3 (60)	3	2 (67)	8	5 (63)
p value		0.442		0.601		0.170
2007						
Australia	102	41 (40)	73	23 (32)	177	65 (37)
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
Asia	2	2 (100)	---	---	2	2 (100)
UK & Ireland	7	4 (57)	11	7 (64)	18	11 (61)
Other	6	3 (50)	2	1 (50)	8	4 (50)
p value		0.361		0.087		0.041

* Total includes people whose gender was not reported or reported as transgender

Table 180 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	150	67 (45)	101	43 (43)	253	112 (44)
Non-English speaking	14	9 (64)	5	2 (40)	20	12 (60)
p value		0.2		0.9		0.2
2004						
English speaking	93	46 (49)	66	32 (48)	162	79 (49)
Non-English speaking	17	5 (29)	5	3 (60)	22	8 (36)
p value		0.1		0.6		0.3
2005						
English speaking	94	40 (43)	74	35 (47)	169	76 (45)
Non-English speaking	28	14 (50)	8	5 (63)	36	19 (53)
p value		0.5		0.4		0.4
2006						
English speaking	90	39 (43)	74	33 (45)	164	72 (44)
Non-English speaking	13	5 (38)	6	1 (17)	19	6 (32)
p value		1.000		0.233		0.338
2007						
English speaking	102	40 (39)	85	30 (35)	188	70 (37)
Non-English speaking	17	9 (53)	3	1 (33)	21	11 (52)
p value		0.301		1.000		0.237

* Total includes people whose gender was not reported or reported as transgender

Tasmania
2003 – 2007

Table 181 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	4	3	3	2	5
N ^o surveyed	N = 118	N=107	N=137	N=150	N=168
Response (%)	32	85		50	45
Gender (%)					
Male	70 (59)	66 (62)	86 (63)	94 (63)	111 (66)
Female	47 (40)	40 (37)	51 (37)	56 (37)	57 (34)
Transgender	1 (1)	---	---	---	---
Not reported	---	1 (1)	---	---	---
Sexual identity (%)					
Heterosexual	93 (79)	94 (88)	124 (91)	130 (87)	138 (82)
Bisexual	10 (8)	5 (5)	5 (4)	14 (9)	12 (7)
Homosexual	1 (1)	---	1 (1)	---	13 (8)
Not reported	14 (12)	8 (7)	7 (5)	6 (4)	5 (3)
Age and duration of injection (years)					
Median age	28	32	31	33	34
Age range	16–51	17 – 57	18-53	16-60	15-57
Age group (%)					
<25 years	37 (31)	13 (12)	23 (17)	21 (14)	26 (10)
25+ years	81 (69)	93 (87)	114 (83)	129 (86)	152 (90)
Not reported	---	1 (1)	---	---	---
Median age 1st IDU	17	19	19	18	18
Age range	10–45	9 – 46	11-49	11-47	10-44
Not reported	1	4	7	---	3
Median years IDU	9	12	11	12	14
Range	<1–32	<1–35	<1-34	<1-40	<1-40
Duration of drug injection (%)					
<3 years	10 (8)	8 (7)	7 (5)	9 (6)	10 (6)
3+ years	107 (91)	95 (89)	122 (89)	137 (91)	155 (92)
Not reported	1 (1)	4 (4)	8 (6)	4 (3)	3 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	100 (85)	96 (90)	121 (88)	121 (81)	141 (84)
Yes	13 (11)	8 (7)	12 (9)	25 (17)	25 (15)
Not reported	5 (4)	3 (3)	4 (3)	4 (3)	2 (1)
Region/Country of birth (%)					
Australia	111 (94)	95 (89)	138 (82)	138 (92)	159 (95)
Other Oceania	1 (<1)	2 (2)	---	1 (<1)	3 (2)
Asia	---	---	---	--	---
UK & Ireland	3 (3)	3 (3)	139 (82)	6 (4)	3 (2)
Other	3 (3)	4 (3)	140 (82)	2 (1)	---
Not reported	---	3 (3)	141 (82)	3 (2)	3 (2)
Main language spoken at home by parents (%)					
English speaking	114 (96)	71 (66)	115 (84)	136 (91)	165 (98)
Non-English speaking	2 (2)	3 (3)	22 (16)	2 (1)	3 (2)
Not reported	2 (2)	33 (31)	---	12 (8)	---
Imprisonment last year (%)					
No	101 (86)	91 (85)	113 (82)	126 (84)	139 (83)
Yes	16 (13)	14 (13)	18 (13)	19 (13)	25 (15)
Not reported	1 (1)	2 (2)	6 (4)	5 (3)	4 (2)
Injected in prison (%)	N = 16	N=14	N=18	N=19	N=25
Yes	6 (38)	10 (71)	89 (61)	3 (16)	11 (44)
Frequency of injection last month (%)					
Not last month	8 (7)	3 (3)	6 (4)	4 (3)	6 (4)
Less than weekly	20 (17)	20 (19)	31 (23)	31 (21)	48 (29)
Weekly not daily	45 (38)	38 (35)	46 (34)	41 (27)	55 (33)
Daily or more	45 (38)	45 (42)	54 (39)	73 (49)	58 (35)
Not reported	---	1 (1)	---	1 (<1)	1 (<1)

Table 182 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 118	N=107	N=137	N=150	N=168
Anabolic steroids	---	1 (1)	1 (<1)	1 (<1)	---
Cocaine	---	---	---	1 (<1)	---
Heroin	1 (1)	---	2 (1)	3 (2)	3 (2)
Methadone	38 (32)	41 (38)	30 (22)	35 (23)	54 (32)
Meth/Amphetamine	33 (28)	33 (31)	64 (47)	73 (49)	50 (30)
Morphine/Other Opioids	28 (24)	20 (19)	27 (20)	24 (16)	43 (26)
Subutex/Buprenorphine	---	1 (1)	1 (<1)	--	1 (<1)
More than one	15 (13)	9 (8)	6 (4)	6 (4)	5 (3)
Other	2 (1)	---	2 (1)	--	9 (5)
Not reported	---	2 (2)	4 (3)	5 (3)	3 (2)
N° Injected last month	N = 110	N = 103	N=131	N=145	N=161
Places injected last month (%)*					
Own home	103 (94)	87 (85)	115 (88)	121 (86)	147 (91)
Friend's home	43 (39)	35 (34)	51 (39)	52 (37)	72 (45)
Dealer's home	15 (14)	7 (7)	11 (8)	11 (8)	17 (11)
Street, park, beach	14 (13)	6 (6)	10 (8)	13 (9)	18 (11)
Car	27 (25)	22 (21)	36 (27)	52 (37)	51 (32)
Public toilet	17 (15)	14 (14)	18 (14)	19 (13)	24 (15)
Commercial injecting room	---	---	---	---	1 (<1)
Squat	2 (2)	1 (1)	---	1 (<1)	5 (3)
Use of new sterile needles & syringes last month (%)					
All injections	90 (82)	88 (85)	112 (86)	114 (79)	131 (81)
Most of the time	18 (16)	10 (10)	19 (15)	26 (18)	27 (17)
Half of the time	---	---	---	1 (<1)	---
Some of the time	1 (1)	1 (1)	---	1 (<1)	1 (<1)
Not last month	---	---	---	---	---
Not reported	1 (1)	4 (4)	---	3 (2)	2 (1)
Re-used another's used needle & syringe last month (%)					
None	102 (92)	86 (83)	121 (92)	127 (88)	132 (82)
One	2 (2)	4 (4)	3 (2)	4 (3)	8 (5)
Twice	2 (2)	5 (5)	2 (2)	5 (3)	3 (2)
3-5 times	---	2 (2)	2 (2)	---	6 (4)
>5 times	2 (2)	1 (1)	---	2 (1)	2 (1)
Not reported	2 (2)	5 (5)	---	7 (5)	10 (6)
Number of people needle & syringe was re-used after last month (%)					
None	99 (90)	86 (83)	114 (87)	127 (88)	132 (82)
One	4 (4)	5 (5)	7 (5)	5 (3)	6 (4)
Two	---	---	---	---	---
Three to five	2 (2)	1 (1)	---	1 (<1)	---
More than five	---	1 (1)	1 (1)	---	1 (<1)
Don't know	---	2 (2)	5 (4)	1 (<1)	4 (2)
Not reported	5 (4)	8 (8)	4 (3)	11 (8)	18 (11)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	5 (5)	5 (5)	5 (4)	5 (3)	7 (4)
Casual sex partner	1 (1)	---	---	1 (<1)	1 (<1)
Close friend	---	3 (3)	4 (3)	2 (1)	2 (1)
Acquaintance	---	---	1 (1)	1 (<1)	2 (1)
Other	---	1 (1)	2 (2)	---	---
Equipment used after someone else last month (%)*					
Spoon	13 (12)	6 (6)	9 (7)	11 (8)	16 (11)
Water	9 (8)	10 (10)	18 (14)	15 (11)	17 (11)
Filter	4 (4)	4 (4)	9 (7)	3 (2)	10 (7)
Drug mix	7 (6)	4 (4)	11 (8)	6 (4)	5 (3)
Tourniquet	9 (8)	8 (8)	12 (9)	12 (8)	12 (8)
None**	---	---	---	98 (69)	112 (75)
Injected by someone after that person injected themselves or others last month (%)					
No	91 (83)	86 (83)	110 (84)	111 (77)	130 (81)
Yes	16 (14)	11 (11)	14 (11)	27 (19)	21 (13)
Not reported	3 (3)	6 (6)	7 (5)	7 (5)	10 (6)

* More than one option could be selected

** New variable in 2006

Table 183 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 118	N=107	N=137	N=150	N=168
Any treatment/therapy for drug use (%)					
No	32 (27)	34 (32)	50 (37)	51 (34)	46 (27)
Yes	86 (73)	73 (68)	85 (62)	95 (63)	120 (71)
Not reported	---	---	2 (1)	4 (3)	2 (1)
History of methadone maintenance treatment (%)					
Currently	57 (48)	48 (45)	49 (36)	52 (35)	66 (39)
Previously	29 (25)	15 (14)	19 (14)	24 (16)	41 (24)
Never	32 (27)	43 (40)	67 (49)	70 (47)	61 (36)
Not reported	---	1 (1)	2 (1)	4 (3)	---
History of other pharmacotherapy treatment (%)					
Currently	6 (5)	2 (2)	6 (4)	3 (2)	10 (6)
Previously	10 (8)	9 (8)	10 (7)	14 (9)	14 (8)
Never	100 (85)	95 (89)	120 (88)	127 (85)	141 (84)
Not reported	2 (2)	1 (1)	1 (1)	6 (4)	3 (2)

Table 184 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007
N° surveyed	N = 118	N=107	N=137	N=150	---
From an NSP last month (%)					
Daily or almost daily	6 (5)	10 (9)	12 (9)	19 (13)	---
A couple of times each week	53 (45)	45 (42)	39 (28)	64 (43)	---
Less than weekly	37 (31)	26 (24)	45 (33)	27 (18)	---
Once last month	16 (14)	19 (18)	28 (20)	22 (15)	---
Not in the last month	6 (5)	5 (5)	11 (8)	16 (11)	---
Not reported	---	2 (2)	2 (1)	2 (1)	---
From a chemist last month (%)					
Daily or almost daily	2 (1)	4 (4)	3 (2)	8 (5)	---
A couple of times each week	9 (8)	5 (5)	15 (11)	23 (15)	---
Less than weekly	9 (8)	5 (5)	14 (10)	23 (15)	---
Once last month	14 (12)	13 (12)	19 (14)	19 (13)	---
Not in the last month	80 (68)	73 (68)	79 (58)	72 (48)	---
Not reported	4 (3)	7 (6)	7 (5)	5 (3)	---

* Not asked in this form in 2007, see Table 187.

Table 185 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N = 118	N=107	N=137	N=150	N=168
Sex last month (%) †					
No	28 (24)	32 (30)	--	--	--
Yes	90 (76)	70 (65)	--	--	--
Not reported	---	5 (5)	--	--	--
Condom use at last sex (%)†					
No	87 (74)	72 (67)	--	--	--
Yes	31 (26)	30 (28)	--	--	--
Not reported	---	5 (5)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	44 (71)	37 (74)	--	--	--
Sometimes	4 (6)	3 (6)	--	--	--
Always	14 (23)	10 (20)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	32 (65)	14 (52)	--	--	--
Sometimes	4 (8)	3 (11)	--	--	--
Always	13 (27)	10 (37)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	25 (66)	17 (68)	--	--	--
Sometimes	3 (8)	1 (4)	--	--	--
Always	10 (26)	7 (28)	--	--	--
Duration of regular sexual relationship (%)** †					
One month	6 (9)	2 (4)	--	--	--
2 - 6 months	9 (13)	5 (9)	--	--	--
6 - 12 months	13 (19)	10 (18)	--	--	--
>12 months	40 (59)	38 (69)	--	--	--
Sex with a regular partner last month (%)****					
No	--	--	45 (33)	55 (37)	63 (38)
Yes	--	--	88 (64)	91 (61)	103 (61)
Not reported	--	--	4 (3)	4 (3)	2 (1)
Condom used with regular partner last month (%)****			N=88****	N=91	N=103
Never	--	--	67 (76)	70 (77)	74 (72)
Sometimes	--	--	9 (10)	9 (10)	15 (15)
Every time	--	--	3 (3)	8 (9)	9 (9)
Not reported	--	--	9 (10)	4 (4)	5 (5)
Sex with other partner/s last month (%)****					
No	--	--	113 (82)	132 (88)	145 (86)
Yes	--	--	21 (15)	9 (6)	16 (10)
Not reported	--	--	3 (2)	9 (6)	7 (4)
Condom used with other partner/s last month (%)****			N=21	N=9	N=16
Never	--	--	7 (33)	4 (44)	7 (44)
Sometimes	--	--	6 (29)	3 (33)	5 (31)
Every time	--	--	7 (33)	2 (22)	3 (19)
Not reported	--	--	1 (5)	---	1 (6)
Sex work last month (%)					
No	113 (96)	93 (87)	129 (94)	134 (89)	157 (93)
Yes	5 (4)	10 (9)	4 (3)	5 (3)	3 (2)
Not reported	---	4 (4)	4 (3)	11 (7)	8 (5)
Condom used at last sex work last month (%)**					
Yes	2 (40)	5 (56)	---	4 (80)	3 (100)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 186 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey

	2003	2004	2005	2006	2007
N ^o surveyed	N = 118	N=107	N=137	N=150	N=168
Previous HIV test (%)					
Yes, last year	76 (64)	58 (54)	61 (45)	71 (47)	92 (55)
> 1 year ago	22 (19)	28 (26)	49 (36)	50 (33)	54 (32)
Never tested	20 (17)	18 (17)	25 (18)	25 (17)	22 (13)
Not reported	---	3 (3)	2 (1)	4 (3)	---
HBV infection (%)					
No	98 (83)	80 (75)	104 (76)	122 (81)	130 (77)
Yes	11 (9)	16 (15)	14 (10)	14 (9)	27 (16)
Don't know	8 (7)	7 (6)	15 (11)	10 (7)	11 (7)
Not reported	1 (1)	4 (4)	4 (3)	4 (3)	---
HBV vaccination (%)*					
No	30 (28)	39 (43)	43 (35)	35 (26)	42 (30)
Yes	67 (63)	45 (49)	63 (51)	77 (57)	88 (62)
Don't know	10 (9)	5 (6)	13 (11)	21 (15)	11 (8)
Not reported	---	2 (2)	4 (3)	3 (2)	---
Previous HCV test (%)					
Yes, last year	82 (69)	65 (61)	70 (51)	81 (54)	99 (59)
> 1 year ago	22 (19)	23 (21)	43 (31)	44 (29)	53 (32)
Never tested	14 (12)	17 (16)	23 (17)	22 (15)	16 (10)
Not reported	---	2 (2)	1 (1)	3 (2)	---
Any treatment for HCV	N = 3	N = 1	N=2	N=5	N=0
Interferon	2	1	1	3	---
Interferon+Ribarvarin	---	---	---	2	---
Other	1	---	1	---	---
No treatment	---	---	---	---	---
Not reported	---	---	---	---	---
Current treatment for HCV	N = 0	N=0	N=0	N=0	N=0

* Number (percentage) among participants not reporting HBV infection

Table 187 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N ^o surveyed	N=168		
Needle/syringe acquisition at time of survey completion (%)			
No	1 (<1)		
Yes	160 (95)		
Not reported	7 (4)		
Source of needles/syringes (%)** N=1490***	In last week	In last month	
Chemist/Pharmacy	9 (6)	18 (13)	
Needle Syringe Program	65 (47)	130 (94)	
Dispensing/Vending Machine	0 (0)	3 (2)	
Friend/Dealer	9 (6)	15 (11)	
Other	0 (0)	0 (0)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=18	3 (17)	15 (83)
Needle Syringe Program	N=130	108 (83)	22 (17)
Dispensing/Vending Machine	N=3	0 (0)	3 (100)
Friend/Dealer	N=15	3 (20)	12 (80)
Other	N=0	0 (0)	0 (0)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 188 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	70	0 (0.0)	46	0 (0.0)	117	0 (0.0)
2004	65	0 (0.0)	39	0 (0.0)	105	0 (0.0)
2005	86	0 (0.0)	51	0 (0.0)	137	0 (0.0)
2006	94	0 (0.0)	56	0 (0.0)	150	0 (0.0)
2007	110	0 (0.0)	56	0 (0.0)	166	0 (0.0)
χ^2 trend p value		---		---		---

HCV antibody prevalence

Table 189 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	70	36 (51)	46	31 (67)	117	67 (57)
2004	66	30 (45)	39	20 (51)	106	50 (47)
2005	86	51 (59)	51	30 (59)	137	81 (59)
2006	93	53 (57)	55	32 (58)	148	85 (57)
2007	91	52 (57)	43	30 (70)	134	82 (61)
χ^2 trend p value		0.217		0.707		0.213

* Total includes people whose gender was not reported or reported as transgender

Table 190 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	55	30 (55)	37	25 (68)	93	55 (59)
Bisexual	5	3 (60)	4	3 (75)	9	6 (67)
Homosexual	0	-	1	0 (0)	1	0 (0)
p value		0.8		0.3		0.4
2004						
Heterosexual	59	28 (47)	34	17 (50)	93	45 (48)
Bisexual	1	1 (100)	4	3 (75)	5	4 (80)
Homosexual	-	-	-	-	-	-
P value		0.3		0.2		0.2
2005						
Heterosexual	82	48 (59)	42	26 (62)	124	74 (60)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual		---	1	1 (100)	1	1 (100)
2006						
Heterosexual	86	51 (59)	43	23 (53)	129	74 (57)
Bisexual	5	2 (40)	8	7 (88)	13	9 (69)
Homosexual	---	---	---	---	---	---
p value		0.646		0.119		0.558
2007						
Heterosexual	83	46 (55)	28	18 (64)	111	64 (58)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	5	4 (80)	4	4 (100)	9	8 (89)
p value		0.626		0.432		

* Total includes people whose gender was not reported or reported as transgender

Table 191 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	4	1 (25)	2	0 (0)	6	1 (17)
20 – 24	16	4 (25)	14	9 (64)	30	13 (43)
25 – 29	19	8 (42)	9	8 (89)	29	16 (55)
30 + years	31	23 (74)	21	14 (67)	52	37 (71)
p value		0.005		0.1		0.01
2004						
< 20 years	1	0 (0)	4	0 (0)	5	0 (0)
20 – 24	6	2 (33)	2	2 (100)	8	4 (50)
25 – 29	13	7 (54)	9	4 (44)	22	11 (50)
30 + years	46	21 (46)	24	14 (58)	71	35 (49)
p value		0.02		0.5		0.04
2005						
< 20 years	-	-	2	0 (0)	2	0 (0)
20 – 24	12	6 (50)	9	4 (44)	21	10 (48)
25 – 29	19	10 (53)	10	7 (70)	29	17 (59)
30 + years	55	35 (64)	30	19 (63)	85	54 (64)
p value		0.5		0.2		0.2
2006						
< 20 years	---	---	3	1 (33)	3	1 (33)
20 – 24	8	2 (25)	9	4 (44)	17	6 (35)
25 – 29	24	13 (54)	11	6 (55)	35	19 (54)
30 + years	61	38 (62)	32	21 (66)	93	59 (63)
p value		0.137		0.534		0.111
2007						
< 20 years	1	1 (100)	3	0 (0.0)	4	1 (25)
20 – 24	2	2 (100)	4	3 (75)	6	5 (83)
25 – 29	20	11 (55)	13	9 (69)	33	20 (61)
30 + years	68	38 (56)	23	18 (78)	91	56 (62)
p value		0.720		0.063		0.368

* Total includes people whose gender was not reported or reported as transgender

Table 192 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	7	1 (14)	4	1 (25)	11	2 (18)
3 to 5 years	7	2 (29)	5	3 (60)	13	5 (38)
6 to 10 years	17	9 (53)	14	13 (93)	31	22 (71)
10 + years	33	22 (67)	21	13 (62)	54	35 (65)
p value		<0.001		0.004		<0.001
2004						
<3 years	5	1 (20)	6	1 (17)	12	2 (17)
3 to 5 years	6	1 (17)	6	2 (33)	12	3 (25)
6 to 10 years	9	4 (44)	8	6 (75)	17	10 (59)
10 + years	45	24 (53)	17	10 (59)	62	34 (55)
p value		<0.001		0.02		<0.001
2005						
<3 years	12	2 (17)	2	1 (50)	14	3 (21)
3 to 5 years	12	5 (42)	12	3 (25)	24	8 (33)
6 to 10 years	9	4 (44)	5	3 (60)	14	7 (50)
10 + years	48	37 (77)	29	21 (72)	77	58 (75)
p value		0.001		0.05		<0.001
2006						
<3 years	4	1 (25)	4	1 (25)	8	2 (25)
3 to 5 years	2	1 (50)	11	3 (28)	13	4 (31)
6 to 10 years	24	12 (50)	16	10 (63)	40	22 (55)
10 + years	60	37 (62)	23	18 (78)	83	55 (66)
p value		0.399		0.014		0.018
2007						
<3 years	5	1 (20)	2	0 (0.0)	7	1 (14)
3 to 5 years	3	1 (33)	5	1 (20)	8	2 (25)
6 to 10 years	17	10 (59)	8	5 (63)	25	15 (60)
10 + years	65	39 (60)	26	22 (85)	91	61 (67)
p value		0.322		0.003		0.007

* Total includes people whose gender was not reported or reported as transgender

Table 193 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	-	-	1	0 (0)	1	0 (0)
Meth/Amphetamine	7	1 (14)	23	8 (35)	33	10 (30)
More than one	-	-	14	9 (64)	15	9 (60)
Other/Not reported	-	-	60	45 (75)	68	48 (71)
p value		0.04		0.01		0.003
2004						
Heroin	-	-	-	-	-	-
Meth/Amphetamine	5	0 (0)	26	8 (31)	32	8 (25)
More than one	2	0 (0)	7	3 (43)	9	3 (33)
Other/Not reported	5	2 (40)	58	36 (62)	65	39 (60)
p value		0.08		<0.001		<0.001
2005						
Heroin	-	-	2	1 (50)	2	1 (2)
Meth/Amphetamine	9	1 (11)	55	29 (53)	64	30 (47)
More than one	1	1 (100)	5	5 (100)	6	6 (100)
Other/Not reported	4	1 (25)	61	43 (70)	65	44 (68)
p value		0.225		0.043		0.008
2006						
Heroin	---	---	3	2 (67)	3	2 (67)
Meth/Amphetamine	6	0 (0)	65	28 (43)	72	28 (39)
More than one	---	---	6	3 (50)	6	3 (50)
Other/Not reported	2	2 (100)	62	48 (77)	67	52 (78)
p value		0.036		<0.001		<0.001
2007						
Heroin	---	---	1	1 (100)	2	2 (100)
Meth/Amphetamine	4	0 (0.0)	33	15 (45)	38	16 (42)
More than one	---	---	8	5 (63)	8	5 (63)
Other/Not reported	3	1 (33)	82	57 (70)	86	59 (69)
p value		0.429		0.070		0.023

* Total includes people who did not report duration of drug injection

Tasmania

Table 194 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	8	2 (25)	60	39 (65)	72	43 (60)
Daily or more	3	0 (0)	38	23 (61)	45	24 (53)
p value		0.3		0.6		0.5
2004						
Less than daily	8	2 (25)	52	28 (54)	61	31 (51)
Daily or more	3	0 (0)	39	19 (49)	44	19 (43)
p value		0.3		0.6		0.4
2005						
Less than daily	10	2 (20)	68	41 (60)	83	46 (55)
Daily or more	4	1 (25)	47	32 (68)	54	35 (65)
p value		0.8		0.4		0.3
2006						
Less than daily	4	1 (25)	66	37 (56)	71	39 (55)
Daily or more	4	1 (25)	65	41 (63)	72	43 (60)
p value		1.000		0.478		0.614
2007						
Less than daily	3	1 (33)	80	53 (66)	84	55 (65)
Daily or more	3	0 (0.0)	41	25 (61)	45	26 (58)
p value		1.000		0.689		0.446

* Total includes people who did not report duration of drug injection

Table 195 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	10	2 (20)	83	53 (64)	101	58 (57)
Yes	-	-	6	4 (67)	6	4 (67)
p value		-		0.9		0.6
2004						
No	10	2 (20)	73	37 (51)	86	40 (47)
Yes	1	0 (0)	10	6 (60)	11	6 (55)
p value		0.6		0.6		0.6
2005						
No	14	3 (21)	101	64 (63)	121	71 (59)
Yes	-	-	6	3 (50)	7	4 (57)
p value		-		0.9		0.5
2006						
No	8	2 (25)	113	67 (59)	125	71 (57)
Yes	---	---	11	8 (73)	11	8 (73)
p value		---		0.524		0.358
2007						
No	5	1 (20)	98	67 (68)	104	69 (66)
Yes	---	---	15	6 (40)	16	7 (44)
p value		---		0.043		0.098

* Total includes people who did not report duration of drug injection

Table 196 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	11	2 (18)	82	50 (61)	100	55 (55)
Yes	-	-	15	11 (73)	16	11 (69)
p value				0.4		0.3
2004						
No	9	1 (11)	78	38 (49)	90	40 (44)
Yes	2	1 (50)	12	8 (67)	14	9 (64)
p value		0.2		0.2		0.2
2005						
No	12	2 (17)	96	60 (63)	113	64 (57)
Yes	1	1 (100)	15	10 (67)	18	13 (72)
p value		0.06		0.8		0.2
2006						
No	7	1 (14)	113	62 (55)	124	65 (52)
Yes	1	1 (100)	18	15 (83)	19	16 (84)
p value		0.250		0.037		0.012
2007						
No	7	1 (14)	100	60 (60)	110	64 (58)
Yes	---	---	20	15 (75)	20	15 (75)
p value		---		0.312		0.214

* Total includes people who did not report duration of drug injection

Table 197 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	10	2 (20)	95	60 (63)	112	65 (58)
Yes	1	0 (0)	3	2 (67)	5	2 (40)
p value		0.6		0.9		0.4
2004						
No	11	2 (18)	78	41 (53)	92	44 (48)
Yes	-	-	10	4 (40)	10	4 (40)
p value		1.0		0.2		0.3
2005						
No	13	3 (13)	109	67 (61)	129	75 (58)
Yes	-	-	3	3 (100)	4	3 (75)
p value				0.2		0.5
2006						
No	6	2 (33)	123	71 (58)	133	75 (56)
Yes	1	0 (0)	4	2 (50)	5	2 (40)
p value		1.000		1.000		0.655
2007						
No	7	1 (14)	115	73 (63)	125	77 (62)
Yes	---	---	2	2 (100)	2	2 (100)
p value		---		0.536		0.526

* Total includes people who did not report duration of drug injection

Tasmania

Table 198 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	60	32 (53)	38	26 (68)	99	58 (59)
Yes	7	2 (29)	6	3 (50)	13	5 (38)
p value		0.2		0.4		0.2
2004						
No	58	27 (47)	36	20 (56)	95	47 (49)
Yes	6	3 (50)	2	0 (0)	8	3 (38)
p value		0.9		0.1		0.5
2005						
No	74	45 (61)	47	26 (55)	121	71 (59)
Yes	8	5 (63)	4	4 (100)	12	9 (75)
p value		0.9		0.1		0.3
2006						
No	73	39 (53)	48	28 (58)	121	67 (55)
Yes	17	11 (65)	6	3 (50)	23	14 (61)
p value		0.432		1.000		0.655
2007						
No	78	44 (56)	35	24 (69)	113	68 (60)
Yes	12	8 (67)	7	5 (71)	19	13 (68)
p value		0.550		1.000		0.614

* Total includes people whose gender was not reported or reported as transgender

Table 199 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	65	31 (48)	44	29 (66)	110	60 (55)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	2	2 (100)	1	1 (100)	3	3 (100)
Other	3	3 (100)	1	1 (100)	4	4 (100)
p value		0.8		0.7		0.7
2004						
Australia	59	25 (42)	35	16 (46)	95	41 (43)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	5	4 (80)	4	4 (100)	9	8 (89)
p value		0.1		0.04		0.009
2005						
Australia	79	45 (57)	47	27 (57)	126	72 (57)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	4	4 (100)	2	1 (50)	6	5 (83)
Other	2	2 (100)	1	1 (100)	3	3 (100)
p value		0.1		0.7		0.2
2006						
Australia	86	47 (55)	50	30 (60)	136	77 (57)
Other Oceania	---	---	1	0 (0)	1	0 (0)
Asia	---	---	---	---	---	---
UK & Ireland	3	2 (67)	3	2 (67)	6	4 (67)
Other	1	1 (100)	1	0 (0)	2	1 (50)
p value		1.000		0.533		0.769
2007						
Australia	86	48 (56)	39	26 (67)	125	74 (59)
Other Oceania	2	2 (100)	1	1 (100)	3	3 (100)
Asia	---	---	---	---	---	---
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	---	---	---	---	---	---
p value		0.754		1.000		0.557

* Total includes people whose gender was not reported or reported as transgender

Table 200 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	66	33 (50)	46	31 (67)	113	64 (57)
Non-English speaking	2	2 (100)	---	---	2	2 (100)
p value		0.2		---		0.2
2004						
English speaking	39	18 (46)	31	15 (48)	71	33 (46)
Non-English speaking	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.9		0.3		0.5
2005						
English speaking	70	40 (57)	45	27 (60)	115	67 (58)
Non-English speaking	16	11 (69)	6	3 (50)	22	14 (64)
p value		0.6		0.4		0.6
2006						
English speaking	81	45 (56)	53	32 (60)	134	77 (57)
Non-English speaking	2	1 (50)	---	---	2	1 (50)
p value		1.000		---		1.000
2007						
English speaking	88	50 (57)	43	30 (70)	131	80 (91)
Non-English speaking	3	2 (67)	---	---	3	2 (67)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Victoria
2003 – 2007

Table 201 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	4	5	5	4	7
N ^o surveyed	N=237	N=228	N=194	N=195	N=243
Response (%)	25	42	44	20	33
Gender (%)					
Male	144 (61)	152 (67)	116 (60)	126 (65)	166 (68)
Female	90 (38)	74 (32)	78 (40)	68 (35)	76 (31)
Transgender	2 (<1)	---	--	---	1 (<1)
Not reported	1 (<1)	2 (1)	--	1 (<1)	---
Sexual identity (%)					
Heterosexual	168 (71)	182 (80)	151 (78)	165 (85)	192 (79)
Bisexual	30 (13)	23 (10)	19 (10)	18 (9)	37 (15)
Homosexual	14 (6)	12 (5)	12 (6)	4 (2)	8 (3)
Not reported	25 (10)	11 (5)	12 (6)	8 (4)	6 (2)
Age and duration of injection (years)					
<i>Median age</i>	31	30	32	32	33
<i>Age range</i>	18 – 58	16-58	16-53	15-54	14-62
<i>Age group (%)</i>					
<25 years	53 (22)	51 (22)	33 (17)	27 (14)	19 (8)
25+ years	183 (77)	176 (77)	161 (83)	167 (86)	224 (92)
Not reported	1 (1)	1 (<1)	--	1 (<1)	---
<i>Median age 1st IDU</i>	18	18	18	18	17
<i>Age range</i>	11 – 48	8 -42	11-35	10-41	10-42
Not reported	5	5	7	1	6
<i>Median years IDU</i>	11	10	12	13	13
<i>Range</i>	<1 – 42	<1-44	<1-37	<1-35	<1-46
<i>Duration of drug injection (%)</i>					
<3 years	15 (6)	19 (8)	11 (6)	7 (6)	12 (5)
3+ years	216 (91)	204 (90)	172 (89)	174 (89)	225 (93)
Not reported	6 (3)	5 (2)	11 (6)	14 (7)	6 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	226 (95)	212 (93)	178 (92)	170 (87)	217 (89)
Yes	6 (3)	9 (4)	9 (5)	14 (7)	14 (6)
Not reported	5 (2)	7 (3)	7 (4)	11 (6)	12 (5)
Region/Country of birth (%)					
Australia	200 (84)	185 (81)	156 (80)	160 (82)	202 (83)
Other Oceania	11 (5)	5 (2)	9 (5)	4 (2)	5 (2)
Asia	2 (1)	9 (4)	3 (2)	2 (1)	7 (3)
UK & Ireland	14 (6)	11 (5)	11 (6)	15 (8)	12 (5)
Other	8 (3)	15 (7)	15 (8)	8 (4)	10 (4)
Not reported	2 (1)	3 (1)	--	6 (3)	7 (3)
Main language spoken at home by parents (%)					
English speaking	217 (92)	154 (67)	158 (81)	171 (88)	221 (91)
Non-English speaking	14 (6)	31 (14)	36 (19)	10 (5)	17 (7)
Not reported	6 (2)	43 (19)	--	14 (7)	5 (2)
Imprisonment last year (%)					
No	192 (81)	185 (81)	162 (84)	161 (83)	195 (80)
Yes	41 (17)	42 (18)	22 (11)	20 (10)	30 (12)
Not reported	4 (2)	1 (<1)	10 (5)	14 (7)	18 (7)
Injected in prison (%)	N = 41	N = 42	N=22	N=20	N=30
Yes	11 (27)	22 (52)	10 (45)	5 (25)	9 (30)
Frequency of injection last month (%)					
Not last month	16 (6)	13 (6)	12 (6)	10 (5)	11 (5)
Less than weekly	47 (20)	27 (12)	31 (16)	31 (16)	30 (12)
Weekly not daily	52 (22)	68 (30)	41 (21)	47 (24)	53 (22)
Daily or more	120 (51)	118 (52)	110 (57)	106 (54)	143 (59)
Not reported	2 (<1)	2 (<1)	--	1 (<1)	6 (2)

Table 202 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 237	N = 228	N=194	N=195	N=243
Anabolic steroids	---	4 (2)	--	1 (<1)	1 (<1)
Cocaine	---	1 (<1)	5 (3)	4 (2)	---
Heroin	137 (58)	134 (59)	96 (49)	71 (36)	131 (54)
Methadone	---	---	3 (2)	3 (2)	6 (2)
Meth/Amphetamine	57 (24)	37 (16)	47 (24)	69 (35)	51 (21)
Morphine/Other Opioids	8 (3)	7 (3)	7 (4)	10 (5)	8 (3)
Subutex/Buprenorphine	8 (3)	18 (8)	19 (10)	22 (11)	27 (11)
More than one	19 (8)	20 (9)	4 (2)	9 (5)	8 (3)
Other	7 (3)	1 (<1)	2 (1)	1 (<1)	6 (2)
Not reported	---	3 (1)	7 (4)	3 (2)	5 (2)
N° Injected last month	N = 219	N= 213	N=182	N=184	N=226
Places injected last month (%)*					
Own home	175 (80)	181 (85)	145 (80)	155 (89)	187 (85)
Friend's home	96 (44)	104 (49)	77 (42)	80 (46)	100 (46)
Dealer's home	38 (17)	52 (24)	20 (11)	30 (17)	35 (16)
Street, park, beach	79 (36)	92 (43)	54 (30)	56 (32)	82 (37)
Car	99 (45)	114 (54)	67 (37)	82 (47)	81 (37)
Public toilet	78 (36)	80 (38)	61 (34)	63 (36)	77 (35)
Commercial injecting room	5 (2)	1 (<1)	--	2 (1)	2 (1)
Squat	34 (16)	23 (11)	11 (6)	14 (8)	21 (10)
Use of new sterile needles & syringes last month (%)					
All injections	164 (75)	141 (66)	131 (72)	117 (64)	150 (66)
Most of the time	45 (20)	57 (27)	47 (26)	48 (26)	64 (28)
Half of the time	4 (2)	8 (4)	3 (2)	8 (4)	3 (1)
Some of the time	4 (2)	2 (1)	--	5 (3)	2 (1)
Not last month	---	1 (<1)	1 (1)	2 (1)	---
Not reported	2 (1)	4 (2)	--	4 (2)	7 (3)
Re-used another's used needle & syringe last month (%)					
None	179 (82)	163 (77)	147 (81)	142 (77)	172 (76)
Once	17 (8)	15 (7)	5 (3)	8 (4)	14 (6)
Twice	4 (2)	13 (6)	7 (4)	9 (5)	9 (4)
3-5 times	4 (2)	9 (4)	5 (3)	10 (5)	9 (4)
>5 times	9 (4)	7 (3)	6 (3)	7 (4)	10 (4)
Not reported	6 (2)	6 (3)	12 (7)	8 (4)	12 (5)
Number of people needle & syringe was re-used after last month (%)					
None	172 (79)	163 (76)	139 (76)	142 (77)	172 (76)
One	26 (12)	23 (11)	20 (11)	19 (10)	24 (11)
Two	2 (<1)	4 (2)	2 (1)	2 (1)	2 (1)
Three to five	1 (<1)	2 (1)	1 (1)	---	3 (1)
More than five	2 (<1)	2 (1)	---	3 (2)	2 (1)
Don't know	6 (3)	2 (1)	5 (3)	5 (3)	8 (4)
Not reported	10 (5)	17 (8)	15 (8)	13 (7)	15 (7)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	19 (9)	16 (8)	18 (10)	16 (9)	21 (9)
Casual sex partner	4 (2)	4 (2)	---	1 (<1)	2 (1)
Close friend	10 (5)	10 (5)	6 (3)	9 (5)	10 (4)
Acquaintance	2 (1)	1 (<1)	5 (3)	3 (2)	6 (3)
Other	1 (<1)	2 (1)	2 (1)	1 (<1)	3 (1)
Equipment used after someone else last month (%)*					
Spoon	81 (37)	82 (39)	52 (29)	63 (36)	70 (34)
Water	44 (20)	63 (30)	42 (23)	34 (19)	43 (21)
Filter	31 (14)	55 (26)	35 (19)	32 (18)	36 (17)
Drug mix	23 (11)	47 (22)	31 (17)	15 (9)	21 (10)
Tourniquet	21 (10)	25 (12)	24 (13)	18 (10)	16 (8)
None**	---	---	---	96 (55)	118 (57)
Injected by someone after that person injected themselves or others last month (%)					
No	169 (77)	178 (84)	147 (81)	155 (84)	182 (81)
Yes	43 (20)	28 (13)	23 (13)	23 (13)	29 (13)
Not reported	7 (3)	7 (3)	12 (7)	6 (3)	15 (7)

* More than one option could be selected

** New variable in 2006

Table 203 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N=237	N = 228	N=194	N=195	N=243
Any treatment/therapy for drug use (%)					
No	57 (24)	29 (13)	22 (11)	22 (11)	23 (9)
Yes	180 (76)	197 (86)	172 (89)	169 (87)	215 (88)
Not reported	---	2 (1)	--	4 (2)	5 (2)
History of methadone maintenance treatment (%)					
Currently	49 (21)	58 (25)	56 (29)	58 (30)	78 (32)
Previously	94 (40)	86 (38)	66 (34)	66 (34)	81 (33)
Never	93 (39)	78 (34)	72 (37)	67 (34)	79 (33)
Not reported	1 (<1)	6 (3)	--	4 (2)	5 (2)
History of other pharmacotherapy treatment (%)					
Currently	61 (26)	74 (32)	55 (28)	48 (25)	61 (25)
Previously	67 (28)	56 (25)	55 (28)	65 (33)	84 (35)
Never	104 (44)	97 (43)	83 (43)	77 (40)	92 (38)
Not reported	5 (2)	1 (<1)	1 (1)	5 (3)	6 (2)

Table 204 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007
N° surveyed	N=237	N = 228	N=194	N=195	---
From an NSP last month (%)					
Daily or almost daily	63 (27)	35 (15)	42 (22)	49 (25)	---
A couple of times each week	79 (33)	81 (36)	63 (32)	51 (26)	---
Less than weekly	42 (18)	67 (29)	46 (24)	52 (26)	---
Once last month	31 (13)	23 (10)	25 (13)	21 (11)	---
Not in the last month	17 (7)	17 (8)	17 (9)	18 (9)	---
Not reported	5 (2)	5 (2)	1 (1)	4 (2)	---
From a chemist last month (%)					
Daily or almost daily	6 (3)	5 (2)	10 (5)	9 (5)	---
A couple of times each week	20 (8)	23 (10)	11 (6)	12 (6)	---
Less than weekly	36 (15)	44 (19)	23 (12)	20 (10)	---
Once last month	43 (18)	39 (17)	27 (14)	34 (17)	---
Not in the last month	125 (53)	113 (50)	121 (62)	112 (57)	---
Not reported	7 (3)	4 (2)	2 (1)	8 (4)	---

* Not asked in this form in 2007, see Table 207.

Victoria

Table 205 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N=237	N = 228	N=194	N=195	N=243
Sex last month (%) †					
No	61 (26)	63 (28)	--	--	--
Yes	173 (73)	162 (71)	--	--	--
Not reported	3 (1)	3 (1)	--	--	--
Condom use at last sex (%)†					
No	163 (69)	169 (74)	--	--	--
Yes	72 (30)	57 (25)	--	--	--
Not reported	2 (1)	2 (1)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	75 (70)	83 (67)	--	--	--
Sometimes	15 (14)	19 (15)	--	--	--
Always	17 (16)	23 (18)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	30 (39)	27 (32)	--	--	--
Sometimes	11 (14)	23 (27)	--	--	--
Always	35 (46)	34 (41)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	36 (49)	28 (39)	--	--	--
Sometimes	9 (12)	18 (25)	--	--	--
Always	29 (39)	26 (36)	--	--	--
Duration of regular sexual relationship (%)**†					
One month	5 (5)	9 (8)	--	--	--
2 - 6 months	12 (12)	20 (17)	--	--	--
6 - 12 months	14 (15)	11 (9)	--	--	--
>12 months	65 (68)	79 (66)	--	--	--
Sex with a regular partner last month (%) ****					
No	--	--	86 (44)	85 (44)	115 (47)
Yes	--	--	107 (55)	101 (52)	114 (47)
Not reported	--	--	1 (1)	9 (5)	14 (6)
Condom used with regular partner last month (%)****			N=107*****	N=101	N=114
Never	--	--	69 (64)	68 (67)	82 (72)
Sometimes	--	--	21 (20)	17 (17)	20 (18)
Every time	--	--	12 (11)	12 (12)	7 (6)
Not reported	--	--	5 (5)	4 (4)	5 (4)
Sex with other partner/s last month (%)****					
No	--	--	156 (80)	158 (81)	194 (80)
Yes	--	--	37 (19)	22 (11)	36 (15)
Not reported	--	--	1 (1)	15 (8)	13 (5)
Condom used with other partner/s last month (%)****			N=37	N=22	N=36
Never	--	--	7 (19)	6 (27)	8 (22)
Sometimes	--	--	5 (14)	6 (27)	13 (36)
Every time	--	--	23 (62)	8 (36)	14 (39)
Not reported	--	--	2 (5)	2 (9)	1 (3)
Sex work last month (%)					
No	199 (84)	201 (88)	168 (87)	169 (67)	218 (90)
Yes	33 (14)	25 (11)	24 (12)	12 (6)	15 (6)
Not reported	5 (2)	2 (1)	2 (1)	14 (7)	10 (4)
Condom used at last sex work last month (%)**					
Yes	27 (82)	22 (88)	47 (98)	10 (83)	12 (86)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 206 Number and (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey

	2003	2004	2005	2006	2007
N° surveyed	N=237	N = 228	N=194	N=195	N=243
Previous HIV test (%)					
Yes, last year	137 (58)	124 (54)	121 (62)	104 (53)	151 (62)
> 1 year ago	77 (32)	77 (34)	55 (28)	66 (34)	65 (27)
Never tested	17 (7)	24 (11)	16 (8)	18 (9)	19 (8)
Not reported	6 (3)	3 (1)	2 (1)	7 (4)	8 (3)
HBV infection (%)					
No	168 (71)	155 (68)	122 (63)	122 (63)	159 (65)
Yes	48 (20)	47 (21)	44 (23)	45 (23)	49 (20)
Don't know	19 (8)	24 (10)	27 (14)	21 (11)	26 (11)
Not reported	2 (1)	2 (1)	1 (1)	7 (4)	9 (4)
HBV vaccination (%)					
No	64 (34)	62 (34)	46 (31)	49 (33)	58 (30)
Yes	99 (52)	98 (54)	77 (51)	75 (50)	100 (52)
Don't know	20 (11)	18 (10)	25 (17)	19 (13)	29 (15)
Not reported	6 (3)	3 (2)	2 (1)	7 (5)	7 (4)
Previous HCV test (%)					
Yes, last year	160 (68)	131 (57)	127 (65)	114 (58)	154 (63)
> 1 year ago	60 (25)	81 (36)	50 (26)	58 (30)	78 (32)
Never tested	15 (6)	13 (6)	15 (8)	15 (8)	6 (2)
Not reported	2 (1)	3 (1)	2 (1)	8 (4)	5 (2)
Any treatment for HCV (%)					
	N = 124	N = 126	N=103	N=101	N=141
Interferon	6 (5)	4 (3)	2 (2)	3 (3)	6 (4)
Interferon+Ribarvarin	1 (<1)	4 (3)	2 (2)	1 (1)	2 (1)
Other	2 (2)	4 (3)	4 (4)	3 (3)	3 (2)
No treatment	114 (92)	110 (88)	95 (92)	92 (91)	122 (87)
Not reported	1 (<1)	4 (3)	--	2 (2)	8 (6)
Current treatment for HCV					
	N = 0	N = 2	N=5	N=3	N=3
Interferon	---	---	1	1	1
Interferon+Ribarvarin	---	1	--	1	1
Other	---	1	4	1	1

* Number (percentage) among participants not reporting HBV infection

Table 207 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N° surveyed	N=243		
Needle/syringe acquisition at time of survey completion (%)			
No	34 (14)		
Yes	190 (78)		
Not reported	19 (8)		
Source of needles/syringes (%)** N=1490***			
	In last week	In last month	
Chemist/Pharmacy	32 (16)	52 (25)	
Needle Syringe Program	117 (57)	191 (94)	
Dispensing/Vending Machine	0 (0)	0 (0)	
Friend/Dealer	32 (16)	52 (25)	
Other	5 (2)	9 (4)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***			
	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=52	4 (8)	48 (92)
Needle Syringe Program	N=191	114 (60)	77 (40)
Dispensing/Vending Machine	N=0	0 (0)	0 (0)
Friend/Dealer	N=52	7 (13)	45 (87)
Other	N=9	0 (0)	9 (100)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 208 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	144	1 (0.7)	90	1 (1.1)	237	2 (0.8)
2004	122	1 (0.8)	65	0 (0.0)	189	1 (0.5)
2005	102	1 (1.0)	76	0 (0.0)	178	1 (0.6)
2006	122	1 (0.8)	68	0 (0.0)	191	1 (0.5)
2007	163	0 (0.0)	76	0 (0.0)	240	0 (0.0)
χ^2 trend p value		0.455		0.184		0.223

* Total includes people whose gender was not reported or reported as transgender

Table 209 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heterosexual	117	0 (0.0)	50	0 (0.0)	168	0 (0.0)
Bisexual	4	0 (0.0)	26	1 (3.9)	30	1 (3.3)
Homosexual	7	1 (14.3)	7	0 (0.0)	14	1 (7.1)
p value		<0.001		(0.3)		0.01
2004						
Heterosexual	101	0 (0.0)	48	0 (0.0)	150	0 (0.0)
Bisexual	8	0 (0.0)	11	0 (0.0)	19	0 (0.0)
Homosexual	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
p value		---		---		---
2005						
Heterosexual	84	0 (0.0)	53	0 (0.0)	137	0 (0.0)
Bisexual	6	0 (0.0)	13	0 (0.0)	19	0 (0.0)
Homosexual	6	1 (16.7)	5	0 (0.0)	11	1 (9.1)
p value		0.001		---		0.001
2006						
Heterosexual	105	0 (0.0)	55	0 (0.0)	161	0 (0.0)
Bisexual	8	1 (12.5)	10	0 (0.0)	18	1 (5.6)
Homosexual	1	0 (0.0)	3	0 (0.0)	4	0 (0.0)
p value		0.079		---		0.120
2007						
Heterosexual	144	0 (0.0)	45	0 (0.0)	189	0 (0.0)
Bisexual	10	0 (0.0)	27	0 (0.0)	37	0 (0.0)
Homosexual	5	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 210 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
< 20 years	2	0 (0.0)	4	0 (0.0)	6	0 (0.0)
20 – 24	26	0 (0.0)	20	0 (0.0)	47	0 (0.0)
25 – 29	26	0 (0.0)	26	0 (0.0)	52	0 (0.0)
30 + years	90	1 (1.1)	39	1 (2.6)	131	2 (1.5)
p value		0.9		0.7		0.7
2004						
< 20 years	2	0 (0.0)	3	0 (0.0)	6	0 (0.0)
20 – 24	21	1 (4.8)	15	0 (0.0)	36	1 (2.8)
25 – 29	30	0 (0.0)	14	0 (0.0)	44	0 (0.0)
30 + years	69	0 (0.0)	33	0 (0.0)	102	0 (0.0)
p value		0.2		---		0.2
2005						
< 20 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
20 – 24	9	0 (0.0)	14	0 (0.0)	23	0 (0.0)
25 – 29	24	0 (0.0)	16	0 (0.0)	40	0 (0.0)
30 + years	64	1 (1.6)	41	0 (0.0)	105	1 (1.0)
p value		0.9		---		0.9
2006						
< 20 years	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
20 – 24	9	0 (0.0)	13	0 (0.0)	22	0 (0.0)
25 – 29	31	0 (0.0)	15	0 (0.0)	46	0 (0.0)
30 + years	80	1 (1.3)	38	0 (0.0)	119	1 (0.8)
p value		1.000		---		1.000
2007						
< 20 years	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
20 – 24	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
25 – 29	34	0 (0.0)	24	0 (0.0)	58	0 (0.0)
30 + years	119	0 (0.0)	43	0 (0.0)	163	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 211 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
<3 years	10	0 (0.0)	5	0 (0.0)	15	0 (0.0)
3 to 5 years	12	0 (0.0)	10	0 (0.0)	23	0 (0.0)
6 to 10 years	41	0 (0.0)	34	0 (0.0)	75	0 (0.0)
10 + years	77	1 (1.3)	39	1 (2.6)	118	2 (1.7)
p value		0.8		0.7		0.6
2004						
<3 years	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
3 to 5 years	11	1 (9.1)	11	0 (0.0)	23	1 (4.4)
6 to 10 years	34	0 (0.0)	19	0 (0.0)	53	0 (0.0)
10 + years	68	0 (0.0)	28	0 (0.0)	96	0 (0.0)
p value		0.2		---		0.2
2005						
<3 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
3 to 5 years	11	0 (0.0)	9	0 (0.0)	20	0 (0.0)
6 to 10 years	13	0 (0.0)	13	0 (0.0)	26	0 (0.0)
10 + years	70	1 (1.4)	42	0 (0.0)	112	1 (0.9)
p value		0.9		---		0.9
2006						
<3 years	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
3 to 5 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
6 to 10 years	28	0 (0.0)	8	0 (0.0)	46	0 (0.0)
10 + years	75	1 (1.3)	38	0 (0.0)	114	1 (0.9)
p value		1.000		---		1.000
2007						
<3 years	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
3 to 5 years	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
6 to 10 years	29	0 (0.0)	23	0 (0.0)	53	0 (0.0)
10 + years	118	0 (0.0)	43	0 (0.0)	161	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 212 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Heroin	81	0 (0.0)	55	1 (1.8)	137	1 (0.7)
Meth/Amphetamine	36	1 (2.8)	20	0 (0.0)	57	1 (1.8)
More than one	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
Other/Not reported	12	0 (0.0)	10	0 (0.0)	23	0 (0.0)
p value		0.4		0.9		0.8
2004						
Heroin	71	0 (0.0)	41	0 (0.0)	113	0 (0.0)
Meth/Amphetamine	16	0 (0.0)	12	0 (0.0)	28	0 (0.0)
More than one	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
Other/Not reported	24	1 (4.2)	7	0 (0.0)	32	1 (3.1)
p value		0.4		---		0.4
2005						
Heroin	44	0 (0.0)	45	0 (0.0)	89	0 (0.0)
Meth/Amphetamine	24	0 (0.0)	18	0 (0.0)	42	0 (0.0)
More than one	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
Other/Not reported	32	1 (3.1)	13	0 (0.0)	45	1 (2.2)
p value		0.4		---		0.2
2006						
Heroin	46	0 (0.0)	23	0 (0.0)	70	0 (0.0)
Meth/Amphetamine	40	1 (2.5)	26	0 (0.0)	66	1 (1.5)
More than one	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
Other/Not reported	30	0 (0.0)	16	0 (0.0)	46	0 (0.0)
p value		0.623		---		0.634
2007						
Heroin	77	0 (0.0)	51	0 (0.0)	129	0 (0.0)
Meth/Amphetamine	38	0 (0.0)	12	0 (0.0)	50	0 (0.0)
More than one	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
Other/Not reported	43	0 (0.0)	12	0 (0.0)	55	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 213 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Not last month	4	0 (0.0)	12	1 (8.3)	16	1 (6.3)
Less than weekly	34	0 (0.0)	12	0 (0.0)	47	0 (0.0)
Weekly not daily	35	0 (0.0)	16	0 (0.0)	52	0 (0.0)
Daily or more	71	1 (1.4)	48	0 (0.0)	120	1 (0.8)
p value		0.8		0.09		0.1
2004						
Not last month	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
Less than weekly	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)
Weekly not daily	41	1 (2.4)	17	0 (0.0)	58	1 (1.7)
Daily or more	62	0 (0.0)	38	0 (0.0)	101	0 (0.0)
p value		0.5		---		0.5
2005						
Not last month	62	1 (1.6)	40	0 (0.0)	102	1 (1.0)
Less than weekly	21	0 (0.0)	18	0 (0.0)	39	0 (0.0)
Weekly not daily	13	0 (0.0)	13	0 (0.0)	26	0 (0.0)
Daily or more	6	0 (0.0)	5	0 (0.0)	11	0 (0.0)
p value		0.9		---		0.9
2006						
Not last month	5	0 (0.0)	4	0 (0.0)	10	0 (0.0)
Less than weekly	16	0 (0.0)	43	0 (0.0)	29	0 (0.0)
Weekly not daily	28	1 (3.6)	18	0 (0.0)	46	1 (2.2)
Daily or more	72	0 (0.0)	33	0 (0.0)	105	0 (0.0)
p value		0.405		---		0.447
2007						
Not last month	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
Less than weekly	18	0 (0.0)	12	0 (0.0)	30	0 (0.0)
Weekly not daily	34	0 (0.0)	16	0 (0.0)	50	0 (0.0)
Daily or more	101	0 (0.0)	41	0 (0.0)	143	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 214 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	113	1 (0.9)	64	0 (0.0)	179	1 (0.6)
Yes	22	0 (0.0)	11	0 (0.0)	34	0 (0.0)
p value		0.7		---		0.7
2004						
No	89	1 (1.1)	49	0 (0.0)	139	1 (0.7)
Yes	23	0 (0.0)	13	0 (0.0)	36	0 (0.0)
p value		1.0		---		1.0
2005						
No	71	1 (1.4)	63	0 (0.0)	134	1 (0.8)
Yes	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		0.6		---		0.7
2006						
No	86	1 (1.2)	53	0 (0.0)	139	1 (0.7)
Yes	24	0 (0.0)	9	0 (0.0)	33	0 (0.0)
p value		1.000		---		1.000
2007						
No	115	0 (0.0)	55	0 (0.0)	170	0 (0.0)
Yes	28	0 (0.0)	12	0 (0.0)	41	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 215 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	111	1 (0.9)	79	1 (1.3)	192	2 (1.0)
Yes	30	0 (0.0)	10	0 (0.0)	41	0 (0.0)
p value		0.6		0.7		0.5
2004						
No	99	1 (1.0)	55	0 (0.0)	155	1 (0.7)
Yes	23	0 (0.0)	10	0 (0.0)	33	0 (0.0)
p value		1.0		---		1.0
2005						
No	82	1 (1.2)	66	0 (0.0)	148	1 (0.7)
Yes	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		0.7		---		0.7
2006						
No	100	1 (1)	57	0 (0.0)	158	1 (0.6)
Yes	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
p value		1.000		---		1.000
2007						
No	125	0 (0.0)	67	0 (0.0)	193	0 (0.0)
Yes	24	0 (0.0)	6	0 (0.0)	30	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 216 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	97	0 (0.0)	64	1 (1.6)	163	1 (0.6)
Yes	47	1 (2.1)	25	0 (0.0)	72	1 (1.4)
p value		0.1		0.5		0.6
2004						
No	97	1 (1.0)	46	0 (0.0)	143	1 (0.7)
Yes	25	0 (0.0)	18	0 (0.0)	44	0 (0.0)
p value		1.0		---		1.0
2005**						
No	33	0 (0.0)	38	0 (0.0)	71	0 (0.0)
Yes	20	1 (5.0)	15	0 (0.0)	35	1 (2.9)
p value				---		0.2
2006**						
No	51	0 (0.0)	34	0 (0.0)	85	0 (0.0)
Yes	10	1 (10)	1	0 (0.0)	11	1 (9.1)
p value		0.164		---		0.115
2007**						
No	54	0 (0.0)	46	0 (0.0)	100	0 (0.0)
Yes	7	0 (0.0)	0	0 (0.0)	7	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

** Question changed to "condom use with regular partner in last month" in 2005.

Table 217 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	131	1 (0.8)	67	1 (1.5)	199	2 (1.0)
Yes	11	0 (0.0)	21	0 (0.0)	33	0 (0.0)
p value		0.8		0.6		0.6
2004						
No	113	0 (0.0)	50	0 (0.0)	163	0 (0.0)
Yes	8	1 (12.5)	15	0 (0.0)	24	1 (4.2)
p value		0.07		---		0.1
2005						
No	98	1 (1.0)	56	0 (0.0)	154	1 (0.7)
Yes	3	0 (0.0)	19	0 (0.0)	22	0 (0.0)
p value		0.9		---		0.7
2006						
No	109	1 (0.9)	55	0 (0.0)	165	1 (0.6)
Yes	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
p value		1.000		---		1.000
2007						
No	152	0 (0.0)	62	0 (0.0)	215	0 (0.0)
Yes	4	0 (0.0)	11	0 (0.0)	15	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 218 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
No	140	1 (0.7)	83	0 (0.0)	226	1 (0.4)
Yes	1	0 (0.0)	5	1 (20.0)	6	1 (16.7)
p value		0.9		<0.001		<0.001
2004						
No	117	1 (0.9)	59	0 (0.0)	178	1 (0.6)
Yes	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
p value		0.9				0.9
2005						
No	94	1 (1.1)	70	0 (0.0)	164	1 (0.6)
Yes	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
p value		0.8				0.8
2006						
No	106	1 (0.9)	59	0 (0.0)	166	1 (0.6)
Yes	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
p value		1.000		---		1.000
2007						
No	144	0 (0.0)	69	0 (0.0)	214	0 (0.0)
Yes	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 219 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
Australia	122	1 (0.8)	76	1 (1.3)	200	2 (1.0)
Other Oceania	---	0 (0.0)	---	0 (0.0)	---	0 (0.0)
Asia	1	0 (0.0)	---	0 (0.0)	1	0 (0.0)
UK & Ireland	8	0 (0.0)	5	0 (0.0)	14	0 (0.0)
Other	11	0 (0.0)	9	0 (0.0)	20	0 (0.0)
p value		1.0		0.9		1.0
2004						
Australia	99	1 (1.0)	54	0 (0.0)	155	1 (0.7)
Other Oceania	---	0 (0.0)	---	0 (0.0)	---	0 (0.0)
Asia	---	0 (0.0)	2	0 (0.0)	2	0 (0.0)
UK & Ireland	2	0 (0.0)	---	0 (0.0)	2	0 (0.0)
Other	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
p value		0.9		---		1.0
2005						
Australia	80	1 (1.3)	64	0 (0.0)	144	1 (0.7)
Other Oceania	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
UK & Ireland	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)
Other	9	0 (0.0)	4	0 (0.0)	13	0 (0.0)
p value		1.0		---		1.0
2006						
Australia	97	1 (1.0)	58	0 (0.0)	156	1 (0.6)
Other Oceania	4	0 (0.0)	---	---	4	0 (0.0)
Asia	---	---	2	0 (0.0)	2	0 (0.0)
UK & Ireland	10	0 (0.0)	5	0 (0.0)	1	0 (0.0)
Other	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007						
Australia	133	0 (0.0)	65	0 (0.0)	199	0 (0.0)
Other Oceania	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
Asia	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
UK & Ireland	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)
Other	6	0 (0.0)	4	0 (0.0)	10	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 220 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003						
English speaking	130	1 (0.8)	84	1 (1.2)	217	2 (0.9)
Non-English speaking	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
p value		0.8		0.8		0.7
2004						
English speaking	77	1 (1.3)	53	0 (0.0)	132	1 (0.8)
Non-English speaking	19	0 (0.0)	6	0 (0.0)	25	0 (0.0)
p value		0.6		---		0.7
2005						
English speaking	81	1 (1.2)	64	0 (0.0)	145	1 (0.7)
Non-English speaking	21	0 (0.0)	12	0 (0.0)	33	0 (0.0)
p value		0.6		---		0.6
2006						
English speaking	105	1 (1.0)	62	0 (0.0)	168	1 (0.6)
Non-English speaking	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		1.000		---		1.000
2007						
English speaking	147	0 (0.0)	70	0 (0.0)	218	0 (0.0)
Non-English speaking	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 221 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	144	95 (66)	90	59 (66)	237	157 (66)
2004	122	82 (67)	65	48 (74)	189	130 (69)
2005	101	64 (63)	76	55 (72)	177	119 (67)
2006	121	84 (69)	67	50 (75)	189	135 (71)
2007	139	100 (72)	65	48 (74)	205	149 (73)
χ^2 trend p value		0.262		0.243		0.119

* Total includes people whose gender was not reported or reported as transgender

Table 222 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	117	79 (68)	50	30 (60)	168	110 (65)
Bisexual	4	4 (100)	26	19 (73)	30	23 (77)
Homosexual	7	0 (0)	7	5 (71)	14	5 (36)
p value		<0.001		0.5		0.03
2004						
Heterosexual	101	67 (66)	48	32 (67)	150	99 (66)
Bisexual	8	6 (75)	11	10 (91)	19	16 (84)
Homosexual	7	4 (57)	4	4 (100)	11	8 (73)
p value		0.8		0.2		0.3
2005						
Heterosexual	83	53 (64)	53	37 (70)	136	90 (66)
Bisexual	6	4 (67)	13	9 (69)	19	13 (68)
Homosexual	6	3 (50)	5	5 (100)	11	8 (73)
p value						
2006						
Heterosexual	105	74 (70)	54	38 (70)	160	113 (71)
Bisexual	8	3 (38)	10	9 (90)	18	12 (67)
Homosexual	1	1 (100)	3	3 (100)	4	4 (100)
p value		0.107		0.311		0.590
2007						
Heterosexual	124	91 (73)	37	30 (81)	161	121 (75)
Bisexual	9	5 (56)	24	16 (67)	33	21 (64)
Homosexual	3	2 (67)	2	1 (50)	6	4 (67)
p value		0.470		0.229		0.289

* Total includes people whose gender was not reported or reported as transgender

Table 223 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	2	1 (50)	4	3 (75)	6	4 (67)
20 – 24	26	15 (58)	20	15 (75)	47	31 (66)
25 – 29	26	16 (62)	26	13 (50)	52	29 (56)
30 + years	90	63 (70)	39	28 (72)	131	93 (71)
p value		0.6		0.2		0.2
2004						
< 20 years	2	0 (0.0)	3	1 (33)	6	1 (17)
20 – 24	21	13 (62)	15	11 (73)	36	24 (67)
25 – 29	30	22 (73)	14	11 (79)	44	33 (75)
30 + years	69	47 (68)	33	25 (76)	102	72 (71)
p value		0.2		0.5		0.05
2005						
< 20 years	5	2 (40)	5	5 (100)	10	7 (70)
20 – 24	9	3 (33)	14	8 (57)	23	11 (48)
25 – 29	24	15 (63)	16	12 (75)	40	27 (68)
30 + years	63	44 (70)	41	30 (73)	104	74 (71)
p value		0.1		0.3		0.2
2006						
< 20 years	1	0 (0)	2	0 (0.0)	3	0 (0.0)
20 – 24	9	7 (78)	13	9 (69)	22	16 (73)
25 – 29	31	20 (65)	15	12 (80)	46	32 (70)
30 + years	79	56 (71)	37	29 (78)	117	86 (74)
p value		0.472		0.132		0.078
2007						
< 20 years	5	0 (0.0)	2	1 (50)	7	1 (14)
20 – 24	4	2 (50)	6	3 (50)	10	5 (50)
25 – 29	29	18 (62)	21	16 (76)	50	34 (68)
30 + years	101	80 (79)	36	28 (78)	138	109 (79)
p value		<0.001		0.346		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 224 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	10	3 (30)	5	0 (0)	15	3 (20)
3 to 5 years	12	5 (42)	10	5 (50)	23	11 (48)
6 to 10 years	41	23 (56)	34	24 (71)	75	47 (63)
10 + years	77	60 (78)	39	29 (74)	118	91 (77)
p value		0.002		0.006		<0.001
2004						
<3 years	7	0 (0)	7	2 (29)	14	2 (14)
3 to 5 years	11	5 (45)	11	7 (64)	23	12 (52)
6 to 10 years	34	23 (68)	19	15 (79)	53	38 (72)
10 + years	68	52 (76)	28	24 (86)	96	76 (79)
p value		<0.001		0.02		<0.001
2005						
<3 years	10	5 (50)	7	6 (86)	17	11 (65)
3 to 5 years	11	5 (45)	9	5 (56)	20	10 (50)
6 to 10 years	13	8 (62)	13	10 (77)	26	18 (69)
10 + years	64	44 (69)	40	29 (73)	104	73 (70)
p value		0.3		0.6		0.4
2006						
<3 years	4	1 (25)	2	1 (50)	6	2 (33)
3 to 5 years	5	3 (60)	7	1 (14)	12	4 (33)
6 to 10 years	28	16 (57)	17	13 (76)	45	29 (64)
10 + years	75	57 (76)	38	32 (84)	114	90 (79)
p value		0.044		0.001		0.001
2007						
<3 years	7	1 (14)	5	1 (20)	12	2 (17)
3 to 5 years	4	0 (0.0)	4	2 (50)	8	2 (25)
6 to 10 years	26	14 (54)	20	17 (85)	47	32 (68)
10 + years	97	81 (84)	35	27 (77)	132	108 (82)
p value		<0.001		0.018		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 225 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	1	1 (14)	128	89 (70)	137	92 (67)
Meth/Amphetamine	8	2 (25)	46	29 (63)	57	33 (58)
More than one	---	---	19	13 (68)	20	14 (70)
Other/Not reported	---	---	23	18 (78)	23	18 (78)
p value		0.6		0.6		0.3
2004						
Heroin	7	1 (14)	106	81 (76)	113	82 (73)
Meth/Amphetamine	4	0 (0)	23	13 (57)	28	14 (50)
More than one	1	1 (100)	15	9 (60)	16	10 (63)
Other/Not reported	2	0 (0)	28	23 (82)	32	24 (75)
p value		0.2		0.1		0.1
2005						
Heroin	5	4 (80)	84	60 (71)	89	64 (72)
Meth/Amphetamine	5	2 (40)	37	21 (57)	42	23 (55)
More than one	---	---	4	2 (50)	4	2 (50)
Other/Not reported	7	5 (71)	37	27 (73)	44	32 (73)
p value		0.548		0.283		0.150
2006						
Heroin	2	1 (50)	67	54 (81)	70	55 (79)
Meth/Amphetamine	3	1 (33)	58	37 (64)	66	42 (64)
More than one	---	---	7	5 (71)	8	6 (75)
Other/Not reported	1	0 (0)	39	27 (69)	45	32 (71)
p value		1.000		0.184		0.289
2007						
Heroin	4	2 (50)	101	78 (77)	106	81 (76)
Meth/Amphetamine	4	0 (0.0)	36	25 (69)	42	27 (64)
More than one	---	---	5	4 (80)	6	4 (67)
Other/Not reported	4	0 (0.0)	45	35 (78)	51	37 (73)
p value		0.273		0.816		0.458

* Total includes people who did not report duration of drug injection

Table 226 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	10	2 (20)	102	66 (65)	115	69 (60)
Daily or more	10	6 (60)	101	75 (74)	120	88 (73)
p value		0.7		0.01		0.03
2004						
Less than daily	5	1 (20)	74	51 (69)	87	58 (67)
Daily or more	11	3 (27)	87	66 (76)	101	72 (71)
p value		0.8		0.3		0.5
2005						
Less than daily	6	2 (33)	67	47 (70)	76	51 (67)
Daily or more	11	9 (82)	83	54 (65)	101	68 (67)
p value		0.5		0.05		>0.9
2006						
Less than daily	3	1 (33)	68	48 (71)	74	52 (70)
Daily or more	3	1 (33)	92	69 (75)	104	77 (74)
p value		1.000		0.590		0.612
2007						
Less than daily	4	0 (0.0)	59	45 (76)	66	48 (73)
Daily or more	7	1 (14)	115	88 (77)	124	91 (73)
p value		1.000		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 227 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	16	6 (38)	157	110 (70)	179	120 (67)
Yes	4	2 (50)	25	20 (80)	34	26 (76)
p value		0.6		0.3		0.3
2004						
No	13	3 (23)	119	86 (72)	139	95 (68)
Yes	3	1 (33)	31	25 (81)	36	28 (78)
p value		0.7		0.3		0.3
2005						
No	13	10 (77)	112	77 (69)	133	93 (70)
Yes	3	1 (33)	16	8 (50)	21	10 (48)
p value		0.1		0.1		0.04
2006						
No	4	1 (25)	127	89 (70)	138	95 (69)
Yes	2	1 (50)	28	24 (86)	33	28 (85)
p value		1.000		0.105		0.084
2007						
No	8	0 (0.0)	129	97 (75)	140	100 (71)
Yes	2	1 (50)	36	28 (78)	39	30 (77)
p value		0.200		0.829		0.549

* Total includes people who did not report duration of drug injection

Table 228 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	17	6 (35)	165	106 (64)	192	118 (61)
Yes	3	2 (67)	37	34 (92)	41	37 (90)
p value		0.3		0.01		<0.001
2004						
No	155	103 (66)	13	2 (15)	155	103 (66)
Yes	33	27 (82)	3	2 (67)	33	27 (82)
p value		0.08		0.06		0.01
2005						
No	14	8 (57)	127	83 (65)	147	95 (65)
Yes	2	2 (100)	14	13 (93)	20	18 (90)
p value		0.2		0.04		0.02
2006						
No	6	2 (33)	142	98 (69)	158	108 (68)
Yes	---	---	17	14 (82)	18	15 (83)
p value		---		0.399		0.279
2007						
No	10	1 (10)	149	111 (75)	163	115 (71)
Yes	1	1 (100)	26	20 (77)	28	22 (79)
p value		0.182		1.000		0.498

* Total includes people who did not report duration of drug injection

Table 229 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	17	5 (29)	172	116 (67)	199	127 (64)
Yes	3	3 (100)	29	22 (76)	33	26 (79)
p value		0.02		0.4		0.09
2004						
No	15	3 (20)	137	97 (71)	163	109 (67)
Yes	1	1 (100)	23	20 (87)	24	21 (88)
p value		0.07		0.1		0.04
2005						
No	16	10 (63)	130	83 (64)	153	98 (64)
Yes	1	1 (100)	18	16 (89)	22	19 (86)
p value		0.4		0.03		0.04
2006						
No	6	2 (33)	146	102 (70)	163	113 (69)
Yes	---	---	12	10 (83)	12	10 (83)
p value		---		0.511		0.514
2007						
No	9	0 (0.0)	170	129 (76)	183	133 (73)
Yes	2	1 (100)	11	8 (73)	13	10 (77)
p value		0.018		0.730		1.000

* Total includes people who did not report duration of drug injection

Table 230 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	140	94 (67)	83	55 (66)	226	152 (67)
Yes	1	0 (0)	5	4 (80)	6	4 (67)
p value		0.2		0.5		1.0
2004						
No	117	80 (68)	59	43 (73)	178	123 (69)
Yes	3	2 (67)	3	3 (100)	6	5 (83)
p value		1.0		0.3		0.5
2005						
No	93	57 (61)	70	50 (71)	163	107 (66)
Yes	5	4 (80)	4	3 (75)	9	7 (78)
p value		0.4		0.9		0.5
2006						
No	105	72 (69)	59	45 (76)	165	118 (72)
Yes	7	6 (86)	6	4 (67)	13	10 (77)
p value		0.673		0.631		1.000
2007						
No	123	87 (71)	60	46 (77)	184	134 (73)
Yes	9	9 (100)	3	0 (0.0)	12	12 (75)
p value		0.113		0.017		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 231 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	122	79 (65)	76	50 (66)	200	131 (66)
Other Oceania	---	---	---	---	---	---
Asia	1	1 (100)	---	---	1	1 (100)
UK & Ireland	8	5 (63)	5	4 (80)	14	10 (71)
Other	11	9 (82)	9	5 (56)	20	14 (70)
p value		0.6		0.7		0.8
2004						
Australia	99	67 (68)	54	39 (72)	155	106 (68)
Other Oceania	---	---	---	---	---	---
Asia	---	---	2	2 (100)	2	2 (100)
UK & Ireland	2	2 (100)	---	---	2	2 (100)
Other	20	13 (65)	9	7 (78)	29	20 (69)
p value		0.6		0.7		0.6
2005						
Australia	79	46 (58)	64	47 (73)	143	93 (65)
Other Oceania	3	2 (67)	5	2 (40)	8	4 (50)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	8	7 (88)	2	2 (100)	10	9 (90)
Other	9	9 (100)	4	4 (100)	13	13 (100)
p value		0.02		0.1		0.03
2006						
Australia	96	67 (70)	57	42 (74)	154	110 (71)
Other Oceania	4	2 (50)	---	---	4	2 (50)
Asia	---	---	2	2 (100)	2	2 (100)
UK & Ireland	10	8 (80)	5	4 (80)	15	12 (80)
Other	6	3 (50)	2	1 (50)	8	4 (50)
p value		0.516		0.885		0.406
2007						
Australia	114	85 (75)	56	40 (71)	171	126 (74)
Other Oceania	2	2 (100)	1	0 (0.0)	3	2 (67)
Asia	4	3 (75)	1	1 (100)	5	4 (80)
UK & Ireland	9	6 (67)	2	2 (100)	11	8 (73)
Other	5	1 (20)	4	4 (100)	9	5 (56)
p value		0.092		0.371		0.753

* Total includes people whose gender was not reported or reported as transgender

Table 232 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	130	85 (65)	84	53 (63)	217	141 (65)
Non-English speaking	9	7 (78)	5	5 (100)	14	12 (86)
p value		0.4		0.09		0.1
2004						
English speaking	77	53 (69)	53	38 (72)	132	91 (69)
Non-English speaking	19	12 (63)	6	4 (67)	25	16 (64)
p value		0.6		1.0		0.6
2005						
English speaking	80	51 (64)	64	45 (70)	144	96 (67)
Non-English speaking	21	13 (62)	12	10 (83)	33	23 (70)
p value		0.9		0.4		0.7
2006						
English speaking	104	72 (69)	62	45 (73)	167	118 (71)
Non-English speaking	6	3 (50)	3	3 (100)	9	6 (67)
p value		0.380		0.561		0.725
2007						
English speaking	126	92 (73)	60	43 (72)	187	136 (73)
Non-English speaking	10	7 (70)	4	4 (100)	14	11 (79)
p value		1.000		0.566		0.763

* Total includes people whose gender was not reported or reported as transgender

Western Australia
2003 - 2007

Table 233 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2003	2004	2005	2006	2007
Number of sites	3	3	3	3	2
N° surveyed	N = 133	N=161	N=169	N=160	N=110
Response (%)	NA	65	48	53	51
Gender (%)					
Male	75 (56)	99 (62)	110 (65)	104 (65)	71 (65)
Female	57 (43)	61 (38)	59 (35)	55 (34)	39 (35)
Transgender	1 (1)	---	---	1 (<1)	---
Not reported	---	1 (1)	---	---	---
Sexual identity (%)					
Heterosexual	104 (78)	133 (83)	137 (81)	135 (84)	93 (85)
Bisexual	9 (7)	11 (7)	14 (8)	14 (9)	8 (7)
Homosexual	7 (5)	8 (5)	8 (5)	7 (4)	7 (6)
Not reported	13 (10)	9 (5)	10 (6)	4 (3)	2 (2)
Age and duration of injection (years)					
<i>Median age</i>	34	35	36	35	36.5
Age range	16 – 55	16 – 60	17-57	16-68	16-55
<i>Age group (%)</i>					
<25 years	18 (14)	30 (19)	30 (18)	18 (11)	10 (9)
25+ years	115 (86)	130 (81)	139 (82)	142 (89)	100 (91)
Not reported	---	1 (<1)	---	---	---
<i>Median age 1st IDU</i>	18	17	18	18	18
Age range	9 – 46	5 – 40	12-40	12-46	12-49
Not reported	6	5	3	---	2
<i>Median years IDU</i>	14	13	15	15	15
Range	<1 – 39	<1 – 46	<1-37	<1-41	<1-37
<i>Duration of drug injection (%)</i>					
<3 years	10 (8)	8 (5)	5 (3)	5 (3)	8 (7)
3+ years	117 (88)	148 (92)	154 (91)	153 (96)	100 (91)
Not reported	6 (4)	5 (3)	10 (6)	2 (1)	2 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	122 (92)	146 (91)	156 (93)	153 (96)	102 (93)
Yes	7 (5)	9 (5)	10 (6)	4 (3)	5 (5)
Not reported	4 (3)	6 (4)	2 (1)	3 (2)	3 (3)
Region/Country of birth (%)					
Australia	105 (79)	123 (76)	138 (82)	130 (81)	90 (82)
Other Oceania	6 (4)	6 (4)	6 (4)	3 (2)	1 (1)
Asia	---	5 (3)	2 (1)	---	1 (1)
UK & Ireland	14 (11)	17 (11)	16 (9)	12 (8)	9 (8)
Other	6 (4)	7 (4)	6 (4)	11 (7)	5 (5)
Not reported	2 (2)	3 (2)	1 (1)	4 (3)	4 (4)
Main language spoken at home by parents (%)					
English speaking	127 (96)	113 (70)	143 (85)	144 (90)	105 (95)
Non-English speaking	3 (2)	15 (9)	26 (15)	6 (4)	2 (2)
Not reported	3 (2)	33 (21)	---	10 (6)	3 (3)
Imprisonment last year (%)					
No	110 (83)	127 (79)	146 (86)	130 (81)	85 (77)
Yes	19 (14)	32 (20)	18 (11)	21 (13)	18 (16)
Not reported	4 (3)	2 (1)	6 (4)	9 (6)	7 (6)
Injected in prison (%)					
Yes	N = 19	N = 32	N=18	N=21	N=18
Yes	7 (37)	17 (53)	11 (61)	7 (33)	6 (33)
Frequency of injection last month (%)					
Not last month	3 (2)	12 (7)	7 (4)	5 (3)	6 (5)
Less than weekly	19 (14)	18 (11)	18 (11)	20 (13)	9 (8)
Weekly not daily	32 (24)	42 (26)	38 (22)	42 (26)	21 (19)
Daily or more	75 (56)	83 (52)	106 (63)	92 (58)	73 (66)
Not reported	4 (3)	6 (4)	---	1 (<1)	1 (1)

Table 234 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2003	2004	2005	2006	2007
Last drug injected (%)	N = 133	N = 161	N=170	N=160	N=110
Anabolic steroids	1 (1)	---	---	2 (1)	---
Cocaine	---	1 (1)	---	---	---
Heroin	39 (29)	31 (19)	48 (28)	30 (19)	28 (25)
Methadone	1 (1)	3 (2)	6 (4)	9 (6)	4 (4)
Meth/Amphetamine	55 (41)	74 (46)	57 (34)	72 (45)	34 (31)
Morphine/Other Opioids	12 (9)	18 (11)	24 (14)	22 (14)	23 (21)
Subutex/Buprenorphine	1 (1)	4 (2)	19 (11)	16 (10)	7 (6)
More than one	9 (7)	21 (13)	3 (2)	4 (3)	5 (5)
Other	11 (8)	---	5 (3)	1 (<1)	6 (6)
Not reported	4 (3)	8 (5)	7 (4)	1 (<1)	3 (3)
N° Injected last month	N = 126	N = 143	N=162	N=154	N=103
Places injected last month (%)*					
Own home	115 (91)	118 (83)	129 (80)	142 (96)	91 (93)
Friend's home	56 (44)	68 (48)	57 (35)	73 (49)	48 (49)
Dealer's home	25 (20)	30 (21)	28 (17)	32 (22)	31 (32)
Street, park, beach	26 (21)	37 (26)	25 (15)	27 (18)	23 (23)
Car	42 (33)	46 (32)	49 (30)	57 (39)	41 (42)
Public toilet	26 (21)	34 (24)	23 (14)	26 (18)	19 (19)
Commercial injecting room	2 (2)	---	---	1 (<1)	---
Squat	6 (5)	13 (9)	2 (1)	2 (1)	8 (8)
Use of new sterile needles & syringes last month (%)					
All injections	78 (62)	91 (64)	103 (64)	102 (66)	58 (56)
Most of the time	38 (30)	37 (26)	44 (27)	40 (26)	29 (28)
Half of the time	5 (4)	8 (5)	5 (3)	6 (4)	6 (6)
Some of the time	4 (3)	6 (4)	4 (2)	3 (2)	7 (7)
Not last month	---	---	1 (1)	1 (<1)	---
Not reported	1 (1)	1 (1)	6 (3)	2 (1)	3 (3)
Re-used another's needle & syringe last month (%)					
None	100 (79)	110 (77)	124 (78)	127 (82)	75 (73)
One	7 (6)	10 (7)	7 (4)	8 (5)	10 (10)
Twice	7 (6)	11 (8)	9 (6)	4 (3)	1 (1)
3-5 times	5 (4)	7 (5)	8 (5)	5 (3)	11 (11)
>5 times	4 (3)	4 (3)	3 (2)	6 (4)	3 (3)
Not reported	3 (2)	1 (<1)	9 (5)	4 (3)	3 (3)
Number of people needle & syringe was re-used after last month (%)					
None	97 (77)	110 (77)	119 (73)	127 (82)	75 (73)
One	19 (15)	12 (8)	17 (10)	14 (9)	13 (13)
Two	3 (2)	5 (4)	3 (2)	---	1 (1)
Three to five	1 (1)	1 (1)	1 (1)	1 (<1)	1 (1)
More than five	1 (1)	-	2 (1)	3 (2)	1 (1)
Don't know	---	9 (6)	5 (3)	4 (3)	4 (4)
Not reported	5 (4)	6 (4)	16 (9)	5 (3)	9 (9)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	14 (11)	10 (7)	15 (9)	9 (6)	12 (12)
Casual sex partner	---	2 (1)	2 (1)	---	1 (1)
Close friend	7 (6)	12 (8)	11 (7)	9 (6)	7 (7)
Acquaintance	3 (2)	1 (1)	4 (2)	1 (<1)	---
Other	---	2 (1)	3 (1)	---	1 (1)
Equipment used after someone else last month (%)*					
Spoon	28 (22)	32 (22)	31 (19)	25 (16)	22 (22)
Water	22 (17)	28 (20)	31 (19)	27 (18)	14 (14)
Filter	16 (13)	23 (16)	25 (16)	23 (15)	13 (13)
Drug mix	6 (5)	17 (12)	16 (10)	17 (11)	12 (12)
Tourniquet	18 (14)	20 (14)	20 (12)	22 (14)	17 (17)
None**	---	---	---	97 (63)	63 (64)
Injected by someone after that person injected themselves or others last month (%)					
No	100 (79)	122 (85)	126 (78)	129 (84)	83 (81)
Yes	22 (17)	20 (14)	24 (15)	22 (14)	16 (16)
Not reported	4 (3)	1 (1)	13 (7)	3 (2)	4 (4)

* More than one option could be selected

** New variable in 2006

Table 235 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2003	2004	2005	2006	2007
N° surveyed	N = 133	N = 161	N=169	N=160	N=110
Any treatment/therapy for drug use (%)					
No	47 (35)	39 (24)	40 (24)	41 (26)	31 (28)
Yes	85 (64)	121 (75)	125 (74)	113 (71)	76 (69)
Not reported	1 (1)	1 (1)	5 (2)	6 (4)	3 (3)
History of methadone maintenance treatment (%)					
Currently	27 (20)	28 (17)	50 (30)	30 (19)	21 (19)
Previously	37 (28)	43 (27)	34 (20)	43 (27)	27 (25)
Never	68 (51)	89 (55)	82 (49)	84 (53)	60 (55)
Not reported	1 (1)	1 (1)	4 (2)	3 (2)	2 (2)
History of other pharmacotherapy treatment (%)					
Currently	22 (16)	28 (17)	42 (25)	25 (16)	14 (13)
Previously	29 (22)	31 (19)	29 (17)	34 (21)	34 (31)
Never	81 (61)	101 (63)	95 (56)	96 (60)	58 (53)
Not reported	1 (1)	1 (1)	4 (2)	5 (3)	4 (4)

Table 236 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2003	2004	2005	2006	2007
N° surveyed	N = 133	N = 161	N=169	N=160	---
From an NSP last month (%)					
Daily or almost daily	6 (5)	20 (13)	12 (7)	7 (4)	---
A couple of times each week	34 (26)	42 (26)	39 (23)	52 (32)	---
Less than weekly	51 (38)	45 (28)	50 (30)	44 (28)	---
Once last month	23 (17)	29 (18)	49 (29)	42 (26)	---
Not in the last month	16 (12)	23 (14)	17 (10)	14 (9)	---
Not reported	3 (2)	2 (1)	1 (1)	1 (<1)	---
From a chemist last month (%)					
Daily or almost daily	4 (3)	9 (6)	4 (2)	5 (3)	---
A couple of times each week	23 (17)	16 (10)	11 (7)	17 (11)	---
Less than weekly	24 (18)	18 (11)	22 (13)	28 (18)	---
Once last month	25 (19)	29 (18)	28 (17)	29 (18)	---
Not in the last month	54 (41)	84 (52)	100 (59)	78 (49)	---
Not reported	3 (2)	5 (3)	4 (2)	3 (2)	---

* Not asked in this form in 2007, see Table 239.

Table 237 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2003	2004	2005	2006	2007
N° surveyed	N = 133	N = 161	N=169	N=160	N=110
Sex last month (%) †					
No	40 (30)	51 (32)	--	--	--
Yes	89 (67)	103 (64)	--	--	--
Not reported	4 (3)	7 (4)	--	--	--
Condom use at last sex (%)†					
No	97 (73)	116 (72)	--	--	--
Yes	31 (23)	43 (27)	--	--	--
Not reported	5 (4)	2 (1)	--	--	--
Condom use with regular sex partner(s) last month (%)* †					
No	42 (74)	51 (73)	--	--	--
Sometimes	3 (5)	5 (7)	--	--	--
Always	12 (21)	14 (20)	--	--	--
Condom use with new sex partner(s) last month (%)* †					
No	15 (50)	26 (49)	--	--	--
Sometimes	5 (17)	6 (11)	--	--	--
Always	10 (33)	21 (40)	--	--	--
Condom use with casual sex partner(s) last month (%)* †					
No	13 (50)	20 (43)	--	--	--
Sometimes	2 (8)	5 (11)	--	--	--
Always	11 (42)	21 (46)	--	--	--
Duration of regular sexual relationship (%)** †					
One month	3 (5)	1 (1)	--	--	--
2 - 6 months	4 (6)	5 (7)	--	--	--
6 - 12 months	6 (9)	15 (20)	--	--	--
>12 months	53 (80)	53 (72)	--	--	--
Sex with a regular partner last month (%) ****					
No	--	--	86 (51)	77 (48)	42 (38)
Yes	--	--	82 (49)	77 (48)	66 (60)
Not reported	--	--	2 (1)	6 (4)	2 (2)
Condom used with regular partner last month (%)****			N=82*****	N=77	N=66
Never	--	--	59 (72)	57 (74)	46 (70)
Sometimes	--	--	8 (10)	9 (12)	8 (12)
Every time	--	--	11 (13)	5 (6)	8 (12)
Not reported	--	--	5 (5)	6 (8)	4 (6)
Sex with other partner/s last month (%)****					
No	--	--	133 (79)	124 (78)	97 (88)
Yes	--	--	32 (19)	29 (18)	11 (10)
Not reported	--	--	4 (2)	7 (4)	2 (2)
Condom used with other partner/s last month (%)****			N=32	N=29	N=11
Never	--	--	8 (25)	10 (34)	2 (18)
Sometimes	--	--	10 (31)	3 (10)	4 (36)
Every time	--	--	13 (41)	14 (48)	5 (45)
Not reported	--	--	1 (3)	2 (7)	--
Sex work last month (%)					
No	115 (86)	141 (88)	159 (94)	145 (91)	99 (90)
Yes	13 (10)	16 (10)	8 (5)	10 (6)	4 (4)
Not reported	5 (4)	4 (2)	2 (1)	5 (3)	7 (6)
Condom used at last sex work last month (%)**					
Yes	11 (85)	13 (81)	12 (92)	7 (88)	4 (100)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partner respectively in the previous month

** Percentages exclude missing data

**** New variable format commenced in 2005

† Data not collected in this format from 2005 on.

Table 238 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey

	2003	2004	2005	2006	2007
N ^o surveyed	N = 133	N = 161	N=170	N=160	N=110
Previous HIV test (%)					
Yes, last year	90 (68)	100 (62)	96 (56)	83 (52)	58 (53)
> 1 year ago	30 (22)	39 (24)	48 (28)	61 (38)	38 (35)
Never tested	12 (9)	21 (13)	25 (15)	12 (8)	12 (11)
Not reported	1 (1)	1 (1)	1 (1)	4 (3)	2 (2)
HBV infection (%)					
No	96 (72)	106 (66)	120 (71)	121 (76)	79 (72)
Yes	26 (20)	33 (21)	30 (18)	18 (11)	12 (11)
Don't know	8 (6)	20 (12)	19 (11)	16 (10)	17 (15)
Not reported	3 (2)	2 (1)	1 (1)	5 (3)	2 (2)
HBV vaccination (%)*					
No	39 (36)	47 (37)	56(40)	45 (32)	31 (32)
Yes	62 (58)	62 (48)	66 (47)	82 (58)	55 (56)
Don't know	5 (5)	17 (13)	16 (12)	11 (8)	9 (9)
Not reported	1 (1)	4 (2)	1 (1)	4 (3)	3 (3)
Previous HCV test (%)					
Yes, last year	94 (70)	106 (66)	103 (61)	94 (59)	62 (56)
> 1 year ago	29 (22)	30 (19)	45 (27)	52 (33)	34 (31)
Never tested	9 (7)	23 (14)	19 (11)	11 (7)	11 (10)
Not reported	1 (1)	2 (1)	2 (1)	3 (2)	3 (3)
Any treatment for HCV (%)	N = 56	N = 62	N=66	N=65	N=31
Interferon	1 (2)	5 (8)	1 (2)	3 (5)	2 (6)
Interferon+Ribarvarin	---	3 (5)	2 (3)	2 (3)	---
Other	1 (2)	---	1 (2)	2 (3)	1 (3)
No treatment	53 (94)	54 (87)	62 (94)	54 (83)	27 (87)
Not reported	1 (2)	---	---	4 (6)	1 (3)
Current treatment for HCV	N = 1	N = 3	N=2	N=2	N=1
Interferon	---	3	---	1	---
Interferon+Ribarvarin	---	---	2	---	1
Other	1	---	---	1	---

* Number (percentage) among participants not reporting HBV infection

Table 239 Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007

	2007*		
N ^o surveyed	N=110		
Needle/syringe acquisition at time of survey completion (%)			
No	5 (5)		
Yes	99 (90)		
Not reported	6 (5)		
Source of needles/syringes (%)** N=1490***	In last week	In last month	
Chemist/Pharmacy	21 (27)	36 (46)	
Needle Syringe Program	20 (25)	52 (66)	
Dispensing/Vending Machine	0 (0)	1 (1)	
Friend/Dealer	28 (35)	35 (44)	
Other	1 (1)	2 (3)	
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source and number (percentage) obtaining from multiple sources ***	N for this source	Exclusive source	Multiple sources
Chemist/Pharmacy	N=36	6 (17)	30 (83)
Needle Syringe Program	N=52	30 (58)	22 (42)
Dispensing/Vending Machine	N=1	0 (0)	1 (100)
Friend/Dealer	N=35	6 (17)	29 (83)
Other	N=2	1 (50)	1 (50)

* New table in 2007

** More than one could be selected

*** Excludes needle/syringe acquisition at time of survey completion. Also excludes missing data.

HIV antibody prevalence

Table 240 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2003	75	0 (0.0)	57	0 (0.0)	133	0 (0.0)
2004	69	0 (0.0)	43	0 (0.0)	113	0 (0.0)
2005	100	3 (3.0)	55	0 (0.0)	156	3 (1.9)
2006	82	1 (1.2)	49	0 (0.0)	132	1 (0.8)
2007	54	1 (1.9)	31	0 (0.0)	85	1 (1.2)
χ^2 trend p value		0.251		---		0.225

* Total includes people whose gender was not reported or reported as transgender

Table 241 HIV antibody prevalence by sexual identity and year of survey

Sexual identity	N° tested	N° with HIV (%)
2003		
Heterosexual	---	0 (0.0)
Bisexual	---	0 (0.0)
Homosexual	---	0 (0.0)
2004		
Heterosexual	---	0 (0.0)
Bisexual	---	0 (0.0)
Homosexual	---	0 (0.0)
2005		
Heterosexual	126	2 (1.6)
Bisexual	14	0 (0.0)
Homosexual	7	1 (14.3)
2006		
Heterosexual	109	0 (0.0)
Bisexual	13	0 (0.0)
Homosexual	6	1 (16.7)
2007		
Heterosexual	73	0 (0.0)
Bisexual	5	0 (0.0)
Homosexual	6	1 (16.7)
p value		0.131

Table 242 HIV antibody prevalence by age group and year of survey

Age group	N° tested	N° with HIV (%)
2003		
< 20 years	---	0 (0.0)
20 – 24	---	0 (0.0)
25 – 29	---	0 (0.0)
30 + years	---	0 (0.0)
2004		
< 20 years	---	0 (0.0)
20 – 24	---	0 (0.0)
25 – 29	---	0 (0.0)
30 + years	---	0 (0.0)
2005		
< 20 years	3	0 (0.0)
20 – 24	22	0 (0.0)
25 – 29	17	0 (0.0)
30 + years	114	3 (2.7)
2006		
< 20 years	3	0 (0.0)
20 – 24	9	0 (0.0)
25 – 29	23	0 (0.0)
30 + years	97	1 (1.0)
2007		
< 20 years	3	0 (0.0)
20 – 24	6	0 (0.0)
25 – 29	15	0 (0.0)
30 + years	61	1 (1.6)
p value		1.000

Table 243 HIV antibody prevalence by duration of drug injection and year of survey

Duration of drug injection	N° tested	N° with HIV (%)
2003		
<3 years	---	0 (0.0)
3 to 5 years	---	0 (0.0)
6 to 10 years	---	0 (0.0)
10 + years	---	0 (0.0)
2004		
<3 years	---	0 (0.0)
3 to 5 years	---	0 (0.0)
6 to 10 years	---	0 (0.0)
10 + years	---	0 (0.0)
2005		
<3 years	5	0 (0.0)
3 to 5 years	10	0 (0.0)
6 to 10 years	17	0 (0.0)
10 + years	114	3 (2.6)
2006		
<3 years	2	0 (0.0)
3 to 5 years	10	0 (0.0)
6 to 10 years	8	0 (0.0)
10 + years	90	1 (1.1)
2007		
<3 years	7	0 (0.0)
3 to 5 years	7	0 (0.0)
6 to 10 years	20	1 (5.0)
10 + years	50	0 (0.0)
p value		0.405

Table 244 HIV antibody prevalence by last drug injected and year of survey

Last drug injected	N° tested	N° with HIV (%)
2003		
Heroin	---	0 (0.0)
Meth/Amphetamine	---	0 (0.0)
More than one	---	0 (0.0)
Other/Not reported	---	0 (0.0)
2004		
Heroin	---	0 (0.0)
Meth/Amphetamine	---	0 (0.0)
More than one	---	0 (0.0)
Other/Not reported	---	0 (0.0)
2005		
Heroin	47	1 (2.1)
Meth/Amphetamine	49	0 (0.0)
More than one	3	0 (0.0)
Other/Not reported	57	2 (3.5)
2006		
Heroin	27	0 (0.0)
Meth/Amphetamine	60	1 (1.7)
More than one	3	0 (0.0)
Other/Not reported	42	0 (0.0)
2007		
Heroin	23	0 (0.0)
Meth/Amphetamine	26	1 (3.9)
More than one	4	0 (0.0)
Other/Not reported	32	0 (0.0)
p value		0.624

Table 245 HIV antibody prevalence by frequency of drug injection last month and year of survey

Frequency of drug injection	N° tested	N° with HIV (%)
2003		
Not last month	---	0 (0.0)
Less than weekly	---	0 (0.0)
Weekly not daily	---	0 (0.0)
Daily or more	---	0 (0.0)
2004		
Not last month	---	0 (0.0)
Less than weekly	---	0 (0.0)
Weekly not daily	---	0 (0.0)
Daily or more	---	0 (0.0)
2005		
Not last month	6	0 (0.0)
Less than weekly	15	0 (0.0)
Weekly not daily	36	2 (5.6)
Daily or more	99	1 (1.0)
2006		
Not last month	5	0 (0.0)
Less than weekly	17	0 (0.0)
Weekly not daily	34	0 (0.0)
Daily or more	75	1 (1.3)
2007		
Not last month	5	0 (0.0)
Less than weekly	7	0 (0.0)
Weekly not daily	18	0 (0.0)
Daily or more	54	1 (1.9)
p value		1.000

Table 246 HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey

Re-used someone else's used needle & syringe last month	N° tested	N° with HIV (%)
2003		
No	---	0 (0.0)
Yes	---	0 (0.0)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	114	2 (1.8)
Yes	26	1 (3.8)
2006		
No	106	1 (0.9)
Yes	17	0 (0.0)
2007		
No	61	1 (1.6)
Yes	15	0 (0.0)
p value		1.000

Table 247 HIV antibody prevalence by imprisonment last year and year of survey

Imprisonment last year	N° tested	N° with HIV (%)
2003		
No	---	0 (0.0)
Yes	---	0 (0.0)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	80	3 (3.8)
Yes	74	0 (0.0)
2006		
No	107	1 (0.9)
Yes	18	0 (0.0)
2007		
No	66	1 (1.5)
Yes	15	0 (0.0)
p value		---

Table 248 HIV antibody prevalence by condom use at last sex and year of survey

Condom use at last sex	N° tested	N° with HIV (%)
2003		
No	---	0 (0.0)
Yes	---	0 (0.0)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005*		
No	66	0 (0.0)
Yes	8	0 (0.0)
2006*		
No	57	0 (0.0)
Yes	3	0 (0.0)
2007*		
No	43	0 (0.0)
Yes	6	0 (0.0)
p value		---

* Question changed to "condom use with regular partner in last month" in 2005 survey.

Table 249 HIV antibody prevalence by sex work last month and year of survey

Sex work last month	N° tested	N° with HIV (%)
2003		
No	---	0 (0.0)
Yes	---	0 (0.0)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	141	3 (2.1)
Yes	8	0 (0.0)
2006		
No	121	1 (0.8)
Yes	7	0 (0.0)
2007		
No	75	0 (0.0)
Yes	4	0 (0.0)
p value		---

Table 250 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey

Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)
2003		
No	---	0 (0.0)
Yes	---	0 (0.0)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	140	3 (2.1)
Yes	10	0 (0.0)
2006		
No	128	1 (0.8)
Yes	2	0 (0.0)
2007		
No	79	1 (1.3)
Yes	5	0 (0.0)
p value		---

Table 251 HIV antibody prevalence by region/country of birth and year of survey

Region/Country of birth	N° tested	N° with HIV (%)
2003		
Australia	---	---
Other Oceania	---	---
Asia	---	---
UK & Ireland	---	---
Other	---	---
2004		
Australia	---	---
Other Oceania	---	---
Asia	---	---
UK & Ireland	---	---
Other	---	---
2005		
Australia	128	3 (2.3)
Other Oceania	5	0 (0.0)
Asia	2	0 (0.0)
UK & Ireland	16	0 (0.0)
Other	4	0 (0.0)
2006		
Australia	---	---
Other Oceania	104	1 (1.0)
Asia	3	0 (0.0)
UK & Ireland	---	0 (0.0)
Other	11	0 (0.0)
2007		
Australia	69	1 (1.5)
Other Oceania	---	---
Asia	1	0 (0.0)
UK & Ireland	9	0 (0.0)
Other	5	0 (0.0)
p value		1.000

Table 252 HIV antibody prevalence by main language spoken at home by parents and year of survey

Main language spoken at home by parents	N° tested	N° with HIV (%)
2003		
English speaking	---	0 (0.0)
Non-English speaking	---	0 (0.0)
2004		
English speaking	---	0 (0.0)
Non-English speaking	---	0 (0.0)
2005		
English speaking	133	3 (2.3)
Non-English speaking	22	0 (0.0)
2006		
English speaking	118	1 (0.9)
Non-English speaking	6	0 (0.0)
2007		
English speaking	82	1 (1.2)
Non-English speaking	2	0 (0.0)
p value		1.000

HCV antibody prevalence

Table 253 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003	75	47 (63)	57	29 (51)	133	77 (58)
2004	69	42 (61)	43	22 (51)	113	65 (58)
2005	101	59 (58)	55	31 (56)	156	90 (58)
2006	82	46 (56)	49	30 (61)	132	76 (58)
2007	54	23 (43)	31	14 (45)	85	37 (44)
χ^2 trend p value		0.031		0.798		0.115

* Total includes people whose gender was not reported or reported as transgender

Table 254 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heterosexual	66	41 (62)	38	19 (50)	104	60 (58)
Bisexual	1	0 (0)	8	6 (75)	9	6 (67)
Homosexual	2	1 (50)	5	1 (20)	7	2 (29)
p value		0.4		0.2		0.3
2004						
Heterosexual	61	38 (62)	35	17 (49)	96	55 (57)
Bisexual	4	2 (50)	5	3 (60)	5	3 (60)
Homosexual	65	40 (62)	3	2 (67)	7	4 (57)
P value		0.6		0.8		0.9
2005						
Heterosexual	89	56 (63)	37	21 (57)	126	77 (61)
Bisexual	4	0 (0)	10	5 (50)	14	5 (36)
Homosexual	4	1 (25)	3	1 (33)	7	2 (29)
p value		0.02		0.7		0.06
2006						
Heterosexual	73	43 (59)	36	22 (61)	109	65 (60)
Bisexual	4	2 (50)	8	6 (75)	13	8 (62)
Homosexual	1	0 (0.0)	5	2 (40)	6	2 (33)
p value		0.601		0.497		0.465
2007						
Heterosexual	50	23 (46)	23	11 (48)	73	34 (47)
Bisexual	1	0 (0.0)	4	1 (25)	5	1 (20)
Homosexual	3	0 (0.0)	3	1 (33)	6	1 (17)
p value		0.253		0.828		0.257

* Total includes people whose gender was not reported or reported as transgender

Table 255 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
< 20 years	2	0 (0)	3	2 (67)	5	2 (40)
20 – 24	4	1 (25)	9	1 (11)	13	2 (15)
25 – 29	15	7 (47)	11	5 (45)	26	12 (46)
30 + years	54	39 (72)	34	21 (62)	89	61 (69)
p value		0.02		0.05		0.001
2004						
< 20 years	1	0 (0)	-	-	1	0 (0)
20 – 24	9	2 (22)	7	1 (14)	16	3 (19)
25 – 29	7	4 (57)	8	2 (25)	15	6 (40)
30 + years	52	36 (69)	28	19 (68)	81	56 (69)
p value		0.02		0.5		0.04
2005						
< 20 years	1	0 (0)	2	1 (50)	3	1 (33)
20 – 24	13	5 (38)	9	3 (33)	22	8 (36)
25 – 29	10	6 (60)	7	1 (14)	17	7 (41)
30 + years	77	48 (62)	37	26 (70)	114	74 (65)
p value		0.03		0.01		0.001
2006						
< 20 years	2	0 (0.0)	1	1 (100)	3	1 (33)
20 – 24	6	5 (83)	3	2 (67)	9	7 (78)
25 – 29	15	7 (47)	8	5 (63)	23	12 (52)
30 + years	59	34 (58)	37	22 (60)	97	56 (58)
p value		0.202		1.000		0.492
2007						
< 20 years	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
20 – 24	4	2 (50)	2	0 (0.0)	6	2 (33)
25 – 29	7	1 (14)	8	4 (50)	15	5 (33)
30 + years	41	20 (49)	20	10 (50)	61	30 (49)
p value		0.211		0.643		0.309

* Total includes people whose gender was not reported or reported as transgender

Table 256 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
<3 years	6	2 (33)	9	1 (11)	16	4 (25)
3 to 5 years	4	1 (25)	8	1 (13)	12	2 (17)
6 to 10 years	6	1 (17)	9	4 (44)	15	5 (33)
10 + years	57	42 (74)	31	23 (74)	88	65 (74)
p value		<0.001		0.004		<0.001
2004						
<3 years	4	2 (50)	-	-	5	3 (60)
3 to 5 years	4	1 (25)	2	0 (0)	6	1 (17)
6 to 10 years	13	5 (38)	9	2 (22)	22	7 (32)
10 + years	45	33 (73)	29	19 (66)	74	52 (70)
p value		<0.001		0.02		<0.001
2005						
<3 years	5	1 (20)	2	0 (0)	5	1 (20)
3 to 5 years	10	5 (50)	4	1 (25)	10	5 (50)
6 to 10 years	17	5 (29)	8	4 (50)	17	5 (29)
10 + years	114	74 (65)	80	50 (63)	114	74 (65)
p value		0.1		0.01		0.01
2006						
<3 years	1	0 (0.0)	---	---	2	0 (0.0)
3 to 5 years	5	2 (40)	5	2 (40)	10	4 (40)
6 to 10 years	18	9 (50)	10	5 (50)	28	14 (50)
10 + years	57	35 (61)	33	22 (67)	90	57 (63)
p value		0.419		0.418		0.111
2007						
<3 years	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
3 to 5 years	4	2 (50)	3	1 (33)	7	3 (43)
6 to 10 years	12	2 (17)	8	1 (13)	20	3 (15)
10 + years	33	18 (55)	17	12 (71)	50	30 (60)
p value		0.036		0.006		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 257 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Heroin	4	0 (0)	34	26 (76)	39	27 (69)
Meth/Amphetamine	5	2 (40)	50	23 (46)	55	25 (45)
More than one	1	1 (100)	8	6 (75)	9	7 (78)
Other/Not reported	6	1 (17)	23	17 (74)	30	18 (60)
p value		0.2		0.02		0.07
2004						
Heroin	---	---	26	20 (77)	28	21 (75)
Meth/Amphetamine	3	1 (33)	42	14 (33)	48	15 (31)
More than one	---	---	14	12 (86)	14	12 (86)
Other/Not reported	2	2 (100)	20	14 (70)	23	17 (74)
p value		0.1		<0.001		<0.001
2005						
Heroin	1	1 (100)	46	30 (65)	47	31 (66)
Meth/Amphetamine	3	0 (0)	47	22 (47)	50	22 (44)
More than one	---	---	3	2 (67)	3	2 (67)
Other/Not reported	1	0 (0)	55	35 (64)	56	35 (63)
p value		0.400		0.232		0.106
2006						
Heroin	1	0 (0.0)	26	20 (77)	27	20 (74)
Meth/Amphetamine	---	---	59	29 (49)	60	30 (50)
More than one	---	---	3	2 (67)	3	2 (67)
Other/Not reported	1	0 (0.0)	40	24 (60)	42	24 (57)
p value		---		0.093		0.185
2007						
Heroin	--	---	22	17 (77)	23	18 (78)
Meth/Amphetamine	4	0 (0.0)	22	5 (23)	26	5 (19)
More than one	1	0 (0.0)	3	1 (33)	4	1 (25)
Other/Not reported	2	0 (0.0)	30	13 (43)	32	13 (41)
p value		---		0.002		<0.001

* Total includes people who did not report duration of drug injection

Table 258 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Less than daily	5	1 (20)	48	25 (52)	54	27 (50)
Daily or more	7	2 (29)	67	47 (70)	75	49 (65)
p value		0.7		0.05		0.8
2004						
Less than daily	2	1 (50)	47	20 (43)	50	22 (44)
Daily or more	2	1 (50)	55	40 (73)	61	42 (69)
p value		0.01		>0.9		0.01
2005						
Less than daily	2	0 (0)	52	29 (56)	57	30 (53)
Daily or more	3	1 (33)	89	55 (62)	99	60 (61)
p value		0.4		0.5		0.3
2006						
Less than daily	2	0 (0.0)	48	27 (56)	51	27 (53)
Daily or more	---	---	74	45 (61)	75	46 (61)
p value		---		0.707		0.364
2007						
Less than daily	5	0 (0.0)	20	7 (35)	25	7 (28)
Daily or more	2	0 (0.0)	51	26 (51)	54	27 (50)
p value		---		0.293		0.088

* Total includes people who did not report duration of drug injection

Table 259 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	7	3 (43)	91	57 (63)	100	61 (61)
Yes	4	0 (0)	19	12 (63)	23	12 (52)
p value		-		0.9		0.6
2004						
No	3	1 (33)	69	41 (59)	75	43 (57)
Yes	1	1 (100)	24	15 (63)	26	16 (62)
p value		0.3		0.8		0.7
2005						
No	3	1 (33)	103	59 (57)	115	64 (56)
Yes	1	0 (0)	23	17 (74)	25	18 (72)
p value		0.5		0.1		0.1
2006						
No	1	0 (0.0)	103	56 (54)	106	57 (54)
Yes	1	0 (0.0)	16	13 (81)	17	13 (76)
p value		---		0.057		0.113
2007						
No	5	0 (0.0)	55	26 (47)	61	27 (44)
Yes	2	0 (0.0)	13	6 (46)	15	6 (40)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 260 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	13	3 (23)	96	60 (63)	110	64 (58)
Yes	2	1 (50)	17	11 (65)	19	12 (63)
p value		0.4		0.9		0.7
2004						
No	4	2 (50)	81	41 (51)	91	45 (49)
Yes	---	---	20	18 (90)	20	18 (90)
p value				0.001		0.001
2005						
No	5	1 (20)	120	67 (56)	133	71 (53)
Yes	---	---	15	13 (87)	17	15 (88)
p value				0.02		0.001
2006						
No	2	0 (0.0)	104	55 (53)	107	56 (52)
Yes	---	---	17	14 (82)	18	14 (78)
p value				0.033		0.070
2007						
No	7	0 (0.0)	59	27 (46)	66	27 (41)
Yes	---	---	14	7 (50)	15	8 (53)
p value				1.000		0.402

* Total includes people who did not report duration of drug injection

Table 261 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	13	4 (31)	100	61 (61)	115	66 (57)
Yes	1	0 (0)	12	11 (92)	13	11 (85)
p value		0.5		0.04		0.06
2004						
No	3	1 (33)	91	52 (57)	99	55 (56)
Yes	1	1 (100)	10	7 (70)	11	8 (73)
p value		0.2		0.4		0.3
2005						
No	5	1(20)	131	78 (60)	146	84 (58)
Yes	-	-	8	4 (50)	8	4 (50)
p value				0.1		0.3
2006						
No	2	0 (0.0)	117	67 (57)	121	68 (56)
Yes	---	---	7	5 (71)	7	5 (71)
p value				0.698		0.698
2007						
No	5	0 (0.0)	69	32 (46)	75	33 (44)
Yes	1	0 (0.0)	3	1 (33)	4	1 (25)
p value				1.000		0.630

* Total includes people who did not report duration of drug injection

Table 262 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
No	72	45 (63)	49	26 (53)	122	72 (59)
Yes	1	0 (0)	6	2 (33)	7	2 (29)
p value		0.2		0.4		0.1
2004						
No	60	37 (62)	40	20 (50)	101	58 (57)
Yes	5	3 (60)	2	1 (50)	7	4 (57)
p value		0.9		1.0		1.0
2005						
No	93	53 (57)	51	29 (57)	144	82 (57)
Yes	6	4 (67)	4	2 (50)	10	6 (60)
p value		0.6		0.8		0.8
2006						
No	81	45 (56)	46	27 (59)	128	72 (56)
Yes	1	1 (100)	1	1 (100)	2	2 (100)
p value		1.000		1.000		0.506
2007						
No	51	21 (41)	28	12 (43)	79	33 (42)
Yes	2	1 (50)	3	2 (67)	5	3 (60)
p value		1.000		0.576		0.647

* Total includes people who did not report duration of drug injection

Table 263 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
Australia	58	37 (64)	46	22 (48)	105	60 (57)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	11	5 (45)	4	3 (75)	15	8 (53)
Other	5	4 (80)	6	4 (67)	11	8 (73)
p value		0.4		0.4		0.6
2004						
Australia	54	32 (59)	32	17 (53)	87	50 (57)
Other Oceania	---	---	---	---	---	---
Asia	2	0 (0)	---	---	2	0 (0)
UK & Ireland	2	1 (50)	2	0 (0)	4	1 (25)
Other	9	7 (78)	2	1 (50)	18	12 (67)
p value		0.2		0.3		0.1
2005						
Australia	84	48 (57)	43	25 (58)	127	73 (57)
Other Oceania	4	1 (25)	1	0 (0)	5	1 (20)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	8	7 (88)	8	5 (63)	16	12 (75)
Other	3	2 (67)	2	1 (50)	5	3 (60)
p value		0.2		0.6		0.1
2006						
Australia	68	37 (54)	36	24 (67)	104	61 (59)
Other Oceania	---	---	3	1 (33)	3	1 (33)
Asia	---	---	---	---	---	---
UK & Ireland	6	3 (50)	4	3 (75)	11	6 (55)
Other	7	5 (71)	4	0 (0.0)	11	5 (45)
p value		0.670		0.034		0.733
2007						
Australia	43	18 (42)	26	13 (50)	69	31 (45)
Other Oceania	---	---	---	---	---	---
Asia	1	1 (100)	---	---	1	1 (100)
UK & Ireland	6	1 (17)	3	1 (33)	9	2 (22)
Other	3	2 (67)	2	0 (0.0)	5	2 (40)
p value		0.230		0.607		0.397

* Total includes people whose gender was not reported or reported as transgender

Table 264 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2003						
English speaking	72	45 (63)	54	29 (54)	127	75 (59)
Non-English speaking	3	2 (67)	---	---	3	2 (67)
p value		0.9		---		0.8
2004						
English speaking	52	32 (62)	29	15 (52)	82	48 (59)
Non-English speaking	4	2 (50)	5	3 (60)	9	5 (56)
p value		0.7		0.6		0.9
2005						
English speaking	84	48 (57)	50	28 (56)	134	76 (57)
Non-English speaking	17	11 (65)	5	3 (60)	22	14 (64)
p value		0.6		0.9		0.5
2006						
English speaking	71	41 (58)	46	28 (61)	118	69 (58)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		1.000		0.404		0.695
2007						
English speaking	52	22 (42)	30	14 (47)	82	36 (44)
Non-English speaking	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
p value		1.000		1.000		0.504

* Total includes people whose gender was not reported or reported as transgender

Methodological Notes

All clients attending selected Needle and Syringe Program (NSP) sites during the 15th to 21st October 2007 were asked to complete a brief, self-administered questionnaire and to provide a capillary blood sample for HIV and hepatitis C antibody testing. In 2007 the survey period was extended from 15th to 26th October at some rural and regional low volume NSP sites. The survey was also conducted at ten additional (non-sentinel) NSP sites in Queensland in 2007. Data from the 298 participants at these non-sentinel sites were not included in this report.

NSP sites were initially selected on the basis of volume of syringes distributed, coverage of all Australian jurisdictions and willingness to participate, with subsequent expansion based on size, geographic coverage and sub-populations targeted. NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey week to assess response rate and representativeness of the survey sample. Some clients visited the site more than once during the survey week. Consequently, it was also necessary to record whether each attendance at the NSP was the first that week for each client so that only one attendance per person was included in the response rate denominator. Ethical approval for the survey was obtained from ethics committees associated with the investigators and participating sites, and verbal rather than written informed consent was obtained to assure the anonymity of participants.

Demographic characteristics and behavioural data, including information on injecting drug use, injecting risk behaviours, needle and syringe acquisition, pharmacotherapy treatment for drug use, sexual behaviour, tattooing and body piercing, and HIV and hepatitis B and C testing history, were captured using a brief, self-administered, anonymous questionnaire.

In 2007 there was a change to the coding system used for last drug injected. The previously used category "morphine" was changed to "morphine/other opioids". This was done to accommodate the increasing numbers of participants reporting non-morphine narcotic analgesics as the last drug injected. In previous years, non-morphine narcotic analgesics were classified under the category "other". These are now classified under the category "morphine/other opioids". Tables reporting last drug injected, including results from previous years, have been updated accordingly.

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using Genetic Systems HIV-1 ELISA tests. Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France).

A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data were analysed using the Stata, Version 10 (Stata Corporation, College Station TX). Changes for HIV and HCV antibody prevalence overtime were assessed using the χ^2 test for linear trends. Associations between demographic, behavioural variables, syringe use, and HIV/HCV antibody prevalence were assessed using the χ^2 test or Fisher's exact test where expected frequencies were less than five. Percentage values may not add to 100 due to rounding.

Further information is available in:

Topp L, Iversen JL, Conroy A, Salmon A, Maher L. Prevalence and predictors of injecting-related injury and disease among clients of Australia's Needle and Syringe Programs. *Australian and New Zealand Journal of Public Health* 2008a; 32:34-37.

Topp L, Iversen JL, Wand H, Day CA, Kaldor JM, Maher L. Representativeness of injecting drug users who participate in HIV surveillance: Results from Australia's Needle and Syringe Program Survey. *Journal of Acquired Immune Deficiency Syndrome* 2008b; 47:632-638.

Featherstone J, Topp L, Black E, Iversen J, Maher, L. Blood borne virus surveillance among sentinel samples of injecting drug users. *IDRS Drug Trends Bulletin*, December 2007. Sydney: National Drug and Alcohol Research Centre, University of New South Wales. 2007.

National Centre in HIV Epidemiology and Clinical Research. *HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2007*. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW. 2007.

MacDonald MA, Wodak AD, Dolan KA, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. *Medical Journal of Australia* 2000;172(2): 57-61.

MacDonald M, Wodak A, Ali R, et al. HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Medical Journal of Australia* 1997; 166: 237-240.

Australian NSP Survey 2007

Thank you for your help.

This is a national study, endorsed by the Australian Injecting & Illicit Drug Users League (AIWL) and local user groups.

BLOOD SPOTS

When you have finished the questionnaire, please supply a blood spot

QUESTIONNAIRE

Fill in this questionnaire and return it to the open (non-sealed) section of the plastic bag. Shade bubbles like this: ●

Not like this: ✗ ◐ ◑ ◒ ◓

You may use a pencil or blue/black pen.



1. Are you Male
 Female
 Transgender
2. Do you identify as Heterosexual
 Bisexual
 Gay/lesbian

6. How often did you inject **last month**?
 More than 3 times most days
 2 to 3 times most days
 Once a day
 More than weekly, not daily
 Less than weekly (on 1 to 5 days)
 Not in the last month → **Go to Q7**

If you are not comfortable with the options available for Q1 or Q2 please specify your preferred gender or sexual identity.

3. How old are you?

4. How old were you when you first injected drugs?

5. What was the **LAST** drug you **INJECTED**?
(MARK ONE ONLY)
 Heroin
 Meth/Amphetamine (Speed, Base, Ice)
 Cocaine
 Methadone
 Morphine
 Anabolic steroids
 Subutex/Buprenorphine
 Other (please specify)

If you **did NOT** inject last month, skip the next section and go to Q7. If you did inject last month, please continue.

- 6a. Mark all the places where you injected **last month**.
 Own home
 Friend's home
 Dealer's home
 Street, park or beach
 Car
 Public toilet
 Commercial "shooting" room
 MSIC (KX injecting centre)
 Squat
 Other (please specify)

- 6b. How often did you use a **NEW** sterile needle and syringe **last month**?
 All injections
 Most of the time
 Half of the time
 Some of the time
 Not last month

- 6c. Mark any equipment that you used after anyone else **last month**.
- Spoon Tourniquet
 Water Drug solution/mix
 Filter Did not share any of the above last month
- 6d. How many **TIMES last month** did someone else inject you after injecting themselves or others?
- More than 5 times
 3 to 5 times
 Once or twice
 None
- 6e. How many **TIMES in the last month** did you re-use a needle and syringe after someone else had used it, including your sex partner (even if it was cleaned)?
- More than 5 times
 3 to 5 times
 Twice
 Once
 None ← Go to Q7
- 6f. How many different people (including your sex partner) have used a needle before you in the last month (even if cleaned)?
- More than 5 people
 3 to 5 people
 2 people
 1 person
 Don't know how many
- 6g. Who were these people?
- Regular sex partner
 Other sex partners
 Close friend
 Acquaintance
 Other (please specify)
- _____
7. Have you **EVER** been in prison?
 Yes No ← Go to Q8
- 7a. If **YES**, were you in prison last year? (the calendar year January to December)
 Yes No ← Go to Q8
- 7aa. If **YES**, did you inject drugs in prison?
 Yes No
8. Have you had sex with a regular partner in the **last month**?
 Yes No ← Go to Q9
- 8a. If **YES**, how often did you use a condom?
 Never
 Sometimes
 Every time
9. Have you had sex with other partners in the **last month**?
 Yes No ← Go to Q10
- 9a. If **YES**, how often did you use a condom?
 Never
 Sometimes
 Every time
10. Have you been paid for sex in the **last month**?
 Yes No ← Go to Q11
- 10a. If **YES**, did you use condoms the **last time** you were paid for sex?
 Yes No

11. Have you ever had hepatitis B infection?
 Yes No Not sure
12. Have you ever had hep B vaccination?
 Yes No Not sure
13. Have you ever been tested for HIV?
 Yes, in the last year
 Yes, more than a year ago
 Never tested
- 13a. If **YES**, what was the result of your last HIV test?
 Did not have HIV
 I have HIV infection
 Don't know result
14. Have you been tested for hepatitis C?
 Yes, in the last year
 Yes, more than a year ago
 Never tested
- 14a. If **YES**, what was the result of your last hep C test?
 Did not have hep C ← **Go to Q16**
 I have hep C ← **Go to Q15**
 Don't know result ← **Go to Q16**
15. What year did you find out you had hep C?

- 15a. Have you **EVER** had any treatment for your hep C?
 No treatment ← **Go to Q16**
 Yes, interferon
 Yes, interferon + ribavirin
 Other (please specify)

- 15b. If **YES**, are you on any treatment for your hep C **NOW**?
 No treatment
 Yes (please specify)

16. Have you ever been on a methadone program?
 Yes, am on it now
 Yes, in the past
 No, never
17. Have you ever been on other programs, eg naltrexone, buprenorphine or LAAM?
 Yes, am on it now
 Yes, in the past
 No, never
18. Have you ever had any other therapies for drug use, eg detox, counselling, N.A.?
 Yes No
19. What was the main language spoken at home by your parents?
 English
 Other (please specify)

20. In which country were you born?
 Australia
 Other (please specify)

21. When were you born? _____ / _____
 month year
22. Are you
 Aboriginal
 Torres Strait Islander
 Both
 Neither
23. How many needles and syringes are you picking up today?

24. Excluding today, have you obtained needles and syringes from any other source in the last week?

- Yes ← Go to Q25a and 25b
- No ← Go to Q25c and 25d

25a. In the last week, how many times have you obtained needles and syringes from the following sources? (write "0" if none)

Pharmacy/Chemist _____
 Needle Syringe Program _____
 Dispensing Machine _____
 Friend/Dealer _____
 Other _____

25c. In the last month, how many times have you obtained needles and syringes from the following sources? (write "0" if none)

Pharmacy/Chemist _____
 Needle Syringe Program _____
 Dispensing Machine _____
 Friend/Dealer _____
 Other _____

25b. In the last week, how many times have you injected? (write the total number of times)

_____ ← Go to Q26

25d. In the last month, how many times have you injected? (write the total number of times)

_____ ← Go to Q26

26. Excluding today, the last time you obtained needles and syringes from the following sources, how many did you get and how many of these did you give away or sell? (write "0" if none)

	How many did you get?	How many did you give away or sell?
Pharmacy/Chemist	_____	_____
Needle Syringe Program	_____	_____
Dispensing Machine	_____	_____
Friend/Dealer	_____	_____
Other	_____	_____

27. Have you been in this survey before?
 Yes No

29. Who completed the questionnaire?
 Self
 Assisted by NSP staff
 Assisted by other (please specify)

28. What are the first two letters of your FIRST name? _____

28a. What are the first two letters of your LAST name? _____

All questions are voluntary. The name code (Q28) is used to see how drug use changes over time. We cannot identify you from the code. If you have been in the survey before, please use the same code. If you use initials other than your own, please use code you will remember for next time.

Place the completed questionnaire in the open (non-sealable) section of the plastic bag. Please complete the blood spot now.



Participating NSP sites

Year		03	04	05	06	07
Number of NSP sites		48	42	52	45	50
Australian Capital Territory						
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales						
Albury	Albury Community Health Centre, GSAHS	✓	✓	✓		✓
Auburn	HIV/Hepatitis C Prevention Service, SWAHS	✓				
Ballina/Byron	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
Bankstown, Cabramatta & Liverpool	Indo-Chinese Outreach Network (ICON)	✓	✓			
Blacktown	HIV/Hepatitis C Prevention Service, SWAHS	✓	✓	✓	✓	✓
Canterbury	Resource and Education Program for IDUs (REPIDU)	✓	✓	✓	✓	✓
Gosford	Gosford Needle Syringe Program, NSCCAHS					✓
Liverpool	Health ConneXions, SSWAHS	✓		✓	✓	✓
Long Jetty	Long Jetty Needle Syringe Program, NSCCAHS					✓
Kings Cross	K2 Health Service, SEIAHS	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre, SEIAHS	✓	✓	✓	✓	✓
Kogarah	St. George NSP, SEIAHS	✓	✓		✓	✓
Merrylands	HIV/Hepatitis C Prevention Service, SWAHS			✓	✓	
Mt Druitt	Kelly Close Needle Syringe Program, SWAHS	✓	✓	✓		✓
Murwillumbah/Tweed	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
Nepean	South Court Primary Care NSP, SWAHS	✓	✓	✓	✓	✓
Newcastle	Hunter Harm Reduction Services, HNEAHS	✓		✓	✓	✓
Newcastle	AIDS Council of NSW (ACON)			✓	✓	✓
Nimbin/Lismore	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
North Sydney	Responsive User Services in Health (RUSH), NSCCAHS – Ryde, Manly and Clinic 16, RNSH St Leonards	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service, SWAHS	✓	✓	✓	✓	✓
Illawarra	First Step Program, SEIAHS – Port Kembla and Nowra	✓	✓	✓	✓	✓
Redfern	Resource and Education Program for IDUs (REPIDU), SSWAHS	✓	✓	✓	✓	✓
Surry Hills	ACON			✓		
Surry Hills	NSW Users and AIDS Association (NUAA)			✓	✓	✓
Northern Territory						
Alice Springs	Northern Territory AIDS Council – Alice Springs			✓		✓
Darwin	Northern Territory AIDS Council – Darwin/Palmerston	✓	✓	✓	✓	✓

Participating NSP sites continued

		03	04	05	06
Queensland					
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network (QuIHN)	✓	✓	✓	✓
Cairns	Cairns Base Hospital NSP	✓	✓	✓	✓
Cairns	Cairns Youthlink	✓			
Gold Coast	QuIHN	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓	✓	✓
Sunshine Coast	QuIHN	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓
South Australia					
Adelaide	South Australia Voice for Intravenous Education (SAVIVE) AIDS Council -Norwood	✓	✓	✓	✓
Adelaide	SAVIVE, Parks Community Health Service	✓	✓	✓	✓
Adelaide	Noarlunga Community Health Service			✓	✓
Adelaide	Nunkuwarrin Yunti Community Health Centre		✓	✓	✓
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓
Port Adelaide	SAVIVE, Port Adelaide Community Health Service	✓		✓	✓
Salisbury	SAVIVE, Northern Metropolitan Community Health Service NSP and Shopfront	✓	✓	✓	✓
Tasmania					
Clarence	Clarence Community Health Centre				✓
Devonport	Devonport Community Health Centre	✓	✓	✓	
Glenorchy	Tasmanian Council on AIDS, Hepatitis and Related Diseases (TasCAHRD)	✓	✓	✓	✓
Hobart	Tasmanian Council on AIDS, Hepatitis and Related Diseases (TasCAHRD)	✓	✓	✓	✓
Hobart	The Link - Youth Health Service	✓	**		✓
Launceston	Salvation Army Launceston				✓
Victoria					
Barwon	Barwon Health Drug and Alcohol Services				✓
Bendigo	Bendigo NSP Services				✓
Collingwood	Melbourne Inner Needle Exchange (MINE)	✓	✓	✓	✓
Dandenong	South East Alcohol and Drug Service		✓	✓	✓
Footscray	Health Works	✓	✓	✓	
Melbourne	Southern Hepatitis/HIV/AIDS Resource and Prevention Service	✓	✓	✓	✓
North Richmond	North Richmond NSP Services				✓
Northcote	Northcote NSP Services				✓
St Kilda	St Kilda NSP	✓	✓	✓	✓
Western Australia					
Bunbury	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓
Northbridge	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓

List of Tables

National

Table 1	Number (percentage) of respondents by demographic characteristics and year of survey.....	9
Table 2	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	10
Table 3	Number (percentage) of respondents by treatment for drug use and year of survey	11
Table 4	Number (percentage) of respondents by source of needle and syringe acquisition last month and year of survey	11
Table 5	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	12
Table 6	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey.....	13
Table 7	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	13
Table 8	HIV antibody prevalence by gender and year of survey	14
Table 9	HIV antibody prevalence by sexual identity, gender and year of survey	14
Table 10	HIV antibody prevalence by age group, gender and year of survey.....	15
Table 11	HIV antibody prevalence by duration of drug injection, gender and year of survey	16
Table 12	HIV antibody prevalence by last drug injected, gender and year of survey	17
Table 13	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey.....	18
Table 14	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey	19
Table 15	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	19
Table 16	HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey	20
Table 17	HIV antibody prevalence by sex work last month, gender and year of survey	20
Table 18	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	21
Table 19	HIV antibody prevalence by region/country of birth, gender and year of survey	22
Table 20	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey..	23
Table 21	HCV antibody prevalence by gender and year of survey	24
Table 22	HCV antibody prevalence by sexual identity, gender and year of survey	24
Table 23	HCV antibody prevalence by age group, gender and year of survey	25
Table 24	HCV antibody prevalence by duration of drug injection, gender and year of survey	26
Table 25	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	27
Table 26	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	28
Table 27	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	28
Table 28	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey ..	29
Table 29	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	29
Table 30	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	30
Table 31	HCV antibody prevalence by region/country of birth, gender and year of survey.....	31
Table 32	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	32

Australian Capital Territory

Table 33	Number (percentage) of respondents by demographic characteristics and year of survey	33
Table 34	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	34
Table 35	Number (percentage) of respondents by treatment for drug use and year of survey.....	35
Table 36	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	35
Table 37	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	36
Table 38	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey	37
Table 39	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	37
Table 40	HIV antibody prevalence by gender and year of survey.....	38
Table 41	HCV antibody prevalence by gender and year of survey	38
Table 42	HCV antibody prevalence by sexual identity, gender and year of survey.....	38
Table 43	HCV antibody prevalence by age group, gender and year of survey	39
Table 44	HCV antibody prevalence by duration of drug injection, gender and year of survey.....	40
Table 45	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey.....	41
Table 46	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey.....	42
Table 47	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	42
Table 48	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .	43
Table 49	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	43
Table 50	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	44
Table 51	HCV antibody prevalence by region/country of birth, gender and year of survey	45
Table 52	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	46

New South Wales

Table 53	Number (percentage) of respondents by demographic characteristics and year of survey.....	47
Table 54	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	48
Table 55	Number (percentage) of respondents by treatment for drug use and year of survey	49
Table 56	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	49
Table 57	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	50
Table 58	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey.....	51
Table 59	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	51
Table 60	HIV antibody prevalence by gender and year of survey	52
Table 61	HIV antibody prevalence by sexual identity, gender and year of survey	52
Table 62	HIV antibody prevalence by age group, gender and year of survey.....	53
Table 63	HIV antibody prevalence by duration of drug injection, gender and year of survey	54
Table 64	HIV antibody prevalence by last drug injected, gender and year of survey	55
Table 65	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey.....	56
Table 66	HIV antibody prevalence by re-use of someone else’s used needle & syringe last month, gender and year of survey	57
Table 67	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	57
Table 68	HIV antibody prevalence by condom use at last sex, gender and year of survey	58
Table 69	HIV antibody prevalence by sex work last month, gender and year of survey	58
Table 70	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	59
Table 71	HIV antibody prevalence by region/country of birth, gender and year of survey	60
Table 72	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey..	61
Table 73	HCV antibody prevalence by gender and year of survey	62
Table 74	HCV antibody prevalence by sexual identity, gender and year of survey	62
Table 75	HCV antibody prevalence by age group, gender and year of survey	63
Table 76	HCV antibody prevalence by duration of drug injection, gender and year of survey	64
Table 77	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	65
Table 78	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	66
Table 79	HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, duration of drug injection and year of survey	66
Table 80	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .	67
Table 81	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	67
Table 82	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	68
Table 83	HCV antibody prevalence by region/country of birth, gender and year of survey.....	69
Table 84	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	70

Northern Territory

Table 85	Number (percentage) of respondents by demographic characteristics and year of survey	71
Table 86	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	72
Table 87	Number (percentage) of respondents by treatment for drug use and year of survey	73
Table 88	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	73
Table 89	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	74
Table 90	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	75
Table 91	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	75
Table 92	HIV antibody prevalence by gender and year of survey	76
Table 93	HIV antibody prevalence by sexual identity and year of survey	76
Table 94	HIV antibody prevalence by age group and year of survey	76
Table 95	HIV antibody prevalence by duration of drug injection and year of survey	77
Table 96	HIV antibody prevalence by last drug injected and year of survey	77
Table 97	HIV antibody prevalence by frequency of drug injection last month and year of survey	78
Table 98	HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey	78
Table 99	HIV antibody prevalence by imprisonment last year and year of survey	79
Table 100	HIV antibody prevalence by condom use at last sex and year of survey	79
Table 101	HIV antibody prevalence by sex work last month and year of survey	80
Table 102	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey	80
Table 103	HIV antibody prevalence by region/country of birth and year of survey	81
Table 104	HIV antibody prevalence by main language spoken at home by parents and year of survey	81
Table 105	HCV antibody prevalence by gender and year of survey	82
Table 106	HCV antibody prevalence by sexual identity, gender and year of survey	82
Table 107	HCV antibody prevalence by age group, gender and year of survey	83
Table 108	HCV antibody prevalence by duration of drug injection, gender and year of survey	84
Table 109	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	85
Table 110	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	86
Table 111	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	86
Table 112	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .	87
Table 113	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	87
Table 114	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	88
Table 115	HCV antibody prevalence by region/country of birth, gender and year of survey	89
Table 116	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	90

Queensland

Table 117	Number (percentage) of respondents by demographic characteristics and year of survey.....	91
Table 118	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	92
Table 119	Number (percentage) of respondents by treatment for drug use and year of survey	93
Table 120	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	93
Table 121	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	94
Table 122	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	95
Table 123	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	95
Table 124	HIV antibody prevalence by gender and year of survey	96
Table 125	HIV antibody prevalence by sexual identity, gender and year of survey	96
Table 126	HIV antibody prevalence by age group, gender and year of survey.....	97
Table 127	HIV antibody prevalence by duration of drug injection, gender and year of survey	98
Table 128	HIV antibody prevalence by last drug injected, gender and year of survey	99
Table 129	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey.....	100
Table 130	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey	101
Table 131	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	101
Table 132	HIV antibody prevalence by condom use at last sex, gender and year of survey	102
Table 133	HIV antibody prevalence by sex work last month, gender and year of survey	102
Table 134	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	103
Table 135	HIV antibody prevalence by region/country of birth, gender and year of survey	104
Table 136	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	105
Table 137	HCV antibody prevalence by gender and year of survey	106
Table 138	HCV antibody prevalence by sexual identity, gender and year of survey	106
Table 139	HCV antibody prevalence by age group, gender and year of survey	107
Table 140	HCV antibody prevalence by duration of drug injection, gender and year of survey	108
Table 141	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	109
Table 142	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	110
Table 143	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	110
Table 144	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	111
Table 145	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey ...	111
Table 146	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	112
Table 147	HCV antibody prevalence by region/country of birth, gender and year of survey.....	113
Table 148	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	114

South Australia

Table 149	Number (percentage) of respondents by demographic characteristics and year of survey	115
Table 150	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	116
Table 151	Number (percentage) of respondents by treatment for drug use and year of survey	117
Table 152	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	117
Table 153	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	118
Table 154	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	119
Table 155	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	119
Table 156	HIV antibody prevalence by gender and year of survey	120
Table 157	HIV antibody prevalence by sexual identity, gender and year of survey	120
Table 158	HIV antibody prevalence by age group, gender and year of survey	121
Table 159	HIV antibody prevalence by duration of drug injection, gender and year of survey	122
Table 160	HIV antibody prevalence by last drug injected, gender and year of survey	123
Table 161	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey	124
Table 162	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey	125
Table 163	HIV antibody prevalence by imprisonment last year, gender and year of survey	125
Table 164	HIV antibody prevalence by condom use at last sex, gender and year of survey	126
Table 165	HIV antibody prevalence by sex work last month, gender and year of survey	126
Table 166	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	127
Table 167	HIV antibody prevalence by region/country of birth, gender and year of survey	128
Table 168	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	129
Table 169	HCV antibody prevalence by gender and year of survey	130
Table 170	HCV antibody prevalence by sexual identity, gender and year of survey	130
Table 171	HCV antibody prevalence by age group, gender and year of survey	131
Table 172	HCV antibody prevalence by duration of drug injection, gender and year of survey	132
Table 173	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	133
Table 174	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	134
Table 175	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	134
Table 176	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	135
Table 177	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	135
Table 178	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	136
Table 179	HCV antibody prevalence by region/country of birth, gender and year of survey	137
Table 180	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	138

Tasmania

Table 181	Number (percentage) of respondents by demographic characteristics and year of survey.....	139
Table 182	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	140
Table 183	Number (percentage) of respondents by treatment for drug use and year of survey	141
Table 184	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	141
Table 185	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	142
Table 186	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	143
Table 187	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	143
Table 188	HIV antibody prevalence by gender and year of survey	144
Table 189	HCV antibody prevalence by gender and year of survey	144
Table 190	HCV antibody prevalence by sexual identity, gender and year of survey	144
Table 191	HCV antibody prevalence by age group, gender and year of survey	145
Table 192	HCV antibody prevalence by duration of drug injection, gender and year of survey	146
Table 193	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	147
Table 194	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	148
Table 195	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	148
Table 196	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	149
Table 197	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	149
Table 198	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	150
Table 199	HCV antibody prevalence by region/country of birth, gender and year of survey.....	151
Table 200	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	152

Victoria

Table 201	Number (percentage) of respondents by demographic characteristics and year of survey	153
Table 202	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	154
Table 203	Number (percentage) of respondents by treatment for drug use and year of survey.....	155
Table 204	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	155
Table 205	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	156
Table 206	Number and (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey.....	157
Table 207	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	157
Table 208	HIV antibody prevalence by gender and year of survey.....	158
Table 209	HIV antibody prevalence by sexual identity, gender and year of survey	158
Table 210	HIV antibody prevalence by age group, gender and year of survey	159
Table 211	HIV antibody prevalence by duration of drug injection, gender and year of survey	160
Table 212	HIV antibody prevalence by last drug injected, gender and year of survey	161
Table 213	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey	162
Table 214	HIV antibody prevalence by re-use of someone else’s used needle and syringe last month, gender and year of survey.....	163
Table 215	HIV antibody prevalence by imprisonment last year, gender and year of survey	163
Table 216	HIV antibody prevalence by condom use at last sex, gender and year of survey.....	164
Table 217	HIV antibody prevalence by sex work last month, gender and year of survey.....	164
Table 218	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	165
Table 219	HIV antibody prevalence by region/country of birth, gender and year of survey	166
Table 220	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	167
Table 221	HCV antibody prevalence by gender and year of survey	168
Table 222	HCV antibody prevalence by sexual identity, gender and year of survey.....	168
Table 223	HCV antibody prevalence by age group, gender and year of survey	169
Table 224	HCV antibody prevalence by duration of drug injection, gender and year of survey.....	170
Table 225	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey.....	171
Table 226	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey.....	172
Table 227	HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, duration of drug injection and year of survey	172
Table 228	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	173
Table 229	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey ...	173
Table 230	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	174
Table 231	HCV antibody prevalence by region/country of birth, gender and year of survey	175
Table 232	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	176

Western Australia

Table 233	Number (percentage) of respondents by demographic characteristics and year of survey.....	177
Table 234	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	178
Table 235	Number (percentage) of respondents by treatment for drug use and year of survey	179
Table 236	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	179
Table 238	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	180
Table 239	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	181
Table 239	Number (percentage) of respondents by source of needle and syringe acquisition in the last week and last month in 2007	181
Table 240	HIV antibody prevalence by gender and year of survey	182
Table 241	HIV antibody prevalence by sexual identity and year of survey	182
Table 242	HIV antibody prevalence by age group and year of survey	182
Table 243	HIV antibody prevalence by duration of drug injection and year of survey	183
Table 244	HIV antibody prevalence by last drug injected and year of survey	183
Table 245	HIV antibody prevalence by frequency of drug injection last month and year of survey	183
Table 246	HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey	183
Table 247	HIV antibody prevalence by imprisonment last year and year of survey	184
Table 248	HIV antibody prevalence by condom use at last sex and year of survey.....	184
Table 249	HIV antibody prevalence by sex work last month and year of survey	184
Table 250	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey ..	184
Table 251	HIV antibody prevalence by region/country of birth and year of survey.....	185
Table 252	HIV antibody prevalence by main language spoken at home by parents and year of survey	185
Table 253	HCV antibody prevalence by gender and year of survey	186
Table 254	HCV antibody prevalence by sexual identity, gender and year of survey	186
Table 255	HCV antibody prevalence by age group, gender and year of survey	187
Table 256	HCV antibody prevalence by duration of drug injection, gender and year of survey	188
Table 257	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	189
Table 258	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	190
Table 259	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	190
Table 260	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	191
Table 261	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey ...	191
Table 262	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	192
Table 263	HCV antibody prevalence by region/country of birth, gender and year of survey.....	193
Table 264	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	194

